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"It is incident, I am afraid, in Physicians




I had little interest in stroke until I chanced upon
a letter in the Lancet in 1988 by Henze et al^ reporting a
patient with vertebrobasilar artery thrombosis, who was
treated with tissue Plasminogen Activator, with excellent
results. To my knowledge, acute ischaemic stroke was one of
the main contraindications to the use of thrombolytic thera¬
py for acute myocardial infarction because of the risk of
cerebral haemorrhage, so Henze's case report seemed very
controversial. Controversy is fascinating, particularly in
medical practice. The history of medicine is littered with
fundamental dogmas which restricted therapy until systemati¬
cally examined and thrown out by evidence from good scien¬
tific research. The teaching of medicine, which should
encourage young enquiring minds, often in my experience
produces doctors who are only too happy to follow the teach¬
ing of their forebears without question.
So, thrombolysis for acute ischaemic stroke? Why not?
As a house officer in 1982, I witnessed the beginning of the
modern use of thrombolysis for acute myocardial infarction,
and all the controversy that that produced. And yet today, a
mere decade later, not only is it established therapy, but
there is good information on adverse effects and which drug
is best. The mechanism of acute ischaemic stroke (acute
arterial occlusion) is the same as the mechanism of acute
myocardial infarction. So I began to search the literature
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for other reports on thrombolysis in stroke.
At that time (1988/89) there was a very limited
amount of information, but in the following year, several
moderate sized "open" trials were published. Even with my
limited knowledge of statistics and of the natural history
of cerebrovascular disease, it seemed to me that the method¬
ology of these "trials" was questionable, and that there
were many unknown factors about the natural history of acute
ischaemic stroke, such as the relationship between reperfu-
sion and oedema formation.
So I applied for a grant, with a hugh amount of
assistance from Professor Warlow, to obtain funding to
enable me to work full time on acute stroke imaging and
thrombolytic treatment for two years. This thesis is the
result of that effort. I hope that the results of this
project go some way towards solving some of the controver¬
sies, and that research on thrombolysis in acute ischaemic
stroke is now on a more methodologically sound footing.
I suppose that the acid test of any treatment must be
"would the proponents of it take it themselves?". For me, if
I had an acute ischaemic stroke, the answer is unequivocally
"yes". If it was my mother having the stroke, I'm not so
sure(!), and I await with great interest the results of
larger multicentre randomised controlled trials of thrombol¬
ysis in acute ischaemic stroke now underway.
ii
The non-invasive cerebrovascular imaging equipment used in
the studies described in this thesis. On the right is the
computer for the gamma camera, and sitting on top of it, the
micro computer used to acquire the Mean Cerebral Transit
Time studies. At the centre back is the gamma camera used
for the Mean Cerebral Transit Time studies. On the left is
the EME TC 64B transcranial Doppler ultrasound equipment,
for measuring the basal intracranial artery blood veloci¬
ties, mounted on a standard NHS tea trolley. Also on the
same trolley are a Sony video printer for hard copies, a
tape recorder for recording long sequences of Doppler sig¬
nal, ultrasound gel, and (not well seen) a Datex "Normocap"
end tidal C02 analyser. The trolley was easily transportable
to the patient's bedside.
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Abstract of Thesis : The purpose of the project which lead to the
writing of this thesis was to:
1) Establish the accuracy, limitations and practicality of a simple
isotope test, the Mean Cerebral Transit Time (MCTT), developed in the
Western General Hospital, Edinburgh, and its ability to diagnose the
pattern of cerebral arterial occlusion in acute ischaemic stroke;
2) Study the effect of early reperfusion of the cerebral infarct on
swelling of the infarct in the acute stage, and clinical outcome in
patients with symptoms of extensive acute cerebral ischaemia;
3) Perform an overview analysis of thrombolytic therapy for acute
ischaemic stroke;
4) Set up a pilot randomised controlled trial of intra-arterial throm
bolysis in acute ischaemic stroke.
The Thesis is divided into four parts. Part One describes: a) the
background to current understanding of the aetiology and pathogenesis
secondary treatment of, and possible primary treatments for acute
ischaemic stroke; b) the anatomy and physiology of the cerebral circu
lation; c) imaging methods for investigating the cerebral circulation
and brain parenchyma - angiography, ultrasound (TCD), radioisotope
methods (particularly the MCTT), SPECT, PET, CT and MRI - and the
contribution each has made to improved understanding of stroke patho¬
physiology.
Part Two describes a study in 120 acute stroke patients (mostly is¬
chaemic) to assess the accuracy of: 1) the Oxfordshire Community
Stroke Project Classification (OCSP) of acute stroke; 2) a simple
method of classifying cerebral infarcts on CT brain scans; and 3) the
MCTT in diagnosing the likely site of cerebral arterial occlusion
compared with transcranial Doppler ultrasound. The OCSP clinical
classification was very accurate in predicting the site of infarction
on the CT brain scan. The CT infarct classification had excellent
interobserver agreement for site/extent, swelling, and haemorrhagic
transformation of the infarct. The MCTT was as accurate as TCD at
diagnosing the likely site of cerebral arterial occlusion. The MCTT
was a surprisingly robust and simple diagnostic test.
Part Three is the relationship between reperfusion of the infarct
shown by TCD, the amount of swelling in the infarct in the acute stag
shown by CT brain scan, and clinical outcome. Clinical outcome at
three months was better, and infarct swelling in the acute stage less
in 47 patients with symptoms of a large cerebral infarct, with TCD
evidence of reperfusion of the infarct in the first few days after th
stroke, than in those with no TCD evidence of reperfusion.
Part Four contains a review of all publications on thrombolysis in
stroke patients and overview analysis of the randomised controlled
trials suggesting that thrombolysis may be beneficial in acute is¬
chaemic stroke. The pilot study of intra-arterial thrombolysis in
patients with extensive acute ischaemic stroke is described, with
detailed discussion of each patient randomised.
Publications arising from the work in the Thesis so far are included.
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The Aims of this Thesis.
The purpose of the project which lead to the writing of this
thesis was to:
1) Verify the accuracy and establish the limitations and
practicality of the isotope mean cerebral transit time
technique (MCTT) for diagnosing the pattern of cerebral
arterial occlusion in acute ischaemic stroke,
2) Devise an imaging strategy for rapid diagnosis of the
site and extent of cerebral arterial insufficiency in pa¬
tients presenting with an acute stroke,
3) Clarify the relationship between reperfusion of the
cerebral infarct, swelling of the infarct in the acute
stage, and clinical outcome in patients with symptoms of
extensive acute cerebral ischaemia,
4) Discuss the potential of thrombolytic therapy to treat
acute ischaemic stroke based on a critical review of the
literature on its use to date in stroke patients and the
success of thrombolysis in treating vascular disease else¬
where in the body, particularly myocardial infarction,
5) Describe the setting up of a small randomised controlled
trial of intraarterial thrombolysis in acute ischaemic
stroke, and the result of the first year of the trial.
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My contribution to this work
I suggested to my colleagues that thrombolysis was worth
testing in acute ischaemic stroke in a randomised controlled
trial. I was fortunate to be in Edinburgh where Professor
Warlow and colleagues have a considerable interest and
expertise in stroke.
I obtained ethical permission for the thrombolysis trial and
for the imaging studies.
I applied for a grant, with considerable assistance from
Professor Warlow to obtain funding to pay my salary and a
small amount of extra money to help fund the study.
I performed the transcranial Doppler ultrasound, isotope
Mean Cerebral Transit Time and duplex carotid ultrasound
studies, and supervised the CT brain scans on the stroke
patients. I performed most of the angiograms on the patients
randomised in the thrombolysis trial.
I organised the intraarterial thrombolysis trial with a
great deal of help from the Neurologists and General Physi¬
cians in the Western General Hospital, and the Chief Pharma¬
cist Margaret Braithwaite.
I reviewed the literature on thrombolysis in acute ischaemic
stroke, wrote to principal investigators of trials, obtained
translations of foreign language papers, and analysed all
the available published data on thrombolysis in acute is¬
chaemic stroke using the overview technique.
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I analysed the results of the imaging studies, including the
setting up of databases, and statistical analysis using
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encouraged me to undertake this work, and helped obtain
funding. Professor C P Warlow was an unending source of
inspiration, encouragement, and I could not have hoped for a
better teacher of clinical research philosophy and methodol¬
ogy. Dr R Sellar also gave a lot of encouragement, and
allowed complete access to the imaging facilities in the
Neuroradiology Department. Dr M V Merrick spent a lot of
time explaining the transit time methodology, and Mr Colin
Ferrington was a great assistance with practical problems
with the transit time. Mr J Slattery advised on statistical
analysis. I am also very grateful to Dr R Lindley and M S
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patients, and without whose constant support and encourage¬
ment, this study would not have been possible. The radiogra¬
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Hospital were always willing to help with imaging of the
stroke patients, and none of this would have been possible
without them. The general medical consultants, Drs Price,
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their patients to take part in the imaging and acute treat¬
ment trials almost without question, and always with great
interest, and I am grateful for their forward thinking
attitude. I am also grateful to Professor JJK Best for
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There are disadvantages to studying diseases affect¬
ing the brain which in part account for the lag in develop¬
ment of treatments for brain diseases behind those affecting
more accessible organs in the body. The brain cannot easily
be palpated, or transilluminated, or auscultated, or per¬
cussed in any useful way as can hearts, chests and kidneys.
Unfortunately the clinical manefestations of brain dysfunc¬
tion, for example hemiparesis, do not allow one to distin¬
guish between permanently damaged brain and "malfunctioning
but viable" brain, until either the malfunctioning brain has
recovered or the permanently damaged brain has not.
A further obstacle which has until recently delayed
the understanding of brain diseases, is that patients do not
always die immediately from the effects of their acute
neurological illness. They may succumb weeks later from a
secondary illness such as bronchopneumonia, allowing the
neurological lesion time to evolve through its natural
history, presenting the pathologist with information co¬
loured by time since the event. Add to this the inherent
complexity of the brain and the result is a sophisticated
puzzle and an enormous challenge - firstly to find out what
causes the disease and secondly how to treat it.
With these thoughts in mind, it should be no surprise
that so far no effective treatment for acute ischaemic
stroke has been found. And yet it is increasingly important
2
to do so. Stroke is the third commonest cause of death in
the Western World and leaves many survivors dependant on
O
others for help in activities of daily living. There have
been major advances in the last 20 years in prevention of
ischaemic stroke, for example aspirin and carotid endarter-
ectomy4 in patients with transient ischaemic attacks (TIAs).
But there is still nothing that can be offered to a patient
in the acute phase of an ischaemic stroke which will defi¬
nitely reduce death and disability.
In the last fifty years, understanding of the patho¬
physiology of acute ischaemic stroke has advanced partly due
to the development of less invasive neuro-investigative
techniques such as CT scanning. This has made possible
study of the brain soon after the acute event with minimal
disturbance to the patient. This, coupled with experimental
work in animals, means that the mechanisms of brain damage
are sufficiently well understood to have prompted trials of
many drugs (old and new) in acute ischaemic stroke in the
last ten years. Some of these are particularly promising and
hopefully it will not be long before we can offer proven
treatments to patients who have sustained an acute ischaemic
stroke.
Fundamental facts established over thousands of years
underly modern understanding of stroke pathophysiology.
Recent epidemiological studies have improved knowledge of
risk factors for and causes of different types of stroke,
3
and the magnitude of the problem for health services. Most
the contribution from imaging techniques has come in the
twentieth century; current management of stroke patients i
dependant on imaging, and future treatment certainly will
be. Before discussing neuroimaging methods in detail, the
background to present ideas on stroke aetiology, pathogene
sis, and epidemiology will be outlined.
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1.1.2 From the Greek Period to the 1900s : A brief summary
of the early history of clinical aspects and pathophysiology
of stroke.
The term "stroke" implies a sudden event with devas¬
tating effect outside the control of the individual - as in
"struck down by the hand of God". Stroke is not just a
disease of modern times. Hippocrates in circa 400 BC recog¬
nised that "persons are most subject to apoplexy between the
ages of 40 and 60" and "unaccustomed attacks of numbness and
anaesthesia are signs of impending apoplexy". He thought
that air normally filled the arteries and attributed apo¬
plexy to an accumulation of phlegm in the arteries of the
brain. Around the time of Christ, Celsus, a Roman physician,
distinguished between "apoplexy" - a paralysis of the whole
body - and "paralysis" - in which the effects were loca¬
lised. At the same time it was realised that the nervous
pathways cross, such that a lesion on one side of the head
caused signs on the other side of the body, and in late
Roman times the term "hemiplegia" was first used.®
Understanding of cerebral function took a giant leap
forward with the concept that blood circulated through the
brain, and the recognition of the vascular interconnections
of the circle of Willis. Willis (1621-1675) was not the
first to describe this anastomosis of arteries at the base
of the brain, but he was probably the first to recognise its
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importance for collateral supply by describing a patient
with occluded right carotid and vertebral arteries who did
7
not suffer apoplexy or paralysis. ' Richard Lower (1631-
1691) a colleague of Willis's demonstrated the ability of
the Circle of Willis to maintain cerebral circulation even
7
when three out of four supplying arteries were tied off.
There followed a series of pathoanatomic studies of
patients who had died of apoplexy, the most important being
those of Johann Jakob Wepfer (1620-1695). He described
intracerebral and subarachnoid haemorrhage, and developed
the theory that obstruction of arterial inflow or venous
outflow of the brain could cause apoplexy. He noted that
carotid narrowing can result from "corpora fibrosa" (small
fibrous bodies) in the arterial wall, and that this could
reduce the blood supply to the brain. He found that apoplexy
was commonest in the obese, those whose face and hands were
livid, and those whose pulse was consistently irregular,
this representing the first realisation that cardiac disease
could predispose to stroke. He recognised that the brain
could not withstand interruption of blood supply even for a
short period of time, that clinical patterns of apoplexy
were variable, and made the first attempt to correlate the
variable clinical manefestations of stroke with underlying
c 7
pathology.°'
Francois Bayle (1622-1709) was the first to relate
c 7
carotid atheroma to apoplexy. ' William Heberden (1710-
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1801) described TIA's and Carolus Linnaeus (1707-1778)
described aphasia.6'7 Samuel Johnson (1709-1784) described
experiencing a TIA.6 Virchow (1847) noted that embolism was
a frequent cause of brain softening, although others before
him had realised that arterial disease could be responsible
for "softening of the brain".6 Burrows in 1846 produced
evidence of a relationship between "cerebral accidents" and
alterations in cerebral circulation either due to a fall in
blood pressure or anaemia. He noted that cardiac and cere¬
bral apoplectic symptoms could occur simultaneously. In his
experiments he demonstrated that the amount of blood in the
brain could vary, and that such variations could be respon-
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sible for clinical signs. The latter was a milestone in the
understanding of cerebrovascular pathophysiology.
From the 1900's to the 1950's.
Around the turn of the century, increasing attention
focussed on carotid atheroma and the heart as sources of
embolism to the brain. Sir William Gowers (1885) described
cerebral embolism as being the result of "a morbid process
elsewhere in the ventricular system commonly the heart" and
that thrombosis resulted from local atheromatous disease.^
In the late 1800's there were several descriptions of cases
of embolism from the heart or "diseased and roughened arter¬
ies" supplying the brain, and that in a number of cases
recovery was rapid and complete. Chiari (1905) emphasised
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the frequency of atherosclerosis in the region of the carotid
bifurcation, believing that such lesions caused cerebral
symptoms from embolisation. He stressed the importance of
examining the cervical portions of the carotid arteries of
all patients dying of stroke, having been caught out himself
by omitting to examine the carotids in a patient dying of
embolic stroke.^
In 1906 Sir William Gowers wrote that "Most cases of
softening of the brain are due to the arrest of the blood
supply by occlusion of an artery The sudden obstruc¬
tion of a large vessel, however produced, frequently entails
a distinct apoplectic attack.... In atheromatous thrombosis,
focal symptoms, especially hemiplegia, come on before coma",
thus noting the frequent progression of symptoms following
Q
large cerebral artery occlusion.
J Ramsay Hunt, in 1914, emphasised that strokes could
be caused by extracranial occlusion of cerebral arteries,
and described the syndrome of internal carotid occlusion,
but unfortunately his work and that of Chiari and Gowers
went largely unrecognised (in America at least) for the next
forty years due to the habit of embalming bodies for which
the undertaker required intact carotid arteries.^
In 1925 Dow11 reported that the carotid bifurcation
and siphon were sites of predilection for atheroma and
occlusion. Hultquist in 1942 published the post mortem
findings of the entire carotid system in 1400 autopsies. He
8
noted the location, pathogenesis, histology, and propagation
12
of thromboembolism and resultant changes in the brain. * In
the 1950s it was realised that carotid artery occlusion was
probably far more freguent than had previously been recog¬
nised, and could occur without symptoms. Although the exact
aetiology of carotid thrombosis was unknown at that time,
the two most commonly associated factors were atherosclero-
1 1
sis and thromboangiitis obliterans. Fisher in 1951 report¬
ed eight patients with internal carotid occlusion and empha¬
sised the relationship between carotid occlusion in the neck
and cerebrovascular insufficiency. He said that internal
carotid artery disease might prove to be a major cause of
stroke. Seven of his eight patients had prodromal TIAs. He
re-emphasised that the relationship between internal carotid
artery thrombosis and symptoms was a function of the adequa¬
cy of collateral arteries, and that thrombosis occurred
secondary to atheroma. He also commented that "unexplained
cerebral embolism may arise from thrombotic material lying
in the carotid sinus". In 1954 he wrote "Mural thrombus
deposited upon atheromatous ulceration within the carotid
sinus is not infrequent, especially if smaller microscopic
deposits are included. Small emboli must often break away
without causing symptoms or even cerebral lesions.... It has
not been possible to get a clear understanding of the manner
in which such emboli arise. Slowing of the blood flow,
turbulence, or mural deposits are among the possibilities.
9
In one case the embolic material was wholly composed of
platelets".^
Thus the major concepts underlying cerebrovascular
disease pathogenesis were established by careful pathologi¬
cal studies and shrewd clinical observation:
- that "strokes" may be due to cerebral haemorrhage or
infarction;
- that cerebral infarcts are due to thrombotic or embolic
cerebral artery occlusion and symptoms depend on the
adequacy of collateral channels;
- that emboli may arise from the heart or atheroma in the
neck;
- that major strokes may be preceded by warning TIA's;
- that the risk factors for stroke include increasing age,
TIAs, cardiac disease and atheroma.
In the 1920s, the development of angiography allowing
examination of the carotid arteries in the living patient,
helped to refocus attention on carotid atheroma as a cause
of stroke and renewed interest in stroke epidemiology. That,
plus better surgical techniques offering the possibility of
preventive treatment, lead in the 1950's to the beginnings
of scientific stroke research laying the groundwork for our
current understanding of stroke pathophysiology, epidemiolo¬
gy, and therapeutic approaches.
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1.1.4 Modern epidemiological studies :
Since the 1950's clinical and experimental work and
advances in neuroimaging have lead to better understanding
of the cerebral circulation, of risk factors for stroke, of
how to investigate stroke and of preventive measures. Al¬
though post mortem studies provide information on disease
pathogenesis, good epidemiological studies are essential to
provide information on true disease incidence, aetiology and
outcome. Only in this way can the relative importance of
each risk factor be assessed and accurate figures on natural
history be generated.
There have been several surveys of the frequency of
stroke. While clinical observation is a satisfactory method
of diagnosing stroke in epidemiological studies, it is not
sufficient to identify the type of stroke. For example it is
not possible clinically to differentiate a cerebral infarct
1 R
from an intracerebral haemorrhage. J The distinction depends
on Computed Tomographic (CT) or Magnetic Resonance (MRI)
brain imaging or necropsy. Hospital based studies, and those
which included all strokes (not just first ever strokes) are
less reliable because they do not reflect the true incidence
of stroke in the community. They are biased towards patients
with more severe strokes or cerebral haemorrhage who are
more likely to be admitted to hospital. At least 25% of
stroke patients in the United Kingdom are probably not re-
11
? n
ferred to hospital, w possibly a higher percentage in less
developed countries. The most reliable epidemiological data
come from the community based studies which looked at the
incidence of first ever stroke, and used CT scanning (or
post mortem) to diagnose the cause of stroke. There are six
such studies now published: The Oxfordshire Community Stroke
Project (OCSP),*6 the SEPIVAC Study from Umbria, Italy,^
1 O
the Rochester study from Rochester Minnesota, USA, the
1 Q O 1
Benghazi Study from Libya, the Shibata study from Japan,
and the Hisayama study from Japan. The cause of stroke by
pathological type as determined in each of these studies is
shown in Figure 1.1.1. In the three Western and the Libyan
studies, about 80% of first ever strokes were due to cere¬
bral infarction, 10% to primary intracerebral haemorrhage
(PICH), 5% to subarachnoid haemorrhage (SAH), and in 5% the
cause was uncertain. The two Japanese studies suggested a
higher incidence of primary intracerebral haemorrhage, but
this could have been due to a lower CT scan rate and greater
reliance on clinical findings than in the other four stud¬
ies. Further evidence supporting these findings comes from
a community-based study of cerebrovascular disease in Perth,
Western Australia, which had a lower CT brain scanning rate
(only 70%) but found that 88% of cerebrovascular disease was
due to cerebral infarction (28% lacunar, 20% large artery
occlusion) and 12% to cerebral haemorrhage including SAH.2^
Cerebral infarcts due to arterial occlusion may be
12
predominantly cortical (large or small) in the territory of
a large or medium sized artery; lacunar in the deep white
matter and basal ganglia (thought to be due to occlusion of
O A
a lenticulostriate artery ) ; borderzone at the edges of
adjacent large artery territories; or involve the cerebellum
and brain stem in the vertebrobasilar artery territory. The
clinical features and natural history of each of these types
of infarction are different and should be taken into account
in trials of new treatments and assessment of preventive
25
measures. J
The OCSP data were used to classify cerebral infarc¬
tion into four clinical syndromes which might be used to
predict the underlying cerebral arterial pathology and risk
factors : Total Anterior Circulation Infarction (TACI)
corresponding to large cortical infarcts; Partial Anterior
Circulation Infarction (PACI) corresponding to small corti¬
cal infarcts; Lacunar Infarction (LACI); and Posterior
Circulation Infarction (POCI) corresponding to cerebellar,
brain stem and occipital lobe infarction.25
A quarter of all patients with first ever cerebral infarc¬
tion had lacunar infarction, 17% had TACI, 34% PACI, and 24%
POCI. The clinical features of each syndrome are described
in detail in Part 2 and Appendix Two. At one year, 11% of
patients with lacunar infarction, 18% with a PACI, 19% with
a POCI and 60% with a TACI were dead. Early recurrent stroke
was most frequent following a PACI stroke. Late recurrent
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stroke (in the first year) was most frequent following a
POCI stroke. The one year outcome after first ever stroke in
the OCSP is shown in Figure 1.1.2.
The common causes of large intracerebral artery
occlusion are embolism from a source outside the head (large
artery atheroma, cardiac or paradoxical embolism from the
leg veins through a defect in the cardiac atrial septum, in
situ thrombosis forming on an atheromatous plaque inside the
head and propagation from thrombus in the carotid arteries
in the neck. Rare causes of stroke include arteritis (tempo¬
ral, Becet's disease, systemic lupus erythematosis, drug
abuse, infective, granulomatous), moya moya, etc, most of
which tend to affect the small intracerebral arteries and
O C
are rare and outside the scope of this thesis. ° In the
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Stroke Data Bank, a hospital based study from America, 31%
of cerebral infarcts were thought to be due to embolism (14%
cardiac), 42% to large artery stenosis or occlusion, and the
cause was uncertain in 29%. This study was biased towards
large infarcts and probably misjudged the cause of mild
stokes. In the OCSP community based study, analysis of the
risk factors for the first 244 cases of first ever cerebral
infarction showed that 20% had a cardiac source of embolism
(13% were in atrial fibrillation), 38% had ischaemic heart
disease, 52% were hypertensive, 14% had had TIAs, 14% had an
9 ft
arterial bruit in the neck, and 10% were diabetic Lacu¬
nar infarcts, or small subcortical infarcts are small in-
14
farcts in the deep white matter of the pons or cerebral
hemispheres, or basal ganglia, and are due to occlusion of a
single deep perforating artery. They probably arise by a
different mechanism than cortical infarcts, possibly local
atheroma at the origin of the perforating artery, or lipohy-
alinosis causing occlusion of the deep perforator, though
O A
there is considerable controversy surrounding this. It is
possible that small emboli are responsible for some lacunar
strokes, although this is speculative.
1.1.5 The role of carotid atheroma as a cause of acute
ischaemic stroke:
Atheroma in the carotid arteries (most commonly at the
common carotid bifurcation though also not infreguently
found at the common carotid artery origin) is a well estab-
0 9 f)
lished cause of stroke. One of the most important
epidemiological points to emerge from the European4 and
*3 1
North American symptomatic carotid surgery trials was con
firmation that carotid atheroma is a major cause of ischaem¬
ic stroke; the more atheroma and the tighter the stenosis,
the greater the risk of stroke. If the cause (atheroma) was
removed, the risk of stroke was greatly reduced. Patients
with atheroma but stenosis less than 30% hardly ever had
strokes, so non-stenosing atheromatous plaques carry a very
low risk of stroke.4 The role of plaque ulceration (angio-
graphically visible) as a separate risk factor to stenosis
15
has yet to be defined.
Despite the extensive literature which has accumulat¬
ed on atheroma, there are still considerable gaps in our
O Q
knowledge of atherogenesis. "Fatty streak" - a macroscop¬
ic, flat, lipid-rich lesion consisting of macrophages and
smooth muscle cells visible even in children - appears to be
O Q
the earliest lesion of atheroma. Later fibrous plague -
consisting of increased intimal smooth muscle cells sur¬
rounded by a connective tissue maitrix containing variable
amounts of intra- and extracellular lipid - appears. "Fatty
streaks" and fibrous plagues tend to appear at similar sites
in arteries lending weight to the precursor-product hypothe¬
sis. Both are most frequent in large arteries particularly
at bifurcations and may in part be a "response to injury" of
o Q on
the arterial intima. ' There is also a complex interrela¬
tionship with plasma lipid concentrations, platelets, leuko¬
cytes and cell-derived mitogens well beyond the scope of
this thesis. The tendancy to develop atheroma may be famili¬
al and diet-related.
Established atheromatous lesions consist of a fibrous
cap projecting into the arterial lumen, containing smooth
muscle and macrophages, leukocytes and connective tissue.
Beneath this there may be an area of necrotic debris, cho¬
lesterol crystals and calcification. Haemorrhage may occur
into plaques causing acute increase in size and possible
rupture, exposing the highly thrombogenic cholesterol mai-
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trix to blood.Thrombus may form on the exposed surface
reducing luminal diameter, and thrombus plus cholesterol-
platelet debris may embolise downstream. Eventually the
plaque may re-endothelialise becoming less thrombogenic and
less active. Acute plaque rupture may result in acute occlu¬
sion even of large arteries like the internal carotid ar¬
tery.^4'40 This may be asymptomatic, or cause minor or major
hemispheric stroke, depending on other factors like collat¬
eral blood supply to the hemisphere and distal propagation
of the thrombus. Progression and regression of carotid
atheroma has been demonstrated in patients using
O C
ultrasound. In a few reported patients, even complete
occlusion (angiographically) of the ICA has resolved41 so
the dynamic nature of atheroma should not be overlooked.
The proposed cyclical behaviour of atheroma, with
haemorrhage into the plaque, plaque rupture and increased
thrombogenicity until the plaque surface has healed, may in
part explain why the greatest risk of a completed stroke is
within six weeks of a warning (TIA).4 It may also explain
why some patients with carotid atheroma develop strokes and
others with apparently similar lesions do not. '37 Apart
from the above, why some patients become symptomatic and
others do not is unclear and presumably depends on a complex
interaction of blood coagulation factors, flow dynamics,
plaque constituents and surface properties, mechanical
factors such as the shape of the carotid bulb, movement of
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the neck and so forth.
Although carotid bifurcation atheromatous stenosis is
a well established cause of stroke, it is only present in a
large minority of patients with strokes and TIA's (45% and
*2 O
36% respectively). Other less common sites for atheroma in
the arteries leading to the head are the origins of the
common carotid arteries and the innominate artery, the
carotid siphons and recently recognised as a possible cause
3 Q
of stroke, aortic arch atheroma.3 In a recent autopsy
series, ulcerated atheromatous plaques in the aortic arch
were found in 16.9% of patients with cerebrovascular disease
during life compared with 5.1% with other neurological
diseases (odds ratio 4.0, P<0.001). The prevalence of ulcer¬
ated aortic arch plaques was 61% among 28 patients with no
known cause of cerebral infarction during life compared with
22% among the 155 patients with a known cause of cerebral
infarction (P<0.001). The presence of aortic arch ulcerated
atheromatous plaques was not correlated with the presence of
extracranial ICA stenosis, suggesting that the two were
independant risk factors for stroke. The true role and
interplay of atheroma at each of the above sites is uncer¬
tain, requiring further study to produce appropriate guide¬
lines for patient investigation and clinical management.
1.1.6 Cardioembolic stroke
Emboli of cardiac origin probably account for about
18
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twenty percent of cerebral ischaemic events. ' Thrombus
forms in: the atrial appendage in patients with atrial
fibrillation; on the ventricular endocardium following acute
myocardial infarction; platelet fibrin thrombi may form on
defective heart valves; or infective vegetations on the
valves in infective endocarditis.42,42 Rarely atrial myxoma
may embolise to the cerebral circulation, and embolic stroke
may occur as a complication of coronary artery bypass sur-
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gery.
Recently, with improved non-invasive methods of
cardiac imaging, the importance of atrial septal deformities
4 c
has been recognised. J Atrial septal defects may allow
paradoxical embolism of thrombus from the leg or pelvic
veins to the arterial circulation,4^'47 and atrial septal
"aneurysm" defects (without a true communication between
venous and arterial sides) may allow stasis of blood leading
4 o
to thrombosis and embolism in the arterial circulation. 0
Post mortem studies of "normal" hearts have shown patent
foramen ovale in approximately one third of persons aged
between one and 29 years, and in about 25% of those aged
over 80 years.4^ Fifty-five percent of young patients with
unexplained ischaemic stroke were found to have a patent
foramen ovale compared with ten to fifteen percent of con¬
trols (using transthoracic echocardiography).4^ Transoeso-
phageal echocardiography is more sensitive than transthorac¬
ic, though so far less available, but is likely to lead to
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improved understanding of the role of cardiac defects in
stroke. Elevation of right heart pressure by even simple
Valsalva-inducing activites such as coughing may reverse the
normal left-to-right pressure gradient and allow paradoxical
embolism to occur.
It is not infrequent to find more than one potential
cause of stroke when investigating patients with cerebrovas-
9 7 9 ft
cular disease. ' It may be difficult to decide which
potential cause was most likely responsible for the stroke,
but with secondary preventive treatments becoming more
clearly defined, it is increasingly important to ensure
accurate identification of the balance of risk factors (see
section 1.1.8). There may be differences in the type of
stroke caused by emboli from a cardiac as opposed to a
4 9 4 9
carotid source, ' 3 but the proported differences vary with
the study and may be the result of selection bias. Haemor-
rhagic infarction which was for some years regarded as a
hallmark of cardioembolic stroke, is probably not simply due
to the cardiac source but rather a function of infarct size
(see section 1.1.7).
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1.1.7 Current understanding of the sequence of events in the
ischaemic brain following cerebral arterial occlusion
The brain requires a steady supply of blood to pro¬
vide substrates for energy metabolism and to carry away
C f)
waste products. u When blood flow is decreased below certain
levels and substrate supply becomes insufficient, neuronal
Cf) CI
function fails. Most of the information concerning
neuronal ischaemic thresholds has been derived from animal
experiments. There is relatively little information from
stroke patients due to (until recently) lack of non-invasive
investigative techniques and methodological difficulties in
getting patients quickly for study in the acute phase. In
the 1970's experimental studies used electrophysiology and
CI CO CO
histology, but recently research has been directed
more toward determination of biochemical markers of reversi¬
ble and irreversible ischaemic damage. A relatively brief
discussion of the likely sequence of events in the brain
distal to an acute arterial occlusion will be given here, as
a much more detailed description will be given in Part One,
Chapter Six (on CT scanning) and in Part Three, Chapter One.
Experimental work on ischaemic thresholds in the
brain has demonstrated two critical levels of decreased
perfusion : first a level representing the flow threshold
for reversible neuronal damage; and second a lower threshold
below which irreversible neuronal membrane failure and
morphological damage occur. The range of perfusion values
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between these limits has been called the "ischaemic penum¬
bra" characterised by the potential for functional recovery
without morphological damage provided that local blood flow
can be reestablished at a sufficient level and within a
C 1
certain time window. The flow thresholds for reversible
and irreversible ischaemia are remarkably similar in a
variety of mammals including rats, cats, and baboons, and
there is reasonable evidence that these flow thresholds will
C A
be similar in humans. The ischaemic tolerance of neurones
varies in different parts of the brain. It is the combina¬
tion of duration as well as the depth of ischaemia which
r n ^ i
determines the development of irreversible damage. U'J1 Mild
flow reduction may be tolerated for hours while profound
flow reduction may cause neuronal death in minutes. As well
as the varying neuronal tolerance to ischaemia, individual
animals of the same species vary in their ability to with-
stand apparently similar ischaemic insults. u For example
Hossmann et al repeatedly demonstrated that even one hour of
complete cessation of blood flow to the brain can be fol¬
lowed by recovery of electrophysiological function and also
by survival and recovery of neurological function in some
animals. J'~'u Similar results have been obtained with some
focal cerebral ischaemia models (MCA occlusion), some ani¬
mals dying early of the cerebral infarct and others making a
good neurological recovery.^ Recent studies on acute stroke
patients using positron emission tomography have clearly
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suggested that the ischaemic but viable brain may survive
for up to 48 hours after the onset of ischaemia in some
C A
patients. This selective tolerance is likely to be due to
a number of factors, the main one being the adequacy of the
collateral circulation, but possibly also the metabolic
state of the animal at the time of onset of ischaemia may be
important. Presumably similar variability occurs in humans
and in part explains the variable response of stroke pa¬
tients to apparently similar vascular lesions, tolerance of
the stroke, and degree of functional recovery.
It is important to stress that cerebral ischaemia is
a dynamic process evolving in time and space within the
brain, dependent on fluctuations in local blood flow, neu¬
ronal vulnerability and the effect of toxic metabolites
released from damaged cells on this dynamic process. In
addition, neurones with normal blood flow but connected to
acutely ischaemic neurones (for example in the cortex over¬
lying ischaemic white matter in the MCA territory) loose
their evoked potential demonstrating an ischaemic effect on
afferent pathways in the white matter.50 White matter can
tolerate longer periods of ischaemia than cortex so func¬
tional impairment due to deafferentation may have a better
prognosis than cortical damage caused by direct cortical
ischaemia. Bearing all this in mind, when faced with an
individual stroke patient in the acute phase it is quite
clear that it is not possible to judge how much brain is
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permanently damaged, and how much reversible ischaemia is
present just by examining the patient clinically. The hemi-
paresis could be due to shutdown of still viable neurones or
equally to permanently damaged neurones.
Most animal experiments used a relatively artificial
S 7
model to produce the ischaemic lesion. Focal ischaemia
models are probably more relevant to stroke patients than
global ischaemia models, but even in the former sampling of
the ischaemic tissue may be from only a relatively small
selected area of the total brain, and it is difficult to
extrapolate from that firstly to the whole animal, and
secondly from there to humans, especially elderly humans.
The usefulness of animal models has been questionned, but so
far there has been little alternative, so their limitations
R 7
must be constantly considered.
The response of ischaemic brain to reperfusion is
unclear. There is some evidence from animal work that it may
c Q
be beneficial in salvaging some of the ischaemic penumbra,
but there is also evidence that reperfusion may trigger a
disastrous process of progressive neuronal injury due to a
cascade of biochemical events started during the
C(] CO
ischaemia. uSevere changes in ion homeostasis, accumula¬
tion of lactate and release of free radicals and excitatory
toxins may all contribute to this relentless process of
neuronal death. There are anecdotal reports of patients who,
following a severe ischaemic insult, make an apparently good
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early recovery only to die a few days or weeks later of
C O
progressive brain damage. ° The role of this toxic process
in acute stroke is unclear, but could potentially limit any
benefit that might result from early reperfusion and salvage
of ischaemic penumbra. However the risk/benefit ratio of
reperfusion of ischaemic tissue for stroke patients will
only be established in the context of large randomised
controlled clinical trials.
It has also been suggested that reperfusion of is¬
chaemic or infarcted brain may worsen swelling of the in-
farcted tissue and increase the risk of haemorrhagic trans-
co c q
formation of the infarct. In fact it has been said that
the major cause of haemorrhagic transformation is reperfu-
c q
sion. Again, the true role of reperfusion is unclear,
there being also evidence from animal work®" and stroke
patients that reperfusion is not the cause of haemorrhagic
transformation. ®Haemorrhagic transformation will be
discussed further in Part One, Chapter Six and infarct
swelling in Part Three, Chapter One.
In conclusion, there is some evidence that some brain
tissue distal to an acute arterial occlusion survives for a
limited period, offering a therapeutic window in which to
intervene to reduce the final amount of neuronal damage, but
it is not clear whether reperfusion of the ischaemic brain
will be beneficial or not.
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1.1.8 Prevention of, and therapeutic options for, acute
ischaemic stroke
In the developed world stroke is still the third
commonest cause of death after heart disease and cancer, and
o
leaves many more people disabled. Despite a decline in the
incidence of stroke in the 1970s and early 1980's,6^'64
anticipated demographic changes suggest that stroke will not
continue to decrease in frequency.66 Preventive measures,
and treatment for the stroke once it has occurred, are
needed more than ever.
Improved understanding of stroke epidemiology has
lead to treatment of risk factors (hypertension, hypercho-
lesterolaemia, reduction in smoking), carotid endarterectomy
for symptomatic carotid stenosis, and aspirin. Reduction of
risk factors may partly account for the decline in the
incidence of stroke observed in the USA in the 1980' s.6^'64
The UK TIA Aspirin Trial showed that aspirin reduces the
odds of suffering a major stroke, myocardial infarction or
-j
vascular death after a TIA by 15%, confirmed in the over¬
view of antithrombotic treatment performed by the Antiplate¬
let Trialists Collaboration.66 Aspirin is now a well estab¬
lished widely used preventive treatment for ischaemic stroke
and other vascular disease, although the optimal dose is
still controversial. The Dutch TIA Trial suggested that a
dose of 30mg daily was as good as 300mg in preventing
stroke, but caused fewer adverse effects.67
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Carotid endarterectomy was an established and common¬
ly performed but unproven preventive treatment for patients
with TIAs until 1991, when the interim results of the Euro¬
pean Carotid Endarterectomy Trial (ECST)^ and the North
■3 1
Americal Symptomatic Carotid Endarterectomy Trial (NASCET)J
were published. Both showed that patients with 70% or great¬
er stenosis of the symptomatic internal carotid artery
benefited more from surgery than best medical therapy alone,
even allowing for the risk of surgery. Patients with less
than 30% stenosis had virtually no strokes so the risk of
surgery was not justified. Both trials are continuing to
randomise patients with 30 to 69% stenosis because the
risk/benefit ratio of surgery in that group is not yet
clear.
Therapeutic approaches so far tested for the treat¬
ment of acute ischaemic stroke once it has occurred, include
haemodilution, antithrombotic drugs, thrombolytics, neuronal
protective agents (ion channel modulators) and free radical
scavengers. Haemodilution does not work in the generality of
ft
acute ischaemic stroke. ° Antithrombotic drugs have been
used in acute ischaemic stroke for many years but without
definite evidence of benefit.69 A large trial of aspirin and
heparin in acute ischaemic stroke has just started in the UK
and is extending to Europe and Asia (The International
Stroke Trial). There are many ion channel modulators which
7 n
have shown promise in experimental studies,but so far
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none have been beneficial in stroke patients. Many such
drugs are currently under trial but often are found to have
unacceptible adverse effects. Thrombolysis is promising but
unproven and will be discussed in detail in Part 4.
The following chapters will describe investigative
techniques for acute ischaemic stroke, their contribution to
the improved understanding of stroke, and how they may be
used to guide therapy.
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Summary of Chapter One
1. A brief historical review discusses how clinical observa¬
tion and pathological studies up to the 1900s provided
fundamental information on the aetiology and pathogenesis of
acute stroke.
2. Community based epidemiological studies have established
the true incidence of stroke and shown similar frequencies
for cerebral infarction and primary intracerebral haemor¬
rhage in all parts of the Western World.
3. Carotid atheroma is the major cause of acute ischaemic
stroke. The tighter the stenosis the greater the risk of
stroke. Non-stenosing atheroma, even if ulcerated, carries a
low risk of stroke.
4. The other common causes of stroke are emboli of cardiac
origin, paradoxical emboli from the venous side of the
circulation, atheroma in the aortic arch, and small arterial
disease causing lacunar stroke.
5. It is likely that some neurones distal to an acute
cerebral arterial occlusion survive in a shut down but
viable state for a variable period of time, and are poten¬
tially salvageable, but it is not clear whether reperfusion
is beneficial or may be associated with worsening of cere¬
bral infarct oedema and haemorrhagic transformation.
6. Stroke is the third commonest cause of death in the
Western World and is likely to remain so. It places an
enormous burden on health care resources. It is important to
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find an effective treatment.
7. Aspirin and carotid endarterectomy are now proven preven¬
tive treatments for acute ischaemic stroke.
8. There is no treatment of proven benefit for acute is¬
chaemic stroke once it has occurred, despite intensive
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■ Primary intracerebral haemorrhage
* Low rate of computerised scanning (CT)
in these studies
Figure 1.1.1 Cause of First Stroke by Pathological Type in
the Community Based Studies. Oxford 1990 = The Oxfordshire
Community Stroke Project (16), Umbria = SEPIVAC (17), Roch¬
ester = The Rochester, Minnesota Study (18), Benghazi =
Benghazi, Libya (19), Hisayama = Japan (22), Shibata = Japan
(21). The Figure was prepared by Dr R Lindley.
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One year outcome after first ever stroke
TACI POCI PACI LAC I
Classification of stroke




Figure 1.1.2 Outcome at One Year After First Ever Stroke
(Cerebral Infarction) by Clinical Classification Data from
the Oxfordshire Community Stroke Project (16): TACI = total
anterior circulation infarction, POCI = posterior circula¬
tion infarction, PACI = partial anterior circulation infarc¬
tion, LACI = lacunar infarction. The clinical classification





A Brief Outline of Normal Cerebrovascular Anatomy and Con¬
trol of Cerebral Blood Flow.
1.2.1 Anatomy of the cerebral circulation
1.2.2 The internal carotid artery
1.2.3 The middle cerebral artery
1.2.4 The anterior cerebral artery
1.2.5 The posterior cerebral artery
1.2.6 The collateral pathways : intracranial, and
intracranial to extracranial pathways
1.2.7 The physiology of cerebral blood flow -
basic principles
1.2.8 The control of cerebral blood flow
1.2.9 Cerebral perfusion reserve
Summary of Chapter
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1.2.1 The anatomy of the cerebral circulation
The brain requires a constant flow of blood for
supply of oxygen and glucose as well as other metabolic
substrates and for removal of products of metabolism, so it
has a good arterial blood supply. The two internal carotid
arteries run anteriorly in the neck to supply the anterior
part of the brain (frontal, parietal and part of the tempo¬
ral lobes), and the two vertebral arteries run posteriorly
in the vertebral canals of the cervical spine to supply the
posterior part of the brain (brain stem and cerebellum,
7 2
occipital and part of the temporal lobes). The internal
carotid arteries (ICA) arise from the common carotid arter¬
ies (CCA) which in turn arise from the brachiocephalic trunk
on the right and direct from the aortic arch on the left.
The CCAs divide, usually at the level of C3/4 or C4/5 verte¬
bral bodies, into the ICAs and external carotid arteries
(ECA). The ECAs supply the extracranial tissues of the head
and the dura. The ICAs enter the intracranial cavity through
the foramena laceri and carotid canals in the skull base,
branch and anastomose with the posterior circulation through
the Circle of Willis. The two vertebral arteries (VA) enter
the head through the foramen magnum and join to form the
basilar artery (BA) which runs superiorly anterior to the
brain stem, dividing at the level of the upper pons into the
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two posterior cerebral arteries (PCA). The PCAs course
posteriorly above the tentorium cerebelli to supply the
occipital lobes, and also anastomose with the anterior
cerebral circulation through the Circle of Willis. Figure
1.2.1a and b show the course of the carotid and vertebral
arteries in the neck, and Figure 1.2.1c and d the main
components of the Circle of Willis.
1.2.2 The Internal Carotid Artery (ICA):
The origin of the ICA has a fusiform widening (the
carotid bulb or sinus). This is the commonest site for
atheroma formation affecting the cranial circulation in
•3 O
Caucasian populations. The purpose of the carotid bulb is
unclear, but it may act as a filter point to trap debris, or
to smooth arterial pulsations so that the brain is not
exposed to violent pulsations. Usually no branches arise
from the ICA until it enters the skull through the foramen
lacerum, where it gives off small arteries to the dura. It
then passes through the carotid canal to the cavernous sinus
where it gives off small arteries to the dura around the
pituitary gland. After leaving the cavernous sinus, the ICA
enters the subarachnoid space, gives off the opthalmic,
posterior communicating and anterior choroidal arteries, and
some small perforating arteries (to the basal ganglia), and
terminates at the medial end of the Sylvian fissure by
dividing into the middle and anterior cerebral arteries
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(Figure 1.2.1b).72 The subarachnoid part of the ICA usually
follows a tortuous course and is called the carotid siphon.
The carotid siphon may also act as a physiological filter to
7 3
catch debris before the blood enters the brain. J
1.2.3 The Middle Cerebral Artery (MCA):
The first part of the MCA passes laterally in the
Sylvian fissure (Ml segment). It measures between 18 and 26
mm in length, and is 2.5 to 4.9 mm wide at its origin (mean
7 4
3 mm). Numerous small perforating arteries (lenticulostri-
ate - LSA) arise from this segment at virtually 90 degrees
to the Ml and pass superiorly into the brain substance to
supply the basal ganglia and internal capsule (Figure
1.2.2). The LSA are end-arteries. Usually those arising
medially are smaller than those arising from the lateral end
of the Ml, and a few may arise from the terminal ICA. The
MCA bifurcates as it turns approximately 90 degrees to run
superiorly and parasagitally in the Sylvian fissure (M2
segment). There are two large divisions in 78%, three large
divisions in 12%, and a continous main stem with no major
divisions in 10% of subjects. In the commonest pattern (two
large divisions), the anterosuperior division supplies the
anterior part of the peripheral MCA territory, and the
posteroinferior division supplies the temporal and posterior
parietal parts. The branches pass through the Sylvian fis¬
sure to the external surface of the cerebral cortex of the
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temporal, parietal and posterior parts of the frontal lobes.
Perforating end-branches pass down into the cortex to supply
the brain parenchyma. The territory supplied by the MCA is
shown in Figure 1.2.3.
1.2.4 The Anterior Cerebral Artery (ACA) :
The ACA arises from the terminal ICA and runs anter-
7 9
omedially inferior to the frontal lobes (A1 segment).
Small perforating branches supply the septal region, hypo¬
thalamus, and a larger branch, the recurrent artery of
Hubner, supplies the caudate nucleus, anterior part of
internal capsule and anterior third of the putamen. The
anterior communicating artery (Ant Co A) links the two ACAs
just anterior to the optic chiasm forming the anterior
anastomosis of the Circle of Willis. There is considerable
variation in the size of the A1 segments and the Ant Co A,
illustrated in Figure 1.2.1c. The ACAs continue in an ante¬
rior direction (A2 segments) for a short distance, then turn
superiorly into the interhemispheric fissure external to the
corpus callosum. The A2 segments divide into the pericallos-
al and callosomarginal arteries, and perforating branches of
these supply the cortex of the frontal lobes and medial
parts of the parietal lobes (see Figure 1.2.3).
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1.2.5 Posterior Cerebral Arteries (PCA) :
These are formed by the bifurcation of the basilar
artery. They run posterolaterally around the midbrain,
medial to the hippocampus, inferior to the optic tract, to
pass over the free edge of the tentorium and thence to
supply the inferior surface of the temporal lobes and the
7 7
occipital lobes. * The posterior communicating arteries
(Post Co A) run anteriorly from the PCAs to join the ICA
siphon and complete the Circle of Willis. Branches of the
PCA supply the thalamus, the brainstem, choroid plexus and
walls of the lateral and third ventricles (Figure 1.2.3).
The posterior circulation anatomy is very variable. Fre¬
quently the main supply to the PCA is from the carotid
arteries via the Post Co A, with only a vestigial supply
from the basilar artery (see Figure 1.2.1c).
1.2.6 The collateral pathways : intracranial and
intracranial to extracranial pathways :
The main intracranial anastomosis is provided by the
Circle of Willis and its twenty-one common variations are
7 R
shown in Figure 1.2.1c and d.,J In most subjects the Circle
of Willis ensures adequate supply to all parts of the brain,
but some individuals may be at risk of impaired cerebral
circulation should a major neck artery stenose or occlude as
their Circle is incomplete. The anterior part of the Circle
provides poor collateral supply in 24% and no collateral
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supply in 7% of subjects studied at post mortem. J Note also
that with age, atheroma may stenose or occlude some compo¬
nents of the Circle reducing its collateral function. Tu¬
mours, emboli, aneurysms, trauma and surgery may also cause
interruption of part of the Circle of Willis. Anastomoses
also exist between the pial branches of the major intracra¬
nial arteries linking their territories though these also
vary in their adequacy.
In addition to the Circle of Willis, there are numer¬
ous potential collateral sources linking the extracranial to
the intracranial arteries which open up when the blood
7
supply via the ICA or VA becomes impaired. The opthalmic
artery is the largest and flow may be reversed through it
when the ICA is tightly stenosed or occluded. Potential
anastomoses also exist between :
- the maxillary artery (anterior tympanic branch), ascending
pharyngeal artery and the posterior auricular artery (stylo¬
mastoid branch) with the ICA dural branches in the carotid
canal - carotico-tympanic anastomosis;
- the internal maxillary artery to the pterygoid branch of
the ICA;
- the middle meningeal artery to the cavernous (dural)
branches of the ICA.
The ECA also anastomoses with the muscular branches
of the VA. The VA also anastomoses with the muscular branch¬
es of the subclavian arteries (thyrocervical trunk) and may
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act as a collateral artery itself when the proximal subcla¬
vian artery is occluded, which if symptomatic is known as
the subclavian steal syndrome.7^
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Figure 1.2.1 Anatomy of the Arteries to the Head and Brain.
A : Carotid and Vertebral Arteries in the Neck,
B : The Main Branches of the Internal Carotid Artery :
a) meningohypophyseal trunk, b) artery of the inferior
cavernous sinus, c) capsular artery, d) ophthalmic artery,
e) posterior communicating artery, f) anterior choroidal ar


















Figure 1.2.1 C : The Circle of Willis : PCA) posterior cere
bral artery, P Com A) posterior communicating artery, A Com
A) anterior communicating artery, SCA) superior cerebellar
artery, other abreviations as in B above.
Basilar A.
D : Diagram illustrating the common variations of the Circle
of Willis ; upper left are the 21 variations of the P Com A
and its connections with the basilar artery ; lower right
are four arrangements of the A Com A and ACAs.
NORMAL TKJN'AL" PRIMITIVE SMALL i ABSENT
SMALL ABSENT
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Figure 1.2.2 The Middle Cerebral Artery :
A) view in the coronal plane of the origin, main trunk (Ml)
and major branches (M2 and M3).
B) view of the lateral aspect of the cerebrum showing the
MCA branches emerging from the Sylvian Fissure to supply the
parietal, temporal and posterior parts of the frontal lobes
(white vessels are the MCA branches within the Sylvian
Fissure and black vessels have left the Fissure and are


















Figure 1.2.3 The Vascular Territories of the Major Cerebral
Arteries. PICA = posterior inferior cerebellar artery, BA =
basilar artery, AICA = anterior inferior cerebellar artery,
SCA = superior cerebellar artery, PCA = posterior cerebral
artery, A Ch A = anterior choroidal artery, ACA = anterior
cerebral artery, MCA = middle cerebral artery, LSA = lentic-
ulostriate arteries.(72)
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1.2.2 The physiology of cerebral blood flow -
basic principals
The control of cerebral blood flow (CBF) is very
complex. The brain is unique in exerting control over its
own blood flow to ensure a constant supply of glucose and
oxygen. Blood flow can be modelled on fluid flowing in a
rigid system of tubes, where
Flow = Pressure / Resistance (1)
Resistance is proportional to the diameter and length of the
tube, and the viscosity of the fluid :
Resistance = 8 . n . 1 / pi . r4 (2)
where n = viscosity of the fluid
1 = length of the tube
pi = pi
r = radius of the tube
The flow of fluids, that behave with Newtonian characteris¬
tics, through rigid tubes in a laminar fashion is described
by the Hagen-Poiseuille Law, which takes into account the
pressure gradient across the tube, the tube length and
radius and the fluid viscosity :
F = dP . pi . r^ / 8.n.1 (3)
where F = volume flow
dP = pressure difference between the beginning
and end of the tube
pi = pi
r = radius of the tube
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n = viscosity of the fluid
1 = length of the tube
However the circulation of blood in the body behaves rather
differently. Blood is non-Newtonian (that is blood viscosity
varies inversely with shear rates, the lower the shear rate
the higher the viscosity), the perfusing pressure is pulsa¬
tile, the tubes are not rigid but have elastic recoil, the
length and diameter of the blood vessels varies, but flow
for the most part is laminar except at bifurcations. Gener¬
ally speaking, for practical purposes, it is accepted that
the Hagen-Poiseuille Law adequately describes the cerebral
circulation for arteries larger than 100 microns in diameter
7 7
at least. In normal conditions in healthy brain the pres¬
sure gradient and radius of the conductance arteries (diame¬
ter greater than 100 microns) are the major determinants of
blood flow, but in areas of focal cerebral ischaemia where
the arterioles are already maximally dilated and autoregula-
tion (see below) is impaired, blood viscosity becomes an
7 7
very important determinant of blood flow. The most impor¬
tant factor influencing blood viscosity is haematocrit,
particularly at low shear rates. Erythrocyte and platelet
aggregation as might occur in brain ischaemia, also influ¬
ence blood viscosity. In the cerebral microcirculation
(blood vessels of 70 microns or less) blood viscosity de¬
creases as blood flows through progressively smaller capil¬
laries. This is probably due to a progressive reduction in
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haematocrit as capillary diameter decreases down to 6 mi¬
crons in diameter - the Fahraeus effect - and is partially
responsible for the failure of the Hagen-Poiseuille Law to
7 8
describe accurately cerebral blood flow. ° The Fahraeus
effect varies with the haematocrit of the incoming blood: at
constant flow rates it is linearly proportional to the
incoming haematocrit whereas at unsteady flow rates the
effect is variable. In addition, in larger capillaries the
Fahraeus effect is inversely proportional to the haematocrit
but is independant of the haematocrit in smaller capil-
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laries. Other factors such as the mechanical properties of
the capillaries and erythrocytes, the behaviour of the
leucocytes and platelets both physiologically and pathologi¬
cally influence the cerebral microcirculation but are beyond
the scope of this introduction.
There are several terms which can be used to describe
cerebral blood flow. They are not interchangeable. Absolute
flow (or volume flow) is the volume of blood entering the
brain or area of interest per unit time in millilitres per
minute. Perfusion is the flow per unit weight of tissue per
minute in millilitres per lOOg of brain per minute. Velocity
flow is the speed at which blood is flowing in centimetres
per second and is independant of the volume flowing. Doppler
ultrasound measures velocity flow. Transit time is the time
taken for an amount of blood to go from one part of the
i 7 Q
circulation to another point in seconds.
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As blood flow is pulsatile, velocity flow can be
expressed as a peak or mean :
mean velocity = F/pi.r"^ (4)
where mean velocity = mean velocity of flow (cm/s)
F = volume flow mls/s
pi = pi
r = radius of the vessel.
Substituting in equation (3) :
mean v = dP.r^ / 8.n.1 (5)
Thus volume (or absolute) flow is proportional to the
fourth power of the radius, and velocity flow is proportion¬
al to the second power of the radius, whereas all other
factors (dP, n, and 1) affect velocity and volume flow in a
linear manner.
The cerebral circulation is also influenced by re¬
sistance to flow, compliance, and intracranial pressure. The
main site of resistance is the smaller pial arteries (66% of
pressure drop) and most of the rest occurs in the larger
pial arteries (33%), but overall resistance in the cerebral
O Q
circulation is low so flow is high during diastole.
The cerebral arteries are very compliant which also
increases the diastolic flow. The cerebral arteries become
stiffer with age, so less compliant, and this contributes to
the slight decline in CBF which occurs with increasing
age.
The influence of haematocrit on CBF is complex. The
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main effect of haematocrit is through its effect on blood
viscosity which increases exponentially as haematocrit
7 9
rises. J The largest changes in blood viscosity with haema¬
tocrit occur in the physiologic range of haematocrit : for
example a rise in haematocrit from 30 to 50 trebles blood
7 7
viscosity. An increase in haematocrit increases the oxygen
carrying capacity of the blood so CBF falls. Reduced flow in
turn raises viscosity further, and a vicious cycle may
7 9
result until stasis occurs. The normal cerebral circula¬
tion may compensate for blood viscosity increases by vasodi¬
lating to overcome the associated increase in cerebrovascu¬
lar resistance. Patients with chronic obstructive airways
disease have a raised haematocrit secondary to chronic
7 Q
hypoxia but their CBF is usually normal. In addition
viscosity autoregulation is independant of metabolic reac¬
tivity to oxygen, as the effects of changes in arterial
oxygen content can be dissociated from changes in blood
viscosity in patients with paraproteinaemia in which a high
O O
viscosity is accompanied by anaemia and CBF is normal. *
Blood viscosity is also influenced by red blood cell pli¬
ability which varies with pH and p02, a fall in pH or p02
increasing red blood cell stiffness and blood viscosity and
7 9
decreasing CBF.'^
Intracranial pressure (ICP) is the other influence on
CBF. Cerebral perfusion pressure is the difference between
the mean arterial blood pressure and the pressure in the
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veins in the subarachnoid space prior to entering the venous
sinuses. If ICP should increase above the venous pressure
the veins would collapse and flow cease, but the venous
pressure tends to increase with rising ICP, and flow stops
7 9
when the ICP approaches arterial pressures. J
1.2.8 Control of cerebral blood flow
The brain does not store energy in any form, so it is
dependant on a constant supply of glucose and oxygen and
therefore blood flow, to sustain its high metabolic rate.
Control of CBF is brought about through several different
mechanisms : autoregulation, metabolic, chemical and neuro¬
genic regulation all working to maintain as constant as
possible a blood supply to the brain in spite of changing
conditions elsewhere in the body.
Autoregulation is the maintenance of constant CBF over
a wide range of mean systemic blood pressures (50 to 130 mm
Hg). Constant flow despite an increase in perfusion pressure
implies an increase in vascular resistance, and since nei¬
ther the viscosity of the blood nor the length of the cere¬
brovascular bed is likely to change in these rapid adjust¬
ments, this implies that as perfusion pressure increases
there is a reduction in the calibre of the principal cere¬
bral resistance vessels leading to increased resistance and
no net change in CBF (Figure 1.2.4a).®^ A decrease in sys¬
temic blood pressure leads to dilatation of the resistance
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arterioles and a fall in cerebrovascular resistance. Auto-
regulation probably takes place through alterations in
smooth muscle tone in the small arterioles responding di¬
rectly to blood pressure changes. If cerebral perfusion
pressure falls below 40 mmHg the cerebral arterioles cannot
dilate any further so the brain extracts more oxygen from
the blood to compensate, and CBF is almost invariably re¬
duced. Similarly when the perfusion pressure exceeds 140
mmHg, the cerebral arterioles are maximally vasoconstricted
7 9
and CBF starts to increase. Chronic hypertension shifts
the autoregulatory response curve to the right, so that the
upper and lower limits of autoregulation are at a higher
O A
systemic blood pressure than in normotensive subjects.
Sympathetic overactivity, such as occurs in response to
trauma or stroke, increases the lower threshold of autoregu¬
lation so that cerebral ischaemia begins to occur when the
perfusion pressure falls below 60 mmHg. Increased intracra¬
nial pressure with no change in systemic blood pressure
reduces cerebral perfusion pressure and autoregulation
similarly acts to maintain CBF. Autoregulation becomes
impaired after a wide variety of systemic and cerebral
insults including trauma, ischaemia, and around cerebral
tumours and abcesses and may lead to a passive pressure-
blood flow response. This is not always observed as some¬
times in severely damaged brain, increases in arterial
pressure after CBF has become reduced, may fail to induce
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any increase in CBF. In these circumstances the patient is
usually comatose and changes in arterial pC02 (see below)
fail to produce the appropriate changes in CBF. Also al¬
though increases in arterial blood pressure fail to raise
CBF, a fall in arterial pressure results in a sharp fall in
CBF. The exact cause of this phenomenon of "false autoregu-
lation" in severely damaged brain is not known but probably
results from increased cerebrovascular resistance due to
7 9
brain oedema or endovascular sludging. Autoregulation may
also be impaired above a carotid ligation so CBF tends to
follow passively changes in mean arterial pressure (see
below).
The cerebral arterioles are also very sensitive to
changes in arterial CO2 concentration, an increase in PaC02
causing vasodilatation and a decrease vasoconstriction.^
CBF can change by 3% or more for each 0.13 kPA change in
arterial C02 tension in the range 4.0 to 8.0 kPA. Even
taking a few deep breaths can alter CBF so it is very impor¬
tant to take account of end tidal C02 (as an indirect meas¬
ure of Pa C02) when measuring CBF (Figure 1.2.4b). The
response to C02 is attenuated when the systemic blood pres¬
sure is lowered, and is impaired by physical insults such as
O 7
trauma to the brain or ischaemia. Hypoxia is a less potent
CBF stimulator until the Pa02 falls below 50 mm Hg.7^'®7
CBF is also regulated by local factors such as a
local increase in metabolic by-products leading to vasodila-
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tation and increased flow. Finally there are also neuro¬
peptides and prostaglandins which alter cerebrovascular tone
7 9
and CBF although these are less well understood. J
Therefore the control of CBF can be thought of in
terms of a complex set of interactions all responding to
different influences, local or global, but all with the same
aim - to maintain a constant or appropriate supply of oxygen
and metabolic substrates to the brain. All these mechanisms
are vulnerable, and are impaired, locally and globally,
following brain damage.
1.2.9 Cerebral Perfusion Reserve (CPR)
Above a carotid ligation (or occlusion or tight
stenosis), resting CBF may be maintained by vasodilatation
of the cerebral arterioles, but the ability of the cerebral
circulation to compensate further, for example for changes
in PaCC>2 or blood pressure, is often impaired because the
cerebral arterioles are already vasodilated and have only
O C
limited vasodilatory capacity left. The amount of reserve
vasodilatory capacity can be usefully expressed by the
concept of cerebral perfusion reserve (CPR). CPR is a meas¬
ure of the amount by which the CBV increases for given falls
in CBF, and is a very sensitive indicator of impaired cere¬
bral perfusion. In other words, CPR is the ratio of the
cerebral blood flow (or how much blood is still entering the
area of brain per unit time) to the cerebral blood volume
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(CBV - or how much the capillaries are already dilated in
that area of brain), ie it is an index of how much reserve
vasodilatory capacity is left in a given area of brain. If
CBF remains constant and CBV increases, as might occur
distal to a carotid stenosis in order to maintain a normal
CBF, the CPR will be reduced and the ability of the cerebral
circulation to compensate for further reductions in CBF also
impaired.
If : CBF x transit time = CBV
and : CPR = CBF / CBV
and : transit time = CBV / CBF
it therefore follows that :
CPR = CBF / CBV = 1 / transit time
This is a clinically useful concept, much more useful
than a simple measure of either CBF or CBV in isolation, as
it shows how much capacity is left to maintain the cerebral
O O
circulation in a given situation.00 CPR may also usefully be
O Q
thought of as an indicator of cerebral perfusion pressure.03
Cerebral perfusion pressure is the difference between mean
arterial blood pressure and the pressure in the cerebral
venous sinuses. As cerebral perfusion pressure falls below a
critical level, CPR will be reduced.
It is really only possible to measure CPR in patients
accurately using positron emission tomography so it has been
measured in a limited number of pathologies. CPR has been
shown to indicate accurately impaired cerebral perfusion in
54
the cerebral hemisphere above a carotid occlusion in asymp¬
tomatic patients and in patients presenting with ipsilateral
O p
carotid territory stroke and TIA. ° Note however that due to
methodological difficulties in imaging acute ischaemic
stroke patients, there is little published information on
CA
CPR in the acute stages of ischaemic stroke. Studies with
positron emission tomography have also shown (in a still
limited number of patients) that once cerebral vasodilata¬
tion is maximal and CPR exhausted, metabolic reserve takes
over keeping tissue alive to a certain point by increasing
c 4
the oxygen extraction from blood. Once metabolic reserve
is exhausted also, the tissue starts to die.
As CPR is proportional to the inverse of transit
time, it follows that cerebral transit time - which can be
measured by simple isotope techniques - may also be a useful
indicator of impaired cerebral perfusion. If CPR is reduced,
cerebral transit time will be prolonged. It also follows
that the transit time is proportional to the cerebral perfu¬
sion pressure. Methods of measuring cerebral transit time
will be discussed in Part 1 Chapter 5.
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Summary of Chapter Two
1. The anatomy of the arterial blood supply to the brain is
described, including the territories supplied by the major
intracranial arteries, the Circle of Willis, and other
collateral pathways.
2. The physics of blood flow are described with respect to
the cerebral circulation.
3. The physiological control of cerebral blood flow is
described including autoregulation, and the influence of
PaC02, Pa02, and metabolites.
4. Different parameters of cerebral blood flow are defined.
5. The concept of cerebral perfusion reserve is discussed,
its importance as a measure of impaired cerebral blood
supply emphasised, and its relevance to the isotope mean
cerebral transit time described in Part 1 Chapter 5, men¬
tioned .
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Preface to the chapters on imaging in cerebrovascular
disease
Although experimental animal and pathological studies
have laid the foundations for much of our understanding of
stroke, more recently developments in Radiology have been
crucial to the improved understanding of stroke epidemiology
and pathophysiology, and made possible important therapeur-
tic interventions.
There are several methods of imaging the brain. The
intention of the rest of the introduction to this thesis is
to describe the neuroimaging techniques relevant to stroke
and outline the contribution each has made to improved
understanding of stroke aetiology and pathophysiology.
Cross-sectional imaging methods which show the brain
parenchymal lesion are Computerised Tomography (CT) and
Magnetic Resonance Imaging (MRI). Prior to the development
of CT scanning it was not even possible to differentiate
reliably between intracerebral haemorrhage and cerebral
infarction as the cause of stroke symptoms. The imaging
methods which show the patency of the cerebral circulation
are angiography, dynamic contrast enhanced CT scanning (of
the basal intracranial arteries), and Magnetic Resonance
Angiography. The first of these is invasive and not without
risk but is still the only sure way of showing the cerebral
arterial anatomy. Doppler ultrasound, simple isotope tech¬
niques using a gamma camera and "first pass" method, Single
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Photon Emission Computed Tomography, and Positron Emission
Tomography give information about blood flow patterns from
which the patency or otherwise of the cerebral arteries can
be inferred.
In acute ischaemic stroke, the two parameters of
particular interest for clinical decision making are :
1. the nature of the brain parenchymal lesion manifesting as
the stroke, and
2. occasionally the patency of the cerebral arteries.
There is no imaging technique yet available which gives the
answers to both these questions, so a combination of imaging
tests is required.
Each of the above techniques has contributed to
improved understanding of the aetiology, pathogenesis, and
natural history of acute ischaemic stroke. The development
of modern ideas about acute ischaemic stroke is closely
linked to information generated by each imaging technique.
Therefore, each technique will be described in some detail
to illustrate the contribution that neuroimaging has made to
the understanding of cerebrovascular pathology, and to put
in perspective the usefulness and practicality of simple




Imaging of the Cerebral Vasculature in Cerebrovascular
Disease - Invasive Methods :
Cerebral Angiography
1.3.1 Introduction and brief history of cerebral angiography
1.3.2 Risks of cerebral angiography
1.3.3 Angiography in cerebrovascular disease : the cervical
carotid and intracranial arteries
1.3.4 Concluding comments
Summary of Chapter Three
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1.3.1 Introduction and brief history of cerebral angiography
X-rays were discovered in 1895, and the first attempt
at angiography was in 1896 using a chalk containing solution
q n
injected into the arteries of an amputated arm. u Cerebral
angiography was first attempted by Moniz in Lisbon, Portugal
Q f)
in 1927^u by injecting sodium iodide as the contrast agent
directly into the carotid artery following surgical exposure
then taking a rapid series of skull x-rays to demonstrate
the contrast medium in the cerebral circulation. The tech¬
nique he used involved considerable risk from the sodium
iodide and surgical exposure of the carotid artery. Further
development of cerebral angiography was dependant on ad¬
vances in contrast agents, needles, plastics for catheters
and guidewires, and radiographic equipment.
Contrast agents have evolved through a series of
increasingly safe ionic iodide solutions to the present day
non-ionic contrast media, such as iohexol and iopamidol.
Non-ionic contrast contains much more iodine per molecule of
carrier so can be given in small amounts, typically 5ml of a
solution containing 300mg of iodine per ml into the carotid
artery, to achieve excellent visualisation of the intracra¬
nial arteries. General anaesthetic is no longer required,
and allergic reactions, the main adverse effect of contrast
media are rare with non-ionic contrast particularly when
used intra-arterially.
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Advances have also been made in catheterisation
techniques. Direct puncture of the carotid or vertebral
arteries using a hollow needle was superceeded in 1953 by
the technique devised by Seldinger in which a catheter could
be inserted into a blood vessel over a flexible guidewire
introduced through a hollow puncture needle after withdraw-
q n
ing the needle. u This permitted examination of all the
cerebral vessels through one femoral arterial puncture in
the groin. The first catheters used were difficult to manoe-
vre so an important advance was the development of flexible,
steerable guidewires and catheters. Catheters now have
preshaped ends which aid positioning of the tip in the
artery of choice. Angiography via the femoral artery route,
has made cerebral angiography a much more practical tech¬
nique. In the presence of severe bilateral aorto-iliac
arterial disease precluding passage of a guidewire from
femoral puncture to the aortic arch, it may still be neces¬
sary to examine the carotid arteries by direct puncture or
by the brachial artery route retrogradely, but this is rare
in practice.
Originally angiogram x-rays were acquired onto a
series of rapidly exposed cut films at a rate of up to 4 per
second over a period of up to 15 seconds depending on the
rate of flow and whether venous as well as arterial images
were required. Manual subtraction of the angiogram film from
a masked film of the skull removed the bones leaving the
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contrast-filled vascular structures more clearly visible but
took up to twenty minutes per image. In the 1970's compute¬
rised x-ray image processing enabled electronic subtraction
which now has virtually replaced cut film angiography for
the cerebral and peripheral circulations. Known as digital
subtraction angiography (DSA), the x-ray image is taken via
the image intensifier into a digitised computer memory and
may be instantly subtracted and played back, to yield angio¬
graphic images within a few seconds of the contrast injec¬
tion. An added advantage is that smaller amounts of more
dilute contrast medium may be used for intra-arterial injec¬
tion, which may reduce the risk of the procedure without
reducing image quality. The contrast may also be injected
intravenously through a catheter with its tip near the
superior vena cava to show the aortic arch and cervical
portions of the carotid and vertebral arteries. Much larger
volumes of contrast are required for this and quality of the
images of the cervical and intracranial circulation is not
q i
usually sufficient for routine use. 1
1.3.2. Risks of cerebral angiography.
The high risk of cerebral angiography when first
introduced (from direct carotid puncture, toxic contrast
agents and general anaesthetic) meant that it was initially
used in the diagnosis of symptoms suggestive of cerebral
tumours and not for cerebral vascular disease. It was felt
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in the 1930's that as there was little that could be done
about cerebrovascular disease, investigating it was meddle-
9 0
some and dangerous. u However increasingly safe and practi¬
cal techniques meant that cerebral angiography could be used
more widely. As currently used, the risks of cerebral angi¬
ography are low but important. The risks are due to:
1) arterial puncture (dissection, disruption of plaque,
gangrene possibly leading to amputation of the leg or
death); 2) adverse reaction to the contrast agent; 3) damage
to the carotid or vertebral artery intima by the catheter
tip (dissection, displacement of atheroma or thrombus); and
4) careless injection of bubbles or particles into the
cerebral circulation causing embolic stroke. The risk may be
highest in patients with ischaemic cerebrovascular disease,
who may have impaired cerebral circulation, more atheroma to
displace, tortuous cervical arteries making catheterisation
more difficult, and poor femoral arteries for access. Review
of the eight prospective and seven retrospective studies
from which it was possible to derive the complication rate
of conventional cerebral angiography in patients with mild
ischaemic cerebrovascular disease, showed a four percent
risk of TIA or minor stroke, and a one percent risk of
Q 9
permanent neurological deficit. * Mortality was less than
0.1%. Systemic complications were more frequent with in¬
travenous DSA, mainly due to the large volume of contrast
medium required. The complication rate was higher with inex-
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perienced angiographers, with increasing duration of the
procedure, and with increasing catheter manipulation. A
prospective study of the complication rate of cerebral
angiography in 200 consecutive patients with carotid ischae-
mi who had previously been screened with carotid Doppler
ultrasound (to exclude those with normal or minimally dis¬
eased arteries) found neurological complications in 10% : 5%
were TIAs, 1% were reversible and 6% were permanent neuro¬
logical deficits, and 1% died from stroke as a direct result
q -3
of cerebral angiography. J The incidence of angiographic
complications was greater in patients with more than 90%
stenosis and in those with persisting signs before angiogra¬
phy (p<0.001); it was also greater if performed by a senior
registrar rather than a consultant (p<0.005).
Despite this, cerebral angiography is still the key
and essential investigation in patients being considered for
carotid endarterectomy, following subarachnoid haemorrhage,
primary intracerebral haemorrhage, and to delineate tumour
circulation, as it is the only method currently available of
accurately showing the arterial pathology.
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1.3.3 Angiography in ischaemic cerebrovascular disease
Angiography was the first means of examining the
cerebral circulation during life in stroke patients. It
enabled study of the cerebral arterial pathology soon after
symptom onset and sequentially, rather than days or weeks
later as with post mortem. Angiography has helped clarify
several points of confusion which had arisen through patho¬
logical studies: 1) the apparent lack of a strong associa¬
tion between arterial occlusion and stroke; 2) stroke symp¬
toms and the site of arterial occlusion; 3) that ICA occlu¬
sion is compatible with life and may be asymptomatic; 4) the
importance of collateral arterial circulation; 5) the dynam¬
ic nature of cerebral arterial occlusion; and 6) it has
helped to define aetiology for example the role of carotid
atheroma. For all that, angiography has not been widely used
in acute ischaemic stroke, as there was so little to offer
the patient therapeutically. It has been more widely used as
a prelude to carotid surgery.
The first report of ICA occlusion demonstrated by
cerebral angiography was that of Sjoqvist in 1936. 9® In 1937
Moniz reported four cases of ICA occlusion in which the
diagnosis was made by arteriography.9® Advances in surgical
and anaesthetic techniques combined with increasing under¬
standing of the relationship between carotid atheroma and




In the early 1950's the first true attempts at carot¬
id endarterectomy took place in France and in the United
States preceeded by angiography to delineate the arterial
lesions. Endarterectomy quickly became both controversial
i o
and popular. The first objective attempt to assess the
value of carotid endarterectomy, the Joint Study of Extra¬
cranial Arterial Occlusion, ran from 1959 until 1970 (total
6,535 patients) but random allocation to surgical or medical
treatment only started in 1961. At that time surgical mor-
Q A
tality was high and overshadowed the potential benefits.
However the data on 6,535 patients produced detailed demo¬
graphic information, described arteriographic techniques,
Q c:
sites, and complications; delineated racial differences in
the clinical and arteriographic manifestations of stroke;
confirmed risk factors for stroke; reported frequency dis¬
tribution and types of atherosclerotic lesions; and gave
specific accounts of various sub-groups of patients, ie
those having TIAs, subclavian steal syndrome, and ICA occlu¬
sion.
The boom in carotid artery surgery, continued until
in the mid 1980's carotid endarterectomy was one of the most
commonly performed operations in the United States and
Q 7
Canada. Fortunately increasing scepticism about its bene¬
fit led investigators to start randomised trials of carotid
endarterectomy for symptomatic carotid stenosis: the Euro¬
pean Carotid Surgery Trial (ECST) began in 19814; the United
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States Veterans Administration Trial began in 1982; the North
Q 1
American Symptomatic Carotid Endarterectomy Trial (NASCET)J
began in the late 1980's and two trials of endarterectomy in
asymptomatic patients are ongoing. Both the ECST and NASCET
interim results showed that endarterectomy was better than
best medical therapy alone in reducing the risk of stroke in
patients with symptomatic carotid stenosis (> 70%) provided
that the surgical morbidity was low. The best treatment for
patients with less than 70% but greater than 30% stenosis is
not yet known and both trials are continuing to randomise
those patients.
Close analysis of the angiograms from patients en¬
tered in the ECST and NASCET trials will provide important
data on different types of carotid lesion, their angiograph¬
ic appearance and stroke risk. At present the association
between plaque ulceration and the appearance of the lesion
o c 07 q o
on angiography is known to be poor. ' ' The most impor¬
tant predictor of completed stroke is the degree of steno-
sis.^'37,98 T^e presence of ulceration (visible angio-
graphically) has not yet been proven to increase stroke
risk.
Despite all this it is still not possible to predict
reliably which patients with ICA stenosis are at high risk
q q
of stroke. J Similarly it is not possible to predict reli¬
ably the patient's response to ICA occlusion, which may
occur "silently" or be preceeded by warning TIA's or precip-
68
itate minor or major hemispheric stroke. Spontaneous reca-
nalisation of ICA occlusion has been documented by serial
angiography in a few patients.41 It is unclear how often ICA
occlusions recanalise, but it is probably infrequent. This
is yet another example of the dynamic nature of the athero-
thrombotic process, being subject to the balance of throm¬
botic and antithrombotic agents in the blood and arterial
wall, as well as pharmacological agents.
Relatively few studies have been done using angiogra¬
phy in the acute phase of ischaemic stroke, yet they have
provided important information. Those in the 1950s and 1960s
were more concerned with the extracranial cerebral circula¬
tion prior to endarterectomy. Several autopsy studies be¬
tween 1920 and 1960 in patients dying after all severities
of acute ischaemic stroke showed only one-half or less of
all cerebral infarcts had a relevant arterial occlusion.
However, Adams and Fisher in a post mortem study of patients
with recent large cerebral infarcts in 1961 found 90-95%
were caused by thromboembolic occlusions.1^1 Jorgensen and
Torvik1^0 also found thromboembolic occlusion could be
demonstrated in 89% of all recent (up to one and a half
months) large infarcts at post mortem. In patients with
small cortical infarcts, Winter and Gyori1®2 found thrombot¬
ic or embolic occlusion of the supplying artery in 16 of 21
cases. Part of the difficulty in demonstrating a relevant
arterial occlusion, even in a recent infarct, at post mortem
69
may be due to rapid spontaneous lysis of the occluding
thrombus. Small infarcts require meticulous dissection to
identify the supplying artery and examine it for thrombus.
Patients with cerebral infarcts, particularly those with
small ones, tend to die weeks or even months after the event
by which time the arterial pathology may have changed. Post
mortem studies are also biased towards hospital-admitted
patients who tend to have larger infarcts or intracerebral
haemorrhage as the cause of symptoms. Patients with small
infarcts (and less disability) may never be admitted to
hospital^® and are absent from many post mortem studies."*"®®
Angiography soon after symptom onset should give a
more accurate indication of the number of ischaemic strokes
due to embolic or thrombotic arterial occlusion. Early
reports of angiography in acute ischaemic stroke suggested
that it was fairly common to find normal looking arteries in
the symptomatic territories ."*"®^ ' ^®^ ' "*"®5 This may have been
the result of : lysis of occluding thrombus; significant
time delay between onset of symptoms and angiography; fail¬
ure to differentiate cortical from lacunar and brainstem
infarction (in the latter two, demonstration of an occluded
perforating artery angiographically is virtually impossible,
and small posterior fossa arterial occlusions may be diffi¬
cult to identify also, giving the impression of normal
arteries); failure to differentiate cerebral infarction from
intracerebral haemorrhage (which would have been associated
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with normal angiograms if small); or difficulty in identify¬
ing occlusion of small peripheral MCA branches due to tortu¬
osity and overlap, and led to hypotheses such as arterial
spasm or sudden falls in systemic blood pressure being the
cause of the stroke rather than acute arterial occlusion.
While thrombotic occlusion of the ICA in the neck was well
recognised, it was increasingly suggested that atheroscle¬
rotic occlusive thrombosis in the MCA was quite rare,^®
particularly in persons of European origin. MCA stenosis has
10 7 10 ft
been reported in Western populations ' albeit less
frequently than it is reported in persons of oriental ori-
1 0 Q
gin. Most of the post mortem and angiogram studies re¬
ferred to in this chapter have assumed that it is possible
to differentiate between in situ thrombosis, embolus, and
stenosis by the appearance of the occlusion. This may not be
correct. It should perhaps be remembered when reading the
following that we do not really know how many intracerebral
arterial occlusions are embolic (artery to artery, or car-
dio-embolic) and how many thrombotic.
In many of the early reports of cerebral infarction
with no arterial occlusion at post mortem or angiography,
there was evidence of a cardiac or arterial source of embo¬
lism.11®-114 In fact the frequently normal intracranial
circulation in patients with acute ischaemic stroke led to
claims that that the clinical diagnosis of embolism must
have been wrong 104/105 and that the stroke must have re-
?1
suited from hypotension or other transient cause of poor
cerebral perfusion.
However there followed a series of reports of lysis
and migration of emboli demonstrated on angiography. Gannon
lie
in 1962 reported a patient with angiographically demon¬
strated occlusion of the MCA two weeks after symptom onset
in whom a second angiogram two weeks later showed a normal
MCA. Hollin and Silverstein in reported four pa¬
tients with angiographically demonstrated occlusion of the
main trunk of the MCA within three days of symptom onset. On
subsequent angiography or post mortem examination all were
found to have patent MCAs. They pointed out that :
the finding of a patent vessel after previous angiographi¬
cally demonstrated occlusion cannot be used as definite
evidence of a beneficial effect from thrombolytic or other
therapies.
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Zats et al in 1965 reported four patients with MCA
occlusions demonstrated by angiography within 24 hours of
symptom onset in whom repeat angiography 24 hours later
showed clearing of the occlusion with no underlying stenosis
or vessel roughening. Two of the patients had received
fibrinolysin but the other two had received placebo. Dalai
1 1 O
et al in 1965 described nine patients with acute ischaem-
ic stroke and a cardiac source of embolism, in whom early
angiography demonstrated appropriate MCA occlusion, which on
follow up was found to have cleared. In some patients,
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clearing of the occlusion was observed only minutes after the
initial angiogram films, the lysis occurring spontaneously.
Dalai went on to describe a prospective study of angiography
in 26 consecutive patients with presumed cardio-embolic
acute ischaemic stroke (their exact neurological findings
1 1 Q
were not stated). Twenty of the twenty-six patients had
percutaneous cerebral angiography within six hours of the
onset of symptoms, and seventeen had a second angiogram
within a hundred hours of symptom onset. Twelve patients had
MCA occlusion, four had ICA occlusion, one a PCA occlusion,
and three patients had normal angiograms. On the second
angiogram or post mortem (three patients), eight MCA occlu¬
sions had returned to normal, the occlusive lesion was
unaltered in nine (including the ICA and PCA lesions), and
the three normal angiograms were still normal.
ion
Allcock in 1966 reported 40 patients with presumed
cardio-embolic stroke due to MCA occlusion. All had angiog¬
raphy soon after symptom onset (exact timing not stated) and
documented occlusion or severe stenosis of the MCA. Ten
patients had repeat angiography : in five the previously
occluded MCAs appeared normal; in three there had been some
improvement in MCA patency; and in only two were the appear¬
ances unchanged.
19 1
Taveras et al in 1969 found occluded intracranial
arteries in 19 of 40 patients with acute presumed ischaemic
stroke (time not stated). Only three patients had normal
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cerebral arteries. The other 18 had capillary blush or early
venous filling, or mass effect consistent with infarction
(or a primary intracerebral haemorrhage) without occlusion
of the territorial artery being demonstrated.
19 9
Fieschi and Bozzao in 1969 reported 100 patients
with clinical evidence of a "major" stroke in the previous
24 hours who had angiography within three days of symptom
onset. Ten patients had presumed cerebral haemorrhage as the
cause of stroke (clinical or post mortem diagnosis). Of the
remaining diagnosed (most clinically and a few at post
mortem) as ischaemic strokes, 57% had complete arterial
occlusion in the neck or the intracranial ICA and its
branches. In the remaining patients angiography showed
localised or diffuse arterial stenosis without occlusion
(site not stated). Repeat angiography or post mortem showed
that the MCA had recanalised in eight patients and the
distal ICA in two patients.
In more recent studies of acute ischaemic stroke, the
angiography has been performed sooner after symptom onset.
Solis and coworkers^4 studied 104 consecutive patients
admitted with acute stroke, and found appropriate cerebral
arterial occlusions on angiography within 24 hours of symp¬
tom onset in 93% with a final diagnosis of ischaemic stroke
(using CT scanning to exclude cerebral haemorrhage). Several
studies have confirmed the high spontaneous lysis rate
following intracerebral arterial, presumed embolic, occlu-
74
1 o o
sion. Mohr et al in 1978 J described cerebral angiography
in 106 of the 215 patients with presumed cerebral embolism
(cardio- or artery-to-artery embolus) studied in the Harvard
Cooperative Stroke Registry, a hospital based study. In 88
patients with complete angiograms, 52 (60%) had arterial
occlusion in the clinically affected territory and eleven of
these had additional findings of stenosis, plaque or occlu¬
sion of the ipsilateral ICA. In the 36 (45%) patients with¬
out arterial occlusion, 22 (25%) showed atheromatous plaque
in the ICA ipsilateral to the infarct, one had an early
draining vein, one had an aneurysm, and twelve had normal
angiograms. Seventy three percent of angiograms done within
two days of stroke were positive for arterial occlusion,
compared with only 28% performed after the second day. They
also noted that there were no significant clinical differ¬
ences between the 52 patients with arterial occlusion and
the 36 patients without with respect to speed of onset,
occurrence of coma, aphasia, seizures, infarction of any
single cerebral lobe, clinical severity, or death in the
hospital, and suggested that the lower incidence of arterial
occlusion in the patients examined after 48 hours was due to
spontaneous lysis of the occluding thrombus.
19 4
Olsen et al in 1985 reported a prospective study
of consecutive acute ischaemic (CT confirmed) stroke pa¬
tients below the age of 75 years admitted to hospital within
three days of symptom onset. 40% had MCA occlusion, 12% had
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ICA occlusion, 14% had severe ICA stenosis (of whom half
were associated with MCA occlusion) and 41% were without
significant MCA/ICA lesions (most of these were considered
to be due to lacunes). This emphasised, with the Harvard Co¬
operative Stroke Registry, the importance of timing of
angiography. Olsen et al had performed CT brain scans on all
their patients and found that large infarcts on CT were
always associated with MCA occlusion or a significant ICA
lesion. In patients with medium sized infarcts on CT, 80%
had a significant ICA or MCA lesion. In patients with a
small or no infarct on CT, MCA occlusion or ICA stenosis
were present in only 11%. They also suggested that the
frequency of presumed thrombotic MCA occlusion was low,
(probably no more than 10% to 20% of MCA occlusions), while
the majority were probably embolic in origin because an
arterial or cardiac source of embolus was found. Eight
patients with MCA occlusion had a post mortem, and in seven
the MCA was patent. They did not routinely repeat the angio¬
gram. ICA occlusion was considered to be due to thrombosis
superimposed on atheromatous stenosis (based on post mortem
or endarterectomy findings in a few patients) and did not
recanalise.
IOC
Fieschi et al in 1989 J reported the results of
angiography in 80 patients with acute ischemic stroke in the
MCA territory studied within six hours of symptom onset.
Although they included patients with large artery territory
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as well as lacunar infarcts, they found that early angiogra¬
phy revealed cerebral arterial occlusion in 76% (66% were
intracranial), and of patients who had repeat angiography
(or transcranial Doppler ultrasound) within 1 week, 70% of
the MCA occlusions had disappeared. Potential embolic
sources, (cardiac or carotid atheroma) were found in more
than 80% of patients. They also commented that patients with
documented intracranial occlusion and scarce or absent
collateral filling at early angiography had the worst clini¬
cal outcome.
The studies of angiography early after onset of acute
ischaemic stroke are summarised in Figure 1.3.1. The earlier
studies tended not to differentiate stroke by clinical
syndrome (ie cortical or lacunar, carotid or vertebrobasilar
territory), and were unable to differentiate cerebral in¬
farction from haemorrhage. Some of the recent studies did
not exclude (or even differentiate) lacunar infarction.
Angiography was not repeated routinely in any of the stud-
IOC
ies, although the study by Fieschi et al J used transcra¬
nial Doppler ultrasound to monitor arterial patency in all
the patients. Of the recent studies, angiography performed
within two days of onset showed occlusion in 76 to 85% of
patients in the ICA or large intracranial branches. Of the
patients who had repeat angiography or post mortem, 13 to
28% had persistent arterial occlusion at about one week
after stroke onset and the remainder had recanalised. Some
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patients died before a second angiogram could be performed
and did not have a post mortem. Therefore none of these
studies gives a really true idea of recanalisation rate, but
taken together, they suggest that around 80% of large is-
chaemic strokes will have an arterial occlusion demonstrable
on angiography performed within 24 hours of stroke onset,
but by the end of one week only in about 25% will the artery
still be occluded. Recanalisation may depend on the site and
nature of the occlusion. MCA occlusions seem to recanalise
frequently and quickly, whereas ICA occlusions seem to
recanalise less frequently, possibly simply as a result of
the larger bulk of clot in the latter. The efficacy of
treatments such as streptokinase, intended to quicken throm¬
bus lysis, must be measured against the spontaneous lysis
rate, and not tested in uncontrolled trials.
Further support for the embolic nature of acute
ischaemic stroke in the West comes from Gacs et al.126 They
studied the spontaneous pathway of a tiny balloon on the end
of a very floppy catheter, introduced into the ICA in 42
patients being investigated for cerebrovascular disease. The
most frequent sites of lodgement of the balloon were the MCA
trifurcation, the angular artery branch, and the MCA main
stem corresponding very closely with the distribution of
spontaneous, presumed embolic, occlusions (Figure 1.3.2).
From this work they were also able to concluded that many
TIAs are probably due to transient embolic occlusion of
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large intracranial arteries. While this may provide circum¬
stantial support for the role of emboli, it must be remem¬
bered that the MCAs are the largest, most constant, of the
basal intracranial arteries, with the most branches supply¬
ing the largest territories. Occlusion of the MCA or its
branches is probably noticed more frequently by patients
than PCA or ACA occlusions, therefore Gacs's work does not
exclude the possibility that some intracerebral arterial
occlusions are thrombotic.
The concept that embolic occlusion of the intracrani¬
al arteries is more common than thrombotic occlusion in
Western peoples has probably arisen partly because of the
apparently normal appearance of the underlying artery once
the occlusion has lysed (plus patient selection bias), al
though atheroma is very common in the intracranial circula¬
tion on angiography for other reasons, such as following
subarachnoid haemorrhage or in the investigation of cerebral
tumours (personal observation), and even at post mortem the
distinction between embolic and thrombotic occlusion may be
difficult. Whatever the truth in Westerners, thrombotic MCA
occlusion is considered to be more common in Oriental and
i n Q i ? ^
Negro peoples. This may be because, certainly in
Oriental peoples, the frequency of cervical carotid atheroma
1 f) Q
is less, therefore other risk factors come to the fore.
It may also reflect differences in the method of diagnosis,
pathological techniques, etc, so these statements about the
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relative importance of embolic/thrombotic occlusion must be
regarded with caution.
In addition to the actual arterial occlusion, other
secondary features of arterial occlusion may be seen with
19 1
angiography. Taveras et al witnessed the effect of an
accidental embolic event during angiography (needle frag¬
ment) and described vasodilatation of arteries distal to the
embolus, and early venous filling in the occluded artery's
territory which occurred very rapidly following cerebral
arterial occlusion. The patient remained asymptomatic de¬
spite involvement of a moderate sized part of the parietal
cortex, illustrating that intracranial artery occlusion may
be asymptomatic. Other secondary features of cerebral artery
occlusion include arteriolar-capillary block (resulting in
an extremely prolonged arterial phase on angiography thought
to be due to occlusion of the capillary bed) ; mass effect
causing displacement of arteries ; arterial vasodilatation
which may still be observed after re-opening of the occluded
vessel and may be the only sign of previous vessel occlusion
(thought to occur due to metabolic abnormalities) ; and
finally lengthening of the circulation time in the whole of
191
the affected hemisphere (longer than 6 seconds). J"£lx Irino et
19 7
al described similar findings and in addition arterial
narrowing (localised or widespread narrowing of the arterial
calibre in the ACA or MCA perhaps due to spasm), capillary
blush (similar to early venous filling), residual stenosis
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(irregular and somewhat stenotic arterial lumen at the ini¬
tially occluded point). This last could be observed during
re-canalization of the artery and was not necessarily indic¬
ative of underlying atheroma.
1.3.4 Concluding comments.
Cerebral angiography has been infrequently performed
in acute ischaemic stroke because of the lack of any therapy
which it might influence, and its associated risks. The few
studies which have been done have documented a high rate of
occlusion of large intracranial arteries in patients with
major ischaemic strokes studied within a few days of onset
and, as suspected from post mortem studies, the occlusion
may lyse spontaneously and quickly. There are no large
series of patients who have had serial angiography in all
cases after an MCA/ICA ischaemic stroke, but it is likely
that up to 80% of MCA occlusions will have recanalised by
one week after onset, and few ICA occlusions.
It is generally accepted that many large intracranial
artery occlusions are embolic in Western peoples (cardio or
artery-to-artery embolus), although the evidence to support
this is somewhat circumstantial.
It is unlikely that angiography will be used more
frequently in acute ischaemic stroke, but it is still essen-
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tial for patients being considered for carotid endarterecto-
my. A large amount of angiography data has been generated by
the European and North American symptomatic carotid endart-
erectomy trials which will be closely studied to try to
improve understanding of the relationship between angio¬
graphic appearance of the stenosis, risk of completed
stroke, and appearance at carotid endarterectomy.
Although ultrasound and magnetic resonance angiogra¬
phy are improving, angiography is likely to remain the "gold
standard" for demonstrating cerebral arterial disease in the
immediate future. Improved radiographic contrast media,
properties of catheters, guidewires, and radiographic equip¬
ment mean that the risks of cerebral angiography are low but
still serious. It is important to try to find other means of
identifying arterial pathology which are more practical,
easier, cheaper and repeatable in acute ischaemic stroke.
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Summary of Chapter Three
1. Cerebral angiography with modern equipment carries a four
percent risk of transient neurological deficit, and a one
percent risk of permanent neurological deficit in patients
being investigated for mild ischaemic cerebrovascular dis¬
ease prior to carotid endarterectomy.
2. Angiography allowing visualisation of the carotid arter¬
ies spurred the development of carotid surgery to prevent
major strokes.
3. Information gained from angiography in acute ischaemic
stroke patients showed that intracranial arterial occlusion
was frequent when performed within the first few days of
stroke onset.
4. Spontaneous lysis of the arterial occlusion was observed
on angiography in the 1960s and 1970s.
5. More recent angiographic studies in acute ischaemic
stroke have confirmed the earlier studies.
6. It is generally considered that emboli are a frequent
cause of acute ischemic stroke in Western populations
(cardio- or artery-to-artery emboli).
7. Thrombosis is considered to be a common cause of ICA
occlusion in the same population.
8. Spontaneous lysis of cerebral artery occlusions occurs
(up to 20% at 24 hours and 80% at 1 week). This must be
taken into account in the design of any therapy trials.
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Recanalisation rate of occluded cerebral arteries on angiography in acute ischaemic stroke
Figure 1.3.1 Estimated Recanalisation Rate of Occluded
Cerebral Arteries Following Acute Ischaemic Stroke - Data
pooled from all published studies which have performed
initial and follow up angiography or (transcranial Doppler
ultrasound) on patients within a few days of onset of acute
ischaemic stroke. Dalai (119), Allcock (120), Fieschi
(122), Mohr (123), 01sen(124), Fieschi (125). Note that none
of the studies performed follow up angiograms on all their
patients.
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Figure 1.3.2 Distribution of Arterial Occlusions in the
Middle and Anterior Cerebral Arteries Compared with the
Distribution of Artificial Emboli, from Gacs et al 1982.
(126) Upper numbers = percent distribution of artificial
emboli (tiny balloon on a thin catheter "floated" into the
internal carotid artery), lower numbers = percent distribu¬
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1.4.1 Introduction
Transcranial Doppler ultrasound (TCD) was developed
by Rune Aaslid in the early 1980s as a non-invasive method
of indirectly assessing cerebral blood flow and arterial
pathology by measuring blood velocity in the basal intracra-
1 OO
nial arteries. ° He designed a small, mobile ultrasound
machine which produced a spectral waveform of the Doppler
blood velocity but without simultaneous B mode imaging. In
children it has been possible for several years to obtain
simultaneous B mode and spectral Doppler ultrasound images
of the brain through the anterior or posterior fontanelle,
using standard 5 to 10 MHz general radiology Doppler ultra¬
sound machines. This was not possible in adults because the
thickness of the skull prevented transmission of the ultra¬
sound beam. Recently low frequency, high power output ultra¬
sound probes have been developed allowing colour flow Dop¬
pler imaging of the brain in adults using general radiology
1 9 Q
ultrasound machines. J Colour flow TCD is an exciting
development combining a grey scale B mode image of the brain
with colour flow Doppler images of the basal intracranial
arteries superimposed, but is still in the early stages of
development. The work for this thesis was done using a
small, mobile, spectral TCD machine similar to that origi¬
nally developed by Aaslid, so the following discussion will
refer to spectral TCD except where indicated otherwise.
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Spectral TCD equipment, because of its mobility, can
be used at the patient's bedside as well as in the clinic.
TCD has provided insights into acute cerebrovascular disease
because it is unique among cerebrovascular imaging tools in
being mobile and costing less than £30000. It is feasible to
study the patient very quickly after onset of symptoms, and
lack of patient cooperation is not generally a problem
unless it is extreme. This contrasts with all the other
cerebrovascular imaging tools, (including CT scanning) which
require the patient to keep still for at least ten seconds
at a time (usually much longer - 20 minutes), are immobile,
and, with the possible exception of a simple gamma camera,
cost in excess of £500000. In this chapter the technique of
TCD, problems with interpretation of results, its sensitivi¬
ty and specificity in acute ischaemic stroke, and the useful
information which it has provided thus far will be dis¬
cussed.
1.4.2 Technique and methodology of TCD
TCD uses the Doppler principle to measure blood
velocity in the basal intracranial arteries - MCA, ACA, PCA,
basilar artery and intracranial ICA. Ultrasound measurement
of blood velocity by the Doppler principle uses the differ¬
ence between the frequency of the emitted sound beam and the
returning sound beam reflected off the moving red blood
cells to calculate the blood velocity taking account of the
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angle of incidence of the beam to the moving column of
blood. Moment to moment velocity is calculated by a fast
Fourier transform technique to yield a constant signal
output which gives "instantaneous" measures of blood veloci-
i T n
ty. Using a "pulsed" ultrasound output, the depth of re
cording can be adjusted to sample individual points along
the length of a vessel. Standard spectral TCD equipment, as
developed by Aaslid, allows sampling at five mm
1 *3 1
intervals.
Doppler shift frequency dF = 2 Fe. v. cos A / c
where Fe = emitted ultrasound frequency
v = calculated velocity from Doppler shift
A = angle of insonation of ultrasound beam to
artery or vein
c = velocity of sound in the body
(= 1540 ms_1 for practical purposes)
The Doppler shift can be expressed in KHz, or in cms-1 if
the angle of insonation is known. As the Doppler frequency
shift depends on the angle of the ultrasound beam to the
moving blood, absolute velocity may not be the same as
perceived velocity if the angle of incidence is not known.
If the angle of insonation is 0 - 30 degrees, its cosine
will be 1 to 0.86, incurring a maximum difference of less
than 15% between absolute and perceived velocities. However
if the angle is greater than 30 degrees, considerable errors
may result from velocity readings which are much lower (or
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much higher) than reality. In extracranial duplex Doppler
ultrasound, where the vessel is imaged (B mode) simultane¬
ously with the spectral Doppler waveform, the angle of
insonation can be measured exactly, but in spectral TCD
there is only the Doppler signal, so it is assumed that the
artery is running parallel to the ultrasound beam so that
the angle of incidence of the beam to the vessel is no more
1 ? ft
than 30 degrees. ° This may not be valid, as the basal
intracranial arteries may be tortuous. Limited experience
with colour flow TCD has already suggested that the angle of
incidence of the ultrasound beam to the MCA is often greater
than 0-30 degrees therefore the absolute blood velocity in
the MCA is likely to be higher than the perceived
13 9
velocityon the other hand, the normal range of blood
velocities found with spectral TCD has been established from
study of large numbers of "normal" subjects, and is likely
to include a wide range of different degrees of arterial
tortuosity.128'133'134'135'136
TCD uses a 2 MHz ultrasound probe and a much higher
power output than is used for ultrasound of soft tissues.
These modifications are necessary for transmission of the
ultrasound beam through the skull bones. There are only
certain parts of the skull which are sufficiently trans-
sonic for ultrasound access. These "windows" to the cerebral
vessels are the temporal bone, where there is usually a
sufficiently thin area just above the zygomatic arch, the
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orbit, and the foramen magnum (Figure 1.4.1). The power
output must be reduced to 10% of that used for trans-tempo¬
ral imaging when using the orbital window, to prevent damage
to the eye. Standard adult TCD equipment should not be used
in children; their thinner skulls allow greater ultrasound
penetration and there is a theoretical risk of damage to the
brain from the high power output.
The MCAs, ACAs, and PCAs may be insonated through the
temporal window. The Ml and M2 segments of the MCA are
assumed to run directly towards the probe, and the A1 seg¬
ment of the ACA directly away, hopefully optimising the
angle of insonation for velocity measurements. However the
intracranial arteries are frequently tortuous, particularly
in the elderly, which may invalidate these assumptions.
i o q i -3 7
, Colour-flow TCD has shown even in limited series
that angles of insonation to the MCA of up to 50 degrees are
1 TO
common. " Generally it is necessary to move the probe over
the temporal region and adjust the probe angle until the
"best" signal at the required depth is obtained, "best"
being highest velocity and most intense signal, and this is
assumed to be the closest to an angle of incidence of zero.
The ICA siphon, ACA, and opthalmic arteries are insonated
through the orbit, the basilar artery through the foramen
magnum, and the vertebral arteries through the foramen
magnum or in the upper neck behind the mastoid process.
TCD is very operator dependant, and although an
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experienced operator may take only ten minutes to complete a
study in a cooperative patient, in a restless and confused
patient it can take longer than half an hour to obtain
satisfactory signals from all the basal intracranial arter¬
ies .
1.4.3 Interpretation of the TCD result.
Normal values for blood velocity in the MCAs, ACAs,
PCAs and ICAs have been established: peak systolic and mean
velocity, and the pulsatility index. The mean velocity may
be expressed in different ways, for example the "time-mean"
velocity is calculated from the outline of the spectral
display and is the mean velocity during one cardiac cycle,
19ft
not taking account of the density of Doppler frequencies.
The "spatial-mean" velocity is more complex and is the
average Doppler velocity weighted by the spectral density;
that is, the relative intensity of the Doppler signal at
each velocity. In TCD it is impossible to know what the
sample volume encloses as the artery cannot be imaged, and
the signal to noise ratio is poor, so the most practical
Doppler reading of velocity is that of the spectral envelope
or outline, ie time-mean velocity. The "time-mean" velocity
will be used in this thesis unless otherwise stated, as that
is what is calculated automatically by the EME TCD machine.
The pulsatility index (PI) may also be calculated in differ-
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ent ways and is a measure of cerebral arterial resistance. In
this thesis the PI used will be the peak systolic minus end
diastolic velocity/time mean velocity, as that is what is
calculated by the EME TCD machine. These are summarised in
Table 1. 4 . 1. ^^8, 133,134, 135,136
Cerebral arterial blood velocity declines with age
(Table 1.4.1). Note also that the velocities in the two MCAs
should not differ by more than 21%, the ACAs by 27%, and the
PCAs by 28% in normal subjects.^8 Serial TCD studies in
normal subjects have shown that the MCA, ACA, and PCA blood
velocities vary by less than 20% during the day, and between
days
In up to ten percent of subjects it is impossible to
obtain a satisfactory signal through the temporal bone
window because the bone is too thick (particularly in elder¬
ly females), or because the artery takes a very tortuous
course.1^®'1^1 In ten to twenty percent of normal individu¬
als one or other of the ACAs cannot be identified, and one
or other of the PCAs in twenty to thirty percent. This is
because of anatomic variants of the circle of Willis, vessel
tortuosity, and poor bone windows.'^3,142,143
Several other factors influence cerebral blood veloc¬
ity and must be taken into account when interpreting TCD.
The patient's PaC02144 is probably the most important varia¬
ble, as even minor changes may produce marked increase or
decrease in cerebral arterial blood velocity. Other factors
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which may affect velocity readings include haematocrit,145
patient posture,146 mental activity (eg eye opening when
recording from the PCA),147'14®'14^ intracranial
ICQ
pressure, and respiratory pattern (eg Cheyne-Stokes
respiration because of alterations in PaCC^)•
A final major problem with interpretation of the TCD
signal is illustrated in Figure 1.4.2 and is a problem for
Doppler studies of blood vessels anywhere in the body. The
Doppler signal is not just a reflection of vascular status
at the sampling point in the vessel (vessel diameter and
flow rate), but reflects factors up and down stream from the
sampling point. For example, vasodilatation of the pial
arteries as occurs with hypercapnia causes increased blood
velocity in the MCA Ml segment without any change in the
calibre of the Ml segment itself. An ICA occlusion in the
neck might result in reduced blood velocity recorded from
the ipsilateral Ml segment without any abnormality of the Ml
segment itself. In Figure 1.4.2, three possible Doppler
signals which might be obtained proximal to an occlusion at
the origin of the first main branch of the MCA are illus¬
trated. The recording from the asymptomatic MCA is shown for
comparison. The Doppler velocity in the symptomatic MCA
might be reduced, or the same as, or increased compared with
the asymptomatic MCA blood velocity, depending on the rela¬
tive contribution of increased flow though the patent branch
to collaterals. If the flow in the patent branch was the
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same as it had been before the embolic occlusion, then only
half of the original pre-occlusion amount of blood would be
flowing through the Ml after the occlusion, so the Doppler
signal would be reduced. If the patent branch supplied some
collaterals (resulting in increased flow in the patent
branch compared with the pre-occlusion state) then the
increase in flow might be sufficient to keep the flow in the
Ml the same as it was prior to the occlusion. This would
mislead the investigator to think that the symptomatic MCA
was "normal". If the patent branch supplied lots of collat¬
erals, then it might be possible to have increased flow in
the Ml after the occlusion compared with the pre-occlusion
flow, causing a higher blood velocity than on the asympto¬
matic side. There is no way of knowing, on an isolated
measurement, which of these is occurring. Serial measure¬
ments to chart the change in blood velocity with time is one
possible way of sorting this out, but retrospectively. A
similar problem arises when trying to decide whether in¬
creased velocity in the symptomatic artery is due to spasm
or hyperaemia in patients with a head injury or subarachnoid
haemorrhage. In these situations, reduced PI tends to indi¬
cate hyperaemia, and increased (or less reduced) PI spasm,
but the relationship between the two is still being evaluat¬
ed.151'152
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1.4.4 Studies of acute ischaemic stroke using transcranial
Doppler ultrasound
Several studies have been published concerning the
use of TCD in acute ischaemic stroke. Mattle et al in
1 C "3
1988 compared TCD findings with conventional intraarte¬
rial angiography in 61 patients with MCA territory TIAs,
minor and major ischaemic strokes and 535 healthy subjects.
Patients had MCA main stem occlusion, branch occlusion, or
MCA stenosis as judged by CT, angiographic and autopsy
findings. The TCD and angiogram examinations were performed
over a wide range of time intervals up to one year (TCD a
mean of 32 days and angiography a mean of 53 days) after
symptom onset. They found that patients with MCA main stem
occlusion had a substantial reduction in MCA blood velocity
compared with the asymptomatic MCA, and increased velocity
in the ipsilateral ACA (to supply collaterals to the MCA
territory). The reduction in symptomatic MCA blood velocity
was much greater if there was ipsilateral ICA disease also.
MCA branch occlusion caused a minor reduction in blood
velocity. In all three situations the symptomatic MCA blood
velocity values showed a wide standard deviation.
1 TO
Zanette et al JO compared intra-arterial digital
subtraction angiography and TCD in 39 patients within four
hours of onset of acute ischaemic stroke in the MCA territo¬
ry. The symptomatic MCA blood velocity was least in MCA
origin or main stem occlusion, with or without ICA occlu-
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sion. The symptomatic MCA blood velocity was less reduced or
normal if only an MCA branch was occluded. They found in¬
creased velocity in the ipsilateral ACA in one third of
patients, implying collateral supply to the ischaemic MCA
territory. Zanette et al devised the "asymmetry index" for
blood velocity in the symptomatic and asymptomatic MCAs
based on these findings. Asymmetry of the MCA blood veloci¬
ties of greater than 21%, of the ACA of greater than 27%,
and the PCAs of greater than 28% was indicative of proximal
artery occlusion.
1 1:4
Kaps et al evaluated TCD against angiography in 23
patients within 24 hours of acute MCA occlusion. TCD was
most suggestive of MCA occlusion when all ipsilateral basal
arteries except the MCA were detected. Increased blood
velocity in the ipsilateral ACA was useful corroborative
evidence of MCA occlusion (proportion of patients not stat¬
ed) . Frequent follow up TCD examinations revealed evidence
of reperfusion (symptomatic MCA blood velocity becoming
detectable or increasing from the admission value) in 60% of
patients. The blood velocity was frequently normal in the
MCA main stem in MCA peripheral branch occlusions. In some
patients an increase in the symptomatic MCA blood velocity
(higher than that in the asymptomatic MCA) occurred a few
days after symptom onset, which when focal, was thought to
be due to a stenosis appearing during recanalisation, and
when diffuse, to hyperaemia.
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Three further studies confirm these findings. Ley-Pozo
ICC
and Ringelstein compared TCD with intra-arterial DSA in
133 consecutive hospital-admitted patients with MCA territo¬
ry ischaemic symptoms including TIAs. The time of each study
after symptom onset was not stated. They found good agreement
between TCD and angiographic evidence of stenosis and/or
occlusion in the carotid siphon and MCA. TCD had a sensitiv¬
ity of 92 (95% confidence interval (CI) 73-99) and specific¬
ity of 97 (95% CI 92-99) for detecting obstructive lesions
compared with angiography.
Kushner et al156 compared TCD with angiography in 42
acute ischaemic stroke patients within six hours of symptom
onset. Reduced MCA velocity was found in 21/21 patients with
proximal MCA occlusions but only 1/8 patients with peripher¬
al MCA branch occlusions. TCD showed normal MCA blood veloc¬
ity in 2/5, and absent MCA blood velocity in 3/5 patients
with ipsilateral ICA siphon stenosis but a patent MCA on
angiography. TCD was normal in all eight patients with
normal angiograms. 18/29 patients showed evidence of reca-
nalisation with increase in the symptomatic MCA blood veloc¬
ity on sequential examinations up to one week after symptom
onset.
1 c 7
Handa et al J compared TCD with angiography in 42
patients with cerebrovascular disease. TCD showed normal MCA
blood velocities in patients with normal angiograms, but
reduced blood velocity in patients with ipsilateral ICA
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siphon or MCA stenosis or occlusion, giving an accuracy of
87% for TCD for detecting occlusive lesions (including
stenoses) of the intracranial ICA and MCA.
Thus, reduced blood velocity in the symptomatic MCA
on TCD correlates well with MCA main stem or major branch
occlusion, or ICA siphon occlusion/stenosis, but may be
normal in small MCA branch occlusions. Recanalisation is
associated with an increase in blood velocity in the sympto¬
matic MCA to a value nearer to that on the asymptomatic
side. The symptomatic MCA blood velocity may rise above that
on the asymptomatic side if a stenosis develops at the point
of previous occlusion during recanalisation, resulting in a
focal, high, turbulent velocity in the MCA main stem. Hype-
raemia may also result in increased velocity in the MCA main
stem, usually more diffusely along the entire length of the
MCA recordable by TCD than in a focal stenosis, though it may
be difficult in some patients to distinguish between steno-
1 C4
sis and hyperaemia with TCD. J The effect of morphologic
changes in ischaemic tissue in the MCA territory, such as
oedema leading to hemispheric swelling, on the MCA blood
velocity and pulsatility have not been studied closely
enough to be certain what effect they would have. Focal
haematomas may displace the MCA from its normal insonation
position, and by stretching it may cause a focal velocity
increase (personal observation).
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1.4.5 Studies of chronic ischaemic cerebrovascular disease
using Transcranial Doppler.
In the diagnosis of chronic intracranial arterial
disease, Spencer and Whisler studied 300 patients presenting
with TIA, minor stroke or dizziness and found a sensitivity
of 73% and specificity of 95% for detection of significant
stenosis or occlusion of the ICA siphon and MCA main stem
(compared with conventional angiography)."'"^®
ICQ
Lindegaard et al compared TCD with angiography in
eleven patients with intracranial ICA and MCA stenoses and
found a clear inverse relationship between residual lumen
diameter on angiography and Doppler flow velocity. Focal
stenosis caused a localised high velocity jet with turbu¬
lence, and distally a reduced and damped velocity waveform.
Grolimund et al compared TCD with angiography in 95
patients with TIA and minor stroke and found TCD had a
sensitivity of 91% and a positive predictive value of 94%
for detecting intracranial ICA and MCA stenoses and occlu¬
sions."'"^"'" They also found that TCD was able to detect with
an accuracy of 94%, collateral flow over the Circle of
Willis in the anterior communicating artery, and of 88% in
the posterior communicating arteries.
Hennerici et al found good correlation between TCD
and angiography for detecting stenoses of 80% or more in the
basal intracranial arteries in 39 patients with TIA or minor
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stroke.160 They were also able to identify collateral arte¬
rial pathways such as reversed flow in the ACA ipsilateral
to an ICA occlusion, reversed flow in the MCA peripheral to
an MCA main stem occlusion, and flow from the basilar artery
to the distal ICA through the posterior communicating artery
in proximal ICA occlusion.
Evaluation of the vertebrobasilar arteries with TCD
is less reliable for detecting stenoses and occlusions.
Firstly it is more difficult to detect the PCAs,
128, 133, 134, 135 ancj there is more variation of normal in the
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posterior circulation anatomy.'*''J Mull et al found TCD was
unreliable for diagnosing significant vertebral or basilar
artery stenosis or occlusion (compared with angiography) in
37 patients with vertebrobasilar TIAs and ischaemic strokes.
They were unable even to identify the proximal basilar
artery in 30% of patients.161
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1.4.6 Use of Transcranial Doppler Ultrasound in other intra¬
cranial diseases
TCD has been used to assess the intracranial arteries
in diseases other than ischaemic stroke, such as:
a) the diagnosis of vasospasm following subarachnoid haemor¬
rhage,
b) identification of the feeding arteries of arteriovenous
malformations and monitoring the haemodynamic effects of
their treatment,
1 S D
c) confirmation of the clinical diagnosis of brain death
d) intensive care unit monitoring of brain-injured
patients,
d) intraoperative and post operative monitoring of neurosur¬
gical patients,
e) intraoperative monitoring of patients undergoing carotid
endarterectomy to detect cerebral emboli,
f) investigation for patent foramen ovale in young patients
with acute ischaemic stroke of probable embolic origin,
and,
g) detection of emboli of cardiac and possibly atheromatous
origin in the cerebral arteries.
Despite this, TCD remains largely a research tool,
albeit an extremely useful one.^7 This is particularly
true in acute ischaemic stroke, because as yet, there is no




TCD is a useful research tool in acute ischaemic
stroke to study patterns of arterial occlusion. Reduced
velocity in the symptomatic MCA main stem with respect to
the asymptomatic MCA is good evidence of MCA main stem or
major branch occlusion, but normal blood velocity does not
completely exclude an important MCA occlusion. Increased
blood velocity in the ipsilateral ACA and PCA (to supply
collateral arteries to the ischaemic MCA territory) is
useful confirmatory evidence of MCA main stem or large
branch occlusion. Gradual increase in the blood velocity in
the symptomatic MCA during the days after an acute ischaemic
stroke is good evidence of MCA recanalisation. Significant
intracranial ICA or MCA stenoses may be identified, but
vertebrobasilar stenoses and occlusions less reliably. TCD
has technical limitations, some of which, for example ina¬
bility to correct for the true angle of incidence of the
ultrasound beam to the artery, may be overcome by colour
flow Duplex TCD which however is less mobile. The lack of a
proven treatment for acute ischaemic stroke means that
knowledge of cerebral arterial occlusion in the acute phase
is academic. But if a treatment was shown to be beneficial,
especially in a subgroup of acute ischaemic stroke, then TCD
would be one quick safe way of identifying those patients
for treatment.
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Summary of Chapter Four
1. TCD is a safe, noil-invasive method of measuring cerebral
blood velocity in the basal intracranial arteries.
2. TCD is a well established research technique in ischaemic
cerebrovascular disease.
3. TCD requires an experienced operator for best results.
4. TCD is unsuccessful in up to 10% of subjects for techni¬
cal reasons.
5. Cerebral blood velocity declines with age, so the rela¬
tive difference between blood velocities in symptomatic and
asymptomatic arteries is a more useful indicator of disease
than the absolute value.
6. The difference in mean velocity between the two MCAs
should be no greater than 21%.
7. Absence of the ACA or PCA signal may not be a reliable
indication of disease in those vessels because of the fre¬
quent anatomic variations of the circle of Willis.
8. Reduced MCA blood velocity correlates well with occlusion
of the Ml or M2 segments, but not with peripheral branch
occlusions.
9. Increased velocity in the ipsilateral ACA is good corrob¬
orative evidence of MCA stenosis or occlusion.
10. In the MCA a focal stenosis causes a focal increase in
blood velocity, whereas hyperaemia causes an increase in
blood velocity throughout the measurable length of the
104
artery.
11. Should a treatment for acute ischaemic stroke become
available, TCD would be one method for diagnosing cerebral
arterial occlusion before treatment, and of monitoring the
response to treatment.
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Table 1.4.1 Normal reference values for blood velocity
the basal intracranial arteries as measured using
TCD 127,132,133,134,135
AGE MEAN RANGE (+/-2SD)
MCA
peak velocity <40 94.5 67.3 -- 121.7
peak velocity 40-60 91.0 57.2 -- 124.8
peak velocity >60 78 . 1 58.1 -- 108.1
mean velocity <40 58.4 41.6 -- 75.2
mean velocity 40-60 57 . 7 34.7 -- 80.7
mean velocity >60 44.7 22.6 -- 66.9
pulsatility index 20 -- 45 0.71 0.51 -- 0.91
pulsatility index 46 -- 63 0.94 0.66 -- 1.22
ACA
peak velocity <40 76 . 4 42.6 -- 110.2
peak velocity 40-60 86.4 46.2 -- 126.6
peak velocity >60 73.3 32.7 -- 113.9
mean velocity <40 47.3 21.3 -- 73.3
mean velocity 40-60 53. 1 32.1 -- 74.1
mean velocity >60 45.3 18.3 -- 72.3
PCA
peak velocity <40 53.2 30.6 -- 75.8
peak velocity 40-60 60. 1 19.1 -- 101.0
peak velocity >60 51.0 27.2 -- 74.8
mean velocity <40 34 .2 18.6 -- 50.0
mean velocity 40-60 36 . 6 17.0 -- 56.4
mean velocity >60 29.9 11.3 -- 48.5
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Figure 1.4.1 Windows for Obtaining Doppler Signals from the
Basal Intracranial Arteries on Transcranial Doppler Ultra¬
sound Examination. A) Temporal bone window immediately
anterior to the trajus and superior to the zygomatic arch,
B) transorbital, through the globe (power output must be




Figure 1.4.2 Possible effect of an occlusion at the first
main branch of the MCA on the Doppler blood velocity record¬
ed from the MCA main stem.
A = Doppler signal from the asymptomatic MCA.
S = Doppler signal from the symptomatic MCA : 1 = reduced
velocity, 2 = velocity apparently "normal" (ie equal to the
asymptomatic MCA blood velocity) because of increased flow
in the still patent MCA branch, 3 = velocity increased
because of hyperaemic flow in the patent branch, but could
also be observed following lysis of the embolus with hype¬
raemic flow in the previously occluded branch. Further




Imaging of the Cerebral Vasculature in Cerebrovascular
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1.5.1 The history of methods of measuring cerebral blood
flow
Attempts to measure cerebral blood flow (CBF) began
in the nineteenth century. Prior to that, observations in
experimental animals led to the idea that the intracranial
cavity had a fixed volume, and that variation in the volume
of one of the compartments (brain, blood or cerebrospinal
fluid) could only occur if there were compensatory changes
1 f\ ft
in the other compartments. DO
Control of CBF was thought to be passive, and follow
haemodynamic changes outside the brain. Roy and Sherrington
in 1890 were the first to suggest that local changes in CBF
might result from local variation in functional activity of
the brain, so that the brain might have more control than
other organs over its blood flow,-*-^ but this idea was
strongly criticised.
The first practical attempts to measure CBF in pa¬
tients were based on the Fick principal. In 1870, Adolf Fick
had described a method of measuring cardiac output or blood
flow based on the idea that cardiac output could be calcu¬
lated from the total quantity of a tracer, in this case
oxygen, taken up by (or removed from) the blood, divided by
the net mean concentration difference between the arterial
and venous blood, provided that the system was in equilibri¬
um and the blood flow was constant during the period of
1 fi ft
measurement. DO Adaptations of the Fick principal have since
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been used to measure blood flow to any part of the body
including the brain.
In 1945 Kety and Schmidt applied the Fick principal
to the measurement of CBF in man using nitrous oxide:
The amount of inert gas taken up by the tissue per unit of
time is equal to the quantity brought to the tissue by the
arterial blood minus the quantity carried away in the venous
blood.170,171
They converted the Fick principal to differential form and
made it applicable to the accumulation of an exogenous non-
metabolised substance in the brain, rather than the absorp¬
tion of oxygen by the lungs. It was necessary to measure
concentrations of tracer in arterial and mixed venous blood
and the amount of tracer taken up by the brain as a whole.
dQ/dt = F(Ca-Cv)
where Q = quantity of inert gas in the brain
F = total cerebral blood flow
C., and C„ = concentration of tracer ina V
arterial and internal jugular blood,
t = time
Because there was no way of measuring continuously the
amount of tracer taken up by the brain, it was necessary in
the original method to permit virtual equilibrium to be
established over a period of at least ten minutes when the
amount of tracer in the venous blood became close to that in
the brain. The original method used N2O continuously inhaled
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at low concentration. Kety verified experimentally that for
normal brain and most abnormal situations (except major
cerebral infarction) ten minutes equilibration was suffi¬
cient, with an error of only 5%. As CBF and cerebral metabo¬
lism are closely linked, it was then possible to quantify
the rate of cerebral oxygen or glucose consumption with the
help of Fick's principal, by measuring the cerebral arterio¬
venous difference and multiplying this by the CBF. Other
tracer techniques developed from this but some involved
direct carotid injection and jugular venous sampling so had
the disadvantage of being invasive and only measuring CBF in
one hemisphere at a time. In the late 1940s, the direct and
indirect (inhalation of tracer) methods were compared and
found to give the same results, and so gained in
1 fi ft
acceptance. 00 An important point to note about Kety's
method is that during the equilibration process, the rate
limiting factor was not diffusion between capillaries and
surrounding tissue, but the disparities between tissues with
different perfusion rates and partition coefficients and the
rate at which tracer concentration in the tissue with the
slowest perfusion approached that in the rest of the brain.
Kety's technique has been applied in a wide variety of
clinical settings, and opened the door to modern study of
CBF. His original technique measured total CBF, but his
equations have been adapted and form the basis for regional
cerebral blood flow measurement (rCBF) using inert diffusa-
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ble tracers, and also clearance, autoradiographic and emis-
179 17*3 174
sion tomographic techniques. 'J/ The following phases
of the uptake cycle have been used to calculate blood flow :
1. the rate of tracer wash in (eg xenon CT)
2. the rate of tracer wash out (eg beta particle emitters
85Kr)
3. total quantity of tracer delivered (autoradiography,
microspheres and some compounds used for imaging with
single photon emission tomography)
4. the variation of amount of tracer present with time
(first pass techniques)
There are important differences in what is being measured
between the first three and the fourth which will be dis¬
cussed below, the main one being that first pass techniques
measure transit time not flow.
Tracers may be divided into two broad categories: a)
non-diffusible, which remain intravascular and are assayed
during their first passage through the brain, are useful for
first pass techniques and measurement of absolute flow (ml
min-1); and b) diffusible tracers which equilibrate with
extravascular tissues and may be used to measure wash-in,
wash-out, or perfusion (ml/lOOgbrain/min). Most modern
tracers have been designed to avoid the need for arterial
sampling. An ideal tracer should not be metabolised, should
not alter any physiological variable (including blood flow)
and should be readily and accurately detectable. Nitrous
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oxide, as used in Kety and Schmidt's original work, is
unsuitable because at the concentration used it has analge¬
sic properties. Recirculation of tracer may affect washout
measurement and must be corrected for. Suitable diffusible
tracers include isotopes of xenon, krypton, iodine, haloge-
nated compounds, oxygen and more complex molecules such as
i o o Q Qm
N-isopropyl-JI-paraiodo-amphetamine (IMP) and JJUlTc(d,l)
hexamethyl propylene amine oxime (HMPAO). Some may be in¬
haled and others injected intravenously making the tech¬
niques more practical. The behaviour of some of these mole¬
cules is not entirely clear and their use in clinical prac¬
tice is based on several assumptions which may not be valid.
Furthermore, their behaviour in damaged brain has not been
well quantified. For example, HMPAO used in SPECT imaging
consists of a mixture of lipophylic and hydrophylic forms
and in vivo and in vitro the lipophylic form is rapidly
17c
converted to the hydrophylic. J Only the lipophylic form is
taken up by the brain with an efficiency of close to 100%,
but the actual uptake depends on the fraction to reach the
17 fi
brain in the lipophylic form. The relationship between
HMPAO uptake and regional cerebral perfusion is not
17 7
linear. Recirculation occurs to a certain extent. The
cerebral distribution of HMPAO is principally a reflection
of regional cerebral blood flow, though may be influenced by
17c
lipid mass and red blood cell volume. J Cerebral retention
of HMPAO may be secondary to conversion of the lipophylic to
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hydrophylic forms which cannot diffuse out through the cell
membrane, so it is possible that HMPAO may not distinguish
17ft
viable from dead but perfused tissues. There is no way of
measuring absolute uptake, only relative uptake, therefore
absolute perfusion cannot be calculated. However the advan¬
tages are that the distribution changes little with time
allowing imaging up to two hours after injection.
The "commonly" available methods of assessing cere¬
bral blood flow using tracers will be discussed in turn. It
should be noted that none are really "commonly" available,
for example to a district general hospital, though a few are
inexpensive and practical enough to become more widely
available in future.
1.5.2 Positron Emission Tomography
Positron emission tomography (PET) was introduced in
the early 1960s. It uses very expensive equipment, very
expensive short-lived radioisotopes (generated by a cyclo¬
tron near the PET scanner), and is very expensive to main-
17 4
tain . Consequently there are only about fifty operating
in the whole world. Positrons, emitted as part of the radio¬
active decay of some radioisotopes, react with electrons
nearby and this annihilation reaction releases two gamma
photons with equal energy which travel in opposite direc¬
tions. Only the photons reaching the detectors in the PET
scanner simultaneously are recorded thus giving very accu-
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rate tomographic information on regional cerebral metabolism
and blood flow. Radioisotopes of elements that are normal
constituents of biological molecules (^C, ^N, ^O) , or
10 co 7c
F, uoGa, Br linked to biologically active molecules may
be used as tracers. Methods of measuring rCBF with PET use
1 C
O-labelled water as the radiotracer (washout) which is
biologically inert, chemically stable and has a short half
life permitting repeated measurements with little time
1 C 1 c
delay. C02 is inhaled and rapidly converted to H20 by
carbonic anhydrase in the red blood cells and circulates to
the brain until after ten minutes a steady state is reached
and rCBF can be measured from the rate of washout.174
The limitations of PET arise from the non-linear
relationship between rCBF and measured tissue radiotracer
concentration. At higher flow levels, a large change in rCBF
1 c
produces a relatively smaller change in brain concentra¬
tion, and as a result, a given error in measurement of
tissue radioactivity produces increasingly larger errors in
the measurement of flow as flow increases. Errors occur due
to statistical variations in radioactive decay, scattered
radiation, in measuring the concentration of tracer in the
arterial input, and in assumptions about the blood-brain
barrier partition coefficient. The partition coefficient may
change in a variety of disease states, notably ischaemia. In
areas with heterogeneous flow patterns (such as occurs in an
infarct) rCBF measured in this way is inaccurate as the
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method assumes that the region of interest is of uniform
1 7 Q
composition and physiologic properties. A second PET
method of measuring rCBF, less prone to errors, uses a
1 C
freely diffusable tracer (H20 administered intravenously
as a bolus and the distribution in the brain then measured,
and compared with the tracer concentration in arterial blood
measured simultaneously with the scan, assuming that the
amount of tracer in each part of the brain is proportional
17c
to the blood flow into it and nothing else. Obviously in
some disease states with blood-brain barrier breakdown this
assumption is not valid, but overall this second technique
ion
is thought to be more accurate.lou
In acute ischaemic stroke it is possible to measure
regional cerebral blood flow (rCBF) and volume (rCBV),
regional cerebral metabolic rate for oxygen (rCMR02) and
glucose (rCMRG) and relate the alteration in rCBF to the
metabolic consequences in fairly small areas of brain.
However, acute stroke is logistically difficult to study
IOI
with PET. 0 Difficulties arise in getting the patient to
the scanner quickly, ensuring that the isotope is available
when needed, patient cooperation, and caring for the patient
while in the scanner. Despite this, the few studies which
have been done have yielded important insights into the
pathophysiology of brain ischaemia. The principal findings
are that within the first 24-36 hours, cerebral tissue in
and around the area of depressed flow exhibits a raised
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oxygen extraction fraction (OEF) indicating that in the
acute phase some ischaemic cerebral tissue is surviving by
using the normal reserve in oxygen carriage. This strongly
suggests that during the first day or so after stroke onset
some areas of cerebral tissue are surviving and that im¬
proved flow would allow an increase in the rate of oxygen
utilisation by the tissue. About one week after the stroke,
the OEF falls to less than normal, and the rCBF improves
(either due to spontaneous recanalisation, collateral flow
or neocapillary growth). Sometimes greatly increased flow
has been found in keeping with the concept of luxury perfu¬
sion. Increased glucose and decreased oxygen utilisation has
been observed, thought to be due to infiltration of white
1 O O
blood cells, as has been shown on histological studies. °
In chronic infarction (one month or more after onset), blood
flow and oxidative metabolism are reduced in and around the
lesion, and glucose/oxygen utilisation reverts to its normal
ratio indicating that the tissue is permanently damaged.
The expense of PET scanning, and the impracticality
of scanning acutely ill patients, mean that PET is likely to
remain a research tool.
1.5.3 Single Photon Emission Computed Tomography
Single Photon Emission Computed Tomography (SPECT) is
less expensive and more widely available than PET, but is
still largely confined to research centers. SPECT may be
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used to measure rCBF quantitatively using JJxenon, or
assess regional perfusion differences using substances like
HMPAO. SPECT uses either a rotating gamma camera which moves
around the subject's head, or fixed position multiple detec¬
tors arranged around the head in similar fashion to a CT
scanner, to acquire the image. The radiotracer may be in-
1 *3 "3
jected intravenously (eg HMPAO or JJxenon) or inhaled
1 O O
(J xenon gas). The intensity of the emitted radiation is
measured by the detectors and a computer builds the informa¬
tion into a cross-sectional "tomographic" map of the brain
proportional to the amount of activity in each small volume
element (voxel). The multipositioned detectors measure
emitted rays from voxels, hopefully eliminating over- and
underlying sources, with a spatial resolution of seven to
1 O O
twenty millimetres. OJ However problems occur due to scat¬
tered radiation.
Drawbacks are several. Firstly SPECT using HMPAO and
similar compounds is similar to a microsphere technique and
does not measure absolute rCBF. It can only be used to
compare one side of the brain with the other, and abnormali¬
ties show up as either high flow (hyperaemia) or low flow
17C 170
(hypoperfusion). Jx ' 0 A difference of greater than 12-16%
between two homologous regions of interest is required to be
considered abnormal. Secondly mathematical models have been
devised to describe the behaviour of the radiotracers in the
brain following intravenous injection which may describe
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their behaviour as accurately as possible in normal brain,
but may not be true for areas of pathological brain where
there is blood-brain barrier breakdown, and altered metabo-
177 i70
lism of the tracer. '-1'0 This potentially large source of
error is difficult to quantify, and is the subject of con-
1 7 R
siderable controversy. Although initial uptake is propor¬
tional to flow, tracer distribution becomes a function of
the partition coefficient with efflux. Imaging must be
carried out soon after injection, and tracers should be used
I7C
with as little efflux from the brain as possible. With
inhaled iJJxenon gas scatter from the nasopharynx may affect
the brain images, and xenon alters cerebral blood flow by up
to twenty percent in concentrations used for
1 R 1 1 R 4
inhalation. OJ' 0 Finally, great care is needed in perform¬
ing SPECT imaging : with HMPAO and similar compounds, the
injection must be given without undue disturbance to the
patient, and the patient must be able to keep still for up
to one hour of acquisition time. Acutely ill stroke patients
are not usually this cooperative.
Several studies have evaluated the sensitivity of
SPECT to rCBF abnormalities in cerebrovascular disease.1®5
In patients with a TIA up to 60% will have rCBF abnormali¬
ties if examined within 24 hours of onset, and 40% on the
second day.1®5 In acute ischaemic stroke, SPECT demonstrates
an area of relative hypoperfusion corresponding to the
ischaemic tissue in most patients studied.175'185 ' 187 '1®8
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After 72 hours the relative rCBF may be increased or de¬
creased, but enhancement on CT (thought to represent luxury
perfusion) is associated with an apparent increase in rela¬
tive rCBF on SPECT."1-89 Areas of decreased rCBF in the
contralateral cerebral hemisphere, ipsilateral cerebellar
hemisphere and ipsilateral cerebral cortex thought to be due
to diaschisis ("shut down" of areas of brain remote from the
i qn
infarct) can also be demonstrated.
SPECT is a relatively cumbersome technique to use
with confused and restless patients, relatively expensive
tracers are used, and controversy surrounds what is actually
being measured (and its accuracy) when HMPAO and associated
compounds are used, so it is likely to remain a research
tool for the forseeable future.
1.5.4 Xenon Computed Tomography and Radioactive Xenon
Cerebral Blood Flow Measuring Methods
Xenon is an inert gas which when inhaled, is taken up
by the brain (because of its fat content). The rate of
washin or washout can be used to measure cerebral blood
1 Q 1
flow. This is accomplished either by using CT to measure
brain density changes (which are proportional to the xenon
concentration in brain tissue) or measuring radioactivity if
I70 1 Q O
a xenon isotope is used. J' Xenon CT is a potentially
attractive method because CT is already widely available,
and consequently it has enjoyed some popularity. Many CT
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scanner manufacturers now make a computer package for per-
1 Q "3
forming xenon CT CBF studies. There are however signifi¬
cant drawbacks to both CT and radioisotope xenon inhalation
techniques. The relatively large volumes of stable xenon
required are expensive. CT scanning time is expensive - it
may take up to two hours to complete a brain blood flow
examination by the xenon CT method. The patient must lie
very still throughout the whole period, which seriously
limits its usefulness in acutely ill patients. The radiation
dose is high to the brain with xenon CT and to the nasophar¬
ynx with radioactive xenon. Radioactive xenon CBF techniques
cannot be repeated quickly (ie within hours) as it takes
1 9 4
some time for the gas to wash out. * Perhaps most impor-
1 qc
tantly, xenon alters CBF in animals and human subjects.
Xenon may increase or decrease CBF in normal subjects and
the effect on pathological areas of brain is unknown. This
could lead to large errors in comparing CBF between the two
hemispheres in conditions where there is a focal abnormality
such as an acute ischaemic stroke.Finally xenon CT
and radioactive xenon techniques can only measure relative,
not absolute CBF, although xenon CT does allow regional
partition coefficient to be measured giving better accuracy.
Although xenon CT has been used in acute ischaemic
stroke,the above impracticalities and unquantifiable
sources of error mean that its use will probably be
limited.
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1.5.5 First pass techniques of assessing the cerebral circu¬
lation
Stewart in 1894 described circulation time as the
time taken for a variety of substances injected as a bolus
to pass from the site of injection to the point of interest.
He called the average time for the bolus to pass the mean
transit time (MTT) and used this as an indirect measure of
blood flow.
Flow = Volume / Time
Further work on this was done by Hamilton in the 1930s who
was able to show that when an intravascular tracer is in¬
jected into a vein and consecutive arterial samples are
taken from a point distal in the circulation, a characteris¬
tic concentration/time plot is produced (Figure 1.5.1)
19 9
irrespective of the intravascular tracer used. "
This plot typically has a sharp upslope as the bolus first
arrives at the sample site, a rounded peak, a slower down-
slope to a higher point than the baseline, followed by a
shallow upslope. The shallow upslope is due to recircula¬
tion. Meier and Zierler, in 1954,^®^ provided a theoretical
basis to show that the flow equation applies to the cerebral
circulation, but only if the tracer used remains intravascu¬
lar .
Stewart and Hamilton both realised that the behaviour
of the bolus was fundamental to the shape of the curve
although they disagreed on what part of the bolus was the
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most physiological. Stewart thought that the leading edge of
the bolus, ie the fastest transit time, was most important
and thought that it would not differ significantly from the
1 QO
mean transit time. Hamilton argued that the mean was more
important because it took account of all the vascular path-
1 Q Q
ways, longest as well as shortest. The mean is the param¬
eter of time most commonly used today. With regard to the
behaviour of the bolus, Stewart also recognised the poten¬
tial errors of his method, most of which still apply to more
modern ways of measuring circulation time :
a) incomplete mixing of the indicator at the injection site
b) problems with intravascular dispersion and recirculation
c) pressure artifacts from the process of injection
d) the osmotic effect of a high concentration of indicator
e) the duration of injection and its relationship to the
cardiac cycle, and
f) the only true transit time measurable is from the start
of injection, no matter how remote - the time/activity
curve at the site of measurement is really a retention
time, not a true transit time.
Various mathematical methods have evolved for analy¬
sing the concentration/time curve to try to minimise these
sources of error. Stewart simply measured the fastest circu¬
lation time with a stopwatch. Hamilton plotted the curve,
cut it out and balanced it on a knife edge to find the
center of balance (method of moments) but this is only
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applicable when the bolus injection is intraarterial immedi¬
ately prior to the organ of study, as dispersion of the
bolus invalidates it. Nylin used the shape of the curve
without any mathematical analysis, and showed that under
normal circumstances the curves for the two cerebral hemi-
901
spheres in an individual are the same. u Crandall avoided
the effect of recirculation by extrapolating the down slope
9 0?
to zero assuming it was linear. Neither of the latter
techniques offered a particularly useful or accurate inter¬
pretation of the time/activity curve.
Oldendorf, in 1960, injected an isotope into an arm
vein and placed scintillation counters over each cerebral
hemisphere avoiding carotid artery and jugular vein sam-
pling. This made the technique less invasive but produced
more dispersion of the bolus because of the longer pathway
from arm to head. He estimated that, following injection
into an arm vein, the bolus would have become stretched out
over a five foot length by the time it reached the brain -
the tail was still entering the brain as the leading edge
left - and recirculation became a real problem. The result¬
ant time/activity curve required more complex mathematical
analysis. Four mathematical techniques have been tried to
overcome these problems:
1. first differential of the time/activity curve
2. evaluation of the elements of the time/activity curve
3. convolution/deconvolution
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4. fitting a gamma variate
The first was used by Oldendorf who calculated the
maximum rate of arrival and of disappearance of tracer from
the head, and assumed that the mean transit time equalled
the difference. However this this did not take into account
the dispersion of the bolus prior to arrival in the cerebral
circulation and has subsequently been shown to measure the
mode, not the mean, transit time.204,205
The second was to concentrate on evaluating different
aspects of the activity curve, avoiding any calculation of
transit time, by calculating a) the time from injection to
9 n fi
appearance in the brain, u b) the gradient of the initial
upslope,206-208 c) the gradient of the downslope,207'208 and
d) time from appearance to disappearance of the isotope. uo
However when none of these methods when subjected to clini¬
cal evaluation were found to be reproducible or reliable,
and the overlap between normal and abnormal values was high.
Britton used convolution/deconvolution analysis which
attempts to extrapolate an ideal time/activity curve (as if
the bolus had been injected directly into the carotid ar¬
tery) from the intravenous curve, and then dividing the area
under the "ideal" curve by its height to calculate the mean
9 n Q
cerebral transit time. This produced "noisy" curves so
only three regions of interest over each hemisphere could be
identified and a parametric image could not be
produced.209'210
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The function called the "gamma variate" is a complex
9 11
power function developed by Thomson in 1964, which can be
used to fit experimental first pass curves effectively
excluding the effects of recirculation. The gamma variate
can be expressed by the formula:
Ct = K(t-AT)a.e~(t_At)/b
where Ct = count rate at time t
K = constant
t = time after injection
At = arrival time of tracer
a,b = arbitrary parameters.
Also the basic eguation for determining the mean
transit time at any point in the circulation is given by:
mean transit time ~ C.t / C
where: C.t = the sum of the product of counts and time
C = the sum of the counts
But for this second equation to be applicable to the cere¬
bral transit time method, the first pass of the bolus
through the brain must be separated from the effects of
recirculation. This can be done by applying the gamma vari¬
ate function, but to calculate the true cerebral transit
time from an intravenous injection, it is also important to
exclude the effect of dispersion of the bolus prior to it
reaching the brain.
Dispersion of the isotope bolus has been the most
difficult factor to compensate for when determining cerebral
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transit time from an intravenous injection. The bolus may
become stretched to as much as five feet in length by the
time the leading edge reaches the brain, and the tail of the
bolus is still entering the brain as the leading edge
on?
leaves. Davenport in 1983 demonstrated that the number of
theoretical mixing chambers through which the bolus must
pass before reaching the head can be represented by (a+1)
where "a" is one of the arbitrary parameters in the gamma
TIT
variate equation. The time taken to empty each theoreti¬
cal chamber is given by "b", the other arbitrary parameter
in the gamma variate equation. The mean transit time is
therefore proportional to b(a+l). A simpler derivation has
one
been described by Merrick et al based on recognising that
transit times are additive, that is, the time taken for the
isotope to pass through each theoretical chamber (represent¬
ed by the peripheral veins, right side of heart, lungs, left
side of heart and aorta) is independent of the time taken to
pass through each individually, but the total transit time
from vein to aorta is the sum of the time taken to pass
through all the chambers. It should therefore be possible to
correct for dispersion of the bolus prior to reaching the
head by measuring the transit time from injection to tra¬
versing the aortic arch and subtracting this value from the
cerebral transit times. The fact that transit times are
additive has been confirmed in an in vitro model.In
practice in patients, a detector is placed over the manubri-
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um sternum to detect the activity curve as the bolus tra¬
verses the aortic arch. A gamma variate function is fitted
to this curve, from which the mean transit time is deter¬
mined by plotting the loge of the fitted counts against lege
O 1 "3
of time. J This converts the fitted curve to a series of
linear points. A linear regression fit is then applied to
the graph, and the gradient of the slope is equal to "b"
(one of the parameters in the gamma variate equation) while
the intercept on the x axis is equal to "a" (the other
arbitrary parameter). By knowing the values of "a" and "b"
the mean transit time can be calculated from b(a+l). The
mean transit time through the aortic arch is then subtracted
from the overall cerebral transit time (calculated in the
same manner), having also included a correction for the time
delay between the bolus leaving the aortic arch and arriving
at the base of the brain. This latter is called the "arrival
time". Thus the final measurement of mean cerebral transit
time reflects the true transit time through the head, having
corrected for bolus dispersion by subtracting the arm-to-
aortic transit from the transit time measured at the vertex,
and by using the gamma variate function to exclude the
effects of recirculation. The "arrival time" allows delay in
transit through the neck, such as might be caused by a tight
carotid artery stenosis, to be identified.
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1.5.6 Development of the Mean Cerebral Transit Time tech¬
nique for clinical use.
The fact that transit times are additive was used to
produce a "parametric" image of MCTT (and its reciprocal
9 0S
cerebral perfusion reserve). A "parametric" image may be
read as having x, y and z dimensions that represent the
parameters of time, distance and isotope concentration.
In practical terms, the subject was placed supine
with the neck extended so that the vertex of the skull was
placed over a small field of view gamma camera with an
ultra-high sensitivity collimator. The camera was angled to
exclude the trunk, and the skull positioned with the radio¬
graphic base line (ie the imaginary line joining the outer
canthus of the eye to the external auditory meatus) parallel
to the camera surface. A one centimeter diameter scintilla¬
tion detector with a cylindrical collimator was placed two
centimeters cephalad to the manubriosternal joint to view
the aortic arch. The camera and scintillation detector were
connected to a computer. A wide bore cannula was inserted
into an anticubital vein and a suitable intravascular, non-
diffusible, radioisotope tracer (such as 600 MBq of Techne-
Q Qm Q Qm
tium" pertechnetate, Technetium" human serum albumin, or
1 9 Sm
Au " ) in less than 1.5 ml of fluid was injected into a
short reservoir tubing attached to the cannula. The computer
was started and the isotope bolus flushed in with 10ml of
saline by hand. Camera and scintillation detector images
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were acquired at the rate of 10 frames per second using a 32
x 32 pixel maitrix (pixel area approximately 8 x 10 mm).
Figure 1.5.2 illustrates a patient correctly positioned for
an MCTT study. The typical time/activity curve detected by
the scintillation detector is shown in Figure 1.5.3a and a
brain curve detected by the gamma camera in Figure 1.5.3b.
These curves were visible on the computer screen during the
acquisition so that the adequacy of the isotope bolus at the
aortic arch and head could be assessed immediately. After
approximately 45 seconds the isotope bolus had passed
through the head and the acquisition phase was complete.
The data were then processed to produce the transit
time image as follows. In the study done for this thesis,
two different computers were used, one to acquire and one to
analyse the data, but it would be possible to incorporate
the analysis program into the acquisition computer if suffi¬
ciently powerful. A modern desktop PC (120 MB hard disk,
640k ram) would be suitable, and this would allow processing
of information more quickly. To process the image, the
initial spike (due to activity in the superior vena cava -
see Figure 1.5.3a) was subtracted from the aortic curve by
fitting a gamma variate function with manual setting of the
start and end points using the computer. A gamma variate
function is then fitted to the aortic curve to exclude
recirculation and obtain the mean transit time from the arm
to the aortic arch (MTTS_A). On the brain time/activity
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curve the frames corresponding to the first pass through the
head were identified. After condensing to 20 frames and
smoothing to improve statistical quality, a three-dimension¬
al 32 x 32 x 20 pixel maitrix is produced. Pixels outside
the outline of the head were set to zero, and each pixel
corrected for dead time. Data points between the first
rising and 70th falling fractile were identified, and MTTs_j
and ta calculated for each pixel. MTTS_A was subtracted and
an image maitrix produced of the MCTT. As discussed in
1.2.9, cerebral blood volume is proportional to cerebral
blood flow multiplied by time, and cerebral perfusion re¬
serve (CPR) is proportional to the cerebral blood flow (CBF)
divided by the cerebral blood volume (CBV), which is also
the reciprocal of the cerebral transit time. Thus a second
image, the reciprocal of the MCTT, could be produced to show
the CPR. A third image was produced representing the differ¬
ence between the arrival of the bolus at the aortic arch and
at each maitrix point in the head (the arrival time image).
The images were displayed as if looking down on the pa¬
tient's vertex, with different time intervals colour-coded,
interpolated to a 128x128 maitrix to give a smoother pic¬
ture. Faster transit times were displayed in shades of blue
and slower in red, with a total of 30 shades each represent¬
ing a half second difference in transit or arrival time.
The arrival time image is also displayed as though
looking down on the vertex using the same colour-coded scale
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and is useful because delay in transit of the bolus through
the neck may indicate underlying atheromatous carotid steno¬
sis, which could be taken into account when viewing the
cerebral transit time image to improve interpretating of the
one
likely site of arterial pathologyA normal MCTT study is
shown in Figure 1.5.4. The cerebral transit time image is
displayed as well as the arrival time image and the absolute
values for hemispheric transit and arrival times.
1.5.7 Validation of the Mean Cerebral Transit Time technique
in preliminary clinical studies
Studies in normal volunteers and "patient controls"
(see below) have shown that normally isotope transit is
fastest through the anterior two-thirds of the brain and
slowest through the posterior third. There should be no more
than one second difference between equivalent points in the
two hemispheres.205' 2 ^ The range of normal hemispheric
transit times was found to be 2.2 to 7.7 seconds, median 4.6
seconds, 95% confidence limits 2.8 to 6.2 seconds in "pa¬
tient controls" (102 patients referred for brain scintigra¬
phy who on follow up to one year were found to have no
neurological or cerebrovascular disease). An MCTT longer
than 6.2 seconds suggested obstruction to the flow of blood
through the hemisphere.205 By displaying the MCTT as a
parametric image from the vertex, it was possible to identi-
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fy not just whole hemispheric abnormalities but also abnor¬
malities affecting only part of the hemisphere. For example,
presumed occlusion of the MCA main stem resulted in delayed
transit through at least the middle two quarters of the
9 14
hemisphere.
In the validation studies, there was no correlation
of MCTT with the subject's age, although the arm-to-aortic
arch transit time did correlate weakly with age (the older
the subject, the slower the arm-aortic arch circulation
one
time). Presumably this is partly due to the increasing
liklihood of impaired cardiac function resulting in reduced
cardiac output in older subjects. Marked impairment of
cardiac function might dilute the tracer bolus in the heart
invalidating the MCTT measurement, but it is not known how
frequently this may occur in practice, or how important it
may be clinically.
The MCTT has also been validated against TCD in normal
O 1 A
subjects at rest, hyperventilating, and rebreathing C02.
A highly significant linear relationship was demonstrated
between end tidal C02 and hemispheric MCTT. Also in 32
patients with first ever acute ischaemic stroke and no
clinical evidence of impaired cardiac function, the MCTT
predicted the site and extent of MCA occlusion accurately
91 c
when compared with TCD. J
These preliminary studies were encouraging, but to
establish the true practicality of the MCTT as a diagnostic
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test for the site and extent of major intracranial artery-
occlusion in acute ischaemic stroke requires evaluation in a
more heterogeneous group of patients with coincident cardiac
and carotid disease.
1.5.8 Potential advantages of the MCTT technique as a diag¬
nostic test in acute ischaemic stroke
The MCTT is inexpensive and quick to perform, taking
less than five minutes to complete the test (including
insertion of the intravenous cannula), the actual imaging
time during which the patient must keep still being less
than one minute. A further five minutes is required for
processing the image, so the final result can be obtained
within ten minutes. The MCTT is not dependant on the skill
or experience of the operator in the way that TCD is. It is
potentially a very "user friendly" technique, ideally suited
to rapid investigation of acutely ill patients who are
unable to cooperate with lengthy procedures. Gamma cameras
with computers are already available in many hospitals.
Thus, if shown to be practical and accurate in a broader
cross section of acute stroke patients, the MCTT could be a
practical non-invasive vascular imaging method for diagnos¬
ing the site and extent of arterial occlusion in acute
ischaemic stroke. Although at the moment there is no clini¬
cal use for this information, it may be useful in research
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and in future, it may be useful to guide acute ischaemic
stroke treatments if any become available, as some may be
more effective in certain subgroups of ischaemic stroke.
The mean cerebral transit time and its reciprocal,
cerebral perfusion reserve, are useful concepts in cerebro¬
vascular disease as they give information on the residual
capacity of the brain to cope with flow reduction, which
simple measurement of CBF does not. Further assessment of
the accuracy and practicality of the MCTT in the generality
of patients with acute ischaemic stroke is required.
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Summary of Chapter Five
1. The background history of attempts to measure CBF is
described.
2. The Fick principal and Kety and Schmidt's modification is
described.
3. Different clinical methods of applying the Kety and
Schmidt method to measure CBF are described.
4. The development of the concept of transit time to measure
blood flow is described.
5. The isotope mean cerebral transit time technique method¬




Figure 1.5.1 Graph of Concentration Against Time obtained
when a bolus injected into the circulation proximally passes
the point of measurement. Typically there is a sharp up-
slope, followed by a rounded peak, a downslope which is less
steep than the upslope, and a second lower flatter peak due
to recirculation.
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PC to aquire and
printer for hard process data
mediastinum reaching the vertex image
Figure 1.5.2 Drawing to show the apparatus required to
perform an MCTT study, correct positioning of the patient,
gamma camera and hand-held scintillation counter.
With the equipment organised thus and a cooperative patient
it was possible for one operator to perform the study, but
otherwise two were necessary - one to steady the patient's




Figure 1.5.3 Typical Time/Activity Curves obtained following
bolus injection of radiolabeled tracer into an arm vein.
A) Measurement over the Aortic Arch : the first (sharp) peak
is due to radioisotope passing through the superior vena
cava; the second (blunter) peak is due to passage of ra¬
dioisotope through the aortic arch. The dotted line is the
"best fit" for the aortic input curve drawn by the computer.
B) Measurement Over the Brain from the Vertex. CPS = counts
(of radioactivity) per second.
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INPUT ARRIUAL TIME 6.4 SEC
INPUT MEAN TRANSIT TIME 6.7 SEC.
LEFT SIDE CBF PARAMETERS
PIXELS MTT AT
23 5.2 3 2
32 4.4 2 9
32 5.0 2 6
29 6 . 1 2.6
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Figure 1.5.4 Example of a normal Mean Cerebral Transit Time
study. Top left is the mean cerebral transit time image
representing the time for the radioisotope to pass through
the brain; top right is the arrival time image representing
the time taken for the radioisotope to pass from the aortic
arch to the base of the brain; bottom left are the absolute
values for the mean cerebral transit (MTT) and arrival (AT)
times in seconds for each hemisphere divided into four
wedge-shaped segments. Note that the images are presented as
though looking down on the top of the head (opposite to the
conventional way of presenting CT scan images of the brain).
Note also the colour scale consisting of thirty colour
shades, each representing 0.5 seconds, blue being the fast¬
est and yellow the slowest times. The vacant box, bottom
right, may be used to present previous images of the same
patient, or the inverse of the transit time image, the




Imaging the Brain Parenchyma in Acute Stroke -
Computed Tomographic Scanning and Magnetic Resonance Imaging
1.6.1 The development of CT scanning
1.6.2 CT scanning in cerebrovascular disease - cerebral
haemorrhage
1.6.3 Cerebral infarction - typical appearance on CT and
changes with time
The contribution of CT scanning to the understanding of the
pathophysiology of cerebral infarction and its importance :
1.6.4 Oedema and mass effect in cerebral infarcts
1.6.5 Haemorrhagic transformation of the infarct
1.6.6 Magnetic Resonance Imaging in cerebrovascular disease
1.6.7 Concluding comments
Summary of Chapter Six
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1.6.1 The development of Computerised Tomographic Scanning
The invention of Computerised Axial Tomography (CT
Scanning) in 1972 revolutionised clinical neurosciences. D
It was developed by Godfrey N Hounsfield working in the
Central Research Laboratories of EMI Ltd, in Middlesex, UK,
who applied computer technology to detect x-rays passing
through the body in cross-section and build up the transmit¬
ted x-rays into a two dimensional image of the structures
through which the x-rays had passed. The image depended on
absorption of the x-ray beam as it passed through the body,
thus using the conventional properties of x-rays, but the
computerised technique was much more sensitive than any
previous methods of detecting x-rays. It became possible to
differentiate between soft tissue structures such as brain
parenchyma and cerebrospinal fluid (CSF) allowing direct
visualisation of brain pathology. Previous neuroimaging
techniques had relied on indirect evidence of disease, such
as shift of vessels on angiography or ventricles on ventric¬
ulography, to diagnose mass lesions and were invasive and
dangerous. The value of CT scanning quickly became
917obvious''1' and within a few years there were hundreds of
scanners in the USA, and other radiographic equipment manu-
7 1 o
facturers had started to produce their own versions. xo
Sadly, EMI was unable to realise the potential of Houns-
field's invention, one of the major advances in medicine
this century. However Godfrey Hounsfield received the Nobel
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Prize in recognition of the importance of his invention. CT
scanners have advanced greatly, with faster scanning times,
greater image detail and use in the body as well as the
head. Perhaps most importantly CT scanning has gone from
being a very expensive and limited resource available to
only a few lucky patients, to being available in many large
District General Hospitals in the UK.
1.6.2 CT Scanning in Cerebrovascular Disease - Cerebral
Haemorrhage
The earliest reports of CT scanning in cerebrovascu¬
lar disease quickly showed how valuable it was for differen¬
tiating between cerebral haemorrhage and infarction (and
other pathologies such as tumours) as the cause of acute
focal neurological symptoms. Ambrose in 1973 stated that "in
the overall investigation of cerebrovascular disease, com¬
puterised tomography will, without doubt, come to be an
invaluable means of distinguishing between haemorrhage and
9 17 9 1 Q
infarction". In 1974 Paxton and Ambrose J reported
positive CT findings in 66 of 66 patients with intracranial
haemorrhage and in 27 of 55 patients with cerebral infarc¬
tion, and observed density changes in the evolution of the
infarcted brain tissue. Acute parenchymatous haemorrhage is
of higher density than normal brain parenchyma (typically
about 80 Hounsfield units (HU) compared with about 35 HU for
normal brain) and this density increase occurs virtually
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immediately. There have been a few reports of cerebral
haemorrhages observed while the patient was in the CT scan-
Tin 99i
ner which confirm the immediacy of the change. ' As
soon as blood stops moving, its density increases to appear
"whiter" on CT. This is true whether the blood is in an
intraparenchymal haematoma or in an embolus in a large
intracranial artery (see below).
Intracerebral haematomas exert mass effect depending
on their size and site, compressing and damaging adjacent
structures. If large, supratentorial haematomas may cause
herniation of the temporal lobe through the tentorial hiatus
and compress vital brainstem structures. The underlying
cause may sometimes be inferred (spontaneous, traumatic,
aneurysmal, or arteriovenous malformation) from the extent,
site and distribution of blood.
The density of the haematoma decreases with time
becoming isodense with brain within a few days to two weeks,
p p O
and later hypodense, so that on CT scans performed sever¬
al months after the onset the haematoma appears as a defect
of water (CSF) density. At this late stage a haematoma may
look identical to an old infarct. Small haematomas become
hypodense more guickly, so to be sure of differentiating a
haematoma from an infarct the CT scan should be performed as
p p O
soon as possible, preferably within seven days of onset.
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1.6.3 Cerebral Infarction - typical appearance on CT and
changes with time
In the mid to late 1970's there were several reports
of CT scanning in ischaemic stroke. ^ 19 , 224 , 225 quality
of scans was poor by today's standards: pixels were large;
scan times slow; and processing algorithms less sophisticat¬
ed. This limited visualisation of small infarcts and of
subtle changes in the early stages of larger infarcts.
9 9 tz
Kinkel et al J examined 111 patients admitted to hospital
with cerebrovascular disease, and found that virtually all
patients with a permanent neurological deficit had a defect
in an appropriate area on the CT scan, whereas the patients
with TIAs did not. He also noted mass effect in the early
stages of large cerebral infarcts which could be confused
with cerebral tumours. In 43% of patients whose CT scan
showed primary intracerebral haemorrhage, the clinical
diagnosis had been acute ischaemic stroke and the haemor¬
rhage would not have been diagnosed without the CT scan.
This was one of the first indications of how unreliable
clinical criteria may be in diagnosing the cause of an acute
9 9 £
cerebrovascular event. Campbell et al in 1978 examined
141 patients admitted to hospital with acute ischaemic
stroke as soon after the onset as possible and again seven
days later, and compared the results with radionuclide
scanning. They found that more than half of the ischaemic
lesions were detected on the first CT scan, and 66% on the
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second scan, compared with 58% on radionuclide scanning (the
only alternative non-invasive diagnostic tool available). It
was considered unusual to see changes of infarction prior to
24 to 48 hours on CT, although occasional ischaemic lesions
2 2 7 228
were seen as early as three to six hours after onset. '
Recently more subtle early signs of cerebral infarc¬
tion have been described. Loss of visualisation of the
insular ribbon and loss of outline of the lentiform nucleus
have been reported as occurring within three hours of onset
in ischaemic strokes of the basal ganglia, probably reflect¬
or a
ing increased sensitivity of modern scanners. ' Loss of
the normal grey-white matter differentiation and effacement
of the overlying cortical sulci are other early signs of
cortical infarction. Small infarcts probably appear later
than large ones (because there is less tissue altering its
density) so lacunar infarcts are less likely to show up in
the first 24 hours (and sometimes not at all) than large
territorial infarcts . ' ^2' Small infarcts in the brain
stem and cerebellum are difficult to visualise with CT
2 2 2
because of artifacts arising from the petrous bones.
Another early, indirect, sign of cerebral infarction
is the "hyperdense artery" sign. This is visualisation of
acute large cerebral artery occlusion as an area of in-
7 *3 A
creased density in the main stem of the artery. The
reliability of this sign is uncertain. It may be valid in
young patients in whom the arteries tend to be less calci-
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fied, but elderly patients frequently have calcified artery
walls which may produce a similar appearance. In one series
of acute stroke patients, the hyperdense artery sign was
present in 50% of angiographically proven acute MCA occlu¬
sions.^^ It has been associated with larger infarcts.
0-37
Yang found the hyperdense vessel sign in only 5% of
patients with acute cerebral infarction.
A typical established large artery infarct is wedge-
shaped, of decreased density compared with normal brain,
sharply demarcated, and occupies a recognised vascular
9 9 9 900
territory. ,JO The presence of recent haemorrhage in the
infarct produces areas of increased density relative to both
normal brain and the infarcted tissue. Lacunar infarcts are
less than 1.5 cm in diameter, usually rounded in shape, and
are sited in the deep white matter and basal
94 9*31 9*39 9^*3
ganglia. ' J Borderzone infarcts lie in the areas
of the brain at the edges of the large artery vascular
territories, ie in the parieto-occipital region for MCA/PCA
and over the vertex for ACA/MCA borderzones.2^'^^'24^
Striatocapsular infarcts are larger than lacunes and occur
in the deep white matter and basal ganglia with preservation
of the overlying cortex. They are thought to arise from
transient occlusion of the MCA main stem (or prolonged
occlusion of the MCA main stem with good cortical collater-
241 242




The site of the lesion on the CT scan has been shown
to correlate well with clinical syndromes .
The middle cerebral artery territory is the most frequently
involved (60%) followed by posterior cerebral artery (14%),
anterior cerebral artery (5%), posterior fossa (5%), and
9 9 9
multiple territories or borderzone in 14%.
Typical evolution of the appearance of the infarct on
CT scan has been described and is illustrated in Figure
1.6.1. Initially the lesion swells and becomes slightly
hypodense compared with normal brain. The infarct becomes
247 248
more clearly demarcated during the first few days. '
The swelling is usually maximal around the third to fifth
days and gradually subsides during the second and third week
9 9 9
(but see below). The significance of visualisation of
decreased density in the ischaemic tissue in the very early
phase (within a few hours of onset) of acute ischaemic
stroke is uncertain. It has been suggested that early visu¬
alisation of the infarct may indicate more profound ischae-
2 4 Q
mia, or a worse prognosis J but as yet there is no evidence
to suggest that early visualisation of an infarct carries a
worse prognosis than if the patient had the same neurologic
deficit with no infarct visible. During the second week the
infarct gradually increases in density sometimes becoming
indistinguishable from normal brain - called the "fogging
effect" because without close inspection even quite sizeable
infarcts may be overlooked. The "fogging effect" may last
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for up to two weeks, then the infarct becomes progressively-
more hypodense. Eventually a sharply demarcated, atrophic,
hypodense defect remains.
The "fogging effect" may make the infarct impossible
to see on CT scans done at this time. It is less pronounced
in large infarcts but may lead to underestimation of infarct
size and extent. It does not occur in all infarcts, and the
rate of occurrence varies between reports. Skriver and
9 R H
Olsen observed it in 54% of cases scanned ten days after
O C 1
onset, whereas Becker found it at some time in all cases
examined with six consecutive CT scans within 42 days of
stroke.
In large infarcts involving the cortex curvilinear
bands of increased density may be seen at the cortical edge,
at the junction of the lesion with white matter and within
the lesion in the second and third weeks after the stroke.
These correspond with areas of petechial haemorrhage seen on
pathological specimens. These areas also enhance markedly
o c o
when x-ray contrast is given and are thought to corre¬
spond with areas where the capillaries are leaky, where
there is blood-brain barrier breakdown and of frank petechi-
997
al haemorrhage. * Rates of occurrence of petechial haemor¬
rhage vary between 15 and 40% in different series (also see
below 1.6.5)62,253,254,255 presumably reflecting patient
selection bias, the increasing sensitivity of CT scanners
and observer variability in reporting.
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Administration of intravenous x-ray contrast changes
the appearance of the infarct. In the first six days it has
very little effect on the appearance.252'255 In the second
and third weeks contrast enhancement occurs frequently
corresponding with the time of maximal blood-brain barrier
breakdown and positivity of radioisotope scans227,257 The
mechanism is probably a combination of blood-brain barrier
breakdown, neovascularisation, and impaired
TCO
autoregulation. JO The tendancy to enhance with contrast
gradually resolves, the time course being illustrated in
Figure 1.6.1. Some authors have suggested that stroke pa-
9 R Q
tients deteriorated after intravenous contrast although
the relationship was not statistically significant. It is
possible that extravasation of neurotoxic contrast agents
could be harmful, but the majority of patients described in
their paper had large infarcts with poor prognosis in any
case. In practice it is rare to need to give intravenous
2 f. n
contrast as a diagnostic aid. Hayman et al suggested that
early prominent contrast enhancement in large infarcts
correlated strongly with development of massive haemorrhagic
transformation later in the course of the infarct. They
suggested that this was due to severe early vasogenic oede¬
ma, however most of their patients had large infarcts (with
poor prognosis who were more likely to develop haemorrhagic
transformation anyway255) and animal studies have shown that
in the early phase of ischaemia, oedema is cellular in
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origin and vasogenic oedema does not usually occur until
9 fi 1 9 fi 9
several days after onset. '
Interobserver reliability in reporting CT scans in
patients with cerebrovascular disease has not been exten¬
sively studied. High levels of agreement (substantial to
perfect) were demonstrated in two studies of the interpreta¬
tion of CT scans in patients with dementia and
9 £ O O £ A
stroke. J' However in one of the studies, all observers
had free access to relevant clinical details so their inter-
2 fi 4
pretation of the CT scan may have been biased. A study by
Bonke et al in which a group of neurologists and radiolo¬
gists reviewed the same two CT brain scans (camouflaged by
an assortment of other CT brain scans) accompanied by mis¬
leading clinical information, showed that the diagnosis of
lacunar infarction did not appear to be biased by informing
the observer that the patient was thought clinically to have
9^9
had a stroke. The lack of bias with knowledge of clinical
details may have been because the study was limited, and is
probably not a true reflection of the difficulties encoun¬
tered in routine practice when faced with a CT scan showing
multiple "holes in the brain" and generalised atrophy. The
former makes the diagnosis of recent lacunar infarction
difficult (it may be impossible to decide which "hole" is
the relevant one unless serial scans show a new "hole"
developing) and the latter makes the diagnosis of small
cortical infarction difficult (when is a large sulcus actu-
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ally an infarct?). Interobserver reliability in the inter¬
pretation of site of infarction, amount of swelling in the
acute stage and of haemorrhagic transformation of infarcts
has not been evaluated.
Contribution of CT scanning to the understanding of the
pathophysiology of cerebral infarction :
1.6.4 Oedema and mass effect in cerebral infarcts
Some degree of mass effect due to infarct oedema may
be observed in most larger infarcts. The mass effect mani¬
fests as compression of surrounding structures such as
cortical sulci, lateral ventricle, or midline shift and
tentorial herniation of the temporal lobes if severe. Swell¬
ing is usually maximal around the third to seventh day after
onset and gradually resolves thereafter. 2^7 ' 2^®' 255'255 The
frequency of severe infarct swelling, the relationship to
infarct aetiology, to reperfusion of the underlying occluded
artery and other possible associated factors such as plasma
glucose concentration at the time of the stroke have not
been studied in stroke patients. From the scant information
available in the literature, it seems that severe infarct
swelling may occur in approximately 5% of all infarcts255
but there have been no large prospective studies where all
patients had serial CT scanning (or post mortem) throughout
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the first month after the stroke. The few serial studies
which have been done concentrated on CT scanning survivors,
so patients who died early were lost to the study, introduc-
O c: A
ing bias. J Further discussion of infarct swelling in the
acute phase will be given in Part Three Chapter One.
1.6.5 Haemorrhagic transformation of the infarct
CT scanning is an excellent method with which to
study the frequency and evolution of haemorrhagic transfor¬
mation in cerebral infarcts. Post mortem studies in the
acute stage of cerebral infarction are biased towards pa¬
tients who die in the early stages of their stroke, and who
are therefore more likely to have had a large cerebral
infarct. The signs of haemorrhage resolve with time so that
in patients dying weeks or months after their stroke it may
no longer be possible to distinguish the relative contribu¬
tion of infarct and haemorrhage to the residual lesion. The
post mortem studies of Fisher and Adams in 195159 suggested
that in most cases of haemorrhagic cerebral infarction the
cause of infarction was an embolus (origin unspecified)
which had broken up and moved distally exposing the ischaem-
ic tissue to arterial blood pressure leading to haemorrhage.
Of 373 brains with vascular occlusion (123 with presumed
embolism, 89 with presumed thrombosis, and 161 of uncertain
cause), 66 had haemorrhagic infarction and in 63 there was
evidence of embolism as the cause of stroke. They did not
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discuss the possibility that some of their infarcts with
open arteries might have been venous infarcts, nor how the
evidence of embolism was obtained. Venous infarcts are
frequently haemorrhagic and obviously the artery to the
infarcted brain would be patent. While venous infarction is
unlikely, failure to recognise it may have contributed to
the estimate of the haemorrhagic infarction rate in Fisher
and Adam's study as well as in others since.
The idea that embolism is the cause of haemorrhagic
7 fi 7
cerebral infarction has become rather entrenched, to the
point of haemorrhagic transformation being used in some
studies as diagnostic of embolic (usually implied cardiac
origin) stroke. Close examination of the literature on
haemorrhagic transformation shows that there is rather poor
evidence to support the reperfusion-haemorrhagic transforma¬
tion hypothesis. As knowledge has increased, it has become
clearer that one of the strongest associations with haemor¬
rhagic transformation is simply size of infarct - the larger
the infarct, the more frequent the haemorrhagic transforma-
tion. JJ It is interesting that in 1953, shortly before
c Q
Fisher and AdamsJJ hypothesis became so widely publicised
and accepted, Globus and Epstein60 published results of
experimental cerebral infarction in monkeys and dogs and
some observations on post mortem brains from stroke pa¬
tients. They observed that haemorrhage into infarcted tissue
was often worse when the occluded symptomatic artery re-
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mained occluded, and that the haemorrhage seemed to occur
around the periphery of the infarct from collateral arteri¬
oles vasodilating to supply the ischaemic tissue and leak¬
ing. They produced massive intracerebral haemorrhages in
dogs by this means, although they noted difference between
the species which seemed to depend on the adequacy of the
collateral supply. This alternative, but equally attractive,
hypothesis has been all but forgotten and deserves further
attention.
Fortunately CT scanning has offered the opportunity
to study haemorrhagic transformation more systematically,
but the aetiology and risk factors remain poorly understood
as there have been few studies which addressed the problem
in a methodologically sound manner as perhaps, until recent¬
ly, CT has been a relatively scarce resource. Most of the CT
studies were retrospective, based only on patients who had
an initial CT scan plus a repeat CT scan, or who survived in
hospital for a certain length of time. Few were prospective,
none included a truly representative cross section of pa¬
tients with all types of cerebral infarction (all were
hospital based so were therefore biased towards patients
with larger infarcts) and none systematically and success¬
fully followed up, with a repeat CT scan or post mortem, all
patients who entered the study. None of the CT studies
managed to repeat CT scan all patients - some died or were
discharged prior to a second scan and only patients who did
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have a second scan were included in the assessment of the
haemorrhagic transformation rate. If all the patients who
died prior to follow up CT scanning had haemorrhagic trans¬
formation, the CT-estimated rate would have underestimated
the true rate and the true clinical importance of haemor¬
rhagic transformation of the infarct.
However, allowing for these inadequacies, CT scanning
has shown that haemorrhagic transformation occurs in a range
of severities from mild petechial to severe confluent haema-
o o c
tomas, with and without symptomatic deterioration. The
reported rate of haemorrhagic transformation, of any degree,
varies in different series being between 15 and 45% for
petechial haemorrhage254'2®® and about 5% for symptomatic
o c c
parenchymatous haematoma formation. Some of the wide
range of reported rates of petechial haemorrhage may be due
to interobserver variation in reporting, but this is less
likely to affect the reporting of focal haematomas. Haemor¬
rhagic transformation occurs in patients treated with and
without anticoagulants.255'269'270'271 Patients with haemor¬
rhagic transformation have continued on anticoagulant thera¬
py without worsening of the haemorrhage or symptomatic
2 fi 9 2 7 2deterioration'* Haemorrhagic transformation may occur
at any time after onset of ischaemic symptoms, from within
the first 24 hours,275 to the end of the first month.254,255
Risk factors for haemorrhagic transformation include
large cerebral infarcts with mass effect,255'26®'274'275
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raised blood pressure,^1'2®® and increasing age of the
patient.A recent large CT series suggests that haemor-
rhagic transformation is equally common in presumed embolic
O C C
(cardiac) as presumed thrombotic infarction, and that
post mortem studies, and previous small CT series have been
biased in suggesting the embolic stroke more commonly under¬
went haemorrhagic transformation.
There is fierce debate about the role of recanalisa-
tion. Until recently it was accepted that early recanalisa-
tion, such as might occur with spontaneous lysis of an
embolus, increased the risk of haemorrhagic transformation.
Several small recent studies have contradicted that, sug¬
gesting (with angiography) that haemorrhage is more common
in infarcts where the artery remains occluded.
61,62,253,276,277,278
Finally the role of antithrombotic drugs is contro¬
versial. Recent series have found no effect on the rate of
haemorrhage with antithrombotic treatment (heparin or throm¬
bolysis) but have suggested that when haemorrhage did occur
it tended to be more extensive.Previous studies have
suggested an increased rate as well as severity of haemor¬
rhage with antithrombotic drugs.The true associ¬
ation between recanalisation, embolism, antithrombotic drug
treatment and haemorrhagic transformation will hopefully be
resolved by the large randomised controlled trials of throm¬
bolytic and antithrombotic drugs in acute ischaemic stroke
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which are underway at the moment (see Part Four).
1.6.6 Magnetic Resonance Imaging in cerebrovascular disease
Magnetic Resonance Imaging (MRI) became a clinical
tool in the early 1980's. The equipment is very expensive,
both to purchase and run, the main reason for the small
number of MRI scanners in clinical use in the UK. MRI has
been little used in acute ischaemic stroke. It is not a
practical technique for use with acutely ill patients : the
patient must be placed inside a tube-like magnet which makes
access for monitoring or administering anaesthetic diffi¬
cult; they must lie still for usually at least five minutes
at a time. Many acute stroke patients are confused, restless
and are frightened by the noise of the scanner (rather like
loud machine gun fire). More recent scanners and scan se¬
quences allow faster image acquisition, but even so, MRI
will probably remain largely a research tool in acute cere¬
brovascular disease for the near future. The great advan¬
tages of MRI are not only its pathoanatomical cross section¬
al imaging properties, but its ability to perform angiogra¬
phy non-invasively and by diffusion and spectroscopic imag¬
ing to elucidate mechanisms of brain damage in ischaemia and
response to experimental treatments.
Several studies of MRI in acute stroke have been
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published recently. In addition to the above practical
considerations, it is difficult to differentiate between
acute cerebral haemorrhage and acute cerebral infarct in the
poi po p
first 24 hours. 0,0 However MRI is much more sensitive to
haemorrhage after the first week because of the paramagnetic
effects of methaemoglobin. Tiny areas of haemorrhagic trans¬
formation not visible on CT may be identified which might
influence the use of anticoagulant drugs in the future
although at the moment there is insufficient knowledge of
the risks and benefits of anticoagulants in cerebral in-
poo
farcts with minor areas of (petechial) haemorrhage. OJ
MRI is more sensitive than CT to changes in tissue
characteristics caused by cytotoxic and vasogenic oedema
thus MRI should be able to detect pathological changes
earlier than CT. MRI is able to detect small infarcts earli¬
er, especially lacunes, which may not visible on CT until
poo
the second week after onset, if at all. Large infarcts
are often visible on CT within six hours of onset, sometimes
earlier than on MRI. ' ^0'28^ Transient lesions thought to
be ischaemic have been described on MRI, but their true
p O A
relationship to TIA's is not clear. ° MRI is more sensitive
to small lesions in the brainstem and posterior fossa than
pqc
CT as there is no interference from bone artifacts. OJ
The earliest ischaemic changes detectable with rou¬
tine MRI (ie not spectroscopy or diffusion imaging) in
stroke patients are loss of the normal flow void in the
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symptomatic artery (within minutes of onset), swelling on
Tl-weighted images without signal change on T2-weighted
images (three hours), signal changes on T2-weighted images
(eight hours), and signal change on Tl-weighted images (16
O O A
hours). " Pronounced brain parenchymal cortical enhancement
following intravenous gadolinium injection has been de¬
scribed within the first 24 hours after onset in patients
with a TIA, partial arterial occlusion or isolated border-
zone infarcts.2®4'2®*'
In the second week after infarct onset, diffuse
enhancement of gyri overlying the infarct is often visible.
This is thought to be due to neovascular capillary prolifer¬
ation or loss of autoregulation in leptomeningeal collater-
p oi 007
als and is visible for up to eight weeks after onset. 0 ' 0
It is mirrored by a similar appearance on CT scanning, at
tributed to areas of breakdown of the blood brain barrier
corresponding with the gyriform petechial haemorrhage seen
at post mortem. In the second to third weeks after onset
some infarcts become isodense with normal brain on CT
(fogging effect) and as they may have lost most of their
mass effect by that stage, may be difficult to identify.
Recent MRI studies have shown changes in T1 (increased
signal), and in T2 (decreased signal) suggestive of diffuse
haemorrhage in the second to third weeks. This effect is
probably due to diffuse petechial haemorrhage from leaky
capillaries, with diapedesis of red blood cells,2®®'2®® and
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would fit with "fogging effect" on CT, as the thinly spread
red blood cells would cause a diffuse increase in Hounsfield
numbers raising the low density of the lesion to that of
normal brain parenchyma.
Long term effects of ischaemic stroke seen on MRI in
elude Wallerian degeneration visible as atrophy and low
OO7
density in the white matter of the brain stem and the ef
fects of haemorrhage. As MRI is much more sensitive to
chronic intraparenchymal haemorrhage, even years after it
has occurred, it may be possible to differentiate between
old lesions due mainly to ischaemia and those due mainly to
focal haemorrhage, whereas CT will just reveal a "hole"
which could have started life as either. This may prove
useful in the assessment of patients presenting late (more
than three weeks) after symptom onset in whom treatment with
anticoagulants is being considered to exclude primary hae¬
morrhage as the cause of symptoms. In practice it may prove
difficult to differentiate old small focal haematomas from
mildly haemorrhagic infarcts as more experience is acquired.
MR angiography allows the acquisition of images of
blood vessels, without injection of contrast, by using the
signal characteristics of flowing blood. This technique is
not yet practical for acute ischaemic stroke (the patient
must keep very still for the longish scanning time) but is
promising for the assessment of carotid stenosis in patients
being considered for carotid endarterectomy.
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Two other ways of using information from MRI, diffu¬
sion-weighted imaging and spectroscopy, promise to be very
useful research tools for acute ischaemic stroke. The tech¬
nicalities are beyond the scope of this thesis, but essen¬
tially diffusion-weighted imaging uses the Brownian motion
of water molecules in the brain and has demonstrated abnor¬
malities in ischaemic tissue within fourteen minutes of
0 9 f) 9 9 1
onset in animal models. In stroke patients, initial
studies have shown alteration of water diffusibility in the
infarcted tissue which varied both within the lesion and
2 9 2
with time. The significance of these changes in relation
to clinical outcome, reperfusion, etc has yet to be evaluat¬
ed. Using MR spectroscopy metabolic changes in ischaemic
tissue can be studied in vivo, particularly hydrogen, phos¬
phate, carbon, fluorine and sodium metabolism.
290,293,294,295,296 Amounts of N-acetylaspartate, creatine
and phosphocreatine, choline-containing compounds, lactate
and pH have been evaluated in preliminary studies in stroke
patients, but it is too early yet to be certain of the
significance of the changes. Perfusion imaging to examine
the cerebral microcirculation can also be performed, but
again, information from stroke patients so far is
2 9 0
limited. It will be possible to study the natural history
of ischaemic stroke and the response to drug treatment in
vivo using these techniques.
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1.6.7 Concluding comments
CT scanning is a practical accurate method of imaging
structural brain abnormalities. It allows easy access to the
patient and is quick, so is ideal for acutely ill uncoopera¬
tive patients. Its main use in acute cerebrovascular disease
is to distinguish cerebral haemorrhage from infarction, and
other less frequent causes of acute neurological disturbance
such as brain tumours. A standard CT brain scan gives no
information about blood flow, and a negative CT brain scan
does not exclude infarction as the cause of the patient's
symptoms.
CT scanners are gradually being installed in most
Health Districts in the UK, so will be available to most of
the population. The proportion of patients with a stroke who
have a CT brain is not known in the UK. In 1985, Sandercock
et al suggested that a CT brain scan was justified on clini¬
cal grounds in only 25% of suspected acute ischaemic stroke
9 Q 7
patients." Now that the benefit of carotid endarterectomy
and aspirin for secondary prevention is established and
interest in acute treatment of stroke is increasing, the
clinical justification for CT brain scanning will increase.
There are several important unanswered questions
about acute ischaemic stroke which could be solved with
methodologically sound studies using CT scanning. There are
no very good studies of the frequency of haemorrhagic trans¬
formation of the infarct and the relationship to symptoms.
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The significance of early infarct visibility is unclear. The
proportion of patients who develop significant infarct
swelling and deteriorate as a result is not known. The
significance of small areas of increased density adjacent to
infarcts (sometimes labled as petechial haemorrhage) is not
known. The effects of antithrombotic, thrombolytic and
neuroprotective treatments on the natural history of acute
ischaemic stroke are unknown. One way of answering some of
these questions is by careful CT scanning (and/or MR imag¬
ing) correlated with information about blood flow patterns,
and clinical features.
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Summary of Chapter Six
1. The development of CT scanning is described.
2. Early studies of patients with acute stroke are de¬
scribed .
3. The typical appearance and evolution of cerebral infarc¬
tion and primary intracerebral haemorrhage on CT are de¬
scribed .
4. CT scanning is an excellent diagnostic tool for acute
cerebrovascular disease -it is quick, there is good access
to the patient, and it differentiates easily between haemor¬
rhage and infarction.
5. Large infarcts may be visible within a few hours of
onset: many are visible by 48 hours, though some small
infarcts and posterior fossa infarcts are never visualised.
6. Acute cerebral artery occlusion may be visible as a
hyperdense artery.
7. The rate of haemorrhagic transformation as seen on CT
scanning is discussed. The reported rates vary and the true
rate may lie somewhere between 15 and 45% for petechial
haemorrhage, and around 5% for large haematomas.
8. Post mortem series which examined the rate of haemorrhag¬
ic transformation were biased towards more severe strokes.
9. A brief description of MRI in acute stroke is given.
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Figure 1.6.1 Evolution of the density of a cerebral infarct
on CT scanning in the first five weeks after acute ischaemic
stroke : y axis = density of the infarct, x axis = time.
The range of normal density of brain parenchyma is shown by
the group of thin lines parallel to the x axis. Typically an
infarct is of low density in the first week after the
stroke, then increases in density in the second week to near
that of normal brain so that the infarct becomes more diffi¬
cult to see (hence "fogging effect"), then declines in
density from the third to fourth week onwards. Intravenous
x-ray contrast raises the density of the infarct and may
result in a higher density than normal brain in the second
week, although the net effect of contrast may be to "mask"
the visibility of the infarct if given between the second
and fourth weeks after stroke onset.(222)
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Summary of Part One
The history of stroke and the evolution of ideas
which underlie modern concepts of acute ischaemic stroke
have been outlined. A brief outline of the sequence of
events in the brain following occlusion of an artery, and
factors influencing cerebral blood flow have been described.
All of the available neuroimaging techniques have been
discussed, including the contribution each has made to
improved understanding of the aetiology, pathogenesis and
natural history of acute ischaemic stroke. The practical
aspects of each technique (or otherwise) have been empha¬
sised and how each might be useful to diagnose rapidly the
site and extent of cerebral infarction and whether the
symptomatic cerebral artery was still occluded or had reca-
nalised spontaneously. Although the latter information is
academic at the moment, if a treatment becomes available for
acute ischaemic stroke, it is possible that the risk/benefit
ratio may depend on the type of infarction. For example the
benefit of treatment such as thrombolysis might outweigh the
risks in large MCA territory infarcts where the prognosis is
very poor, but not in lacunar infarcts or small MCA branch
occlusions where the prognosis is much better.
Investigations should contribute as little as possi¬
ble to the morbidity of the disease which they are being
used to investigate. In acute ischaemic stroke it is likely
that if any treatment is to work, that it will need to be
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administered very quickly after onset of stroke therefore
investigations should give results as quickly as possible -
time delay could contribute to increased morbidity just as
much as the more "direct" adverse effects of investigations
(such as the one percent permanent neurological deficit
following angiography).
CT brain scanning is rapid, practical, reasonably
widely available, and the best way of excluding primary
haemorrhage or other cause of acute neurological symptoms.
However it does not give positive evidence of cerebral
infarction in all cases (so cerebral infarction is a diagno¬
sis by exclusion) and gives no information on arterial
patency.
There is no perfect non-invasive imaging method to
show cerebral arterial occlusion or patency. The most prac¬
tical options are Transcranial Doppler Ultrasound and the
Isotope Mean Cerebral Transit Time because they are inexpen¬
sive (and therefore potentially widely available), quick and
cause little disturbance to the patient. All the others are
expensive, slow, of little use in restless patients and not
available outside specialist centres.
Further evaluation of the Isotope Mean Cerebral
Transit Time technique will be described in Part Two. An
investigation of the relationship between cerebral blood
flow patterns, swelling in the infarct and outcome after
large acute ischaemic strokes using non-invasive imaging
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techniques will be described in Part Three. The setting up
a trial of thrombolysis in acute ischaemic stroke, using t
information gained from Parts Two and Three, will be
described in Part Four.
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Part Two
Evaluation of a Rapid Non-Invasive Method of Diagnosing
Cerebral Arterial Occlusion - The Comparison of Transcranial
Doppler Ultrasound and Isotope Mean Cerebral Transit Time in
Diagnosing the Pattern and Extent of Cerebral Arterial




Evaluation of a Rapid Non-Invasive Method of Diagnosing
Cerebral Artery Occlusion - The Comparison of Transcranial
Doppler Ultrasound and Isotope Mean Cerebral Transit Time
Imaging the Pattern and Extent of Cerebral Arterial Occlu¬
sion in Acute Ischaemic Stroke.
Introduction
2.1.1 Aim of the study
2.1.2 Introduction and Background Information
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2.1.1 Aim of the Study
The aim of the study was the further validation of
the isotope Mean Cerebral Transit Time (MCTT) as a diagnos¬
tic test for patterns of cerebral arterial occlusion in
patients with acute ischaemic stroke. The accuracy of the
MCTT was compared with Transcranial Doppler Ultrasound (TCD)
as the only practical non-invasive test of cerebral arterial
patency available, using the combination of clinical exami¬
nation and CT brain scanning as a "surrogate gold standard"
to identify the probable site of cerebral arterial occlu¬
sion, in a broad cross section of patients with acute
stroke. The intention was to devise a rapid and practical
investigative imaging strategy for patients with acute
ischaemic stroke with which to diagnose the likely site and
pattern of cerebral arterial occlusion.
2.1.2 Introduction and Background Information
Acute ischaemic stroke is heterogeneous in its patho¬
physiology, including small and large artery occlusion,
subcortical and cortical infarcts, embolic and in situ
thrombosis. No treatment is yet available, but it is con¬
ceivable that each type of stroke might respond differently
to particular forms of treatment, and that risks may vary
accordingly. For example one might be prepared to offer a
riskier treatment to a patient with a large infarct whose
prognosis without treatment was poor, but not to a patient
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with a small infarct because the latter's prognosis without
9 R
treatment was so much better. In this situation it would
be important to confirm the underlying vascular pathophysi¬
ology suggested by the clinical features guickly so that
treatment could commence as soon as possible. The longer the
time delay, the greater the number of permanently damaged
neurones and the worse the outcome. Figure 2.1.1 illustrates
schematically the concept of the "ischaemic penumbra" which
is now a relatively well established idea fundamental to the
R 1
testing of treatments for acute ischaemic stroke. If all
the neurones in the territory distal to an arterial occlu¬
sion died instantly no treatment to reduce neuronal damage
would be possible. However it is likely that variable num¬
bers of neurones survive for hours, possibly days in a "shut
down" but recoverable state, and it is for salvage of these
neurones that acute ischaemic stroke treatments are current¬
ly being tested.
In order to identify the site and extent of cerebral
arterial occlusion quickly, a simple rapid non-invasive test
is required. Like the ECG for myocardial infarction, it must
be quick, easy to do, inexpensive, and widely available as
stroke is so common. This would confirm the clinical diagno¬
sis, and could convey information about prognosis, likely
complications (for example aspiration and pneumonia in
patients with extensive MCA territory ischaemia) and treat¬
ment options.
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The two practical non-invasive imaging methods cur¬
rently available are Doppler ultrasound (TCD) and the Iso¬
tope Mean Cerebral Transit Time (MCTT). SPECT, PET, XENON CT
and MRI, as discussed in Part One, are not widely avail¬
able, are cumbersome and expensive and likely to remain so,
therefore will never be available to the generality of acute
ischaemic stroke patients. The theory and initial validation
of the MCTT has been discussed in Part One, Chapter
Five.205'214'215 It is a simple, rapid, inexpensive, non-
operator dependant test, potentially widely available as it
uses inexpensive gamma camera technology. It has previously
been found to be accurate in differentiating proximal MCA
from small cerebral artery occlusions, but the study pa¬
tients were carefully selected and few in number (only
32), J and its overall practicality and accuracy have not
been assessed in the generality of patients with acute
ischaemic stroke. The true accuracy and value of the MCTT
will only be known after it has been tested in as heteroge¬
neous a group of stroke patients as possible, including
those with cardiac disease, carotid artery stenosis, and
previous cerebral infarction. Anticipated problems include
the possibility of non-diagnostic studies in patients with
poor cardiac function (due to dispersion of the isotope
bolus), and poor patient cooperation causing movement arte¬
fact making the result uninterpretable.
Transcranial Doppler ultrasound has been available
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since 1982 and has been used in several published studies of
acute ischaemic stroke . ^8 ' ^ Training
and experience are required to obtain diagnostic results
with TCD and it is non-diagnostic in approximately ten
percent of patients because of acoustically dense bone
i no
windows. ° It may be less sensitive to cortical branch
occlusions than the MCTT. The range of normality with TCD
has been confirmed in several studies . It
is a good standard against which to evaluate the MCTT.
However, TCD is not a "gold standard" for the diagnosis of
cerebral arterial occlusion. Its operator dependancy, spa¬
tial limitations and the variability of normal cerebral
arterial anatomy mean that there is a margin of error in the
interpretation of TCD of uncertain magnitude. Cerebral
angiography with intracarotid or vertebral injection of
contrast (via the femoral route) is still the only reliable
"gold standard" for delineating cerebrovascular pathology.
But cerebral angiography is unpleasant for the patient,
invasive, carries a small but significant risk of serious
Q O Q O
complications, ' requires patient cooperation and it is
unethical as well as impractical to subject patients with
acute ischaemic stroke to angiography unless for a very good
reason. MRI angiography is becoming more practical but still
requires cooperation and is unsuitable for use in confused,
acutely ill patients without sedation. In the future, if the
treatment offered to a patient following an acute ischaemic
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stroke is directed by the underlying cerebral arterial
pathology, then it will be important to have quick, safe
methods of delineating that pathology. Cerebral angiography
will never be available to the majority of acute ischaemic
stroke patients, even in specialist neuroradiology centres -
the number of stroke patients is too great and cerebral
angiography is expensive, labour intensive and impractical.
For the purpose of testing the MCTT, the pattern of cerebral
arterial occlusion can reasonably be inferred from the CT
brain scan (patterns of infarction resulting from occlusion
at different arterial sites have been well worked out on
O Q O
CT JO) which differentiates subcortical from cortical and
posterior circulation infarction.2^®'2^^'2^2'2^ Careful CT
correlation of acute ischaemic stroke patients studied in
the Oxfordshire Community Stroke Project (OCSP) allowed the
clinical symptomatology to be matched to the vascular terri¬
tory affected and the likely underlying site of arterial
occlusion. '25'When the clinical examination findings
were expressed in terms of the OCSP classification as total
or partial anterior, posterior circulation or lacunar in¬
farction, the underlying pattern of cerebral arterial occlu¬
sion could be inferred. For example total anterior circula¬
tion infarction was likely to be due to proximal MCA main
stem occlusion, and lacunar infarction was likely to be due
to occlusion of a single lenticulostriate artery with patent
large arteries. J Good correlation between the OCSP clinical
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syndrome and the site of occlusion of the major intracranial
arteries as shown by TCD has also been found in a small
o n 1
group of patients. u The combination of CT brain scan and
clinical examination findings could therefore be used as a
reliable "surrogate gold standard" for diagnosing large
artery as opposed to small artery occlusion against which
TCD and the MCTT could be compared. Spontaneous recanalisa-
tion of the occluded cerebral artery is known to occur -
possibly up to 20% at 24 hours and up to 80% by one week
after symptom onset although the frequency of recanalisation
probably varies with the cause of the occlusion (embolic or
thrombotic) and site (large artery or small branch occlu¬
sion) .115/116/118,122,125 n vj_ew Qf this, it is only reason¬
able to assume that the symptomatic artery is occluded
within 24 hours, possibly up to 48 hours, after symptom
onset, but thereafter it will be impossible to decide from
the "surrogate gold standard" which patients have recana-
lised. Therefore the "surrogate gold standard" is only valid
within, at most, the first 48 hours after symptom onset.
It is likely that TCD, by showing increasing blood
velocity in the symptomatic MCA with time after symptom
onset, can demonstrate recanalisation of the basal intracra¬
nial arteries. It is not clear whether the MCTT can do this.
A tracer which is intravascular as long as the blood brain
barrier is intact may leak out and lead to an erroneous
result in infarcted tissue where there is blood brain barri-
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er breakdown. It is not clear what effect this might have on
Q Q jri
the MCTT. The previous study used "mTc tabled human serum
albumin rather than 99m,pc pertechnetate to avoid leakage of
tracer into infarcted brain, but the former is more expen¬
sive and the latter more accessible and practical for rou¬
tine use, therefore ^mTc pertechnetate will be used in this
study. It could be a serious drawback of the MCTT if it were
unable to demonstrate recanalised arteries in infarcted
brain (as opposed to persistently occluded arteries in
17ft
infarcted brain). Though suspected for some time, the
problems caused by altered behaviour of radiolabled tracers
used in SPECT scanning, notably HMPAO ("ceretec"), have
recently been confirmed in stroke patients and represent a
serious limitation to the use of SPECT in acute ischaemic
stroke.
Often developments - inventions, new drugs, new tech
niques - that are promising in the initial testing stage,
prove to be impractical, unreliable or dangerous when ap¬
plied in "routine" clinical practice. This study to assess
the MCTT deliberately set out to be as near to "real life"
as possible. The patients were as mixed a group as possible
- all ages, some with previous stroke, all degrees of cardi¬
ac impairment - were included. Virtually all the TCD and
MCTT studies were done by one operator as soon as possible
after admission, but within practical constraints imposed by
the clinical condition of the patient, availability of
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porters, etc. The operator had minimal help when performing
the MCTT studies, most of them were not performed in a
dedicated Nuclear Medicine Department but in a side room of
the Neuroradiology Department. Therefore whatever the result
of this comparison, it will hopefully be directly translata¬
ble into general hospital practice.
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Figure 2.1.1 The Ischaemic Penumbra. Soon after a middle
cerebral artery occlusion, the neurones in the center of the
vascular territory die (black area). The neurones in more
peripheral parts of the MCA territory survive in a viable
but "shut down" state, possibly for several hours (stippled
area), though probably most of the ischaemic neurones are
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Cerebral Arterial Occlusion - The Comparison of Transcranial
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The study population consisted of as many patients as
possible admitted to the Western General Hospital, Edin¬
burgh, within 24 hours of a sudden onset neurological event
that was most likely a stroke, including patients with
previous stroke. Patients with TIAs, subarachnoid haemor¬
rhage, or who were disabled prior to this stroke (previous
severe stroke or other cause of severe disability - Appendix
8) were not included. The study ran between the 25th Novem¬
ber 1990 and the 31st August 1991. As this study was hospi¬
tal based, the study population was biased towards more
severe strokes and a higher proportion of intracerebral
haemorrhages than in a community based study.-''6,300 The
proportion of patients with each type of stroke was not
representative of their true incidence.
2.2.2 Clinical identification of patients
All patients were examined by a physician with an
interest in stroke (Dr Martin Dennis for the first six
months and Dr Richard Lindley for the last three months) and
their stroke clinical syndrome classified according to the
Oxfordshire Community Stroke Project (OCSP) clinical classi¬
fication of acute stroke (Appendix Two and see below
also).^
The beginning of the study coincided with an observa¬
tional survey of all patients with a stroke admitted to
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hospital in the North Lothian District undertaken by Dr
Martin Dennis (North Lothian Stroke Survey [NLSS]). Dr
Martin Dennis, Senior Lecturer in Stroke Medicine, in the
Department of Clinical Neurosciences at the Western General
Hospital (WGH), set up the survey to gather data on numbers
of stroke patients admitted to hospital in North Lothian,
type of stroke, use of investigations, inpatient care,
rehabilitation and outcome, as well as patients' and rela¬
tive's opinions about the adequacy of care received. This
was to provide data (there was none on stroke numbers or
current care practice) on which a comprehensive stroke serv
ice for North Lothian could be based. The NLSS started on
October 1st 1990 and ended on 31st May 1991. Dr Martin
Dennis personally examined all strokes admitted to the North
Lothian Hospitals, within 24 hours of admission, except for
a few who were examined by Dr Surat Boonyakarndle, visiting
neurologist from Thailand. Patients were identified by a
daily round of the WGH and associated hospitals, by checking
through the Casualty Department admission sheets, by direct
referral once the interest in stroke became more widely
known in the hospitals, and when patients were referred for
CT scanning. This produced as complete a list as possible of
all patients admitted to the WGH with a stroke.
After the end of the NLSS, patients were identified by
Dr Richard Lindley, Research Registrar in the Department of
Clinical Neurosciences. He continued to keep a list of all
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patients admitted with an acute stroke to the WGH by meeting
the receiving Medical Registrar every morning to find out
about the previous day's admissions, and by checking the
Casualty Department admissions list. He also carried a
radiopager for an acute stroke treatment trial (the Interna¬
tional Stroke Trial [1ST]) and was available for advice
regarding randomisation of stroke patients in the 1ST admit¬
ted to the WGH. Thus a complete list of all patients with an
acute stroke admitted to the WGH was obtained from the 25th
November 1990 until the 31st August 1991.
2.2.3 Clinical classification of the stroke syndrome
A thorough history was obtained either from the
patient, close relative, or person who found the patient if
they lived alone and were unable to give a history them¬
selves. Time of symptom onset, past medical history (partic¬
ularly of hypertension and cardiac disease) and drug treat¬
ment prior to the stroke were sought. If the patient awoke
with the stroke the time of onset was taken to be midway
between the time of going to sleep and waking. If the pa¬
tient was unable to give a history, the time of stroke was
deduced from a combination of the time at which the patient
was found and what the patient appeared to have been doing
at the time of the stroke (for example eating breakfast or
getting dressed).
Hypertension was classified as "treated controlled",
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"treated uncontrolled", or "untreated". "Treated controlled"
hypertension was based on a statement from the GP in the
referral letter or in the patient's hospital case notes from
previous attendance that the patient was hypertensive and on
treatment. "Treated uncontrolled" hypertension was based on
the same information from the GP or case notes, but the
patient's diastolic blood pressure was more than 95 mmHg
(recorded by the ward nurses) at the time of admission.
"Untreated" hypertension was if the patient's diastolic
blood pressure was more than 95 mm Hg at the time of admis¬
sion with no past history of hypertension. These categories
were not intended to make the diagnosis of hypertension, but
simply to be a practical and quick method of identifying
possible hypertensive patients prior to performing the MCTT.
Blood pressure may be elevated on admission to hospital and
following an acute stroke even in patients who on follow-up
are found to be normotensive. However some sort of "yard¬
stick" was required to identify a group of patients whose
MCTT might be non-diagnostic because of impaired cardiac
function. Similarly evidence of previous myocardial infarc¬
tion, angina, atrial fibrillation, cardiac failure or cardi¬
ac valve disease was sought, as these might be useful simple
markers of impaired cardiac function.
A careful clinical examination including detailed
neurological examination was performed and the patient was
classified into one of the categories of stroke according to
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the OCSP clinical classification of acute stroke syndromes.
The OCSP clinical classification classifies all acute stroke
patients into one of four clinical syndromes: J
Total Anterior Circulation Syndrome (TACS)
Partial Anterior Circulation Syndrome (PACS)
Posterior Circulation Syndrome (POCS)
Lacunar Syndrome (LACS)
This is a simple classification to apply and most patients
fit fairly easily into one of the categories. When used to
describe cerebral infarction, the abreviations TACI, PACI,
LACI and POCI were used, the "I" indicating "infarction".
The clinical features of each of the syndromes are as fol¬
lows :
1) Total Anterior Circulation Infarction (TACI) : Patients
had to have all three of a) new higher cerebral dysfunction
(eg dysphasia, dysgraphia, visuospatial disorder); b) homo¬
nymous visual field defect; and c) ipsilateral motor and/or
sensory deficit of at least two areas of the face, upper
limb and lower limb. If the conscious level was impaired and
formal testing of higher cerebral function or the visual
fields was not possible, a deficit was assumed to be
present.
2) Partial Anterior Circulation Infarction (PACI) : Patients
presenting with only two of the three components of the
TACI; or with higher cerebral dysfunction alone; or with a
motor/sensory deficit more restricted than those classified
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as a LACI (eg confined to one limb, or to face and hand but
not to the whole arm).
3) Posterior Circulation Infarction (POCI) : Patients pre¬
senting with any of the following; ipsilateral cranial nerve
palsy with contralateral motor and/or sensory deficit;
bilateral motor and/or sensory deficit; cerebellar dysfunc¬
tion without ipsilateral long tract deficit (ie not ataxic
hemiparesis); or isolated homonymous visual field defect.
4) Lacunar Infarction (LACI) : Patients presenting with pure
motor stroke, pure sensory stroke, sensori-motor stroke, or
ataxic hemiparesis. Although patients with faciobrachial and
brachiocrural involvement were included, those with more
restricted deficits were not (these being PACIs).
2.2.4 Consent for participation in the study
The permission of the patient (or relative if the
patient was unable to communicate) and the attending medical
staff was obtained prior to performing the imaging studies.
In many cases the CT brain scan was performed at the request
of the attending physician to aid clinical management, and
was not done purely for research purposes. Approval for the
studies was obtained from the Lothian Area Ethics of Medical
Research Subcommittee, and for the use of radioisotopes from
the UK Administration of Radioactive Substances Advisory
Committee (ARSAC).
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2.2.5 Timing of the imaging studies
The TCD, MCTT and CT brain scans were performed as
soon as possible after stroke onset, but with a maximum time
lapse of 48 hours. The TCD and MCTT studies were performed
at the same time if possible, but with a maximum time lapse
between the two of twelve hours. Occasional patients with
symptoms of extensive acute cerebral ischaemia had their
first imaging study later than 48 hours (usually because of
delay in admission to hospital) because these cases were of
particular interest to the study of the relationship between
oedema in cerebral infarcts and cerebral perfusion (see Part
Three), and were included in the comparison of TCD and MCTT.
End Tidal CO2 was measured using a Datex "Normocap
200" end tidal C02 monitor and a light plastic mask which
fitted gently over the nose and mouth without interfering
with the patient's breathing, during the TCD and MCTT stud¬
ies to ensure that any discrepancy between the results was
not simply due to variation in respiration.
2.2.6 Imaging Studies - CT Brain Scans
The CT brain scans were all performed in the Depart¬
ment of Neuroradiology, Western General Hospital, using a
IGE 8800 Scanner with a fast image processing upgrade. A
standard axial brain scan was performed with the patient
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supine (or as near to as possible) in one centimetre slice
intervals (one cm thick) from the foramen magnum to the
vertex. In cases of suspected posterior fossa ischaemia
additional images at 0.5 cm intervals were obtained of the
posterior fossa. Intravenous radiographic contrast was not
given routinely. The CT brain scans were done as soon as
possible after symptom onset, preferably within 24 hours.
Many patients had their CT brain scan repeated in the second
week after the stroke, although this was not specified in
the study protocol. The follow up CT brain scan was per¬
formed either as part of the International Stroke Trial
Pilot protocol, or as part of the study described in Part
Three of this thesis.
The scans were initially reviewed by myself and a
simple coding system worked out for describing the site and
extent of the symptomatic lesion (described below). Evidence
of previous stroke was noted. Later the CT scans were re¬
viewed blind to the clinical, TCD and MCTT information
independently by myself and Dr RJ Sellar, Consultant Neuro¬
radiologist to assess interobserver variability in reporting
of the scans, and to obtain objective and unbiased descrip¬
tions of the abnormalities.
A "recent" infarct was identified as an area of
decreased density (with respect to normal brain parenchyma),
usually associated with some mass effect, on the CT scan
which conformed to an arterial territorial distribution as
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described in Part One, Chapter Six. An "old" infarct (ie
more than three months old) was identified as a well defined
area of marked hypodensity with respect to normal brain (of
similar density to CSF) associated with some atrophy of
adjacent structures. A haematoma was identified as a rounded
area of increased density with respect to normal brain,
associated with mass effect.
The need for a simple classification of cerebral
infarcts as seen on CT brain scans was identified because
previous attempts to describe infarcts on CT brain scans
have simply measured infarct volume and sometimes
site.2^4'^5 This conveys no information about the site or
extent of the infarct or its likely clinical impact. It also
does not allow separation of the extent of the infarct from
the amount of mass effect caused by it or the amount of
haemorrhagic transformation. The ability to separate these
factors would be useful as it might then be possible to
assess the impact of various therapeutic manoevres on the
progress of the infarct, for example whether infarct swell¬
ing was altered by a particular treatment, as seen on CT.
After review of about fifty CT brain scans showing cerebral
infarcts (some from the patients included in this study and
some from non-study patients) it became clear that the
appearance of the infarcts tended to follow fairly typical
and repetitive patterns. Thus it was possible to devise a
classification for the appearance of the infarct on the CT
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scan in which the site and extent of infarction, the amount
of mass effect due to the infarct and any haemorrhage asso¬
ciated with it could be coded independently. The CT scan
coding system is shown in Table 2.2.1. For example a typical
infarct in the MCA territory might involve the posterior
half of the peripheral MCA territory (cortex and white
matter immediately deep to it of the posterior temporal and
parietal lobes) but spare the basal ganglia and anterior
half of the peripheral part of the MCA territory. Another
typical though less common pattern was infarction of the
basal ganglia with sparing of the overlying cortex and white
matter (striatocapsular infarct). Infarcts outside the MCA
territory also followed fairly repetitive patterns in the
ACA, PCA and borderzone areas between the major arterial
territories and in the brain stem and cerebellum. Patterns
of cerebral infarction and the site of underlying arterial
occlusion have been elucidated in previous studies.
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Although some variability of vascular territo¬
ries in the brain is recognised, in general patterns of
infarction tend to be fairly repetitive,^®4 as arterial
vascular territories are relatively consistent.
Infarcts in the MCA territory were coded from "10" to
"80" according to increasing extent, "10" being a small
cortical infarct and "80" being an infarct of the whole MCA
territory. PCA infarcts were coded "01", ACA were "02",
infarction of any borderzone was "03", cerebellar and brain
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stem were "04", and lacunar infarcts were "05". Combinations
of codes could be used for patients with more than one
recent symptomatic infarct, for example "41" was infarction
of the anterior half of the peripheral MCA territory plus
the PCA territory. This classification was found to be
simple to apply. Figure 2.2.1a illustrates the coding for
the site and extent of the infarct, Figure 2.2.1b for the
amount of swelling in the infarct, and Figure 2.2.1c for
haemorrhagic transformation of the infarct. The coding for
infarct swelling and haemorrhagic transformation are includ¬
ed here for completeness, but apply to the study described
in Part Three.
Interobserver reliability for the CT infarct classi¬
fication was tested using Kappa statistics following the
review of all the study patients' CT brain scans independ¬
ently by the author and Dr R J Sellar, blind to clinical
information and classification according to the coding
system illustrated in Figure 2.2.1a - c. Where ther was any
disagreement, discussion was held and a consensus diagnosis
reached. In cases where there was still disagreement (very
few) a third blinded opinion was obtained from another
consultant Neuroradiologist (Dr GT Vaughan or Dr D Kean).
The accuracy of the OCSP clinical classification in
predicting the site and size of the cerebral infarct on CT
brain scanning was also tested. The clinical syndrome -
TACI, PACI, LACI, or POCI - in the patients with infarcts
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(as opposed to haemorrhages) was compared with the CT brain
scan appearance of the recent infarct and the sensitivity,
specificity, positive and negative predictive value and
accuracy of the OCSP classification calculated. Table 2.2.2
shows the clinical syndromes and the types of infarction
shown on the CT scan which were considered to be compatible.
A large MCA territory infarct involved the whole of the
cortex and adjacent white matter, plus part or all of the
basal ganglia supplied by the MCA ("60" to "80") and was
considered compatible with a TACI. A medium-sized MCA terri¬
tory infarct involved about half of the cortex and adjacent
white matter supplied by the MCA but spared the basal gan¬
glia ("40" to "50") and was considered compatible with a
TACI or a PACI. A small cortical infarct involved only a
small area of cortex, ie less than one quarter of the whole
cortex supplied by the MCA ("10") and was compatible with a
PACI. A large subcortical infarct (striatocapsular - "20" or
"30") was considered compatible with a TACI or a PACI.
Medium-sized cortical and large subcortical infarcts were
considered to be compatible with the clinical diagnosis of
either a TACI or a PACI because clinically there is a grey
area of overlap between the two syndromes - the exact dis¬
tinction is probably not important - a PACI which is nearly
severe enough to be a TACI and a true TACI both indicate
significant cortical or subcortical damage. Small subcorti¬
cal infarcts ("05") were considered compatible with a LACI.
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Infarcts in the territory of the PCA, brain stem or cerebel¬
lum were considered compatible with a POCI. PAtients with a
PACI or LACI clinical syndrome and a borderzone infarct on
the CT scan were classified as "borderzone PACI" or "border-
zone LACI". Patients whose CT scan did not show a recent
infarct (ie CT negative) were considered to be "unconfirmed"
PACI, LACI or POCI depending on the clinical syndrome.
The CT brain scan and clinical examination findings
were then combined to be used as the "surrogate gold stand¬
ard" for assessment of the probable pattern of cerebral
arterial occlusion, against which TCD and MCTT could be
assessed. If the clinical examination and CT brain scan
findings were in agreement, then the "gold standard" was
acceptable. However if the clinical diagnosis differed from
the CT brain scan, for example clinical examination suggest¬
ed a lacunar syndrome and the CT brain scan showed a recent
small cortical infarct but no lacunar infarct, then the CT
brain scan diagnosis was taken to be correct. In patients
whose CT brain scan failed to show a recent infarct the
clinical diagnosis was used prefixed with the qualification
"unconfirmed" for example "unconfirmed LACI".
2.2.7 Imaging Studies - Transcranial Doppler (TCD)
TCD was performed using equipment mounted on a stand¬
ard National Health Service tea trolley which could be taken
to the patient, thus reducing time delays. An Eden Medical
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Electronics (EME) TC 64B machine with a hand held 2MHz probe
was used. Beam intensity was kept at the minimum level at
which satisfactory Doppler signals could be obtained. For
each patient both ACAs, MCAs, and PCAs were insonated
through the temporal bone windows, and the opthalmic arter¬
ies and carotid siphons through the orbits routinely, as
described in Part One Chapter Four. The vertebral arteries
were insonated from the posterior auricular approach, and
the basilar artery through the foramen magnum in occasional
patients but not routinely.
The MCA was insonated from its origin to the M2
segment by altering the focus of the beam from 65 to 35 mm
depth. The ACA was insonated at 65 to 75 mm depth, and the
PCA from 60 to 80 mm depth, at which point it was often
possible to record the bidirectional signal from the tip of
the basilar artery.
The TCD studies were done as soon as possible after
admission of the patient (within a maximum of 48 hours of
stroke onset), as blind as possible to the clinical state of
the patient, only the stroke patient's name and ward being
known. The TCD studies were often done at the patient's
bedside, with the patient supine. The TCD result was written
down on the patient's study record sheet prior to finding
out the clinical examination findings or the CT scan or MCTT
results.
As the blood velocity in the intracranial arteries
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varies with age, blood pressure, haematocrit,
128,133,144,145,146 and possibly position of the patient,
the absolute value of the blood velocity in the symptomatic
artery is not very meaningful. It is more useful to record
the velocity in the symptomatic artery as a proportion of
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the velocity in the asymptomatic artery. A simple
coding system was devised as a way of expressing this in a
ranked scale, shown in Table 2.2.3. This coding allowed the
pattern of each patient's intracranial blood velocity to be
described with a simple three digit number that stated the
degree of reduction in the MCA flow velocity on the sympto¬
matic side (first digit), the adequacy of collateral flow to
the MCA territory from the ACA and PCA (second digit), and
the likelihood of ICA disease in the neck by identifying
reversed direction of flow in the opthalmic arteries and the
ACA (third digit). The symptomatic MCA blood velocity had to
be reduced by at least 25% of the value on the asymptomatic
side to count as a reduction (or increased by more than 25%
to count as an increase) and reduction by further 25% incre¬
ments used to indicate further degrees of reduction in
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symptomatic MCA blood velocity. JO Similarly the ACA and PCA
blood velocities had to be increased by at least 25% of the
value on the asymptomatic side to count as an increase,
although it should be noted that there is greater side to
side variation in the ACA and PCA velocities due to greater
anatomical variation than in the MCA's.
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The three digit code facilitated comparison with the
pattern of cerebral arterial occlusion suggested by the MCTT
(discussed below) and with the combined "gold standard" of
the clinical examination and CT brain scan findings. For
example a "600" (normal MCA blood velocities) would be
compatible with a lacunar infarct or a small MCA cortical
infarct (small PACI) or a POCI; a "500", "400" or possibly a
"300" (indicating decreased blood velocity in the symptomat¬
ic MCA) would be compatible with a medium sized MCA cortical
infarct (PACI or TACI); and a "300", "200", "100" or "000"
would be compatible with a large MCA cortical infarct
(TACI).
2.2.8 Imaging Studies - the isotope Mean Cerebral Transit
Time (MCTT)
The MCTT studies were done according to the method
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described in Part One, Chapter Five. Technetium Pertech-
netate (600MBq) was used as the tracer. The studies were
done in either the Department of Nuclear Medicine just above
the hospital Admissions area, or in the Department of Neuro¬
radiology. Studies acquired in the Department of Neuroradi¬
ology were saved onto a floppy disc, taken to the Department
of Nuclear Medicine, and transferred into the computer
system for analysis and storage of data. The MCTT studies
done in the Department of Neuroradiology were all done by
myself, occasionally with the assistance of the nurse accom-
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panying the patient (who had no radiographic or nuclear
medicine training). In the Nuclear Medicine Department the
MCTT studies were done by radiographers trained in the
technique and occasionally myself. The computer processing
of the studies was done by the radiographers, Dr MV Merrick,
one of the Nuclear Medicine registrars (radiology trainees)
or myself. The MCTT studies were interpreted blind to the
patients' clinical details, TCD or CT brain scan results by
Dr MV Merrick and myself. The MCTT studies were done as soon
as was possible and practical after symptom onset, as close
to the TCD study as possible but within a maximum of twelve
hours of the TCD study..
The result of the MCTT study was presented as a
colour coded two dimensional image of the arrival time of
the isotope in each pixel of a 32 by 32 maitrix image, and
the transit time through each pixel with a different colour
shade for each half second time difference. A normal example
is shown in Figure 1.5.4. A numerical value for arrival and
transit times in seconds for each hemisphere divided into
four "boxes" was also presented (Figure 2.2.2a). This divi¬
sion of the brain image into rectangular boxes appeared
unphysiological so the processing program was rewritten (by
Colin Ferrington, physicist) so that the brain image was
divided into eight "pie" segments (four per hemisphere)
approximately reflecting the territories of the MCA, ACA,
and PCA as viewed from the vertex (Figure 2.2.2b). To obtain
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the segmental arrival and transit time values, all the
studies were reprocessed (by myself) and the values obtained
by the "box" and "pie" methods compared with the absolute
blood velocities obtained by TCD for each intracranial
artery to see which gave the best match.
In normal subjects there should be no more than one
second difference in arrival and transit times between
one 9 14,
equivalent parts of the hemispheres. u ' Thus the right
and left frontal, parieto-temporal and occipital areas
should have arrival and transit times which differ by no
more than one second (ie two colour shades). More than one
second difference indicated a delay in arrival or transit in
part or all of the hemisphere depending on how much of the
hemisphere was affected. Transit through the front two
thirds of the hemispheres was normally faster by one to two
seconds than transit through the posterior one third. Loss
of this normal "anteroposterior gradient" of transit time
may indicate bilateral internal carotid artery stenosis or
occlusion in the neck, bilateral hemispheric infarcts, or
possibly that the study was flawed technically. The range of
normal transit times has been shown to be between 2.2 and
7.7 seconds (median 4.6 seconds).2®5 Note that the range of
normal was established, not in normal volunteers, but from a
subgroup of 102 patients selected from over 2000 referred
for routine brain scintigraphy, who on follow up at one year
were confirmed as having no neurological disease. In the
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present study a transit time for the whole head above the
upper limit of the normal range was considered to be "gener¬
ally prolonged" but note that the anteroposterior gradient
and right to left symmetry could still be preserved despite
this.
The MCTT studies were coded for comparison with TCD
using the transit abnormality on the symptomatic side ex¬
pressed in terms of the asymptomatic side as shown in Table
2.2.4. The transit time pattern could be described in a
simple ranked three digit code, in similar fashion to the
TCD codes for blood velocity. The first digit described
prolongation of the transit time in the symptomatic hemi¬
sphere with respect to the asymptomatic side, "6" being
normal and "2" indicating prolongation of the transit af¬
fecting the whole of the symptomatic hemisphere. The second
digit described the amount of difference in seconds between
the two sides (ie one to two, or more than two seconds) or
whether the transit time was generally prolonged. The third
digit described loss of the normal anteroposterior gradient.
Thus an MCTT code of "200" implied occlusion of the MCA main
stem or terminal ICA and would be compatible with a TCD code
of "200" to "000", a CT brain scan showing infarction of
most of the MCA territory and a TACI clinical syndrome. An
MCTT code of "500" implied a peripheral MCA branch occlusion
and would be compatible with a TCD code of "500" to "300", a
CT brain scan showing a small to medium cortical infarct in
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the MCA territory and a PACI clinical syndrome. A normal
pattern ("600") would be compatible with a normal TCD exami¬
nation and a lacunar infarct; a "600", "500" or "400" would
be compatible with a PACI, a "400", "300" or "200" with a
TACI, and a "600" or "500" with a POCI. Thus the pattern of
cerebral arterial occlusion shown by the MCTT could be
compared with the pattern shown by TCD, and both with the
combined "surrogate gold standard" of CT brain scanning and
clinical examination findings. For analysis, both codes and
absolute values of transit time and arterial blood velocity
were used.
2.2.9 Imaging Studies - Doppler ultrasound examination of
the carotid and vertebral arteries in the neck
Duplex ultrasound (combined B mode imaging and con¬
tinuous or pulsed wave spectral Doppler) of the cervical
carotid and vertebral arteries was performed on as many
patients in the study as possible within one week of the
stroke. In most cases this was possible, but patients who
died or were discharged soon after the stroke, or were too
restless to obtain a satisfactory result, were omitted. The
examination was done to identify significant carotid disease
to aid retrospective interpretation of the TCD and MCTT.
Occasional studies were done at the reguest of the attending
clinician.
A maximum peak systolic blood velocity greater than
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1.2 ms_1 in the ICA was taken to indicate approximately 50%
stenosis, and greater than 3 ms_1 to indicate approximately
80% stenosis, combined with appropriate B mode imaging
findings. Occlusion of the ICA was diagnosed when no Doppler
signal could be obtained from the ICA and correct position¬
ing of the sampling cursor was confirmed by B mode imaging.
2.2.10 Exclusions
Some patients were later excluded from analysis when
further investigation showed the symptoms to be due to a
condition other than stroke, eg tumour. On a few occasions
the medical staff caring for the patient, or the relatives
refused permission to move the patient for a CT brain scan
or MCTT study, or the patient died before a CT brain scan or
MCTT study could be performed. Some patients were initially
misdiagnosed as a condition other than stroke, and by the
time the correct diagnosis was made, several days had
passed. Patients admitted on a Friday afternoon, or on
Saturday but whose symptoms had begun on Friday or Thursday,
and were not identified until Monday, were excluded because
the time delay to imaging was too long.
2.2.11 Statistical Analysis
The clinical and imaging data for each patient were
entered into a database (dBase 4) and analysed using the
Statistics Package for the Social Sciences program (SPSS/PC)
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using formulae for nonparametric data. Previous studies have
shown that the MCTT data are not normally distributed.
205/214 Analysis of patient characteristics, eg drug treat¬
ment, cardiac history, etc was done by hand using a Chi
sguared test. The interobserver variability (Kappa) tests
were done by hand according to the method of Sackett, Haynes
and Tugwell.^06,307
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Table 2.2.1 Coding for the CT brain scans in patients with
acute ischaemic stroke
a) Site and extent of lesion (refers only to recent lesions
ie likely to be symptomatic)
00 normal (includes age-appropriate atrophy, and
generalised periventricular lucency)
infarcts in the MCA territory :
10 small cortical infarct in the MCA territory
20 infarct involving most of the basal ganglia (larger
than 1.5 cm diameter - striatocapsular)
30 infarct in the white matter lateral to the lateral
ventrical (larger than 1.5 cm diameter - also
striatocapsular but nearer to the vertex)
40 infarct of the front half of the peripheral MCA
territory excluding the basal ganglia
50 infarct of the posterior half of the peripheral MCA
territory excluding the basal ganglia
60 infarct of the whole of the peripheral MCA
territory not including the basal ganglia
70 infarct of the whole of the peripheral MCA territo¬
ry plus the lateral part of the basal ganglia
80 infarct of the entire MCA territory
infarcts outside the MCA territory :
01 infarct of part or all of the PCA territory
02 infarct of the ACA territory
03 borderzone infarct (MCA/PCA, or MCA/ACA)
04 brainstem or posterior fossa infarct
05 lacunar infarct (small subcortical infarct less
than 1.5 cm diameter)
other :
90 primary intracerebral haemorrhage - site indicated
by code as for infarcts
Infarcts at more than one site were indicated by combining




b) Definition of the amount of swelling of the infarct
0 no swelling
1 effacement of the sulci overlying the infarct
2 1 + slight compression of the ipsilateral lateral
ventricle
3 complete effacement of the ipsilateral lateral
ventricle
4 effacement of the ipsilateral lateral and third
ventricles
5 shift of the midline structures away from the
infarcted side
6 effacement of the basal cisterns
(swelling causing midline shift but incomplete effacement of
the ipsilateral lateral ventricle was coded "5")
c) Definition of the amount of haemorrhagic transformation
of the infarct
0 none
1 petechial haemorrhage (minor punctate areas of
blood density (approx 60 to 80 Hounsfield Units) at
the margins of or within the infarct)
2 small confluent haematoma < 2 cm in diameter within
the infarct
3 haematoma > 2 cm in diameter
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Table 2.2.2 Appearance of the infarct on the CT brain scan
and the clinical diagnoses which were considered to be
appropriate to that appearance. "Small", "medium" and
"large" cortical infarcts are described in the methods.
"Large subcortical" infarct = striatocapsular infarct ("20"
or "30" in the CT infarct classification); "small subcorti¬
cal" infarct = lacunar infarct ("05" in the CT infarct
classification).
CT Brain Scan Appearance Clinical Diagnosis
large cortical infarct in the middle
cerebral artery territory TACI
medium-sized cortical infarct in the
middle cerebral artery territory TACI or PACI
small cortical infarct in the anterior
or middle cerebral artery territory PACI
large subcortical infarct TACI or PACI
small subcortical infarct LACI
cortical infarct in the posterior
cerebral artery territory POCI
brainstem or cerebellar infarct POCI
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Table 2.2.3 Codes for describing the likely pattern of
cerebral arterial occlusion suggested by TCD in patients
with acute ischaemic stroke
primary codes describing the symptomatic MCA blood velocity:
700 symptomatic MCA blood velocity 25% greater than
asymptomatic (ie hyperaemia)
600 symptomatic MCA blood velocity = asymptomatic
500 symptomatic MCA blood velocity = 50-75% (ie more than
25% reduction) of the asymptomatic blood velocity
400 focal high velocity in the symptomatic MCA with
decreased velocity superficially (ie focal stenosis)
300 symptomatic MCA blood velocity = 25 to 50% of the
asymptomatic blood velocity
200 symptomatic MCA blood velocity less than 25% of
asymptomatic blood velocity
100 absent symptomatic MCA blood velocity
000 absent symptomatic MCA and ACA blood velocity
secondary codes describing collateral flow via the
ipsilateral ACA and PCA
(to be used in conjunction with primary) :
010 increased blood velocity ACA on symptomatic side
(by 25% more than asymptomatic side)
020 increased velocity PCA on symptomatic side
(by 25% more than asymptomatic side)
030 increased velocity both ACA and PCA on symptomatic
side
tertiary codes describing collateral pathways suggesting ICA
disease proximal to the skull base
(to be used in conjunction with the primary) :
001 reversed direction of flow in the ACA on the
symptomatic side
002 reversed opthalmic artery flow on the symptomatic side
003 reversed ACA and opthalmic artery flow on the
symptomatic side
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Table 2.2.4 Codes for describing the likely pattern of cere
bral arterial occlusion suggested by the MCTT in patients
with acute ischaemic stroke
primary codes describing abnormalities in the symptomatic
hemisphere:
700 transit time on the symptomatic side faster than
on the asymptomatic
600 transit time on the symptomatic side = asymptomatic
500 transit time prolonged in the posterior half of the
symptomatic side
400 transit time prolonged in the middle half of the
symptomatic side
300 transit time prolonged in the anterior half of the
symptomatic side
200 transit time prolonged in the entire symptomatic
hemisphere
secondary codes describing the amount of transit time dif¬
ference in seconds in the area described by the first digit:
020 1-2 second difference
010 2 or more seconds difference
030 bilaterally prolonged transit (more than 7.6 seconds in
both hemispheres)
tertiary code suggesting ICA disease proximal to the skull
base :
001 loss of the normal antero-posterior gradient
The normal range of hemispheric transit time was 2.5 to 7.7
seconds, with no more than one second difference between
equivalent parts of the hemispheres. Transit time was nor¬
mally faster in the anterior 2/3 to 3/4 of the brain than in
the posterior 1/3 to 1/4, therefore loss of the normal
anteroposterior gradient indicated that the transit time
posteriorly equalled that anteriorly.
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Figure 2.2.1 A : Templates for the coding used to describe
the site and extent of the recent cerebral infarct on the CT
brain scan - i) middle cerebral artery territory infarcts.
00 (not shown) = no infarct visible, 10 = small cortical
infarct, 20 = basal ganglia infarct (>2x2x2 cm), 30 = in¬
farct of the white matter lateral to the lateral ventricle
(>2x2x2 cm), 40 = infarct of anterior half of the peripheral
MCA territory, 50 = infarct of the posterior half of the
peripheral MCA territory, 60 = infarct of the whole of the
peripheral MCA territory, 70 = 60 + infarct of lateral part
of basal ganglia, 80 = infarct of whole of MCA territory.
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Figure 2.2.1 A : Templates for the coding used to describe
the site and extent of the recent cerebral infarct on the CT
brain scan - ii) anterior and posterior cerebral arteries
territories, cerebellar and lacunar infarcts.
02 = anterior cerebral artery, 01 = posterior cerebral
artery territory (part or all of), 04 = cerebellar or brain
stem infarct, 05 = lacunar infarct (< 1.5 cm in diameter),
03 = borderzone infarct (MCA/ACA, or MCA/PCA).
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Figure 2.2.1 B : Templates for the coding used to describe
swelling in recent middle cerebral artery territory infarcts
on the CT brain scan. The shaded area indicates the infarct.
0 = no swelling, 1 = effacement of the sulci overlying the
infarct, 2=1+ minor effacement of the adjacent lateral
ventricle, 3=1+ complete effacement of the lateral ven¬
tricle, 4=1+ effacement of the lateral and third ventri¬
cle, 5=4+ shift of the midline away from the side of the
infarct, 6 (not shown) = 5 + effacement of the basal cis¬
terns. Swelling causing midline shift but incomplete efface¬
ment of the ipsilateral lateral ventricle was coded "5".
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1 2 3
Figure 2.2.1 C : Templates for the coding used to describe
haemorrhagic transformation of the recent infarct on the CT
brain scan - any arterial territory. The shaded area indi¬
cates the infarct and the solid black area the haemorrhage.
0 = no haemorrhage, 1 = minor petechial haemorrhage, 2 =
small haematoma < 2 cm in diameter, 3 = haematoma > 2 cm in
diameter.
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Figure 2.2.2 Method of dividing the image of the cerebral
transit time into (A) boxes, or (B) wedge shaped "pie"




Evaluation of a Rapid Non-Invasive Method of Diagnosing
Cerebral Arterial Occlusion : Comparison of Transcranial
Doppler Ultrasound with the Isotope Mean Cerebral Transit
Time in Diagnosing the Pattern and Extent of Cerebral Arte
rial Occlusion in Acute Ischaemic Stroke
Results
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2.3.2 Study patient characteristics
2.3.3 CT brain scanning results including:
a) the interobserver reliability of the CT infarct
classification, and
b) the accuracy of the OCSP clinical classification
acute ischaemic stroke in predicting the site of
infarction as seen on the CT brain scan
2.3.4 Transcranial Doppler ultrasound results
2.3.5 Isotope Mean Cerebral Transit Time results
2.3.6 Comparison of the Mean Cerebral Transit Time
with the Transcranial Doppler results
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2.3.1 Study population
From 25th November 1990 to 31st May 1991 170 patients
were admitted to the Western General Hospital with a stroke
documented in the North Lothian Stroke Survey. Ninety of
these patients (53%) were included in the imaging study.
Between the end of the North Lothian Stroke Survey and the
31st August 1991 a further 51 patients were admitted to the
Western General Hospital with a stroke identified by Dr R
Lindley on a daily search of the hospital and through refer¬
rals to the acute stroke treatment trials. Thirty of these
(59%) were included in the imaging study. Reasons for exclu¬
sion of patients are given in Table 2.3.1. Fifty patients
were unsuitable for the study because they were disabled or
dependant prior to stroke, admitted electively for investi¬
gation of previous stroke, or admitted directly to the
neurosurgeons with primary intracerebral haemorrhage.
Thirty-three were missed because of admission on a Friday,
Saturday, holiday or CT scanner service day. Eleven patients
were incorrectly diagnosed by the admitting medical staff -
some as strokes which were other pathologies (five), and
vice versa (six).
It was not possible to perform an MCTT study in a
further 35 patients because: a) the attending physician
thought that the patient was too ill to be moved to the
imaging department (although the patient could be transport-
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ed and imaged on their bed) 10/35; b) the time lapse between
the TCD and MCTT studies would have been more than twelve
hours by the time the MCTT study could be performed due to
ethical and logistical problems (14/35); c) there was no
isotope available (the daily allocation for the study - two
doses - had already been used) 8/35; d) the patient was dis
charged rapidly (2/35); or e) the patient refused to have
the MCTT study (1/35). None of these exclusion criteria
would apply if the MCTT was an established diagnostic test,
rather than an experimental technique, and could be justi¬
fied on clinical grounds. The imaging survey included at
least 70% of suitable patients, a not unreasonable figure
given the practical constraints of the Neuroradiology De¬
partment hours of work.
The direct comparison between the TCD and MCTT tech¬
niques was restricted to the 85 patients who had both stud¬
ies done. However the results of TCD in all 120 patients
will also be discussed as it will be useful to compare the
patterns of vascular pathology as shown by TCD with the OCSP
clinical classification.
2.3.2 Study Patient Characteristics
The mean age of the study group was 70 years (SD: 13
years). The youngest patient was 20 and the oldest 91 years.
TCD was performed in 108 patients with acute cerebral
infarction and twelve with primary intracerebral haemorrhage
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(PICH). Of these patients MCTT was performed in 76 with
acute ischaemic stroke and nine with PICH.
When classified according to the OCSP, there were
33/108 TACI, 43/108 PACI, 19/108 LACI, 13/108 POCI in the
infarct group who had TCD : 21/76 TACI, 25/76 PACI, 16/76
LACI and 8/76 POCI of these also had an MCTT study. There
were 37/120 (31/85) patients with a past history of stroke
or TIA.
The prevalence of cardiac disease, hypertension, or
carotid stenosis as risk factors for stroke in the patients
who had both TCD and MCTT studies is shown in Table 2.3.2.
Several patients had more than one risk factor, for example
23 patients had cardiac disease and hypertension. Smoking,
family history and history of peripheral vascular disease
were not included because the primary concern was with
medical conditions which might technically impair the MCTT
result. Cardiac disease and hypertension might impair cardi¬
ac output (diluting and prolonging the isotope bolus), and
carotid stenosis might slow the arrival of the isotope on
the ipsilateral side of the brain. Smoking, family history of
stroke and peripheral vascular disease were unlikely to
influence the MCTT directly.
Cardiac disease in some form was present in three
guarters of the TACI, PACI and POCI patients, but only 40%
of LACI and PICH patients. A history of hypertension was
most common in the POCI, then LACI and PICH patients. Carot-
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id stenosis was the least frequent abnormality and was
commonest in the TACI patients (42% of the 27 patients
examined), followed by the PACI patients (24% of the 36
patients examined). Six of the TACI and one of the PACI
patients died, and six PACI and four LACI patients were
discharged before the Duplex carotid ultrasound examination
could be performed. Most of the PICH and POCI patients did
not have carotid Duplex examination because it was consid¬
ered unethical to move them to the Neuroradiology Department
(or detain them in the Department at the time of the CT
scan) just for research purposes.
Additional evidence of possible impaired cardiac
function, the patients' drug history, was examined. Fifty-
seven patients were on one or more drugs for cardiac disease
or hypertension : 28 were taking one drug, 21 were taking
two drugs, five were taking three drugs, and three were
taking four drugs.
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2.3.3 Imaging Studies - CT brain scan results including:
a) the interobserver reliability of the CT infarct classifi¬
cation, and
b) the accuracy of the OCSP clinical classification in
predicting the site of infarction on CT
All 120 patients had a CT brain scan. The mean time
to the CT scan from the stroke was 2.2 days, SD +/- 2 days
(Table 2.3.3a). The patients who on initial clinical exami¬
nation appeared suitable for entry into a stroke treatment
trial, or where the attending medical staff requested a
scan, tended to have their CT brain scan sooner than those
in whom the CT scan was not requested for clinical reasons.
a) the interobserver reliability of the CT infarct classifi¬
cation
The interobserver agreement (Kappa) for the site and
extent of the recent infarct, amount of mass effect (swell¬
ing) in the infarct and haemorrhagic transformation are
shown in Table 2.3.4. The Kappa statistics represent the
degree of agreement over and above that expected by
chance.^^'^7 A Kappa of zero represents the degree of
agreement expected by chance alone, a value of one indicates
perfect agreement. It has been suggested that a Kappa sta¬
tistic of less than 0.2 represent poor agreement, 0.21-0.4
fair agreement, 0.41-0.6 moderate agreement, 0.61-0.8 good
220
•307
agreement and 0.81 -1.0 excellent agreement. The Kappa
for infarct site and extent was 0.78 (95% Confidence Interval
(CI) 0.69 to 0.87); for infarct swelling it was 0.8 (95% CI
0.68 to 0.92); and for infarct haemorrhagic transformation
it was 0.3 (95% CI 0 to 0.77). Thus agreement was "good" and
"excellent" for infarct site and extent and for infarct
swelling respectively, but only "fair" for haemorrhagic
transformation. However the poorer agreement for haemorrhag¬
ic transformation was due to disagreement over minor degrees
of petechial haemorrhage, not over the presence of focal
haematomas. There were no important disagreements over
infarct swelling or site and extent. The Kappa for infarct
site and extent for the subgroup of patients with medium to
large cortical and subcortical infarcts (72 patients) was
0.87 (95% CI 0.77 to 0.97), and was 0.59 (95% CI 0.42 to
0.76) for the subgroup of patients with small to medium
sized cortical and small subcortical infarcts (46 patients).
This indicated that the interobserver agreement for the site
and extent of the infarct in patients with large infarcts
was "excellent" as was the agreement for infarct swelling.
The agreement for the site and extent of smaller infarcts
was only "good" due to more disagreement about a) which
"hole" in the brain was the recent infarct and b) when a
large cortical sulcus was actually an infarct or just an
enlarged space. Thus for the two experienced neuroradiolo¬
gists at least, the CT infarct classification seemed simple
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to apply and reliable with good to excellent interobserver
agreement.
b) the accuracy of the OCSP clinical classification in
predicting the site of infarction as seen on CT
The CT brain scan findings for all 120 patients are
shown in Table 2.3.5 and their OCSP clinical syndrome. Table
2.2.2 shows the OCSP clinical syndromes and CT infarct
appearances considered to be compatible, but briefly a
medium to large sized MCA territory cortical infarct or a
large sub-cortical infarct (more than two cm diameter) was
felt to be compatible with a TACI clinically. A small or
medium sized MCA territory cortical infarct and possibly a
large sub-cortical infarct were felt to be compatible with a
PACI. Small deep subcortical infarcts (less than 1.5 cm
diameter) were compatible with a LACI. Infarcts in the brain
stem, cerebellum or occipital lobes were compatible with the
clinical diagnosis of a POCI.
In the patients diagnosed clinically as a TACI (33)
the CT brain scan showed a medium to large MCA territory
infarct in 30 (91%). In three patients the CT brain scan
showed that the clinical diagnosis of infarct site and
extent was wrong - two patients had infarcts of the whole
PCA territory (left side) considered to be inappropriate,
and one patient had only a small cortical MCA territory
infarct considered appropriate as the patients symptoms had
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improved rapidly during the first 48 hours after symptom
onset. This latter patient had presented with a right hemi¬
sphere TACI syndrome which rapidly improved to a PACI syn¬
drome (weakness of the left hand only) within 48 hours of
onset. The admission CT brain scan (performed within twelve
hours) was normal in only one TACI patient, the rest all
showing subtle but definite evidence of the full extent of
their infarct on the admission CT scan (confirmed by at
least one follow up CT brain scan).
In the patients diagnosed clinically as a PACI (43)
the CT brain scan showed a small to medium sized MCA terri¬
tory infarct in 27 (63%), and an infarct of the borderzone
between the MCA and PCA territories (both right hemisphere)
in two (5%). In seven patients the CT brain scan failed to
show a recent infarct - "negative" scan - (16% - one patient
had a negative follow up CT brain scan and six did not have
a follow up scan). In seven patients (16%) the CT brain scan
showed that the clinical diagnosis of the site and extent of
infarction was wrong : one patient had an infarct of most of
the right MCA territory (inappropriately large for a PACI),
one had an infarct of part of the right PCA territory and
five (12%) had lacunar infarcts (all five were in the left '
cerebral hemisphere) all considered inappropriate. The
patient with the infarct of most of the MCA territory was
elderly, there was some difficulty in assessing her, and
debate about whether she should be classified as a TACI or
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PACI. The incorrect diagnosis of the five lacunar infarcts
(on CT) as PACI syndromes clinically may have occurred
because of occasional problems in differentiating between
minor degrees of dysphasia and dysarthria (particularly as
all were in the left hemisphere) and whether or not a mono¬
paresis was affecting the whole of or only part of a limb.
In the patients diagnosed clinically as LACI syn¬
dromes (19) the CT brain scan showed a small subcortical
(lacunar) infarct in eleven (59%), and a small infarct in
the white matter lateral to the lateral ventricle in the
borderzone between the MCA and PCA (small centrum semiovale
infarct) in one (5%). The CT brain scan was negative in five
(26% - one patient had a negative follow up CT brain scan
and four did not have a follow up scan). The CT brain scan
showed the clinical diagnosis to be wrong in two patients
(10%) who had small cortical MCA territory infarcts (one in
each cerebral hemisphere) and should have been classified as
PACI syndromes.
There were 13 patients diagnosed clinically as POCI
syndromes of whom 8 (61%) had an infarct in the brain stem,
cerebellum or occipital lobes on their CT brain scan. In
five, CT failed to show a recent infarct (38% - one patient
had a negative follow up CT brain scan and four did not have
a follow up scan). No infarcts were found in the carotid
territory in the POCI patients.
CT showed intraparenchymal haematomas in 12 patients,
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considered probably to be primary in origin. The haematomas
were of various sizes and in various sites.
The clinical diagnosis was compared with the CT brain
scan diagnosis for overall agreement. The sensitivity,
specificity, positive and negative predictive values (PPV
and NPV respectively) and accuracy of the OCSP clinical
classification for the site and extent of the infarct as
shown on CT scanning are shown in Table 2.3.6. Considering
the 91/108 patients whose CT brain scan showed a definite
recent infarct, the OCSP classification was correct in 80
(88% 95% CI 77 to 92%). The accuracy, sensitivity, specific¬
ity, PPV and NPV were best for the TACI patients. For the
analysis of all 108 patients, where in some PACI, LACI and
POCI patients the CT brain scan failed to show a recent
infarct, a "best" and "worst" scenario have been calculated.
"Best" scenario would be if the patients with persistently
negative CT scans did indeed have a recent infarct in the
area of brain predicted clinically. "Worst" scenario would
be if the patients with persistently negative CT scans
actually had an infarct in part of the brain outside the
area predicted clinically. The "best" scenario PPVs were
0.84, 0.89 and 1.0 for the PACI, LACI and POCI patients
respectively, but dropped to 0.67 (PACI), 0.63 (LACI), and
0.61 (POCI) for the "worst" scenario. The true PPVs probably
lie somewhere in between these values. Excluding the pa¬
tients whose CT scan failed to show a recent infarct from
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the analysis gives PPVs of 0.81, 0.86 and 1.0 for the PACI,
LACI and POCI patients respectively. The true accuracy of
the OCSP clinical classification probably lies somewhere in
between the "best" and "worst" scenarios, and is not best
represented by excluding those patients whose CT scan failed
to show a recent infarct.
Therefore in this group of hospital-admitted stroke
patients, the OCSP clinical classification of cerebral
infarction was shown to be reasonably accurate in predicting
the site and extent of cerebral infarction as seen on the CT
brain scan. The most freguent clinical error was diagnosing
a PACI clinically in patients whose CT scan showed a recent
lacunar infarct. The cause of the diagnostic error seems to
have been in distinguishing minor dysarthria from dysphasia.
The other main error was in diagnosing an MCA syndrome
clinically (two TACI and one PACI) in patients with a PCA
territory infarct on CT scan. This confusion has been de¬
scribed previously and occurs because proximal PCA occlusion
may cause infarction of the temporal lobe and lead to hemi-
paresis and speech disturbance in addition to visual field
•3QO
loss. yjo The clinical errors which occurred were relatively
minor, were mainly in patients with small infarcts and are
probably avoidable with greater awareness of the potential
sources of error.
A final caveat to the use of CT brain scanning as the
standard against which to judge the clinical diagnosis was
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that small infarcts (anywhere in the brain) were difficult
to diagnose particularly if the patient had marked cerebral
atrophy or periventricular low attenuation areas. It was
useful to have a normal admission CT brain scan followed by
a scan showing a new abnormality a few days later because
that was the best way of being sure that the visible lesion
was the cause of the symptoms. In patients whose admission
CT scan already showed a small infarct, particularly if it
was a lacune, it was more difficult to be certain that the
visible lesion was definitely the cause of symptoms. This
was reflected in the lower Kappa value for the group of
patients with small cortical and subcortical infarcts (0.59)
compared with the Kappa for the group of patients with large
cortical and subcortical infarcts (0.8) on blind independant
viewing of the CT brain scans by the same two neuroradiolo¬
gists. Had the ten patients with PACI and LACI syndromes and
negative admission CT brain scans without a follow up CT
scan had a repeat scan some recent symptomatic lesions might
have become visible. Of the four PACI and LACI patients with
negative admission CT brain scans who did have a follow up
scan, one of each became positive and one of each remained
negative even up to twelve days after the stroke.
For the following comparison of the pattern and
extent of cerebral arterial occlusion as shown by TCD and
MCTT, the combined "surrogate gold standard" of clinical and
CT findings was used (Table 2.3.7). Patients whose CT brain
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scan failed to show a recent infarct were classified as
"unconfirmed" PACI, LACI, or POCI. Patients with a border-
zone infarct on the CT brain scan were classified as "bor-
derzone" PACI or LACI. The final number of patients accord¬
ing to the "surrogate gold standard" who had TCD was 31
TACI, 30 PACI, seven unconfirmed PACI, two borderzone PACI,
16 LACI, five unconfirmed LACI, one borderzone LACI, 11
POCI, five unconfirmed POCI and 12 primary intracerebral
haemorrhages. The number of patients who also had an MCTT
study was 21 TACI, 23 PACI, three unconfirmed PACI, two
borderzone PACI, 15 LACI, three unconfirmed LACI, one bor¬
derzone LACI, eight POCI and nine PICH.
2.3.6 Imaging Studies - Transcranial Doppler Ultrasound
results
All 120 patients had a TCD study as soon as possible
after symptom onset. In 14 patients (11%) it proved impossi¬
ble to obtain a diagnostic signal through the temporal
bones, though signals could be obtained through the orbits.
This failure rate was similar to that found by previous
investigators,128,133,140,141
The mean end tidal C02 during the TCD studies was
4.4% (95% CI 3.2% to 5.6%).
The mean time from symptom onset to initial TCD study
was 1.8 days (SD +/- 2.9 days). The mean time to first TCD
study by stroke type is shown in Table 2.3.3b. The PACI
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patients had a longer mean time to the first TCD study (2.4
days) because of the inclusion of three patients in the
calculation who were not imaged until more than ten days
after symptom onset. The mean time to TCD for the PACI group
without these three was 1.5 days (SD +/- 1.8). In these
three patients, the true time of symptom onset was not clear
when first seen, but it was decided that these patients
should be included because the comparison with the MCTT was
still useful.
The cerebral blood velocity pattern shown by the
first TCD after admission to hospital is shown in Table
2.3.8. In Table 2.3.8 the figures in bold refer to the 85
patients who had both a TCD and an MCTT study but the fol¬
lowing text refers mainly to the 120 patients who had TCD
for clarity. In 14/120 patients it proved impossible to
obtain a Doppler signal through the temporal bone windows
(12%, 95% CI 7% to 22%). In 11 of the 85 patients who had an
MCTT study the Doppler signal was unobtainable through the
temporal bone windows (13%, 95% CI 7% to 22%).
In the thirty-one patients with large MCA territory
infarcts (surrogate gold standard : TACI) the symptomatic
MCA blood velocity was normal in four (13%) and appropriate¬
ly reduced (by more than 25% of the asymptomatic MCA blood
velocity) in 26 (84%). TCD was unsuccessful in one patient.
In the 30 patients with a small to medium sized MCA
territory infarct (surrogate gold standard : PACI) TCD was
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normal in eleven (37%), appropriately reduced compared with
the asymptomatic MCA in 14 (47%) and reduced by more than
was considered appropriate in two (7%) ie virtually undetect¬
able MCA signal. One of the two patients with a "borderzone"
PACI infarct had a normal MCA blood velocity, and TCD was
unsuccessful in the other. Five of the seven "unconfirmed"
PACI patients (66%) had normal MCA blood velocities, one
had an appropriately reduced MCA blood velocity and in one
TCD was unsuccessful.
In the 16 patients with lacunar infarcts (surrogate
gold standard : LACI) TCD was normal in eight (50%), showed
an inappropriate reduction of the MCA velocity in four
(25%), and was unsuccessful in four (25%). The one patient
with a "borderzone" LACI infarct had an inappropriately
reduced MCA blood velocity. Four of the five "unconfirmed"
LACI patients had normal MCA blood velocities, and in one
TCD was unsuccessful.
In the 16 patients with posterior circulation in¬
farcts (surrogate gold standard : POCI) 15 (94%) had normal
MCA blood velocities and TCD was unsuccessful in one. The
PCA, BA and VA blood velocities will not be discussed.
Of the 12 patients with primary intracerebral haemor¬
rhage, seven (58%) had normal MCA blood velocities, three
(25%) had an inappropriately reduced MCA blood velocity, and
TCD was unsuccessful in two.
Thus the TCD result was considered "appropriate" to
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the surrogate gold standard in 92/120 patients, or 77%, 95%
CI 69% to 84% (64/85, or 75%, 95% CI 65% to 84%), assuming
that all TACI patients should have had some evidence of
impaired flow in the symptomatic MCA. The proportion of
patients with "inappropriate" TCD findings was 14/120 pa¬
tients, or 12% (10/85, orl2%). If it is considered that the
patients with a TACI were likely to have an MCA main stem or
major branch occlusion, and the patients with PACI, LACI,
POCI and PICH should have had a patent MCA main stem and
major branches (though PACI patients could have had MCA
branch occlusions) then the accuracy of TCD for detecting
MCA main stem or major branch occlusions was 86% (95% CI 75%
to 94%). The sensitivity, specificity, PPV and NPV for TCD
detection of MCA main stem or branch occlusion is shown in
Table 2.3.9. Conversely the ability of TCD to demonstrate
likely MCA patency (ie patients with a LACI syndrome) is
shown, with the MCTT results in Table 2.3.13.
TACI infarcts should be due to MCA main stem or major
branch occlusion and consequently be associated with the
greatest decrease in the symptomatic MCA blood velocity.
However a normal blood velocity might be found in the main
stem of the MCA if early spontaneous reperfusion had oc¬
curred prior to the first TCD study, or the occlusion was in
a major branch but the flow in the patent branches was
increased in an effort to supply collateral channels. Four
of the TACI patients had a normal MCA blood velocity in the
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symptomatic MCA on the first study after admission to hospi¬
tal. One of them first evaluated with TCD six hours after
the stroke had had a myocardial infarct six days previously
and was having paroxysmal atrial fibrillation. On the morn¬
ing of the stroke she had had a negative transthoracic
echocardiogram (immediately prior to the stroke), but car-
dioembolic stroke was considered most likely. Her CT brain
scan showed an infarct of the posterior part of the peripher¬
al MCA territory so she most likely had an embolic occlusion
of a large MCA branch which could be compatible with a
normal blood velocity in the MCA main stem whether the
branch was blocked or not. Another TACI patient with normal
symptomatic MCA blood velocity (twelve hours after the
stroke) presented with the stroke but in retrospect had had
a "silent" myocardial infarction immediately prior to the
onset of the stroke (diagnosed on sequential cardiac enzyme
and ECG changes). Her CT brain scan showed infarction of
most of the MCA territory. She had a tight stenosis of the
ipsilateral ICA origin, so it is possible that her stroke
was due to hypotension at the time of the myocardial infarct
leading to impaired perfusion due to carotid stenosis. One
TACI patient with normal symptomatic MCA blood velocity (at
1.5 days after the stroke) had infarction of the anterior
half of the peripheral MCA territory in keeping with occlu¬
sion of a large MCA branch which could be compatible with a
normal blood velocity in the MCA main stem whether the
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branch was still blocked or not. The fourth TACI patient
with normal symptomatic MCA blood velocity did not have the
TCD until two days after the stroke by which time spontane¬
ous recanalisation might have occurred.
PACI strokes if large (ie two of the three components
of a TACI syndrome) would be expected to be due to a large
MCA branch occlusion so could be associated with some de¬
crease in MCA velocity, but the small PACI strokes (ie only
one of the three components of a TACI syndrome) due to small
peripheral MCA branch occlusion would not. One of the two
PACI patients with greater reduction in their MCA blood
velocity than was considered appropriate (when examined at
24 hours after the stroke) developed a striatocapsular
infarct. She had occlusion of the ipsilateral ICA and re¬
versed flow direction in the ipsilateral ACA. The MCA blood
velocity had markedly improved two days later. This suggests
that the infarct was due to terminal ICA and MCA origin
occlusion correctly detected by TCD as a low initial veloci¬
ty in the symptomatic MCA, but due to good cortical collat¬
eral arteries and early recanalisation of the MCA, the area
of the infarct remained small causing only a PACI clinical
syndrome. There was no good explanation for the inappropri¬
ately low MCA blood velocity at 24 hours in the other PACI
patient.
Lacunar infarcts due to occlusion of small lenticu-
lostriate arteries should not be associated with any de-
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crease in MCA blood velocity therefore the decrease observed
in four patients was considered inappropriate as it suggest¬
ed the presence of a large MCA branch occlusion. One of
these patients, with their infarct in the centrum semiovale
borderzone, had an ipsilateral ICA occlusion and increased
(presumably collateral) flow in the ipsilateral PCA. The
reduced MCA blood velocity could be due to the blood travel¬
ling via a long clooateral pathway from the opposite hemi¬
sphere or basilar artery to reach the MCA. In the other
three patients with LACI syndromes, there were only very
minor reductions in the symptomatic MCA blood velocities
(which perhaps should have been ignored) with no obvious
reason.
Posterior circulation strokes (presumably due to
vertebrobasilar/PCA disease) should be associated with
normal MCA blood velocities. All the patients in whom TCD
was successful had normal MCA blood velocities, even those
with infarcts of the entire PCA territory. The PCAs are more
variable anatomically and more difficult to detect reliably
with TCD.-*-4^ The failure to detect a PCA is less reliably
associated with disease than is failure to detect an MCA,
therefore (and in view of the small number of patients with
posterior circulation ischaemia) analysis of the PCA veloci¬
ties has not been performed.
Primary intracerebral haemorrhage should not have
been associated with any MCA blood velocity change unless
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the haematoma was large and compressed or displaced the MCA
1 fi *3
on the symptomatic side. Of the three patients with
reduced symptomatic MCA blood velocities, two had large
haematomas in the temporoparietal lobes but only a minor
reduction in ipsilateral MCA blood velocity, and one had a
small haematoma but more marked MCA velocity reduction. The
latter patient also had a stenosis of the ipsilateral ICA
and increased velocity in the ipsilateral ACA suggesting the
presence of coincidental atherosclerotic MCA disease.
Additional confirmation of the accuracy of TCD was
provided by post mortem examination in two patients, and by
cerebral angiography in four. In each case the vascular
pathology had been correctly shown by TCD.
2.3.5 Imaging Studies - Isotope Mean Cerebral Transit Time
85 out of the 120 patients had an MCTT study. It was
not possible to perform an MCTT study on 35 of the 120
patients because : a) the attending physicians thought that
the patient was too ill to be moved to the imaging depart¬
ment (although the patient could be transported and imaged
on their hospital bed) - 10/35; b) there was no isotope
available (the daily supply had already been used - the
supply of isotope was limited to two doses daily if used in
the morning or one dose if not used until the afternoon) -
8/35; c) the time lapse between the TCD and the MCTT studies
would have been more than 24 hours by the time the MCTT
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study could be performed due to ethical and logistical
problems (14/35); d) the patient was discharged rapidly
(2/35); or e) the patient refused to have the MCTT study
(1/35). None of these exclusions would apply if the MCTT was
an established diagnostic test rather than an experimental
technique, and could be justified on clinical grounds.
The patients' mean end tidal C02 during the MCTT
studies was 4.3% (95% CI 3.2% to 5.4%). The difference
between the end tidal C02s during the TCD and the MCTT
studues was not significant ( mean value during TCD studies
: 4.4%, 95% CI 3.2% to 5.5%).
The timing of the MCTT studies is shown in Table
2.3.3c. The mean time to performing the MCTT was 33.6 hours
(+/- 20 hours), slightly longer than the mean time to TCD
(26 +/- 17.5 hours), reflecting the greater mobility of TCD.
The mean difference between the time to TCD and to the MCTT
studies from stroke onset was -8.6 hours (95% CI of the
difference -6 to -11 hours).
Three of the MCTT studies were unsuccessful due to
technical faults in acquiring or in processing the data
(gamma camera failure or computer fault). In a further six
patients the MCTT was non-diagnostic because of a poor
isotope bolus input curve (visible on the computer screen
during the acquisition phase of the study) due either to
faulty injection technique (too large a volume, too slow an
injection, injection through too small a guage of needle,
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partial extravascular injection) or to impaired cardiac
function leading to dilution of the bolus as it passed
through the heart. Thus there were nine patients in whom the
MCTT was totally uninterpretable (10.5%, 95% CI 5% to 19%).
There were a further six patients whose MCTT was symmet¬
rically prolonged through both hemispheres (beyond the upper
limit of normal) but who did not have a particularly pro¬
longed and flattened input curve. The interpretation of this
finding was uncertain. One patient had tight bilateral
cervical carotid stenoses on Duplex carotid ultrasound
examination but the other five had evidence of cardiac
disease and will be discussed in detail below. If these six
were also included as "unsuccessful" MCTT studies then the
total number of unsuccessful studies was 15/85 (18%, 95% CI
10% to 27%). The difference between the proportion of TCD
and MCTT studies which were unsuccessful was not significant
(observed difference -5, 95% CI of the difference -20 to
10) .
Table 2.3.10 shows the results of the MCTT studies by
stroke type as determined by the "surrogate gold standard"
of CT brain scan and OCSP clinical findings. In the 21
patients whose combined clinical and CT brain scan findings
showed a TACI stroke, the MCTT was abnormal in all 16 pa¬
tients (76%) in whom it was successful showing delay in
transit in half or more of the symptomatic cerebral hemi¬
sphere in 15 patients and more rapid transit in the sympto-
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matic hemisphere in one. Note that this latter patient had
presented with a TACI syndrome which resolved to a mild PACI
syndrome over five days. There was evidence of reperfusion
on serial TCD studies. The faster transit in the symptomatic
hemisphere would be in keeping with reperfusion, but without
knowing which side was symptomatic, it would be easy to
misinterpret this as delay in transit in the opposite
(asymptomatic) hemisphere. The MCTT was unsuccessful in five
patients (24%) due to dilution of the isotope bolus second¬
ary to impaired cardiac function in four and generally
prolonged transit time in one (with apparently satisfactory
input bolus). Figure 2.3.1 illustrates the CT brain scan,
TCD and MCTT findings in a patient with a TACI syndrome.
In the 23 PACI patients ("surrogate gold standard" :
PACI) the MCTT was normal in four (17%) and was appropriate¬
ly abnormal (prolonged transit in less than half of the
symptomatic cerebral hemisphere) in thirteen (56%). In two
patients (8%) the MCTT showed delay in transit affecting the
whole hemisphere and this was felt to be inappropriate as it
suggested a larger deficit than was apparent clinically or
on the CT brain scan. One of these latter two patients had
an ipsilateral ICA occlusion. The other patient had a TACI
syndrome clinically at presentation which resolved to leave
a minor PACI deficit within 24 hours (only a small cortical
infarct was visible on the CT brain scan). As with the TACI
patient mentioned above, the transit was faster through the
238
symptomatic hemisphere, the MCA velocity was normal on TCD,
and this combination of findings suggests early spontaneous
reperfusion of an initially large area of ischaemic brain.
Again, not knowing which side of the brain was symptomatic,
blind review of the MCTT study suggested that the abnormali¬
ty was in the asymptomatic hemisphere. In the three "uncon¬
firmed" PACI patients (PACI clinically but negative CT brain
scan) the MCTT was normal in one, showed an appropriate
abnormality in one and prolongation of the transit time
affecting the whole hemisphere (considered inappropriate) in
the other. In two patients with a PACI syndrome clinically
and a borderzone infarct on the CT brain scan ("borderzone
PACI"), one had an appropriate transit abnormality and the
other had bilaterally prolonged transit. Figure 2.3.2 illus¬
trates the CT brain scan, TCD and MCTT results in a PACI
patient.
In the 15 patients with a lacunar infarct, the MCTT
was normal in five (33%), and showed minor insignificant
transit time asymmetry in a further four (27%) and was
inappropriately asymmetrical in three (20%). All three
patients with "unconfirmed" lacunar infarction, had a normal
MCTT study. The one patient with a lacunar syndrome clini¬
cally, a borderzone infarct on the CT brain scan (small
centrum semiovale infarct) and reduced blood velocity in the
symptomatic MCA showed minor insignificant transit abnormal¬
ity only. Figure 2.3.3 illustrates the CT brain scan, TCD
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and MCTT findings in a LACI patient.
In the eight posterior circulation infarction pa¬
tients the MCTT was normal in three, showed appropriate
minor transit abnormalities in the posterior parts of the
cerebral hemispheres in four patients and showed unexplained
abnormal transit in the anterior part of the symptomatic
cerebral hemisphere in one patient. Figure 2.3.4 illustrates
the CT brain scan, TCD and MCTT findings in a POCI patient.
In the nine patients with primary intracerebral
haemorrhage, the MCTT was normal in five, showed a minor
insignificant transit abnormality in one and a large hemi¬
spheric deficit in one patient (considered inappropriate).
Thus the MCTT showed an "appropriate" result in 62 of
the 85 patients (73%, 95% CI 62 to 82%). The sensitivity,
specificity, PPV and NPV for the MCTT in detecting probable
MCA main stem occlusions (ie the patients likely to have
reduced blood velocity in their symptomatic MCA and a TACI
syndrome clinically) are shown in Table 2.3.12. The accuracy
of the MCTT and TCD in detecting a patent MCA (ie patients
likely to have a LACI syndrome) is shown in Table 2.3.13.
Closer examination of the patients with non-diagnos¬
tic MCTT studies showed a higher frequency of certain mark¬
ers of impaired circulatory function than in patients with
studies which were considered to be non-diagnostic (Table
2.3.11). Atrial fibrillation (with rapid or controlled
ventricular rate) or untreated congestive cardiac failure
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were particularly likely to yield a non-diagnostic MCTT
study (odds ratios 4.3 and 5.5 respectively) whereas a
history of myocardial infarction or hypertension were not
(odds ratios 1.5 and 0.5 respectively). Angina was apparent¬
ly associated with greater likelihood of a non-diagnostic
MCTT study, but this was probably due to the coexistance of
atrial fibrillation in all three patients who had angina.
Previous stroke had no influence on the technical adequacy
of the MCTT : of the 31 patients with a history of previous
stroke, 27 had diagnostic and four (13%) had non-diagnostic
MCTT studies, compared with the 54 patients with first ever
stroke in whom 43 had diagnostic and 11 (20%) had non-diag¬
nostic MCTT studies.
2.3.6 Comparison of the Mean Cerebral Transit Time with the
TCD results : a) the ability of each to demonstrate likely
MCA patency or occlusion,
b) the results of the few follow-up MCTT studies performed
and comparison with serial TCD examinations, and
c) the comparison of the absolute values of the hemispheric
transit time and MCA blood velocity.
a) the ability of the MCTT and TCD to demonstrate likely MCA
patency or occlusion
The accuracy and practicality of TCD and MCTT in
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diagnosing the pattern and extent of cerebral arterial
occlusion were compared in the 85 patients who had both
studies using the combined CT brain scan and clinical find¬
ings as the "surrogate gold standard" for the likely site of
cerebral arterial occlusion (Table 2.3.10).
TCD was unsuccessful due to poor temporal bone win¬
dows in eleven of the 85 patients (13%, 95% CI 7 to 22%).
There were nine patients in whom the MCTT result was totally
uninterpretable (10.5%, 95% CI 5 to 19%). There were a
further six patients whose MCTT was bilaterally and symmet¬
rically prolonged beyond the upper limit of normal who did
not have a particularly prolonged or flattened isotope input
curve. If these six were also included as unsuccessful MCTT
studies then the total number of unsuccessful studies was 15
(18%, 95% CI 10.2 to 27.4%). The difference between the
proportion of MCTT and TCD studies that were unsuccessful
was not significant (observed difference -5, 95% CI -20 to
6).
The TCD result was considered "appropriate" in 64 of
the 85 patients (75%, 95% CI 65% to 84%) and the MCTT showed
an "appropriate" result in 62 of the 85 patients (73%, 95%
CI 62 to 82%). If the patients who had a "bilaterally and
symmetrically prolonged transit" were considered to have a
"normal" result (ie no hemispheric asymmetry) then the
proportion of patients with an "appropriate" MCTT result was
67 of the 85 (79%, 95% CI 67 to 87%). The proportion of
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patients with "inappropriate" TCD findings was ten out of 85
or 12% (95% CI 6 to 21%), and the proportion with "inappro¬
priate" MCTT results was nine out of 85 or 10.6% (95% CI 4
to 18%).
The patients in whom there was disagreement between
the TCD and MCTT results were as follows. Four of the pa¬
tients with clinical and CT brain scan findings compatible
with a TACI, in whom the blood velocity in the symptomatic
MCA should have been reduced compared with the asymptomatic
side, actually had normal blood velocity in the symptomatic
MCA on TCD. In two of these patients, the MCTT was techni¬
cally a failure; in another the MCTT was non-diagnostic
probably due to impaired cardiac function (the patient had
recently had a myocardial infarct and was in atrial fibril¬
lation) ; in the fourth, the MCTT showed a transit abnormali¬
ty in the symptomatic cerebral hemisphere, but smaller than
that expected from the CT and clinical features. This latter
patient had ipsilateral ICA origin and MCA stenoses (diag¬
nosed by Duplex examination of the cervical carotid arteries
and TCD) and in retrospect had probably suffered a myocar¬
dial infarct immediately prior to the onset of the stroke
symptoms. It is possible that the cerebral infarct was
secondary to a hypotensive episode around the time of the
myocardial infarct superimposed on the ICA and MCA stenoses,
but that no actual mechanical arterial occlusion occurred.
This would explain both the apparently normal MCA blood
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velocity and the small transit abnormality on the MCTT, but
is conjectural.
The patients with combined CT brain scan and clinical
features in keeping with a PACI tended to have fewer abnor¬
malities detected by TCD (10 normal : 11 appropriate) than
by the MCTT (4 normal : 15 appropriate). This suggested that
the MCTT was more sensitive to MCA branch occlusions than
was TCD.
The patients with the combined CT brain scan and
clinical features in keeping with lacunar infarction should
all have had normal TCD and MCTT studies, but four patients
had reduced blood velocity in the symptomatic MCA on TCD and
three had prolonged transit in the symptomatic hemisphere on
MCTT. Of the three patients with reduced MCA blood velocity,
one had mildly prolonged transit in the symptomatic hemi¬
sphere; two had normal transit, and in the fourth an MCTT
study was not performed. Of the remaining two patients with
inappropriately prolonged transit time in the symptomatic
hemisphere, one had normal symptomatic MCA blood velocity
and TCD was unsuccessful in the other. There were no good
explanations for the reduced MCA blood velocities, or the
transit abnormalities in any of these patients. The patient
with the borderzone LACI had decreased blood velocity in the
symptomatic MCA probably due to ipsilateral ICA occlusion,
as discussed above. The MCTT was normal.
The patients with posterior circulation infarction
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all had normal MCA blood velocities as expected. The PCAs
are difficult to evaluate with TCD as there is so much
normal variation in the arterial anatomy therefore the PCA
velocity findings are not regarded as reliable in acute
ischaemic stroke. The MCTT showed transit abnormalities in
the posterior part of the symptomatic hemisphere in four of
the eight patients and was therefore considered quite sensi¬
tive to posterior circulation ischaemia.
If it is considered that the patients with a TACI
clinical syndrome and an extensive MCA territory infarct on
their CT brain scan should have had an MCA main stem or
major branch occlusion and the patients with PACI, LACI,
POCI and PICH should have had a patent MCA main stem and
major branches (though PACI patients would have had minor
MCA branch occlusions) then the sensitivity of TCD for
detecting MCA main stem or major branch occlusion was 90%
(95% CI 70 to 99%) and of the MCTT was 94% (95% CI 71 to
99%), if those patients with bilaterally prolonged transit
were counted as "normal" MCTT results (Table 2.3.9 and
2.3.12). Using the same criteria, the specificity of TCD for
MCA main stem or major branch occlusion was 85% (95% CI 72
to 93%), and of MCTT was 86% (95% CI 75 to 94%). The post
test positive predictive value of TCD was 70% (95% CI 50 to
86%) and of the MCTT was 67% (95% CI 45 to 84%). The post
test negative predictive value of TCD was 96% (95% CI 85.5
to 95.5%) and of MCTT was 98% (95% CI 90 to 100%). There was
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no significant difference in any of these figures between
the two techniques.
If it is considered that patients with lacunar in¬
farction on the CT scan and a lacunar syndrome clinically
should have had a patent ipsilateral MCA then the accuracy
of TCD for detecting a patent MCA in patients with a LACI
was 60% (95% CI 47% to 71%) and of the MCTT was 90% (95% CI
80% to 96%). The sensitivity, specificity, PPV and NPV as
well as accuracy are shown in Table 2.3.13.
b) results of the few follow-up MCTT examinations performed
and comparison with results of serial TCD examinations
The majority of the comparison described in Part Two
was to determine the ability of TCD and the MCTT to diagnose
the pattern of arterial occlusion on the first examination
after symptom onset. However some patients with TACI or
extensive PACI syndromes had serial TCD examinations as part
of the study described in Part Three. Ten of these patients
had a second MCTT study also. There were six patients with
definite evidence of improved blood velocity in the sympto¬
matic MCA on serial TCD examinations within the first two
weeks of stroke onset. In all six the MCTT showed a less
pronounced transit abnormality on the second study at seven
to ten days compared with the admission MCTT study, which
would be in keeping with improved blood flow to the sympto¬
matic hemisphere. The other four patients, with no evidence
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of any improvement in symptomatic MCA blood velocity on TCD
within two weeks of stroke onset, showed no change in trans¬
it time through the symptomatic hemisphere on the second MCTT
study, in keeping with persistent arterial occlusion.
Note that there were two further patients, one with a
TACI and one a PACI clinical syndrome, whose symptoms re¬
solved rapidly after admission. The TACI patient had reduced
blood velocity in the symptomatic MCA on admission which
increased to normal within the first three days of admis¬
sion. The PACI patient had normal blood velocity from admis¬
sion onwards. Both showed faster transit through the sympto¬
matic hemisphere than through the asymptomatic on the MCTT
study done at 36 hours after the stroke, but without the
clinical information of which side of the brain was sympto¬
matic, it would be easy to misinterpret this finding as
delayed transit in the hemisphere which was actually asymp¬
tomatic .
There is therefore some evidence that the MCTT tech¬
nique may show changes compatible with reperfusion, and
further evidence of its agreement with the patterns of
arterial occlusion as showm by TCD. It must be emphasised
however that the ability of the MCTT to demonstrate reperfu¬
sion is based on a very limited patient sample and that the
study was not primarily designed to examine serial MCTT
findings. A much larger prospective study will be required
to define the true accuracy of the MCTT in demonstrating
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reperfusion.
c) the comparison of the absolute values of transit time and
blood velocity
For a final comparison of TCD and the MCTT, the peak
and mean blood velocities in the symptomatic and asymptomat¬
ic MCAs were plotted against the absolute values of the mean
transit time from the part of the cerebral hemisphere corre¬
sponding with the MCA territory. When originally devised,
the computer analysis of the MCTT image gave a numerical
value for transit through the whole hemisphere (in seconds)
and also subdivided each hemisphere into four rectangular
parts giving a numerical value for transit through each
quarter of the hemisphere (as in Figure 2.2.2). The division
of the hemisphere into "boxes" seemed unphysiological and
might not have allowed the best use to be made of the infor¬
mation yielded by the MCTT. The computer program was rewrit¬
ten, subdividing each hemisphere into four "wedge" or "pie-
shaped" segments, more closely corresponding with the major
arterial territories (Figure 2.2.2b). To decide which,
"boxes" or "wedges" was most likely to mirror the arterial
territories, the blood velocities in the MCAs, ACAs and PCAs
were compared with the transit times in the central two, the
anterior and the posterior boxes and wedges respectively.
There was a slightly better correlation between the
MCA blood velocity (peak and mean) and the wedge-shaped
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divisions of the corresponding hemisphere than with the
rectangular divisions. MCA peak velocity and MCTT wedges:
correlation 0.57, R2 0.33, P<0.0000; MCA peak velocity and
MCTT rectangles : correlation 0.54, R2 0.29, P< 0.0000.
Therefore for future studies looking more closely at indi¬
vidual arterial territories, the wedges should be used. The
difference between the two methods is not great, probably
because the number of pixels in each rectangle or wedge is
small. However on theoretical grounds and on the results of
this comparison between arterial blood velocities and trans¬
it through the anatomical area of brain corresponding with
the arterial territory, the wedges appear to fit better with
the blood velocities. The part of the cerebral hemisphere
taken to correspond with the MCA territory was the middle
two wedges shown in Figure 2.2.2.
It had previously been shown that the blood velocity
was inversely proportional to the transit time, in that the
9 14.
lower the velocity, the longer the transit time. This was
because measurement of hemispheric transit time and MCA
blood velocity both provide an index of velocity flow in the
cerebral circulation. Volume flow is proportional to the
fourth power of the radius of the artery whereas velocity
flow is proportional to the second power of the radius. The
non-linear relationship of the MCTT and the MCA blood veloc-
9 14
ity observed previously suggested that changes in MCA
blood flow velocity reflected changes in the dynamic ratio
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between cerebral blood flow and cerebral blood volume^®
assuming that the MCA radius and length remained constant
(see discussion Part Two Chapter Four). Therefore in this
comparison the reciprocal of segmental mean transit time was
plotted against MCA blood velocity to obtain a linear rela¬
tionship.
In the symptomatic hemisphere, the reciprocal of the
transit time was significantly linearly related to the MCA
blood velocity (Figure 2.3.5). Both the peak velocity and
the mean velocity were closely correlated with transit time
(correlation coefficient 0.58, R squared 0.33, P<0.0000 and
correlation coefficient 0.53, R squared = 0.28, P<0.0000
respectively).
In the asymptomatic hemisphere, there was a less
definite relationship between peak or mean MCA blood veloci¬
ty and transit time (Figure 2.3.6), mean : correlation
coefficient 0.096, R squared = 0.009, P = 0.43, and peak :
correlation 0.07, R squared = 0.005, P = 0.54).
There are several possible reasons for this apparent
discrepancy. In the asymptomatic hemisphere, the normal
autoregulatory responses should be active, whereas in the
symptomatic hemisphere, the damaged arteries and arterioles
may no longer have been able to maintain normal cerebral
blood flow so the cerebral perfusion reserve decreased and
the transit time became prolonged. No correction was made
for the patient's age, and as cerebral blood velocity has
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1 'J')
been shown to decline slightly with age whereas hemi¬
spheric transit time is unaffected by age (at least in the
one
102 "patient controls" whose age was not specified), this
may have influenced the relationship between transit time
and blood velocity in the asymptomatic hemisphere. Plotting
the transit time in the asymptomatic hemisphere against the
patients' age suggested that there might be a relationship
between the two : correlation 0.32, R 0.1, P = 0.01.
Plotting the reciprocal of the transit time in the asympto¬
matic hemisphere against age yields an even stronger corre¬
lation : correlation -0.39, 0.14, P = 0.002. Furthermore
it is possible that when the cerebral circulation is func¬
tioning normally there may be a range of blood velocities
for any given transit time and vice versa. It may be that it
is only when the cerebral circulation is stressed that the
relationship between falling blood velocity and prolongation
of the transit time becomes more obvious. No account was
taken of the patient's end tidal C02 either, but as the end
tidal C02 was the virtually identical at the time of TCD and
MCTT in each patient and alteration in end tidal C02 has
been shown to exert the same magnitude of effect on blood
9 1 A
velocity as on transit time, it would seem reasonable to
ignore end tidal C02 in the comparison.
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Summary of Chapter Three
1. A broad cross section of acute ischaemic stroke patients
were studied using the OCSP clinical classification, CT
brain scanning, TCD and the MCTT.
2. Good agreement was found between the OCSP clinical clas¬
sification of acute stroke syndrome, and the site and extent
of cerebral infarction on the CT brain scan.
3. The method of classifying cerebral infarcts as shown on
CT brain scans, intended to separate the effect of swelling
in, and haemorrhagic transformation of the infarct from the
infarct site and extent has excellent interobserver agree¬
ment between experienced neuroradiologists.
4. Transcranial Doppler ultrasound was unsuccessful in 11%
of all patients. TCD had an accuracy of 86% in diagnosing
MCA main stem occlusion.
5. The MCTT was as accurate as TCD in demonstrating likely
cerebral arterial pathology with a similar failure rate.
6. The MCTT was more often non-diagnostic in patients with
cardiac disease particularly atrial fibrillation. Presumably
this was because impaired cardiac output diluted the isotope
bolus.
7. In six patients with probable MCA main stem occlusion on
admission, a second MCTT study showed a reduction in the
hemispheric transit abnormality suggestive of reperfusion,
supported by TCD findings of increasing blood velocity in
the symptomatic MCA.
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8. There is a linear relationship between TCD blood velocity
and the reciprocal of the transit time in the symptomatic
hemisphere, but not on the asymptomatic side. Possible
reasons for this are discussed.
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Table 2.3.1 Reasons for exclusion of patients from the
TCD/MCTT imaging survey
Reason NLSS* Post Total
NLSS
Christmas or other holiday period
(emergency service only) 9 7 16
More than two day lapse from
symptom onset (eg admitted on a Friday) 7 6 13
Admitted electively for investigation
of a minor stroke (many days after event) 15 N/R+ 15
Admission direct to the neurosurgeons
with suspected PICH 15 N/R+ 15
Previous disabling stroke or dementia 15 5 20
Not diagnosed as a stroke until five
or more days after symptom onset 5 1 6
Final diagnosis not stroke
(eg TIA, cerebral metastasis) 4 1 5
CT scanner service day or breakdown 3 1 4
Stroke occurred in hospital
and referral delayed 1 0 1
Reason not known 6 0 6
Total patients admitted to hospital
Total excluded from the study










* NLSS = North Lothian Stroke Survey
+ N/R =no longer relevant as these patients were no sought
after the end of the NLSS
PICH = primary intracerebral haemorrhage
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Table 2.3.2 The prevalence of cardiac disease, hyperten¬
sion, and carotid stenosis as risk factors for stroke in the
study population by stroke clinical syndrome
TACI PACI LAC I POCI pic:
Total patients 33 43 19 13 12
A) Cardiac Disease:
No cardiac disease 9 14 11 3 7
Atrial Fibrillation 10 11 2 0 0
Previous Myocardial
Infarction 8 11 3 2 0
Angina 5 8 1 0 1
Congestive cardiac
failure - controlled 7 4 0 0 0
- active 0 1 0 0 0
Cardiac valve
disease 2 5 1 0 0
Total with at least one
cardiac abnormality
(and % of total) 24(73) 29(67) 8(42) 10(76) 5(41)




of total) 11(33) 12(28) 8(42) 9(69) 5(42)
C) Carotid Disease in the neck (diagnosed by Duplex carotid
Doppler ultrasound) - symptomatic side only referred to
(POCI patients either side of the neck):-
Normal carotids 8 13 4 4 4
< 50% ICA stenosis 6 13 8 2 1
> 50% ICA stenosis 3 5 0 0 1
ICA Occlusion 7 3 2 0 1
Not examined 9 9 3 6 5
% with > 50%
ICA stenosis 42 24 13 0 28
(of those examined)
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Table 2.3.3 Mean time from stroke onset to imaging studies
TACI PACI LAC I POCI PICH ALL
PATIENTS
A) Mean time to CT brain scan
Mean time (days) 2.3 2.6 2 . 8 1.7 1.6 2.2
+/- one SD 2.2 3.7 4.4 1.9 1.5 2.0
earliest (days) 0.06 0.16 0. 13 0. 18 0. 13 0.06
latest (days) 8.0 6.0 7.0 6.0 6.0 8.0
B) Mean time to first TCD study
mean time (days) 1.6 2.4 1.1 1.9 0.9 1.1*
+ /- one SD 1.8 4 0.9 2.5 0.5 0.73
C) Mean time to first MCTT study
mean time (days) 2.5 2.3 1.7 0.85 3.1 1.41*
+/- one SD 2 2 1 0.5 3.5 0.85
* mean of difference between the timei to the first TCD study
and the time to the MCTT study (on a paired t -test) was
-0.345 days, 95% CI = -0. 45 to - 0.24 days (ie -8 hours 20
minutes, 95% CI -10 hours 50 minutes to -5 hours 45
minutes).
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Table 2.3.4 Interobserver agreement for the two experienced
neuroradiologists using the CT infarct classification shown
in Table 2.2.1 and Figure 2.2.1
Parameter of Infarct Examined
Infarct site and extent
(all scans)
Infarct site and extent
(medium and large cortical and subcortical infarcts)
Infarct site and extent
(small cortical and subcortical infarcts)
Infarct swelling
Infarct haemorrhagic transformation
Kappa (95% confidence interval)
0.78 (0.69 to 0.87)
0.87 (0.77 to 0.97)
0.59 (0.42 to 0.76)
0.8 (0.68 to 0.92)
0.3 (0.0 to 0.77)
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Table 2.3.5 The OCSP classification in the patients with
cerebral infarcts and the appearance of the infarct on their
CT brain scan.
"Borderzone" infarcts are included as "medium-sized cortical
MCA" (2 patients) or "small subcortical" (1 patient) in¬
farcts where appropriate. Large, medium and small cortical,
and large and small subcortical infarcts are defined in the
methods (Part 2.2.6).
CT Brain Scan Diagnosis Clinical Diagnosis of Infarct Site
of Infarct Site TACI PACI LACI POCI Total
Large or medium cortical,
or large subcortical MCA/
ACA territory infarct 30 1 0 0 31
Medium or small cortical,
or large subcortical MCA/
ACA territory infarct 1 29 2 0 32
Small subcortical infarct
in the carotid territory 0 5 12 0 17
Occipital, brainstem
or cerebellar infarct 2 1 0 8 11
No recent infarct visible 0 7 5 5 17
Total 33 43 19 13 108
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Table 2.3.6 The sensitivity, specificity, positive (PPV) and
negative (NPV) predictive values, and accuracy of the OCSP
clinical classification compared with CT scanning.
"Best" scenario assumes that patients whose CT brain scan
failed to show a recent infarct did actually have their
infarct in the site predicted clinically; "worst" scenario
assumes that these patients actually had their infarct in a
part of the brain other than that predicted clinically.
Clinical Diagnosis Sensitivity Specificity Positive Predictive Negative Predictive Accuracy
of Infarct Site Value Value
TACI 0.97 0.96
PACI: best scenario 0.95 0.90
worst scenario 0.94 0.82
LACI: best scenario 0.77 0.98
worst scenario 0.71 0.92
POCI: best scenario 0.81 1.00









Table 2.3.7 The "surrogate gold standard" for the likely-
diagnosis of the site of cerebral arterial occlusion - the
combination of the clinical findings (using the OCSP classi¬
fication) and the CT brain scan result.
Number of patients with each stroke type
Number having :: TCD only TCD +
TOTAL 120 85
TACI/large
MCA infarct 31 21
PACI/small-medium
















or brain stem infarct 11 8
"unconfirmed" POCI 5 0
PICH 12 9
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Table 2.3.8 The site of likely cerebral arterial occlusion
as diagnosed by TCD in comparison with the combined OCSP
clinical and CT brain scan "surrogate gold standard".
Numbers in brackets refer to patients with "bilateral prolonged
transit time" (see text for interpretation). The patients with
"borderzone" PACI (2 patients) and LACI (1 patient) are included
as PACI and LACI respectively.
Stroke Type : TACI PACI PACI LACI LACI POCI PICH TOTAL
(unconf) (unconf)
TCD findings in 120 patients :
Total number 31 32 7 17 5 16 12 120
normal 4 12 5 8 4 15 7 55
appropriate 26 14 1 0 0 0 0 41
inappropriate 0 2 0 5 0 0 3 10
unsuccessful 1 4 1 4 1 1 2 14
TCD findings in the 85 ]patients who also had an MCTT :study :
Total number 21 25 3 16 3 8 9 85
normal 2 10 2 8 2 7 5 36
appropriate 19 11 0 0 0 0 0 30
inappropriate 0 2 0 4 0 0 2 8
unsuccessful 0 2 1 4 1 1 2 11
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Table 2.3.9 The sensitivity, specificity, positive (PPV) and
negative (NPV) predictive values, and accuracy of TCD in diagnos
ing likely MCA main stem or major branch occlusion in both the
120 patients and the 85 patients who also had an MCTT examina¬
tion, in comparison with the "surrogate gold standard". The
"bilaterally prolonged" MCTT studies are counted as "normal" in
this calculation, as they suggested that there was no interhemi-
spheric asymmetry, and therefore no proximal MCA occlusion.
Number of patients 85 120
accuracy 86% 87%
95% CI 75 to 94% 77 to 94%
sensitivity 90% 87%
95% CI 70 to 99% 69 to 96%
specificity 85% 87%
95% CI 72 to 93% 77 to 94%
positive predictive 70% 72%
value
95% CI 50 to 86% 55 to 86%
negative predictive 96% 94%
value
95% CI 86 to 99% 86 to 98%
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Table 2.3.10 The site of likely cerebral arterial occlusion as diag¬
nosed by the MCTT (and TCD) in comparison with the "surrogate gold
standard" of clinical and CT brain scan findings in the 85 patients
who had both studies.
Numbers in brackets refer to patients with "bilateral prolonged trans
it time" (see text for interpretation). The patients with "borderzone
PACI (2 patients) and LACI (1 patient) are included as PACI and LACI
respectively.





Total number 21 25 3 16 3 8 9 85
TCD :
normal 2 10 2 8 2 7 5 36
appropriate 19 11 0 0 0 0 0 30
inappropriate 0 2 0 4 0 0 2 8
unsuccessful 0 2 1 4 1 1 2 11
MCTT :
normal 0 4 1 10 3 3 5 21
appropriate 16 15 1 0 0 4 1 41
inappropriate 0 1 1 3 0 1 1 8
unsuccessful 5(1) 5(3) 0 3(2) 0 0 2 15(6)
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Table 2.3.11 The frequency of circulatory abnormalities in the pa¬
tients with "satisfactory" and "unsatisfactory" MCTT results.





cardiac failure 4 3 5.5 1 to 29
atrial 10 5 4.3 1 to 16
fibrillation
angina 6 3 3.5 1 to 17
cardiac
valve disease 4 2 3 0.5 to 16
previous
myocardial 18 4 1.5 0.4 to 5
infarct
hypertension 27 3 0.5 0.1 to 2




abnormality 23 7 3 1 to 10
no "circulatory"
abnormality 28 1 0.1 0.02 to 1
TOTAL 70 12 (+ 3 failed studies)
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Table 2.3.12 The sensitivity, specificity, positive (PPV) and
negative (NPV) predictive values, and accuracy of TCD and the
MCTT in diagnosing likely MCA main stem or major branch occlusio
in the 85 patients who had both examinations, in comparison with
the "surrogate gold standard". The "bilaterally prolonged" MCTT
studies are counted as "normal" in this calculation, as they
suggested that there was no interhemispheric asymmetry, and



























95% CI 86 to 99% 90 to 100%
265
Table 2.3.13 Accuracy, sensitivity, specificity, positive and
negative predictive values of TCD and the MCTT in predicting
likely MCA patency in the 85 patients who had both studies, usin
the OCSP clinical/CT brain scan diagnosis as the "surrogate gold
standard" for likely MCA patency, ie the ability of both tech¬

































Figure 2.3.1 Patient with a Total Anterior Circulation
Infarction : a) CT brain scan on day 3, b) MCTT study at 12
hours, and c) right PCA and left MCA blood velocities at 12
hours after symptom onset. No right MCA was detected. Note




Figure 2.3.2 Patient with a Partial Anterior Circulation
Infarction : a) CT brain scan at 4 hours, b) MCTT study at 4
hours, and c) right and left MCA blood velocities at 4 hours
after symptom onset. Note that the orientation of the MCTT




Figure 2.3.3 Patient with a Lacunar Infarction : a) CT brain
scan at 24 hours, b) MCTT study at 6 hours, and c) right and
left MCA blood velocities at 6 hours 4fter symptom onset.















Figure 2.3.4 Patient with a Posterior Circulation Infarction
: a) CT brain scan at 8 days, b) MCTT study at 7 hours, and
c) right and left PCA blood velocities at 7 hours after
symptom onset. Note that the orientation of the MCTT is
opposite to the CT scan.
c)
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Evaluation of a Rapid Non-Invasive Method of Diagnosing
Cerebral Arterial Occlusion : Comparison of Transcranial
Doppler Ultrasound with the Isotope Mean Cerebral Transit
Time in Diagnosing the Pattern and Extent of Cerebral Arte¬
rial Occlusion in Acute Ischaemic Stroke
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2.4.2 The accuracy of the OCSP clinical classification in
comparison with CT brain scanning
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classification
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2.4.6 On the comparison of the absolute values of middle
cerebral artery blood velocity and hemispheric mean
transit time
2.4.7 General points concerning the imaging investigation of
patients with acute ischaemic stroke
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Study population
The study population consisted of as many patients as
possible admitted to our hospital with acute stroke. The
largest group of patients excluded were those who reached
hospital on a Friday afternoon, Saturday or Sunday so that
the time lapse to the TCD and MCTT studies would have been
longer than 48 hours from symptom onset. It is unlikely that
patients who have their stroke towards the end of the week
are very different from those who have their stroke early in
the week, so it is not considered that this will have intro¬
duced any significant bias in terms of stroke type. Patients
who were severely disabled prior to this stroke were exclud¬
ed whether the disability was due to previous stroke or
other cause and this may have introduced some bias. However
patients with previous non-disabling stroke were included.
Most of the other patients were excluded because they did
not have an acute ischaemic stroke as the cause of symptoms.
It was very fortunate that the North Lothian Stroke Survey
was undertaken during the same period as the imaging studies
as it gave an exact count of the number of patients admitted
to our hospital with a stroke. Otherwise it would have been
difficult to obtain reliable numbers easily. Hospital in¬
patient discharge statistics are unreliable with both sig¬
nificant false positive and negative diagnoses (Dr M S
Dennis, personal communication).
The mean age of the study patients was 70 years which
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is virtually the same as the mean age of the patients in the
Oxfordshire Community Stroke Project.^One third of the
study patients had had a stroke previously and approximately
two thirds had evidence of cardiac disease of some sort or
hypertension. Therefore the study population is considered
to be reasonably representative of hospital admitted is-
chaemic stroke patients. Patients with subarachnoid haemor¬
rhage and primary intracerebral haemorrhage were largely
excluded as not relevant to the study.
2.4.2 The accuracy of the OCSP clinical classification in
comparison with CT brain scanning
At the time of the study, the OCSP clinical classifi¬
cation had not previously been evaluated prospectively. When
originally devised, each patient in the OCSP was reviewed
and their clinical and CT brain scan (where available)
findings discussed before the stroke syndrome was diagnosed.
That process is rather different to that which normally
takes place in clinical practice where, especially for acute
medical emergencies, it is necessary to decide on a working
diagnosis prior to implementing sensible investigations and
treatments. Therefore prospective assessment of the accuracy
of a clinical classification is necessary before its true
reliability can be established. The interobserver reliabili¬
ty of the OCSP clinical classification af acute stroke has
been evaluated prospectively (blind to all CT brain scan or
275
other imaging results) by Dr M S Dennis and Dr R I Lindley
-j i r\
and found to be "moderate" to "good". The classification
is practical enough for routine use to classify stroke
patients in general hospital practice. The observers agreed
in the majority of patients and the level of agreement is
likely to represent the sort of agreement found in routine
clinical practice. The level of agreement was similar to
•3 11
that found in a study by Shinar et alJ on interobserver
agreement between staff neurologists with a special interest
in stroke eliciting neurological signs in seventeen patients
with stroke.
In the present study of hospital-admitted stroke
patients, the OCSP classification was shown to be accurate
in predicting the site and extent of cerebral infarction as
shown on the CT brain scan. In the "worst" scenario, where
the patients with negative CT scans might have had an in¬
farct in a place other than that predicted clinically, the
positive predictive value fell from around 0.8 (or "best"
scenario) to around 0.7, with a similar effect on the sensi¬
tivity. However, this interpretation is unlikely to be
completely correct and it is more likely that the true
positive predictive value lies somewhere in between the
"best" and "worst" scenarios. Excluding the patients whose
CT scans did not show a recent infarct from the analysis
would not give a better estimate of accuracy as there will
always be some acute stroke patients with negative CT, or
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even MRI, brain scans for whatever reason : the lesion might
be too small to resolve with modern imaging, or there might
have been early reperfusion in some way masking the lesion.
Whatever the reason for negative imaging, these patients
might represent a different subgroup of stroke patients, but
it would be wrong to exclude them from analysis. Therefore,
the accuracy of the OCSP clinical classification has been
expressed as a range of possible values. MRI, with its
001 9 ft ^ oftS
greater sensitivity for small ischaemic lesions, °/OJ/
might give a better estimate of the accuracy of the clinical
classification. However MRI is less widely available than CT
scanning (in the UK at any rate). It is a less practical
technique for acutely ill, confused patients who may require
sedation and the scanning times are longer than for CT. It
may be difficult to exclude intracerebral haemorrhage very
2 Q 2
early after symptom onset with MRI, ° so for all these
reasons, MRI is unlikely to become a routine test for acute
TQf) "3 1 O
stroke, though it will be very useful in research. JU/J
The most frequent clinical error in this series was
diagnosing a PACI clinically in patients who actually had a
lacunar infarct on the CT brain scan (five patients). In all
of these patients the infarct was in the left cerebral
hemisphere and the source of difficulty seems to have been
in distinguishing between dysarthria and minor degrees of
dysphasia. This difficulty was also found in the Stroke Data
Bank study of interobserver agreement for neurological signs
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recorded for patients with acute stroke, where their Kappa
value for language was 0.54 and for dysarthria was 0.53,
Oil
both indicating "moderate" agreement only. Dysphasia plus
hemiparesis implies a cortical localisation and is a PACI
whereas dysarthria plus hemiparesis implies a subcortical
9 R
localisation and is a LACI. Of the two patients thought
clinically to have a LACI (but with a small cortical infarct
on their CT brain scan) one had a left and the other a right
hemisphere infarct. In the patient with the infarct in the
left hemisphere it was difficult to decide whether there was
minor dysphagia or dysarthria. The other main source of
error was in diagnosing an MCA syndrome clinically in pa¬
tients with a PCA territory infarct on the CT scan (two TACI
and one PACI patients). This confusion has been described
previously and arises because proximal PCA occlusion may
cause infarction of the temporal lobe and lead to hemipare¬
sis and speech disturbance in addition to visual field
loss.308
No clinical test, or radiological test for that
matter) is 100% accurate and the OCSP clinical classifica¬
tion was intended to be a simple, rapid, fairly reliable and
thus practical method of categorising acute ischaemic stroke
patients, which would be clinically useful to predict prog¬
nosis, plan secondary prevention and aid communication and
management decisions at a very early stage before any in¬
farct is visible on the CT scan or indeed before CT can
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practicably be performed. At present the main advantages are
the prediction of outcome and improved interdisciplinary
communication. For example 95% of patients with a TACI are
dead or disabled at one year, compared with 45% of PACI, 33%
of POCI and 33% of LACI (Figure 1.1.2).2^ PACI patients are
more likely to have early recurrent strokes than LACI pa¬
tients so should be investigated guickly to identify risk
factors (for example carotid stenosis) for appropriate
secondary prevention. As far as communication is concerned,
describing a stroke patient as having had a "TACI" is much
more informative than simply saying that the patient has a
dense hemiparesis. "TACI" indicates that the patient is
probably drowsy, may be dysphasic or have neglect (so be
difficult to communicate with and manage), compared with a
patient who has a dense hemiparesis due to a LACI who would
have good comprehension, be alert and therefore easier to
manage. By predicting the site and extent of cerebral in¬
farction the clinical classification perhaps also predicts
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the underlying pattern of arterial pathology.XJ The clini¬
cal classification is also being used for risk/benefit
analysis of clinical stroke subgroups in acute stroke treat¬
ment trials.it is possible that, in the future, the
classification could be used to identify quickly subgroups
of acute ischaemic stroke patients with a particularly poor
prognosis who might benefit from certain, perhaps more risky
types of treatment should any of them be shown to work. The
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OCSP classification may also remind doctors to examine stroke
patients for specific abnormalities, such as parietal dys¬
function and visual field loss, points which are easily and
often overlooked by the inexperienced and lead to errors in
diagnosing the site of the lesion, identifying risk factors,
recognising the extent of the patient's disability, and
initiating effective clinical management.
This prospective study has shown that usually the
OCSP clinical classification does predict the site and
extent of cerebral infarction. The clinical errors identi¬
fied are considered to be relatively minor and probably
avoidable with greater awareness of the pitfalls. The over¬
all accuracy is excellent. It is important that clinical
classifications of acute stroke are simple and quick to
apply, so that doctors will be more likely to use them, the
more likely that patients will be investigated quickly and
appropriately to guide secondary prevention, and the more
likely that acute stroke treatment trials will succeed.
2.4.3 The interobserver reliability of the CT infarct
classification
The classification of cerebral infarcts as seen on CT
brain scans was devised after a thorough review of the
literature failed to reveal a method of describing cerebral
infarct morphology which was sufficiently simple to use, and
made any attempt to separate the effect of different varia-
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bles on infarct appearance, in particular infarct swelling
and haemorrhagic transformation.Templates for the
very accurate identification of cerebral arterial territo¬
ries have been described but these are necessarily complex
and only refer to infarct site, not the other
o o o 94,^
features. ' With increasing interest in treatments for
acute ischaemic stroke and continued confusion over the
relationship between reperfusion of the occluded artery,
infarct swelling and haemorrhagic transformation, it will be
important to be able to study cerebral infarct morphology
closely. CT scanning is a very good way of doing this in
life (MRI is also useful) as post mortem studies are ham¬
pered by the fact that the patient may not die until days or
months after the stroke onset by which time the acute fea¬
tures of the infarct will have resolved. Also post mortem
rates for patients thought to have had a stroke have de¬
clined in the USA and probably also in the UK, so there is
less opportunity for pathologists to examine the brain after
an acute ischaemic stroke.
The classification described was devised after review
of many CT brain scans from acute stroke patients and was
intended to reflect the frequently observed patterns of
infarction. Although perhaps appearing complex at first, it
proved remarkably simple to use. Only three codes were
needed for describing haemorrhagic transformation and six
for infarct swelling. More codes were required for infarct
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site and extent but mainly because of the subdivisions of
the MCA territory infarcts. As the majority of infarcts
occur in the MCA territory and there was particular interest
in factors which might influence infarct swelling, it was
considered important to have sufficient MCA infarct subdivi¬
sions to allow definative separation of the effect of in¬
farct swelling from site and extent. If the classification
were to be used for other purposes, then the MCA territory
infarcts could be simplified to only four categories instead
of eight.
The interobserver agreement for infarct site and
extent (particularly for large infarcts) and infarct swell¬
ing between the two experienced neuroradiologists was excel¬
lent. It is therefore possible to use the classification as
a means of separating the effect of infarct site and extent
from infarct swelling. For example it is possible to distin¬
guish reliably between an infarct of site and extent "60"
with amount of swelling "2" and a "60" with amount of swell¬
ing "5".
The agreement for infarct haemorrhagic transformation
was less good, but this was due to disagreement over the
presence of minor amounts of petechial haemorrhage, not
about focal haematomas. The margins of an infarct, particu¬
larly the cortical margins, may appear of higher density
than surrounding normal brain. This may be partly an effect
on the eye due to the low density of the infarct making the
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adjacent normal cortex appear brighter, or there may be a
genuine increase in tissue density around the margin of an
o c p o c o
infarct ascribed to luxury perfusion, ' or there may be
true petechial haemorrhage.'S16 The disagreement over the
presence of petechial haemorrhage may explain some of the
large difference in haemorrhagic transformation rates re¬
ported in different CT (and MRI) studies. Some studies have
reported rates of petechial haemorrhage up to 45%254,316
o c c
whereas others only found it in 5% of patients. There are
other possible reasons for the wide variation in reported
rates of haemorrhagic transformation between studies includ¬
ing bias in patient selection (all studies), concurrent
treatment with antithrombotic drugs,254'^'S16 differences
q i 7
between CT scanners, and scanning at different times
after the stroke, but poor interobserver agreement may
have contributed. All studies of haemorrhagic transformation
so far have been biased because only surviving patients were
examined in the CT and MRI studies and only the patients who
died were examined in the post mortem studies. Haemorrhagic
transformation can occur without any symptomatic deteriora¬
tions1^'^17 or could be the cause of sudden deterioration in
the patient's clinical state leading to death. It is there¬
fore not valid to exclude patients who were not scanned (or
did not die) from the analysis. Nor is it reasonable to
include only patients with "presumed cardioembolic stroke"
or other subtype for example, as, with increasingly sophis-
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ticated investigative tools, it is becoming clearer that it
was probably not valid to make assumptions about the stroke
aetiology as was done in previous studies. Only a study
which includes all patients with ischaemic stroke who all
have either serial CT (or MRI) examinations or post mortem
can yield a true haemorrhagic transformation rate.
To reduce the interobserver disagreement, it would be
possible to measure the brain tissue density directly from
the image on the CT scanning consul, but not so easily from
the hard copy. However this would prolong the time taken to
review and report the CT scans and would not be practical to
do routinely, but greater awareness of this pitfall of
interobserver reliability in reporting of petechial haemor¬
rhage might help to improve accuracy.
Interobserver agreement was less good for the group
of patients with small to medium sized cortical and subcor¬
tical infarcts. The mean age of the patients in the study
was 70 years at which age generalised cerebral atrophy,
periventricular white matter lucencies and enlarged perivas¬
cular spaces (in the internal capsule and basal ganglia) are
•31 O
common. ° Patients with a history of previous stroke were
also included in the study. Although a previous study found
no evidence of bias in reporting lacunar infarcts on CT
o o o
brain scans from accompanying clinical information"6with¬
out any clinical information it can be difficult to discrim¬
inate small cortical infarcts from enlarged sulci and if
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there are numerous "holes in the brain", to decide which is
likely to be the cause of recent symptoms. The interobserver
agreement for large cortical and subcortical infarcts was
better as it was easier to identify and date large lesions.
The infarct swelling codes were not intended to describe
mass effect from large haematomas. The classification could
equally be used to describe cerebral infarcts as seen on
MRI. The interobserver agreement for the CT infarct classi¬
fication was better than has been described previously for
experienced clinicians using clinical stroke classifica-
-3 1 n 711 7iQ
tions. U/JAA/J 3 It was also on the whole better than the
interobserver agreement reported in previous studies of CT
scans in acute ischaemic stroke patients, which was in any
j 263,264case good. '
Therefore the method of classifying cerebral infarcts
as seen on CT brain scans is sufficiently good and reliable
to be useful in stroke research as well as in clinical
practice. Use of the infarct morphology classification would
allow study of the effect of therapeutic interventions for
acute ischaemic stroke, for example thrombolysis, neuropro¬
tective agents, etc, on infarct morphology (swelling and
haemorrhagic transformation) as surrogate, but useful,
endpoints.
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2.4.4 The accuracy of Transcranial Doppler Ultrasound
There have now been numerous studies of cerebral
arterial blood velocities in acute ischaemic
stroke,2^8'^9'^" some with angiographic correlation,
138, 143, 154,156, 158,159 an(^ some which matched the clinical
stroke type (ie large artery occlusion or lacune) to the TCD
O1O 701
findings. ± All have depended on identifying a reduced
or "missing" arterial blood velocity signal in one of the
basal intracranial arteries (usually the MCA) on the sympto¬
matic side when compared with the asymptomatic side to
diagnose arterial occlusion. Side to side variability in the
peak and mean blood velocities in the basal intracranial
arteries has been established in several studies, all of
which were in agreement that a reduction in the mean blood
velocity in the MCA of about 25% or more was
1 *3 Q 11Q 1C7
abnormal. Therefore a reduction in arterial blood
velocity greater than that is a reasonably reliable indica¬
tor of occlusion of the artery in one of the major branches
or more proximally. In general, the greater the reduction in
blood velocity on the symptomatic side relative to the
asymptomatic, the more proximal the occlusion. Note however
that it may be possible to record a near normal blood veloc¬
ity from an MCA with a major branch occlusion if the blood
flow in the patent branch has increased to supply collateral
flow to the ischaemic brain supplied by the occluded branch,
the net result being a "normal" blood velocity in the MCA
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main stem. All of these factors must be taken into account
when interpreting the TCD result, but in experienced hands
TCD does appear to be a reliable indicator of the presence
of significant MCA occlusions. It is less reliable for ACA
or PCA disease as there is more variability in their normal
anatomy.
In the present study, the blood velocity in the
symptomatic MCA was usually abnormal when a proximal MCA
main stem or major branch occlusion was expected from the
clinical and CT brain scan findings. The accuracy in pre¬
dicting likely MCA main stem or major branch occlusion was
good at 86% in accordance with the previous studies. The
accuracy in identifying a probably patent MCA was less good
(60%), although the likelihood of having significant MCA
disease in the presence of a normal symptomatic MCA blood
velocity was low (NPV 89%). Reasons for failure to find an
arterial signal, other than arterial occlusion, include
displacement of the artery by swollen brain, poor operator
technique, unco-operative or restless patient, and tortuous
course of the MCA dipping down low into the temporal fossa
out of the line of sight of the TCD probe. Great care is
necessary to ensure that the failure to identify an MCA
blood velocity signal is not simply due to any of these
factors rather than the presence of MCA occlusive disease.
Reasons for finding a "normal" symptomatic MCA blood veloci¬
ty include early spontaneous recanalisation and persistent
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branch occlusion with hyperaemic flow in the patent branches
as described above. The closer the TCD examination to the
onset of stroke symptoms, the greater the chance of finding
a reduced MCA blood velocity. In the present study the
"normal" MCA blood velocities in four of the patients with a
TACI syndrome may have been due to either of these mecha¬
nisms .
The failure to identify any arterial signal in 11% to
13% of patients is also similar to that found in previous
studies.'141''154'The proportion of patients with
dense temporal bone windows increases with age and repre¬
sents a significant drawback to the use of TCD in acute
1 O O
ischaemic stroke patients.
TCD requires a skilled and experienced operator for
correct performance and interpretation, particularly in
acute ischaemic stroke. A radiological background is proba¬
bly beneficial. Personal experience of teaching non-radiolo¬
gists to do ultrasound shows that the lack of an inbuilt "3D
image processing ability" (something only learnt with years
of practice at cross-sectional imaging) is a serious disad¬
vantage, even when performing cervical carotid Duplex ultra¬
sound where there is a clear image to help orientation. TCD,
with its reliance on the operator's skill and spatial aware¬
ness, and its lack of a guiding image, is more difficult and
is unlikely ever to be available outside specialist centres.
Colour flow TCD may help overcome some of these problems by
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providing the guiding image, but even with the benefit of the
grey scale image, colour flow TCD is still difficult, re¬
quires a skilled and patient operator, and the equipment is
more cumbersome so less mobile than for spectral TCD.
2.4.5 The accuracy of the isotope Mean Cerebral Transit Time
In the present study, the MCTT was evaluated in a
broad cross section of acute stroke patients and found to
perform well in comparison with TCD. Despite including
patients with impaired cardiac function and previous stroke,
the MCTT appears to be a remarkably robust, simple and
inexpensive technique. The accuracy in diagnosing likely MCA
main stem or major branch occlusion was good (88%) and the
MCTT seemed more sensitive to probable MCA small branch
occlusions and PCA territory infarcts than TCD, the MCTT
being more frequently appropriately abnormal in the patients
with a PACI or POCI syndrome than TCD. The accuracy of the
MCTT in diagnosing likely patent MCA was better than with
TCD (90% with MCTT and 60% with TCD). The number of non¬
diagnostic studies (11% to 18%) was similar to the failure
rate of TCD, and may decrease further with more experience
of transit time patterns in acute ischaemic stroke. Problems
were encountered in twelve of the patients in whom the
cerebral transit time was generally prolonged, or there was
loss of the normal anteroposterior gradient, but there was
no asymmetry between the hemispheres. In six of these,
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observation of the aortic and brain input curves during
acquisition of data showed a slow rising, flat input curve
indicating that the bolus had become dispersed and the
result would not be valid. In the other six the input curve
appeared relatively satisfactory on the computer screen so
there was less warning that the data might be difficult to
interpret. For this reason the latter six were included in
the MCTT result "normal" when calculating the accuracy
because this is an obvious area where errors in interpreta¬
tion might occur. All apart from one of the twelve patients
had evidence of a cardiac abnormality, and atrial fibrilla¬
tion was by far the most frequent of these. Bilaterally
prolonged transit and loss of the normal anteroposterior
gradient may also reflect generally deranged cerebral blood
flow in the acute phase of stroke, raised intracranial
pressure, as well as cardiac impairment (primary or second¬
ary to the acute stroke). Further study will be required to
determine the true significance of these transit abnormali¬
ties .
The markers of cardiac or circulatory abnormality
were chosen to be easily identifiable from simple history or
clinical examination to act as warnings that the MCTT study
should be interpreted with caution. Patients more likely to
have a non-diagnostic MCTT study could thus be readily
identified by simple criteria. Tight stenosis or occlusion
of the ICA only caused problems in interpretation in one
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patient because in the majority there was clear asymmetry on
the arrival time image which was taken into account in
interpretation of the transit time image. As more experience
is gained with the transit time it should become easier to
interpret these sort of results.
The present study has also suggested that the MCTT
may be able to demonstrate cerebral arterial recanalisation
as a shortening of the transit time. In the early validation
"3 f) Q
studies concern was expressed that in the presence of
extensive blood brain barrier breakdown, as would occur in
all large infarcts, marked leakage of isotope into the
extravascular space would occur during passage through the
brain leading to artificially prolonged transit time. This
might mean that it would be impossible to identify patients
with extensive infarcts in whom the occluded artery had
already (spontaneously) recanalised, as their transit would
be similar to that of patients whose artery was still oc¬
cluded. However the limited evidence presented here suggests
that that will not be the case - recanalisation appears to
be associated with a shortening of the transit time, possi¬
bly even to a faster transit in the symptomatic than in the
asymptomatic hemisphere. However a further larger study will
be required to examine the effect of recanalisation on the
MCTT, to establish its reliability in diagnosing patients
with large infarcts who have already recanalised their
symptomatic artery.
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The drawbacks to the MCTT technique in the present
study were mainly due to the availability of isotope. 1200
MBq of isotope were delivered on weekdays for the study,
which was sufficient for two doses in the morning, but only
one dose if not used until the afternoon due to the decay of
the isotope. A generator was available in the Department,
but if old, it was not often possible to ensure that a
sufficiently concentrated dose of isotope could be obtained.
Too large a volume of injection would invalidate the MCTT
examination. Problems were experienced with supply of iso¬
tope from Amersham for a three week period in the middle of
the study. The Department of Nuclear Medicine operated an
emergency only service on the same basis as the Department
of Neuroradiology. These restrictions lead to exclusion of
some patients from the study because they were admitted to
hospital at the weekend, but most of these limitations could
be easily overcome if the MCTT were an established clinical
tool that could be justified on clinical grounds.
The hospital was spread over a large area, and the
General Medical Wards, Nuclear Medicine and Neuroradiology
Departments were separated by a good five minute walk and
several lifts so it was sometimes difficult to justify
moving a sick, confused patient on a separate journey for an
MCTT on the days when the CT scanner was out of action or
when it had not been possible to perform the MCTT at the
same visit to the Neuroradiology Department as the CT scan.
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Normally both tests would be done in the Neuroradiology
Department on one visit. A map of the hospital is shown in
Appendix Six, illustrating the geographical problems. The
MCTT can be performed using a mobile gamma camera which,
although rather cumbersome (like a 1970's portable x-ray
machine), could be kept in the medical ward or acute stroke
unit thereby reducing delays in investigation.
The MCTT was easy to perform and required minimum
patient cooperation. The patient could be kept comfortable
while preparations were made for the study, then put into
the imaging position with the neck extended just for the
acquisition phase (approximately 30 seconds), then quickly
moved back to a more comfortable position. Many of the MCTT
tests in this study were performed single handed. This was
satisfactory when the patient was cooperative, but two
persons were required for restless patients. If the MCTT was
to be adopted more widely, it would probably be based in
Nuclear Medicine or General Radiology Departments where
there would be two persons for the short time required for
the study. The isotope used in this study, technetium®®™
pertechnetate is inexpensive and readily available. Minimum
operator training is required for correct performance and
interpretation of the MCTT study. All of this contrasts with
the other currently available non-invasive methods of evalu¬
ating cerebral perfusion - SPECT with HMPAO or equivalent,
PET, XENON CT, XENON radioisotope methods - all of which use
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more expensive tracers, take more time, require more patient
cooperation, use more expensive equipment and are simply not
practical for the widespread, rapid investigation of a
disease as common as acute ischaemic stroke. Also, although
all these methods assess cerebral blood flow, they do so
indirectly, and some are non-quantitative. SPECT with HMPAO
■3 f) O
may overestimate hyperaemia in infarcted tissue. Although
non-tomographic, the MCTT by rapidly measuring cerebral
perfusion reserve, may be giving more useful information,
than simply measuring cerebral blood flow. Cerebral blood
flow on its own does not give enough information about the
state of the cerebral circulation - information on cerebral
blood volume is also important.
If in the future any treatments for acute ischaemic
stroke are to work then it is likely that they will have to
be administered with minimum time delay, so any necessary
pretreatment imaging tests have got to be simple, rapid and
practical. The MCTT is inexpensive, and gamma cameras are
already available in many District General Hospitals as well
as teaching hospitals. A high sensitivity collimator, a
hand-held scintillation counter, a simple interface to link
to a micro computer (IBM or equivalent - an old BBC was used
in this study) plus appropriate software is all that would
be required. It is by far the most promising and practical
method so far of assessing cerebral arterial occlusion in
acute ischaemic stroke so far available.
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2.4.6 On the comparison of the absolute values of middle
cerebral artery blood velocity and hemispheric mean
transit time
The present study concentrated on the pattern of
transit abnormality rather than on the absolute values of
the transit time because the aim was to test the MCTT as a
simple, rapid, unsophisticated diagnostic test to answer the
simple question "is there a major arterial occlusion or
not?" The MCTT had not been widely tested in patients likely
to have impaired cardiac function and it was uncertain what
impact including such patients would have on the interpreta¬
tion of the results. It therefore seemed appropriate to
concentrate on the colour pattern of the MCTT result rather
than on the absolute values. Patients with cardiac abnormal¬
ities caused fewer problems than anticipated, so a limited
examination was made of the relationship between the
absolute values of transit time and the blood velocity in
the MCAs. Previous studies have shown the reciprocal of the
hemispheric transit time is directly proportional to the
arterial blood velocity - the faster the blood velocity the
shorter the transit time.^^Both TCD and MCTT give an
index of velocity flow within the cerebral circulation.
Velocity flow is proportional to the second power of the
vessel radius whereas volume flow is proportional to the
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fourth power of the vessel radius. Previous studies have
also demonstrated a non-linear relationship between MCA
O O O
blood velocity and perfusion and cerebral transit time
o o o
and perfusion^ J in addition to the validation studies by
9 14 ^ n Q
Naylor, Merrick et al. ' This suggests that changes in
MCA blood velocity, in these studies, were due to changes in
the volume of blood passing through the artery assuming that
there was no change in the arterial radius or length. One
angiographic study showed no change in the calibre of the
O O A
MCA during hypo- and hyper-capnoeabut angiography may
not be a very accurate way of measuring arterial calibre.
Even as little change in arterial calibre as 10% may result
in a 36% change in the resistance to flow. More recent
evidence from carefully controlled TCD studies has suggested
that there may be changes in MCA diameter with posture in
normal individuals as part of the autoregulatory
response.14® It is therefore probably not valid to assume
that the MCA diameter remains constant under physiological
conditions. Further study is required to evaluate this
relationship in the light of new information on the beha¬
viour of the basal intracranial arteries under physiological
conditions.
In the present study, the MCA blood velocity was
proportional to the reciprocal of the transit time in the
symptomatic but not in the asymptomatic hemisphere. This
discrepancy may be because when the cerebral circulation is
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functioning normally, as it might be in the asymptomatic
hemisphere, that there may be a range of blood velocities
for any given transit time. It may be that it is only when
the cerebral circulation is stressed, as in the symptomatic
hemisphere, that the relationship between falling blood
velocity and prolonged transit time becomes apparent. The
study by Naylor et al examined the relationship between
transit time and blood velocity during hypo- and hyper-
914 ^ D Q
capnoea, not at rest. x ,JU;7 In 32 carefully selected pa¬
tients with first-ever acute ischaemic stroke and no evi¬
dence of cardiac impairment, Naylor et als' findings were
similar to those in the present study, though the difference
in the closeness of the relationship between blood velocity
and transit time in the symptomatic and asymptomatic hemi-
•3 0 q
spheres was less obvious. It may be that the results in
the present group of 85 patients were diluted by inclusion
of the patients with the bilaterally prolonged transit as
the latter reflected impaired cardiac function and was
nothing to do with the cerebral circulation. It may also be
that a more comprehensive control population is required to
examine more closely the relationship between transit time
9 n r
and age. In the original validation study no relationship
was found with age in the 102 "patient controls" but they
may have been a younger, generally healthier age-group
(their age was not specified) than the age-group typically
affected by acute ischaemic stroke, and at extremes of age
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there may be a relationship between age and prologation of
the transit time. Examination of the relationship between
age and transit time in the asymptomatic hemisphere in the
patients in the present study certainly suggested that there
may be an important relationship, but this may have been
because cardiac abnormalities increase in frequency with age
leading to greater likelihood of a prolonged transit time.
Further study of this specific patient group is required to
clarify the importance of this observation.
2.4.7 General points concerning the imaging investigation of
patients with acute ischaemic stroke
At the present time, in the United Kingdom at least,
access to imaging investigations for acute stroke patients
is generally restricted and poor. Many physicians caring for
patients with an acute stroke are frustrated by the lack of
availability of CT scanning for their patients (personal
survey of members of the British Stroke Research Group).
Until recently, CT scanners were regarded as a relative
luxury, rather than as a basic workhorse for neuroimaging as
in the USA. This reflects differences in health care funding
and general lack of resources, or failure to target re¬
sources effectively, in the UK. As it is generally perceived
that there is no treatment for acute ischaemic stroke, it is
also commonly thought that there is no point in doing inves-
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tigations to diagnose the cause of the stroke. However now
that there are secondary prevention treatments of proven
benefit in acute ischaemic stroke, it is important to diag¬
nose the cause of the stroke in patients being considered
for carotid endarterectomy, aspirin or anticoagulant therapy
to use these treatments effectively. It is generally per¬
ceived that patients being considered for secondary preven¬
tion can be investigated in the second or third week after
symptom onset - there is no need to perform investigations
rapidly and a reasonable number of acute stroke patients may
actually have a CT brain scan at some point after the acute
event (it is not known how many) though not within 24 hours.
This may or may not be an appropriate way to manage these
patients, but if the primary treatment of acute ischaemic
stroke is ever to advance, it is likely that investigations
will need to be performed as soon as possible after symptom
onset so that treatment can be started as soon as possible
to limit ischaemic brain damage.
Parallels can be drawn with the progress which has
been made since the early 1960s in the hospital care of
acute myocardial infarction patients. Prior to the 1960s
many MI patients were cared for at home as there seemed
little point in sending them to hospital if nothing could be
done. Then with the development of pacemakers and drugs to
treat arrhythmias, hospital care was perceived as offering
some benefit. Coronary care units were established associat-
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ed with the idea that acute MI patients had to reach hospi¬
tal quickly for maximum benefit. Once the network of CCUs
was established, it then became relatively easy to test
treatments such as thrombolysis, beta blockers, calcium
antagonists. But it has taken nearly thirty years to arrive
at this level of sophistication for acute MI patients, and
doctors are still looking for ways of getting patients to
hospital faster and optimising use of hospital facilities.
Care of acute ischaemic stroke is at a similar stage to care
of acute MI in the early 1960s. There are a lot of organisa¬
tional problems to be overcome before any acute stroke
treatments can be effectively delivered to the correct
patients. The major differences between acute MI and acute
stroke are that a) the diagnostic test for acute MI, the
ECG, is mobile, cheap and quick, whereas a CT scanner is
static and expensive, and b) acute MI patients can complain
loudly until someone does something about their chest pain,
whereas many acute stroke patients cannot complain at all!
The layout of the Western General Hospital is proba¬
bly fairly typical of many UK hospitals and illustrates some
of the logistic problems encountered in trying to investi¬
gate patients rapidly. There are long distances between
departments involved in the care of stroke patients (Appen¬
dix 6) with poor access to lifts and hospital porters. In
many hospitals there is no dedicated team of professionals
to care for the stroke patients although many hospitals are
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now setting up acute stroke units to rectify this. There is
increasing evidence that acute stroke units benefit the
patient by reducing time in hospital and improving patient
■j o c
independance after discharge. Therefore the investigation
of acute stroke patients has to be kept as simple as possi¬
ble to counteract the complexities already present in the
hospital system.
It is clear therefore that there is no longer any
place for a nihilistic attitude towards investigation of
acute stroke patients. The first step must be to diagnose
the cause of the stroke and CT scanning is the best commonly
available method for this. It may not be possible to make a
positive diagnosis of ischaemic stroke with CT, but it will
exclude intracerebral haemorrhage, tumours, and infection
reliably. It is not possible to differentiate reliably
clinically between these diseases. Scanning the patients in
the present study caused a certain amount of friction in the
Neuroradiology Department - acute stroke patients were
perceived as causing a major increase in the number of
patients scanned resulting in a doubling of the outpatient
waiting list and in the out of hours workload. In fact the
number of acute stroke patients scanned in proportion to the
total number of patients going through the CT department was
very small, with no increase in out of hours work, but
stroke patients drew a disproportionate amount of attention
to themselves as they were often sent without a nurse escort
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and needed extra nursing attention while in the Department.
Simple measures such as ensuring that a nurse came with the
patient, that the patient was on a trolley not in a wheel
chair if they were unable to weight-bear, and that the
patient was referred to CT scanning as soon as possible
(not, for example, at 1600 hours when they had been in the
hospital since 1000 hours) helped ensure the smooth running
of the CT service with good access for stroke patients.
There is plenty of room for improvement in the 0900 to 1700
provision of CT scanning for stroke patients before worrying
about the out of hours service.
A patient with suspected acute ischaemic stroke
should have a careful clinical examination to define the
likely site and extent of the infarct and underlying arteri¬
al occlusion followed by a CT brain scan to exclude tumour
or PICH. If in future treatments become available which are
dependant on the type of arterial occlusion, for example
thrombolysis, then an assessment of cerebral perfusion could
be made using the MCTT or TCD. Equipment to perform these
could be sited either near the CT scanner or the acute
stroke ward. Many of the treatments under trial for acute
ischaemic stroke at the moment such as aspirin, heparin,
thrombolysis, glutamate antagonists, free radical scaveng¬
ers, etc, have serious and unpleasant side effects and so
the ratio of beneficial to adverse effects may depend on the
type of ischaemic stroke. For example in a patient with a
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lacunar stroke whose prognosis is good without any treatment
should probably not be exposed to a treatment with benefi¬
cial but also serious adverse effects, whereas in a patient
with a TACI syndrome whose prognosis is so bad the treatment
may be worth while.
In conclusion, the MCTT may be sufficiently accurate
and practical to be the rapid, widely available diagnostic
test for the likely site of arterial occlusion in patients
with acute ischaemic stroke. It may also be extremely useful
in research into the natural history of acute ischaemic
stroke, and in the assessment of the action of novel drugs
in acute ischaemic stroke.
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Summary of Part Two
1. The need for a rapid method of diagnosing cerebral arte¬
rial insufficiency in acute ischaemic stroke is discussed.
2. The methodology of the study to evaluate the accuracy and
practicality of the isotope Mean Cerebral Transit Time
(MCTT) is discussed, using a combination of clinical exami¬
nation and CT brain scan findings as the "surrogate gold
standard" for the site of infarction, and Transcranial
Doppler ultrasound as an alternative non-invasive diagnostic
tool against which to test the isotope MCTT.
3. The Oxfordshire Community Stroke Project clinical classi¬
fication of acute stroke syndromes was found to be accurate
in predicting the site of cerebral infarction as diagnosed
by CT brain scanning.
4. A simple classification of cerebral infarcts as seen on
CT brain scans was found to have excellent interobserver
agreement, and to be a reliable way of differentiating
between similar sized infarcts with different amounts of
swelling in the acute phase.
5. The accuracy of TCD in diagnosing the likely site of
cerebral arterial occlusion was similar to that described in
previous studies of patients with acute ischaemic stroke.
6. The accuracy of the MCTT is similar to Transcranial
Doppler.
7. The main drawback of the MCTT is its dependance on good
cardiac function for a diagnostic study although this caused
304
problems in surprisingly few patients. Patients in atrial
fibrillation were most likely to have a non-diagnostic MCTT
study.
8. The MCTT is a less operator dependant technique than TCD,
is as quick or quicker, and the facilities to do it are
already available in many District General Hospitals.
9. General problems encountered in ensuring that acute
stroke patients are investigated appropriately and rapidly,
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3.1.1 Aim of the study
The aim of this study was to examine prospectively
the relationship between blood flow to the infarcted cere¬
bral tissue in the first few days after stroke onset, and:
1) the amount of swelling in the infarct; and
2) the final clinical outcome.
The hypothesis being tested is that an increase in blood
flow to the ischaemic or infarcted brain lessens (or at
least does not worsen) the amount of infarct swelling in the
acute stage, and leads to a better clinical outcome. Clear¬
ly, if reperfusion of the infarct led to worse infarct
swelling and a poorer clinical outcome, there would be
little point in testing thrombolytic (or possibly antithrom¬
botic) drugs in acute ischaemic stroke where the intended
mechanism of action is to improve infarct perfusion.
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3.1.2 Introduction
Cerebral infarction is always followed by oedema
formation in the infarcted tissue (apparent microscopically
though not always macroscopically), as part of the response
to injury. 326 ^ Thi.s may cause the infarct to swell, compress
surrounding brain and possibly damage otherwise viable
neurones at the margins of the infarct by impeding their
blood supply further. If severe, a cerebral hemispheric
infarct may swell so much that tentorial herniation occurs,
and the patient dies of brain stem compression in the first
few days after the stroke.2^
The influence of early reperfusion of the infarct on
infarct swelling is unclear, there being conflicting results
from experimental work52'327'32®'329'330 and little informa¬
tion from stroke patients . 5275 '293' 551' 552 Experimental
models, discussed in more detail in the next section, are
useful but the results should not be extrapolated directly
c 7
to stroke patients. There are many examples of new drug
treatments for stroke, which appear promising when tested in
animals, but have no beneficial effect, or unsuspected
7 0 11
adverse effects, in stroke patients.Koudstaal et alJJ in
1988 described two patients who developed massive cerebral
infarct oedema and died following intravenous thrombolytic
therapy for acute ischaemic stroke. One patient dying two
and a half days after the stroke had patent cerebral arter¬
ies at post mortem, but there was no information on the
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patency of the other patient's arteries. Koudstaal et al
concluded that "Thrombolytic treatment.... started three to
four hours after a major ischaemic stroke may be hazardous,
not because of haemorrhagic transformation but because early
reperfusion may promote massive, potentially fatal cerebral
oedema". This anecdotal but high-profile report has been
cited as a good reason for not attempting to improve blood
supply to acute ischaemic strokes in the acute phase. Part
of the difficulty in examining the relationship between
blood flow to and swelling in cerebral infarction has been,
until recently, the lack of readily available non-invasive
blood flow imaging techniques.
CT brain scanning has been available for longer, and
there have been several studies of the change in appearance
of cerebral infarcts on CT scanning with time which have
noted that swelling of the infarct occurs in the first week,
followed eventually by atrophy. These
studies examined mass effect or made serial volume measure¬
ments of the infarct, but did not attempt to distinguish the
site and extent of the infarct from the effect of swelling.
Also, there have been no prospective studies which have
tried to assess causes of cerebral infarct swelling in
stroke patients. There is also little information on the
frequency of severe infarct swelling, or on whether increas¬
ing blood flow to the infarct in the first few days after
onset improves or worsens outcome.
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Until recently, lack of practical non-invasive imag¬
ing technigues for assessing cerebral blood flow hampered
attempts to study the pattern of cerebral arterial occlusion
in acute stroke patients. However TCD is now an established
method which can be used with minimal disturbance to the
patient (see Part 1.4). Although Doppler ultrasound measures
blood velocity and does not measure blood flow directly, the
adeguacy of the blood supply to an area of brain can be
inferred from the velocity signal. TCD has been used in
studies to monitor cerebral arterial patency following acute
ischaemic stroke. A normal blood velocity in
the MCA main stem (Ml segment) implies "good" flow to the
MCA territory even if one of the main branches is blocked,
compared with a velocity reduced to half or even less of
that in the asymptomatic MCA with the identical anatomical
lesion, which implies "poor" flow to the MCA territory. A
velocity increase in the symptomatic MCA main stem during
the first week after stroke from barely detectable to a near
normal TCD signal implies that the flow in the MCA has
"improved", whether due to recanalisation or to persistent
occlusion with hyperaemic flow in the patent branches feed¬
ing collaterals at the margins of the infarct (Figure
1.4.2). Furthermore, a normal or near normal symptomatic MCA
blood velocity with 24 hours of stroke in a patient with
symptoms of extensive MCA territory ischaemia, would be
compatible with: 1) early recanalisation of an MCA main stem
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occlusion; 2) persistent occlusion of a major branch of the
MCA with increased flow in the patent branches giving a net
"normal" or near-normal blood velocity in the main stem; or
3) occlusion of one or more minor branches of the MCA
(either the primary cause of the stroke or due to fragmenta¬
tion and migration of an embolus). These possibilities are
indicated schematically in Figure 1.4.2. As long as very
simple criteria are used to define blood velocity, the
conditions under which the measurements are made are care¬
fully controlled and only large increases or decreases in
velocity (excluding focal stenoses) counted as change, then
it is reasonable to infer blood flow changes from blood
velocity changes.
Now that non-invasive imaging tools are available,
with reasonably well understood limitations, it is feasible
to study acute infarct swelling prospectively, without undue
disturbance to the patient, taking advantage of the tendancy
of the occluded cerebral artery that caused the stroke, to
recanalise spontaneously (see Part 1.1, Part 1.3 and Figure
1.3.1). Up to 20% of large cerebral artery occlusions may
recanalise spontaneously within 24 hours, increasing to
possibly 80% by the end of one week after stroke
onset.115,117-120,122,123,125
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3.1.3 The mechanism of ischaemic cerebral oedema formation
and the relationship to reperfusion - results from experi¬
mental work.
The sequence of events leading to cellular ischaemia
and death following interruption of the blood supply to part
of the brain has been studied in primates and other
mammals.51'^4. As blood flow decreases, progressively more
cell homeostatic functions fail (Figure 3.1.1). Following
complete and sudden interruption of the blood supply, elec¬
trical activity of the neurones stops in a few seconds,
followed by failure of the sodium pump and glucose deple-
o n r
tion. Intracellular oedema, mostly derived by fluid
movement from the extracellular space into the cells, is
evident after a few minutes and there is a massive rise in
c o
tissue lactate. J Up to this stage, the process is poten¬
tially reversible, but thereafter a stepwise sequence of
organelle failure occurs as thresholds for survival are
reached and passed. The same impairment in cerebral blood
flow, in mis per 100 grams of brain per minute, is associat¬
ed with a similar degree of cell malfunction in all mammals
tested (cats, gerbils, baboons), and it is reasonable to
C O
assume that similar levels would apply in humans. The
preservation of some circulation might prolong the time
taken for this sequence of events to occur, and provided the
blood hydrostatic pressure remains low in the infarct, the
blood brain barrier remains intact and there is virtually no
313
leak of protein from the intravascular to extravascular
space.^2®'^^'^^ Note that, as shown in Figure 3.1.1,
cellular oedema formation begins prior to irreversible cell
damage, at a higher threshold than calcium and potassium
pump failure in the cell membrane.
Although the response to reduced blood flow is simi¬
lar within and between species at the cellular level, the
response, in terms of decrease in blood flow in the arterial
territory following acute cerebral arterial occlusion, is
very variable between individuals. Experiments in monkeys
have shown that distal to an MCA main stem occlusion the
3 3 7
blood flow decreases to 25 percent of normal. Autoradio¬
graphic blood flow studies in animals have shown flows which
range from near zero to near normal values in the territory
^ fi
of an occluded vessel. Therefore it is probable that some
blood flow usually persists distal to a major cerebral
arterial occlusion, supplied via the collateral circulation,
which slows down the development of the infarct and may even
arrest the process at any stage. This variation in blood
flow distal to an apparent MCA occlusion could explain the
observation of reduced but clearly measurable, blood veloci¬
ty with TCD in stroke patients distal to an angiographically
proven MCA occlusion.1^®
Other experimental work has shown that the presence of
venous obstruction (as well as arterial) worsens the ischae-
mia. Ischaemic damage and swelling are less if the veins are
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patent, and less still if the ischaemic tissue is perfused
"3 O Q
with saline during arterial occlusion. ^ These experimental
results imply that both stasis and accumulation of metabo¬
lites are important factors in ischaemic damage.Reduc¬
tion in systemic blood pressure may further worsen the
O O O
ischaemic insult. JO Other factors which may contribute
to ischaemic cerebral oedema formation include systemic
■3 "3 C "3 "3 Q
hypertensionJand hyperglycaemia, though in both cases
the evidence of cause and effect is conflicting, ie are
hypertension and hyperglycaemia simply the conseguences of a
severe stroke, or vice versa. In stroke patients two factors
which might also affect infarct swelling are the age of the
patient and the plasma albumin. It is possible that younger
patients might have a more aggressive response to tissue
injury, or that they might have less room for infarct swell¬
ing which would correspondingly appear more severe. A low
plasma albumin might encourage leakage of fluid from the
intra- to extravascular space and increase infarct swelling.
These latter two factors are purely hypothetical.
The development of cytotoxic oedema is followed by
vasogenic oedema, which is secondary to breakdown of the
blood brain barrier with leakage of protein and water into
the extracellular space. It has been show to be maximal at
seven to ten days in rhesus monkeys,corresponding with
the time of maximal contrast enhancement of infarcts on CT
9 9 7
brain scans in stroke patients. *' The time of maximal
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oedema formation in monkeys is four days, JO and in humans
three to five days2^5 (based on CT brain scanning and autop¬
sy data), though in smaller mammals it occurs earlier.22^
The period of maximal infarct swelling is therefore likely
to be due to a combination of intra and extracellular oede¬
ma .
The earliest sign of cerebral infarction on a CT
brain scan is decreased density in the ischaemic or infarct-
ed tissue, ^ shown in animal experiments to indicate oedema
formation.24^ It is therefore conceivable that in the terri¬
tory of an occluded MCA, one might see cerebral oedema
formation on a CT brain scan, in the hours after stroke
onset, indicating ischaemic but not irreversibly damaged
tissue.
Although the blood brain barrier is intact to large
molecules up to several days after the onset of ischaemia,
it may be leaky to water, and evidence from several animal
experiments suggests that reperfusion of the occluded artery
after ischaemic damage has occurred is associated with a
massive rise in extracellular water and worse oedema than if
the artery had remained occluded.'24^ For example, in
gerbils restoration of blood flow within an hour of ischae¬
mia caused a reduction in the brain water content, whereas
if restoration of flow is delayed until three hours, there
is a massive rise in brain water content.^27 Symon et al^2®
found that reperfusion after 30 minutes of MCA occlusion in
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monkeys was not associated with any significant increase in
brain water content, whereas reperfusion after 90 minutes of
occlusion was associated with an increase in water content
where the reperfusion had occurred. Bell et al-"1 showed that
in baboons, the cerebral blood flow threshold for oedema
formation is 40% of normal, and that flow levels less than
this can be tolerated for up to 30 minutes without permanent
damage being sustained. Reperfusion after 30 minutes of
ischaemia was not associated with any increase in brain
water content, but reperfusion after 100 minutes of ischae¬
mia was associated with increased brain water content par-
ticularly in grey matter. Sundt et alJ found that restora¬
tion of blood flow after three hours of MCA occlusion in
squirrel monkeys or six hours in cats reduced infarct size
but that oedema was slightly worse in the cerebral infarct
following reperfusion than in those animals without reperfu¬
sion. Crowell et al343 found that deficits from ischaemia
were commonly reversible after 30 minutes and four hours of
MCA occlusion in monkeys, but rarely reversed after eight
hours or more of occlusion. Other experiments in rats have
suggested that reperfusion in the first few hours following
ischaemia is associated with greater damage to the cerebral
arteriole endothelium on microscopy (than persistent arteri¬
al occlusion) leading to greater permeability to plasma
constituents and brain oedema.341 One possible mechanism of
"early reperfusion injury" is increased calcium ion flux
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into the ischaemic neurones. ,JJ
The brain can survive mild ischaemia for some time,
but is intolerant of profound ischaemia for even short
periods, so that the depth and not just the duration of
o n o
ischaemia are both important factors. The greater and
longer the decrease in cerebral blood flow, the greater the
amount of ischaemic damage and brain oedema.
A further factor to be considered is whether early
reperfusion of ischaemic tissue (with apparently favourable
early symptomatic response) may be followed by "delayed
reperfusion injury" with progressive neurological deteriora-
c p
tion occurring one to two weeks later. Three case reports
c p
and two experimental studies referred to by CaplanJO concern
seguelae of global cerebral anoxia not focal acute cerebral
infarction. The mechanism and pathophysiology of global
cerebral ischaemia may be guite different to focal ischae-
K 7
mia. There is no evidence as yet that "delayed reperfusion
injury" occurs following acute focal cerebral ischaemia.
There is scant information on the relationship be¬
tween reperfusion and infarct swelling in stroke patients,
most obtained indirectly from studies designed to address
other issues. The anecdotal report of two patients by Koud-
■3 "3 I
staal et alJJ has already been mentioned in the Introduc¬
tion to Part Three (3.1.2). Ogata et al61 suggested that
ischaemic cerebral oedema was worse in acute ischaemic
stroke patients whose ICA or MCA remained occluded (on
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angiography), than in those who reperfused early. Overgaard
et al described three patients treated with thrombolytic
drugs following acute ischaemic stroke (whose occluded
arteries did not recanalise) who developed severe fatal
n o o 9 7 fi
cerebral infarct oedema. Mori et al in a trial of in
travenous thrombolysis in acute carotid territory ischaemic
stroke, found severe infarct oedema with mass effect was
more frequent in patients whose artery remained occluded on
angiography (7/20) than in those who reperfused (1/11).
Several other recent reports have examined the rela¬
tionship between reperfusion and clinical outcome. Ringel-
9 Q R
stein et al, using TCD and angiography, showed that
haemorrhagic transformation of the infarct was more frequent
and clinical outcome much worse in patients whose symptomat¬
ic arteries remained occluded than in those whose arteries
recanalised. Moulin et al34f* found that 5/9 patients with
recanalisation (shown angiographically) following thromboly¬
sis recovered to live independantly by one month after onset
(none died), compared with only 1/9 with no recanalisation
(four died). Baird et al,347 in a pilot study of thromboly¬
sis, found that reperfusion (measured by SPECT) correlated
with significant neurological improvement, whereas patients
with persisting hypoperfusion made a poor neurological
recovery.
These results in stroke patients conflict with the
experimental results, as the experimental studies suggest
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that treatments aimed at improving perfusion to an infarct
might be detrimental if not initiated very early, ie within
30 minutes of symptom onset. This is obviously impractical
in stroke patients. However the results of some of these
c 7
experimental models may not be directly applicable to man.
Tthe experimental studies also disagree on the duration of
ischaemia that can be tolerated. The important questions
are: 1) whether any increased damage due to "reperfusion
injury" is counterbalanced by benefit in terms of salvage
of ischaemic but viable neurones by reperfusion; and 2) for
how long after the onset of ischaemia will reperfusion be
beneficial? The answer to both questions must probably await
the result of large trials of reperfusion vs no reperfusion
(by therapeutic means) in stroke patients. It is however an
important point to resolve, as at present much time and
effort is being expended on testing acute ischaemic stroke
treatments specifically intended to increase tissue perfu¬
sion, namely thrombolysis, aspirin and heparin. These would
obviously be contraindicated if they were only to make
matters worse. The disagreement among the experimental
studies on the tolerable duration of ischaemia, and the
indirect evidence suggesting likely benefit of reperfusion
in stroke patients (all at various time windows up to 24
hours), provide strong arguments for assessing acute stroke
treatments at different time intervals after stroke, and not
just adopting a rather empirical six hour onset-to-treatment
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cut off.
As the relationship between cerebral blood flow and
infarct oedema is controversial and poorly understood in
man, and is fundamental to the understanding and development
of treatments of acute ischaemic stroke, a study was set up
to examine this prospectively in patients with symptoms of
extensive cerebral infarction in the MCA territory, using
non-invasive imaging techniques.
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Figure 3.1.1 Thresholds of cerebral ischaemia and infarction
- the Ischaemic Penumbra The cerebral blood flow thresholds
for failure of neuronal function are shown on the y axis.
Similar thresholds have been found in all mammals tested, so
it is likely that the same thresholds apply in stroke pa¬
tients . (50,51,54)
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As many patients as possible admitted to the Western
General Hospital between 25.11.90 and 31.08.92 within 24
hours of onset of extensive acute ischaemic stroke in the
MCA territory were included in the study. These were
therefore patients with either a TACI or "large PACI" acute
ischaemic stroke. A TACI syndrome indicates ischaemia or
infarction of a large part or all of the MCA territory, and
consists of the triad of a) hemiparesis affecting face, arm
and leg, 2) hemianopia, and 3) new higher cerebral dysfunc¬
tion (for example dysphasia or neglect). A "large PACI"
suggests ischaemia or infarction of at least half of the MCA
territory and consists of two of the triad of signs for a
TACI. The diagnostic criteria for TACI and PACI are de¬
scribed in detail in Part 2.2, and in Appendix 2. Patients
with symptoms suggestive of less extensive ischaemia were
excluded as it might be more difficult to measure the in¬
farct size on CT scans and because they would be less likely
to have abnormal MCA blood velocities.
Patients with first ever stroke and recurrent stroke
were included, but only if the previous stroke had been
minor (minor, non-disabling anterior or posterior circula¬
tion infarct). There was no upper age limit for inclusion,
although patients below the age of 18 were excluded. Pa¬
tients were also included regardless of their drug treatment
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before and after the stroke, regardless of other concurrent
illness and regardless of the suspected cause of the cere¬
bral infarct. Patients were included in the study as long as
they or a close relative and attending physicians gave their
consent for participation, and as long as it was considered
ethical for that particular patient to be included in the
study.
3.2.2 Clinical identification and classification of patients
Patients were identified by Dr Martin Dennis during
the North Lothian Stroke Survey (NLSS), or Dr Richard Lind-
ley after the NLSS, as described in Part 2.2. All patients
had a thorough clinical examination as soon as possible
after admission (but within 24 hours at most) and careful
history was obtained of stroke risk factors, past medical
history and time of stroke onset, either from the patient or
a close relative or friend. In patients who awoke with a
stroke, the time of onset was taken to be midway between the
time of going to sleep and time of waking. If the patient
was found collapsed with the stroke unable to give a histo¬
ry, then the time of onset was estimated from knowledge of
when the patient was last seen prior to the stroke, and what
the patient appeared to have been doing at the time of the
stroke (for example eating breakfast, or getting dressed).
No attempt was made to change referral patterns or speed of
referral of patients to hospital.
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The patient's plasma glucose and haemoglobin were
measured within 24 hours of admission to hospital, and
plasma albumin within one week of symptom onset.
3.2.3 Clinical follow up
Outcome was assessed at one and three months after
the stroke as: 1) dead; 2) no improvement neurologically
from the time of admission with the stroke; 3) improving
neurologically but still in hospital; 4) in long term care;
5) in rehabilitation (aiming to go home eventually); or 6)
home. This information was obtained from ward staff if the
patient was still in hospital, from the NLSS or Streptoki¬
nase Trial follow up done by one of the members of the
Department of Clinical Neurosciences, or from the patient's
GP. The scale was very simple to apply, and although it did
not take account of the patient's disability relative to
their social circumstances, it did allow simple differentia¬
tion between death and severe disability on the one hand,
and independant living on the other.
2.2.4 Timing of imaging studies
All patients had a CT brain scan and TCD examination
as soon as possible after admission ("0 to 2 day" examina¬
tion) . Two more CT brain scans were performed in surviving
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patients. The second CT brain scan was between three and
seven days (as near to three to four days as possible - "3
to 7 day" examination), and the third between eight days and
three weeks (as near to fourteen days as possible - "14 day"
examination) after the stroke onset. The exact timing of the
CT scans was, to some extent, determined by clinical factors
and practicality in a busy Neuroradiology Department. It was
hoped that the second CT brain scan would show the maximum
infarct swelling, as previous studies have suggested that
maximum swelling occurs between three and five days after
symptom onset.^®'^^'^^ The third CT brain scan was done
to examine the duration of infarct swelling, and to look for
change in the extent of the infarct from the admission CT
brain scan.
TCD studies were done daily in the first week, twice
in the second week, and once in the third week.
As mant patients as possible had a carotid Duplex
ultrasound examination to look for significant carotid
disease in the neck such as tight ICA stenosis or ICA occlu¬
sion. This was to provide corroborative evidence to back up
the TCD findings.
Some patients died or were considered too ill to move
(for non-neurological reasons, for example unstable cardiac
status following an acute myocardial infarct), or were
discharged prior to completing the three weeks of imaging.
All available data on all the patients has been included.
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3.2.5 Imaging studies - CT brain scans
The CT brain scans were performed in the axial plane,
at ten millimeter intervals, without radiographic contrast,
using an IGE 8800 CT scanner with a fast image processing
upgrade. The entire brain was examined.
The CT brain scans were reviewed blind to the clini¬
cal information, and blind to all other CT brain scans for
the same patient, by two neuroradiologists, Dr R Sellar,
Consultant, and myself. The CT scans were examined for the
presence of a recent infarct and then coded for the site and
extent of the recent infarct, the amount of swelling in the
recent infarct, and the presence of any haemorrhagic trans¬
formation (Figures 2.2.1a - c). A recent infarct was identi¬
fied as an area of decreased density relative to normal
brain (often best appreciated by comparison of the brain
densities in equivalent parts of the two hemispheres) con¬
forming to an arterial territory as described in Part One
Chapter Six. Signs such as loss of the normal outline of the
o o o 9 ? n
lentiform nucleus, 7 loss of the insular ribbon, and
loss of the normal grey-white matter differentiation were
9 9ft
particularly sought. Recent infarction was usually associ¬
ated with some mass effect causing loss of visibility of the
cortical sulci when minor, to midline shift and effacement
of the basal cisterns when massive. The maximum amount of
swelling in the infarct was simply the largest amount of
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swelling seen on any of the patient's CT brain scans (usual¬
ly the second one). The extent of the infarct was taken as
the maximum extent seen on any of the scans. An old infarct
(ie older than three months) was identified as an area of
marked low density compared with surrounding brain associat¬
ed with atrophy of adjacent structures. A haematoma was
identified as a rounded area of increased density relative
to normal brain associated with mass effect. The presence of
any haemorrhagic transformation of the infarct was noted to
ensure that any increase in infarct swelling was not simply
due to the development of a large focal haematoma within the
infarct. This study was not designed to examine the rela¬
tionship between blood velocity changes and haemorrhagic
transformation. Larger numbers of patients would be required
to do that, and it would be more appropriate to examine all
ischaemic strokes, not just large ones.
The codes used to describe infarct site/extent,
swelling and haemorrhagic transformation were the same as
those described in Part Two, Chapter Two and found to have
"excellent" interobserver agreement for infarct site/extent
for large infarcts and for infarct swelling when tested for
interobserver reliability (Part Two, Chapter Three). For
infarct site/extent only the codes describing infarcts in
the MCA territory were used (codes "10" to "80") therefore
the zeros were omitted (ie the codes became "1" to "8").
Where there was any disagreement on coding of the infarct
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appearance, the scan was discussed and an agreement reached.
It was not necessary to obtain a third opinion on any scan.
The codes are also listed in Appendix Three.
3.2.6 Imaging studies - transcranial Doppler ultrasound
The TCD studies were performed blind to all clinical
information apart from the name of the patient and the side
of the infarct. The result was interpreted and recorded on
the patient's record sheet before the results of other
imaging tests were known.
An Eden Medical Electronics TC 64B ultrasound machine
with 2 MHz hand-held probe was used, as described in Part
2.2. Recordings of the peak and mean blood velocities were
obtained from the MCAs (65 to 35 mm depth), ACAs (65 to 75
mm depth) and PCAs (60 to 80 mm depth) through the temporal
bone windows, and of the ICAs and opthalmic arteries through
1 n o
the orbits. Where the symptomatic MCA was undetectable,
clear signal from the ipsilateral ACA or PCA had to be
obtained to ensure that failure to detect the MCA was due to
occlusion of its origin and not due to failure of the tech¬
nique. Patients in whom it was impossible to obtain a signal
from any one of the basal intracranial arteries were consid¬
ered to have a poor temporal bone window and excluded from
the study.
The mean blood velocity (time averaged mean) in the
330
symptomatic MCA was expressed as a proportion of the mean
blood velocity in the asymptomatic MCA using the coding
system described in Part 2.2 and Appendix Four. The ACA and
PCA blood velocities relative to the asymptomatic side
(normal, increased or decreased) and direction of flow in
the ACA and opthalmic artery (normal or reversed) were also
expressed using the coding system. The coding system was
very useful because it enabled the often complex relation¬
ship between blood flow velocities in the major arteries in
the base of the brain to be condensed into a three digit
numeral which could also be used to describe changes in the
blood flow velocity with time. A difference in the MCA blood
velocity between symptomatic and asymptomatic sides of
1 O O
greater than twenty-five percent was considered abnormal. JO
Change in symptomatic MCA blood velocity during the first
five days or until the second CT brain scan (whichever was
the sooner) was defined as an increase of at least twenty-
five percent in the symptomatic MCA blood velocity of the
blood velocity on the asymptomatic side. Thus an increase in
the symptomatic MCA blood velocity from undetectable to
twenty-five percent, or from twenty-five to fifty percent,
etc, or even from an apparently normal value (ie 100%) to
twenty-five percent greater than that on the asymptomatic
side (ie 125%) was counted as an increase. The maximum
change in the symptomatic MCA blood velocity was taken as
the blood velocity immediately prior to the second CT brain
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scan (days "3 to 7") minus the admission value. Care was
taken to distinguish between increased velocity due to
stenosis (a focal area of velocity increase in the MCA main
stem with damped low velocity distally) and hyperaemia
(increased velocity throughout the whole detectable MCA main
stem). Where a stenosis was suspected, the velocity detected
in the part of the MCA immediately distal to the area with
the high velocity was used to calculate the difference
between the symptomatic and the asymptomatic MCA blood
velocities.
Some patients also had an MCTT study done to confirm
the pattern of vascular pathology as predicted by TCD. A few
patients were randomised in the streptokinase trial (see
Part 4) so also had a cerebral angiogram pre and post treat¬
ment infusion. Both of these techniques provided useful
confirmation of the pattern of cerebral arterial occlusion
as shown by TCD.
The patients' End Tidal C02 was measured at the time
of each TCD studies using the Datex Normocap 200 as de¬
scribed in Part 2.2, to ensure that blood velocity changes
were not simply due to altered respiration. Sequential TCD
studies were done with the patient in the same position,
usually supine, and as near to the same time of day as
possible.
332
3.2.7 Consent for imaging studies
Consent for the CT brain scans and TCD studies was
obtained from the patient or a close relative and the at¬
tending medical staff. Often the initial CT brain scan was
requested by the attending medical staff to assist with
clinical management, but the second and third were usually
purely for research purposes, so consent was obtained.
3.2.8 Statistical Analysis
The results of clinical examination, CT brain scans
and TCD examination were entered into a database (dBase IV
Ashton Tate) on an IBM microcomputer. The time course of
acute infarct swelling was examined to find the time of
maximum swelling. The results were analysed for the effect
of change in blood velocity during the first three to five
days, and the effect of a "good" initial velocity, on a) the
maximum amount of swelling shown on the CT brain scan be¬
tween days three and five, and b) outcome at one and three
months. The effects of the age of the patient, plasma albu¬
min and glucose on maximum swelling were also examined.
These relationships were analysed using the Statistic Pack¬
age for the Social Sciences program (SPSS/PC), and odds
ratio analysis, with assistance from Mr J Slattery, Statis¬
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3.3.1 Study patient characteristics
There were 47 patients with symptoms of an extensive
MCA territory acute ischaemic stroke in whom it was possible
to obtain a satisfactory TCD signal of the basal intracrani¬
al arteries through the temporal bones. These were the study
subjects.
Of the 47 patients, 32 had a TACI and 15 had a "large
PACI" acute ischaemic stroke. The mean age of the patients
was 72 years (range 29 to 90 years). Fifteen patients gave a
history of previous stroke.
The probable cause of the cerebral infarct in each
patient was established by careful consideration of, and
search for, all common risk factors, particulary evidence of
a cardiac source of embolus or ICA stenosis or occlusion.
The most likely cause of stroke is given as the probable
cause recognising that definite causes are difficult to
define and some patients may have more than one risk factor.
Seventeen patients had a severe stenosis or occlusion of the
ICA. Sixteen patients had evidence of cardiac disease as a
possible cause of embolism (recent myocardial infarction,
atrial fibrillation, valve disease). In fourteen patients
the cause of stroke was "uncertain" including one patient
who had had a laparoscopic cholecystectomy in the previous
week, with no other risk factors, and may have been partly
dehydrated. In a few "uncertain" cases, there was more than
one possible cause of stroke, for example evidence of ICA
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stenosis and recent myocardial infarction. In one patient
the cerebral infarct may have occurred secondary to a pro¬
found drop in blood pressure following an acute myocardial
infarction, superimposed on a tight ipsilateral ICA steno¬
sis. In three patients considered to have cardioembolic
stroke, the stroke was the presenting illness and the diag¬
nosis of "silent" acute myocardial infarction was only made
retrospectively on the basis of ECG and cardiac enzyme
changes in the following week. Two other patients had sus¬
tained a definite acute myocardial infarct in the week
preceding their acute ischaemic stroke. One of these had had
a negative echocardiogram immediately prior to the acute
ischaemic stroke, but an embolus of cardiac origin remained
the most likely cause.
Most patients received no specific treatment for
their acute ischaemic stroke. Ten patients were randomised
in a trial of aspirin, heparin, both or neither (given for
the first two weeks after stroke), and three other patients
were randomised in a pilot trial of intraarterial streptoki¬
nase for the acute ischaemic stroke, described in Part Four.
3.3.2 Haematology and biochemistry results:
The plasma glucose, albumin and blood haemoglobin
levels for the study group are shown in Table 3.3.1. The
haemoglobin values were within the normal range, but the
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haematocrit values were at the lower end of the normal
range. The plasma glucose (measured within 24 hours of
stroke) was above the upper limit of the normal laboratory
reference range in 37/47 patients. The plasma albumin (meas¬
ured within one week of stroke) was below the lower limit of
the normal laboratory reference range in 8/47 patients.
3.3.3 Clinical outcome
Twelve TACI patients had died by one month, and a
further two had died by three months after stroke onset.
Only one PACI patient died within three months of stroke
onset. By three months, ten patients had returned home.
Three were still alive but had made no neurological improve¬
ment. Ten patients were in long term care, and three were in
rehabilitation but making good progress intending to return
home eventually. The cumulative survival by infarct type up
2 R
to three months is shown in Figure 3.3.1. In the OCSP the
case fatality rate for TACI patients was 39% at one month,
and for PACI it was 8%. The figures for the present study
are similar, with 38% of TACI and no PACI patients dead at
one month.
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3.3.4 Summary of imaging studies performed
All patients had at least one CT brain scan, and TCD
study. Eight patients died before the third CT brain scan
could be performed, and it was not possible to CT scan
twelve patients within three days of stroke (because of CT
scanner breakdown or servicing, delay in admission, or
unwillingness of the attending medical staff to allow the
patient to be moved for a CT scan). Five patients died after
the first CT brain scan before the second, and seven died
after the second and before the third. Three were discharged
back to their referring hospital after the second CT brain
scan. Therefore not all patients had all three CT brain
scans. Seven patients had three, twenty patients had two and
twenty had just one CT brain scan (but twelve of these were
between days three and seven). Regardless of this all pa¬
tients had TCD examinations, as described in the method,
daily from admission in the first week, twice in the second
week and once in the third week, unless the patient died or
was discharged. The cumulative CT brain scan rate is shown
in Figure 3.3.2 and summarised in Table 3.3.2.
Twenty-seven patients had a diagnostic MCTT study at
the time of the first TCD study and thirteen patients also
had a follow up MCTT study which provided additional corrob¬
orative evidence of the pattern of cerebral arterial occlu¬
sion as shown by TCD. Of the patients who did not have an
MCTT study, two died within four days of symptom onset and
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underwent post mortem examination, and four had cerebral
angiography. Thus there were 12/47 patients where TCD was
the only method of showing the pattern of cerebral arterial
occlusion.
3.3.5 Imaging results - CT brain scans
The mean time to the first CT scan from stroke onset
for the whole patient group was 0.68 days (SD +/- 0.61
days), to the second CT scan was 3.9 days (SD +/- 1.4 days),
and to the third CT scan was 14 days (SD +/- 4.5 days). Nine
patients were CT scanned within six hours, and a further 10
patients between six and twelve hours of the stroke onset.
a) Site and extent of cerebral infarction as shown by CT
brain scan :
In most patients there was a visible infarct in the
symptomatic area of the brain on the first CT brain scan
(days "0 to 2"). Only one TACI patient had a normal CT brain
scan within the first 24 hours of symptom onset (which later
became abnormal), the other 31 all having clearly visible
infarcts in the MCA territory, including those scanned
within the first six hours. One PACI patient still had a
normal CT brain scan at three days after onset (the patient
was discharged to the referring hospital so no follow up CT
brain scan was obtained) but the rest of the PACI patients
had a visible infarct in the symptomatic area of brain on
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the first CT scan (days "0 to 2").
Most patients showed the same extent of infarct on
their second or third CT brain scan as was shown on the
first scan. Only three patients had a more extensive infarct
on the second CT brain scan than on the first, as follows :
one TACI patient scanned within 1.5 hours of stroke had a
negative CT brain scan, but showed a predominantly cortical
MCA territory infarct (code 4) on the second CT brain scan
at four days - presumably the first CT scan was too early
for the infarct to be visualised ;
another TACI patient had her initial CT brain scan at 12
hours after the stroke, showing an obvious extensive infarct
(code 6), which had become even more extensive (code 7) by
the second CT brain scan on day four (this patient had a de
crease in symptomatic MCA blood velocity suggesting a de¬
crease in blood flow to the symptomatic area during the four
days, which may have caused the ischaemia to increase. The
patient died on day five and post mortem examination con¬
firmed occlusion of the MCA from its origin distally) ;
the third patient, also a TACI, had a predominantly cortical
infarct visible on the initial CT brain scan at six hours
(code 4), which had extended to involve the whole MCA terri¬
tory on the second CT brain scan at four days (code 8). No
TCD flow signal was detected in the symptomatic MCA at any
time in the first four days in this patient, in keeping with
MCA occlusion.
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No patient had a more extensive infarct on the third CT
brain scan than on the second.
b) Amount of swelling in the cerebral infarct as shown by CT
brain scanning :
The time course of swelling in the cerebral infarct
is shown in Figure 3.3.3. This graph includes all the CT
scans performed, so if a patient had more than one CT brain
scan, all are included at the appropriate time. The time of
peak infarct swelling was between two and four days, as
o/rc n cc O A Q
found in previous studies. ' ' Some swelling was
still visible in some patients up to 18 days after the
stroke. Haemorrhagic transformation of the infarct with
haematoma formation was not the cause of infarct swelling in
any patient as there were no large haematomas.
c) Haemorrhagic transformation of the cerebral infarct as
showm by CT scanning :
Only a few patients in this series developed definite
areas of haemorrhage in their cerebral infarct. Two patients
had haematomas between two and five cm in diameter (one on
CT scan at two days, one at five days); one patient de¬
veloped a haematoma less than two cm in diameter (CT scan at
14 days); and 13 patients developed minor areas of increased
density bordering the infarct which were thought to repre¬
sent petechial haemorrhage. The two "two to five cm" haema-
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tomas did not appear to contribute greatly to the amount of
infarct swelling, as the area of infarction was large in
both patients and most of the infarct swelling
appeared to be due to swelling of ischaemic brain.
3.3.6 Imaging results - transcranial Doppler ultrasound
The changes in the symptomatic MCA blood velocity
(expressed as a proportion of the asymptomatic MCA blood
velocity) with time after the stroke are plotted separately
for TACI and PACI patients, to make the graphs less clut¬
tered, in Figures 3.3.4A (TACI) and 3.3.4B (PACI). Consecu¬
tive TCD studies in the same patient are indicated by lines
connecting the points. Some patients had only one study
prior to death. (As this discussion concerns only the veloc¬
ity in the MCA, only the first digit of the three digit TCD
code is used on the graphs).
The symptomatic MCA blood velocity increased between
the admission recording and the time of the second CT brain
scan (between three and seven days) in eighteen patients. Of
these, twelve patients had a gradual and progressive veloci¬
ty increase throughout the recordable MCA length. In the six
other patients a focal, very high, velocity appeared in the
symptomatic MCA main stem with a low amplitude, damped
velocity signal more distally, for 24 to 48 hours, later
resolving to a normal velocity. The latter would be consist-
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ent with the presence of a stenosis during recanalisation of
icqthe occluded artery, and the velocity recorded in the MCA
distal to the stenosis was used to calculate the symptomat¬
ic : asymptomatic MCA velocity ratio. In five of the eighteen
patients the blood velocity increased along the whole re¬
cordable length of the symptomatic MCA (65 to 35 mm depth-
from the temporal bone window) to a value greater than that
on the asymptomatic side during the first five days after
1 C 1 1 COstroke, consistent with "hyperaemic" flow. J J Twenty-
seven patients showed no change in symptomatic MCA blood
velocity from the admission value, and in two patients there
was a definite decrease in symptomatic MCA blood velocity.
The maximum increase observed in symptomatic MCA blood
velocity (calculated as the value immediately prior to the
second CT brain scan on days three to seven, minus the
admission value) was 125% (ie from zero to 25% greater than
the asymptomatic MCA blood velocity), and the maximum de¬
crease observed was minus 50% (from 50% of the asymptomatic
value to zero).
The admission symptomatic MCA blood velocity was
considered to be "good" (normal or at least 75% of the blood
velocity on the asymptomatic side - code 5 and 6) in seven¬
teen patients, and "poor" (less than 75% of the velocity on
the asymptomatic side - codes 4 or less) in thirty patients.
The TCD results were confirmed by angiography in four
patients and by post mortem in two. Thirty-five patients
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also had an MCTT study. Twenty-six showed complete agreement
between the TCD and MCTT findings. One MCTT study suggested
a worse deficit then the TCD. In the other eight the MCTT
was technically unsatisfactory due to poor cardiac output.
Three of the patients who developed hyperaemia in the symp¬
tomatic MCA on TCD showed a corresponding shortening of
transit time.
If an increase in the symptomatic MCA blood velocity
does indicate recanalisation, then the rate in our study
(15/34 of the patients still alive and in hospital at ten
days) was lower than the rate described in angiographic
studies of 20% at 24 hours and 80% at one week after stroke
1 1 Q 1 O O IOC
(see Figure 1.3.1). '' This may be because our study
was biased towards patients with ICA and MCA main stem
occlusions (which may recanalise less easily) and excluded
patients whose clinical features suggested a lacunar syn¬
drome, whereas angiographic studies have included peripheral
MCA branch occlusions which may recanalise more easily, and
some also included patients with lacunar strokes whose basal
intracranial arteries were probably never occluded.
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3.3.7 Severe cerebral infarct swelling - association with
the age of the patient, plasma glucose and albumin levels
There was no association between the maximum amount
of swelling in the infarct and the age of the patient (P =
0.6, R2 = 0.009, correlation -0.09). However the study
included very few patients under sixty years of age.
There was no definite association between plasma
albumin (R2 0.015, correlation coefficient 0.12, P = 0.5)
measured in the first week after stroke onset, or plasma
glucose (R 0.07, correlation coefficient 0.2, P=0.15)
measured in the first 24 hours after stroke onset and in¬
farct swelling (Figure 3.3.5 A and B).
One reason for the lack of association between bio¬
chemical factors and infarct swelling was the small number
of patients in the study. Another reason for lack of associ¬
ation between plasma glucose and infarct swelling (which may
also explain some of the disagreement between previous
O O Q
studiesJJJ) might be that the value measured within 24 hours
of stroke was guite different from the patient's plasma
glucose at the time of the stroke. Stress response, lack of
food, failure of diabetic patients to take hypoglycaemic
agents after the stroke and before the patient reached
hospital could all influence plasma glucose, changing it
quite markedly from the value at the time of stroke onset.
The lack of any definite association in this study should
not be taken to indicate a lack of influence of blood glu-
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cose levels on acute infarct
the need for a better method
the time of the stroke, such
Al.
swelling. It merely indicates
of estimating blood glucose at
as measurement of haemoglobin
3.3.8 Severe cerebral infarct swelling - association with
size and extent of infarct
The association between extent of infarct and amount
of swelling is shown in Figure 3.3.6. The maximum amount of
swelling (in most cases seen on the CT brain scan between
three and seven days) is plotted against the maximum extent
of the infarct (maximum extent seen on any of the patients
CT scans). Only 43 patients were included as two were CT
scanned within six hours and died within 24 hours of stroke
onset (of non-neurological causes), and a further two were
not scanned between three and seven days, and the infarct
swelling shown at these very early and late times was un¬
likely to be maximal.
There was a very clear association between infarct
extent and maximum swelling. As might be expected, the more
extensive the infarct the greater the amount of swelling.
This association was highly significant (P<0.000) with a
correlation coefficient of 0.744 and R of 0.55. One would
expect that the greater the amount of damaged tissue, the
greater the amount of oedema and necrosis.
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3.3.9 Severe cerebral infarct swelling - association with
the symptomatic MCA blood velocity - initial value and
changes in the first five days after the stroke
The main aim of the study was to examine the effect
of blood velocity changes on infarct swelling, therefore two
parameters of blood flow to the infarct have been examined :
1) the change in the symptomatic MCA blood velocity in the
first five days after the infarct, and
2) the initial symptomatic MCA blood velocity.
1) To examine the relationship between MCA blood velocity
changes and infarct swelling the patients were divided into
two groups : those in whom the symptomatic MCA blood veloci¬
ty increased in the first five days or until the second CT
brain scan whichever was the sooner, as defined in Part 3
Chapter 2.7 (called the "velocity increase" group) and those
in whom the symptomatic MCA blood velocity did not change or
decreased in the same time span ("velocity no change"
group). The maximum infarct swelling was plotted for both
groups and shown in Figure 3.3.7.
An improvement in the symptomatic MCA blood velocity
("velocity increase" group) was associated with a 93% reduc¬
tion in the odds of severe infarct swelling (CT codes "4" to
"6") compared with the group with no improvement or a de¬
crease ("velocity no change") in the symptomatic MCA blood
velocity (95% confidence interval 99% to 45% reduction, P <
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0.05). In other words 6/17 patients with no change or a
decrease in the symptomatic MCA blood velocity, and 0/11
patients with an increase in symptomatic MCA blood velocity
within the first three to five days after the stroke de¬
veloped "severe" infarct swelling : a 7.6 fold increase in
the odds of severe infarct swelling in the "velocity no
change" group (95% CI 1.2 to 46.4 fold increase, 2p = 0.03).
2) To examine the relationship between initial symptomatic
MCA blood velocity and maximum infarct swelling, the pa¬
tients were divided into those with "good" blood velocity in
the symptomatic MCA on admission (normal or at least 75% of
the value in the asymptomatic MCA - TCD code "5" or "6"), or
"bad" initial velocity ( 50% or less of the asymptomatic
value - TCD codes "0" to "4"). A graph of the initial MCA
blood velocity ("good" or "bad") and maximum cerebral in¬
farct swelling is shown in Figure 3.3.8. A "good" initial
blood velocity, ie near normal or normal, probably indicated
better blood flow to the infarct than in a patient with MCA
blood velocity reduced by 50% or more - "bad" flow. A "good"
initial blood velocity was associated with a reduction of
92% in the odds of having massive swelling (codes "4" to
"6") compared with "bad" initial velocity (95% confidence
interval 99% to 70% reduction, P < 0.05). The numbers were
small, but this does appear to be favouring a trend towards
less acute infarct swelling with better initial flow to the
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infarct. Following the explanations given in Parts 3 Chapter
1.2 and Part 1 Chapter 4, this could mean early recanalisa-
tion was associated with less swelling, or simply that good
collateral flow (through patent MCA branches) was associated
with less swelling. In both situations, the smaller amount
of swelling could be because of an association with a small¬
er cerebral infarct.
Although the numbers were small, this result appears
to favour a trend towards improved blood flow to the infarct
being associated with less swelling, contradicting evidence
from experimental work, 52 / 327 , 341, 344 , 345 j;)ut not from the
small studies in stroke patients . ' ^47
The relationship between initial admission symptomat¬
ic MCA blood velocity and maximum infarct swelling (maximum
amount seen) is also shown in Figure 3.3.9. Despite the wide
scatter of points there is an inverse association between
the initial symptomatic MCA blood velocity and maximum
infarct swelling on subsequent CT brain scans (Spearman rank
correlation coefficient -0.77, 95% confidence interval -0.88
to -0.59, P<0.05). The more normal the initial velocity, the
less the infarct swelling that developed. Again, this might
have been because a better initial MCA blood velocity (due
to recanalisation or good collaterals or other reason) was
associated with a smaller infarct and hence less swelling.
The change in MCA blood velocity, particularly an
increase indicating better flow to the infarct, rather than
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the absolute value, might be more likely to cause more in
farct swelling according to experimental work. The relation¬
ship between change in MCA blood velocity between the admis¬
sion value and the value immediately prior to the second CT
brain scan (at three to seven days), and maximum infarct
swelling for all the patients is shown in Figure 3.3.10.
There was no significant association between change in MCA
blood velocity and maximum infarct swelling (Spearman rank
correlation coefficient -0.09, 95% confidence interval -0.5
to 0.35). This indicated that improved flow to the infarct
does not obviously worsen infarct swelling, contradicting
much of the experimental work.
However the effect of the increasing flow might still
be masked if only the absolute maximum infarct swelling is
considered. Examination of the effect of change in sympto¬
matic MCA blood velocity between the admission value and the
value immediately prior to the second CT brain scan (at
three to seven days) on the change in infarct swelling up to
the second CT brain scan done between three and seven days
after onset when maximum infarct swelling is expected, might
indicate more directly an association between blood velocity
increases and infarct swelling. To assess the change in
infarct swelling the difference in swelling between the
zero-to-two and the three-to-seven day CT brain scans in
patients who had both scans (20 patients), and the differ¬
ence in symptomatic MCA blood velocity between the TCD
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studies coinciding with the two CT scans was used. Also
included were some of the twelve patients who had only one
CT brain scan at three-to-seven days but who had a TCD study
within six hours of stroke, assuming that the change in
infarct swelling equalled the day three-to-seven value, and
the change in symptomatic MCA blood velocity equalled the
value at the time of the three-to-seven day CT scan minus
the admission value. Figure 3.3.11 shows the relationship
between change in MCA blood velocity and change in infarct
swelling in the first five days after stroke onset as de¬
fined above. Contrary to experimental work, an increase in
MCA blood velocity was associated with significantly less
infarct swelling (Spearman rank correlation coefficient
-0.48, 99% confidence interval -0.78 to -0.01, 0.05>P>0.01)
than if the MCA blood velocity remained low. Therefore an
improvement in blood flow to the infarct in the first three
to five days after stroke onset was associated with less
swelling in the infarct than was persistently poor blood
flow. Therefore treatments intended to improve blood flow to
the infarct in the first few days after onset may not worsen
infarct swelling (as suggested by experimental studies), and
may be beneficial.
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3.3.10 Clinical outcome after acute ischaemic stroke -
influence of changes in the symptomatic MCA blood velocity
in the first five days after the stroke
The outcome at three months was related to infarct
size. The more extensive the infarct, the worse the outcome
(P = 0.001).
The influence of change in the symptomatic MCA blood
velocity on clinical outcome is shown in Figure 3.3.12 with
the patients divided into those whose symptomatic MCA blood
velocity increased ("velocity improved") and those whose
velocity did not change or deteriorated ("velocity no
change") as defined above. Patients whose MCA velocity
improved tended to have a better outcome than those whose
MCA velocity remained unchanged or decreased : the only
patients who reached home were those who had had an improve¬
ment in MCA blood velocity in the first five days after the
stroke. More than 50% of those with no improvement in MCA
blood velocity were dead by three months. If a "good out¬
come" was defined as at home or in rehabilitation expecting
to return home, and a "poor outcome" was anything else, then
27/29 patients in the "velocity no change" group, and 9/18
in the "velocity increase" group had a poor outcome ; a ten
fold increase in the odds of a poor outcome if the sympto¬
matic MCA blood velocity did not improve in the first three
to five days after the stroke (95% CI 2.7 to 41.6 fold in
crease, 2p = 0.0007). Improvement in MCA blood velocity was
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associated with a non-significant reduction in the odds of
death of 66% (95% confidence interval 93% reduction to 50%
excess) but a reduction in the odds of death or disability
(defined as still in hospital and not improving) of 93% (95%
confidence interval 99% to 30% reduction). The numbers were
small but favoured a trend towards improved blood flow to
the infarct in the first five days leading to improved
outcome.
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Summary of Chapter Three
1. Cerebral infarct swelling was maximal between tree and
five days after the onset of the stroke symptoms.
2. The factor which most influenced cerebral infarct swell¬
ing was the size of the infarct - the larger the infarct,
the greater the amount of swelling.
3. Patients with evidence of improved flow in the symptomat¬
ic MCA on transcranial Doppler ultrasound had less severe
swelling in their cerebral infarct than those with no evi¬
dence of improvement in the symptomatic MCA blood velocity.
4. Clinical outcome was better in the patients with evidence
of improvement in the symptomatic MCA blood velocity in the
first three to five days after the stroke than in patients
with no evidence of any increase in MCA blood velocity.
5. The TCD results were verified by post mortem, angiography
and the MCTT in about half of the patients.
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Table 3.3.1 Haemoglobin, plasma glucose and plasma albumin
levels for the study patients
Haemoglobin : normal range : 120 to 180 g/1
mean of study group 132
SD +/- 20
Haematocrit : normal range : 40 to 54%
mean of study group 40
SD +/- 4
Plasma Glucose : normal range : 3.9 to 5 mmol/1
mean of study group 6.96
SD +/- 2.8
Plasma Albumin : normal range : 35 to 50 g/1
mean ofstudy group 38
SD +/- 4.8
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Table 3.3.2 Number of CT Scans Performed in Each Time Window
Total
CT scan 0-2 days
CT scan 3-7 days
CT scan 8 - 14+ days
The numbers in brackets refer to
had only one CT scan at the time
Patients having 3 CT brain scans
Patients having 2 CT brain scans
Patients having 1 CT brain scan : 20 (12 of these were
between days 3 and 7)
Patients who died :
after the 1st CT brain scan, before the 2nd : 5
after the 2nd CT brain scan, before the 3rd : 7
Patients discharged :
after the 1st CT brain scan, before the 2nd : 2
after the 2nd CT brain scan, before the 3rd : 7
Permission for repeat CT brain scan refused :
by attending medical staff : 5 (2 unstable condition after
myocardial infarction,
1 haematemesis,
2 too emotionally unstable)
by patient or relative : 1
other reasons : lack of CT scanner time : 5
severe movement disorder : 1










Table 3.3.3 MCA Blood Velocity Changes in the First Three
Weeks After Acute Ischaemic Stroke
total number of patients 47
symptomatic MCA blood velocity
improved between : d 0-5 18
: d 5-20 8
symptomatic MCA blood velocity
did not change between : d 0-5 27
: d 5-20 18
symptomatic MCA blood velocity
decreased between : d 0-5 2
: d 5-20 6
(9 patients died and 5 were discharged prior to the third
week after stroke)
initial symptomatic MCA blood
velocity "normal" 7
"hyperaemic" blood velocity in the
symptomatic MCA at some time in
the first week 5
focal stenosis in the symptomatic
MCA at some time in the first week 6
initial symptomatic MCA blood velocity :
"good" (code"5"-"6") 24
"bad" (code"0"-"4") 17
velocity days 0-3 not known 6
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SURVIVAL UP TO THREE MONTHS AFTER MAJOR ACUTE ISCHAEMIC STROKE
TIME AFTER STROKE IN MONTHS
Figure 3.3.1 Cumulative survival of patients with symptoms
of medium to large cortical and subcortical infarcts in the
carotid territory. The 32 patients with a TACI are shown by
the closed circles and the 15 patients with an extensive
PACI are shown by open circles.
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Days after symptom onset
CT scan days 0 to 2.9
CT scan days 3 to 7.9
CT scan days 8 to 15
—i
2 0
Figure 3.3.2 Number of patients having a CT brain scan in
each time period : open boxes 0 to 2.9 days, diamonds 3 to
7.9 days, closed boxes 8 to 15 days after symptom onset.
Five patients died after the first CT scan before the second
could be performed. Seven died after the second before the
third could be performed. Three patients were discharged
after the second CT scan.
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Figure 3.3.3 The time course of swelling in the cerebral
infarct as shown on the CT brain scan. All CT scans on all
patients are included. The code for the amount of swelling
in the infarct as seen on the CT scan is indicated on the y
axis. 0 = no swelling, 1 = effacement of cortical sulci
overlying the infarct, 2=1+ mild effacement of the ipsi-
lateral lateral ventricle, 3=1+ complete effacement of
the ipsilateral lateral ventricle, 4=3+ effacement of the
third ventricle, 5=3+ midline shift away from the side of
the infarct.
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Change in MCA blood velocity in the first three
weeks after acute ischaemic stroke - TACI
Days after onset of stroke
Figure 3.3.4 Symptomatic middle cerebral artery blood veloc¬
ity changes in the first three weeks following a large acute
ischaemic stroke - (A) patients with a TACI clinical syn¬
drome Consecutive studies on individual patients are indi¬
cated by lines joining the dots. TCD codes (y axis) are
explained in Table 2.2.3 and Appendix Four. Only the first
digit of the TCD code is shown on the y axis : the code
indicates the symptomatic MCA blood velocity as a proportion
of the asymptomatic blood velocity, 6 being normal velocity,
5 velocity reduced to 50 to 75%, 4 a focal stenosis, 3
velocity reduced to 25 to 50%, 2 velocity reduced to less
than 25%, 1 no detectable MCA velocity, 0 no MCA or ACA
velocity detected, and 7 MCA velocity increased to 125% or
more (ie hyperaemia).
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Change in MCA blood velocity in the first three
weeks after acute ischaemic stroke - EXTENSIVE PACI
Days after onset of stroke
Figure 3.3.4 Symptomatic middle cerebral artery blood veloc¬
ity changes in the first three weeks following a large acute
ischaemic stroke - (B) patients with a PACI clinical syn¬
drome Consecutive studies on individual patients are indi¬
cated by lines joining the dots. TCD codes (y axis) are
explained in Table 2.2.3 and Appendix Four. Only the first
digit of the TCD code is shown on the y axis : the code
indicates the symptomatic MCA blood velocity as a proportion
of the asymptomatic blood velocity, 6 being normal velocity,
5 velocity reduced to 50 to 75%, 4 a focal stenosis, 3
velocity reduced to 25 to 50%, 2 velocity reduced to less
than 25%, 1 no detectable MCA velocity, 0 no MCA or ACA
velocity detected, and 7 MCA velocity increased to 125% or
more (ie hyperaemia).
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PLASMA ALBUMIN AND ACUTE INFARCT SWELLING
Figure 3.3.5 A: Maximum cerebral infarct swelling (on the
day three to seven CT brain scan) and plasma albumin level
(g/1) measured within the first week of stroke onset.
The CT codes for infarct swelling (y axis) are described in
Table 2.2.1 and Figure 2.2.IB. "0" indicates no swelling and
"6" is massive swelling with midline shift and effacement of
the basal cisterns. Slope y = 0.96 + 0.04x, R - 0.01, corre¬
lation 0.12, P = 0.54.
363
Figure 3.3.5 B: Maximum cerebral infarct swelling (on the
day three to seven CT brain scan) and plasma glucose level
(mmol/1) measured within the first 24 hours of stroke onset.
The CT codes for infarct swelling (y axis) are described in
Table 2.2.1 and Figure 2.2.IB. "0" indicates no swelling and
"6" is massive swelling with midline shift and effacement of
the basal cisterns. Slope y = 1.36 + 0.15x, R = 0.07,
correlation 0.27, P = 0.15.
364
1 2 3 4 5 6
Maximum Infarct Extent (by CT Code)
—r
7
Figure 3.3.6 The relationship between the extent of the
cerebral infarct and the maximum amount of swelling in the
infarct. The extent of the infarct (x axis) is the maximum
extent seen on any of the patient's CT brain scans ("8" is
infarction of the whole MCA territory). The maximum swelling
in the infarct is the maximum infarct swelling seen on any
of the patient's CT scans, but usually this was on the scan
at three to seven days ("6" is massive swelling with midline
shift and effacement of the basal cisterns). Slope of line :
y = -0.39 + 0.55x, correlation coefficient 0.74, R = 0.55,
P < 0.000). Codes for infarct extent and swelling are ex¬
plained in Figure 2.2.1A and 2.2.IB, and Appendix Three.
Only 43 patients are shown as two were CT scanned within six
hours and died within 24 hours of stroke onset (of non-
neurological causes) and a further two were scanned only
before three and after seven days, and the infarct swelling
shown at these very early and late times was unlikely to be
maximal.
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Figure 3.3.7 Maximum infarct swelling seen on the three to
seven day CT scan in patients with a definite improvement in
the symptomatic MCA blood velocity ("velocity increased")
compared with patients with no change or a decrease in the
symptomatic MCA blood velocity ("velocity no change") within
the first three to five days after stroke onset.
The amount of swelling is indicated by the CT code, "3" to
"5" being considered severe swelling. An improvement in MCA
blood velocity was associated with a 93% reduction in the
odds of severe infarct swelling compared with the "velocity
no change" group (95% CI 99% to 45% reduction, P<0.05).
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Maximum acute infarct swelling
Figure 3.3.8 Maximum infarct swelling seen on the day three
to seven CT scan in patients whose MCA blood velocity when
first measured was "good" (ie normal or not reduced by more
than 25% - TCD code "5" or "6") compared with those whose
blood velocity was "poor" (ie reduced by 25% or more - TCD
codes "0" to "4") A : TACI, B : PACI patients.
The odds of having massive infarct swelling (CT codes "3" to
"5") were reduced by 92% (95% CI 99% to 70% reduction) in
the group whose symptomatic MCA blood velocity was "good"
when compared with those whose velocity was "poor".
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Initial MCA blood velocity (days 0 to 2.9) and maximum swelling
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Initial MCA blood velocity days 0 to 2.9 (by TCD code)
Figure 3.3.9 Symptomatic MCA blood velocity when first
measured and maximum infarct swelling as seen on the CT scan
at three to seven days. On the y axis "0" = no swelling and
"5" = massive swelling. On the x axis "0" = MCA blood veloc¬
ity undetectable, "6" = normal. Slope y = 4.2 - 0.41x, R2 =
0.3, correlation -0.77, 95% CI -0.88 to -0.59, P <0.05.
Codes for MCA blood velocity are explained in Table 2.2.3
and Appendix Four (only first digit of code used in the
plot), and for cerebral infarct swelling in Figure 2.2.1b
and Appendix Three.
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change in MCA blood velocity (days 0 to 5)
Figure 3.3.10 Change in the symptomatic MCA blood velocity
within the first three to five days of stroke onset and
maximum infarct swelling as seen on the CT scan at three to
seven days.
"0" = no swelling and "6" = maximum swelling. The change in
symptomatic MCA blood velocity is indicated as the differ¬
ence between the value on admission and the value immediate¬
ly prior to the day three to seven CT scan using the first
digit of the TCD code (ie a "2" on admission and a "5" prior
to the day three to seven CT scan would be an increase in
MCA blood velocity of "+3"). The correlation coefficient was
-0.09 (95% confidence interval -0.5 to 0.35, NS). Codes for
infarct swelling are given in Figure 2.2.1b and Appendix
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Figure 3.3.11 Change in the symptomatic MCA blood velocity
in the first three to five days after the stroke and the
change in infarct swelling between the day 0 to 2.9 and the
day 3 to 7 CT scans in the 20 patients who had both scans.
Also included are some of the twelve patients who had only
one CT scan at three to seven days but who had their first
TCD study within six hours of the stroke, assuming that the
change in infarct swelling equalled the day three to seven
value. The change in symptomatic MCA blood velocity is
indicated as the difference between the value on admission
and the value immediately prior to the day three to seven CT
scan using the first digit of the TCD code (ie a "2" on
admission and a "5" prior to the day three to seven CT scan
would be an increase in MCA blood velocity of "+3").Correla¬
tion coefficient -0.48, (95% confidence interval -0.78 to
-0.01, 0.05>P>0.01). Codes for infarct swelling are given in





■ NO CHANGEOR DECREASED
BETWEEN DAYS "0 to 2"
AND DAYS "3 to 7"
DEAD HOSP LTC REHAB HOME
OUTCOME AT THREE MONTHS AFTER STROKE
Figure 3.3.12 Outcome at three months after acute ischaemic
stroke in patients whose symptomatic MCA blood velocity
increased ("velocity increased") compared with those whose
blood velocity did not change or decreased ("velocity no
change") in the first five days after stroke onset. "LTC" =
long term care, "HOSP" = still in hospital with no improve¬
ment neurologically, "REHAB" = in a rehabilitation ward with
a good chance of returning home. A "good outcome" = at home
or in rehabilitation expecting to return home. Thus, 27 of
29 patients in the "velocity no change" group, and 9 of 18
patients in the "velocity increased" group had a poor out¬
come : a 10 fold increase in the odds of a poor outcome (95%




Does Early Reperfusion of the Cerebral Infarct Worsen Cere¬
bral Infarct Oedema Formation and Clinical Outcome?
Discussion
3.4.1 Discussion of the results
3.4.2 Summary of Part Three
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3.4.1 Discussion of the results
In the simplest terms, this study has shown that
improved blood flow to the ischaemic brain in the first few
days after stroke was associated with lesser degrees of
infarct swelling and a better clinical outcome than if the
symptomatic artery had remained occluded.
The number of patients in this study was small, but
it represents the largest prospective study of cerebral
infarct swelling and blood flow changes following acute
ischaemic stroke to date, and was the largest study of blood
velocity changes and clinical outcome.
Only patients with symptoms of extensive MCA territo¬
ry ischaemia were included as the MCA is the easiest and
most reliable of the basal intracranial arteries to record
from by TCD.128'129'134'139'140 The entry point to the
study was symptoms indicating extensive MCA territory is¬
chaemia, not the CT brain scan appearance, or MCA blood
velocity abnormalities. If the CT brain scan appearance had
been the entry point, patients with symptoms of extensive
MCA territory ischaemia, but no (or only minimal CT signs)
of infarction, would have been excluded, thus immediately
biasing the study.
The small proportion of patients who actually had all
three CT brain scans illustrated the difficulty of studying
acute ischaemic stroke patients. The mortality from exten¬
sive MCA territory ischaemia is high, and five patients had
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already died before the second CT brain scan could be per¬
formed. Another seven died after the second CT brain scan
before the third could be performed. This, plus the inevita¬
ble loss of scanning facility because of CT scanner break¬
downs and service days, meant that the CT scanning rate was
lower than originally hoped for. On several occasions, it
was difficult to persuade the attending medical staff to
allow the patient to be moved, even though the patient could
be transported on their bed to the CT scanner. The prevail¬
ing attitude towards stroke patients among the general
physicians seemed to be that there was nothing to be learned
from doing investigations (regarded as meddlesome), an
attitude which was also responsible for the very low post
mortem rate in our hospital, but also apparently in the
QIC
USA. J This, plus the low priority given to stroke patients
by ambulance and hospital staff, probably hampers acute
stroke research everywhere, and a change to a more positive
attitude would probably be helpful.
In this study a blood velocity increase in the MCA
was interpreted as improved blood flow to the arterial
territory, but there were a number of possible explanations
of the mechanism of the velocity increase : 1) recanalisa-
tion of the occluded MCA main stem ; 2) persistent MCA major
branch occlusion with hyperaemia in the patent branches ; 3)
reperfusion of an occluded major branch without any hyperae¬
mia ; or 4) recanalisation of multiple distal branch occlu-
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sions. In each case, whether by reperfusion or hyperaemia,
the blood flow to the ischaemic area was improving, though
whether it was to the periphery of the infarct or to the
core cannot be determined from simple velocity readings from
the MCA main stem. The validity of extrapolating blood
velocity changes to blood flow changes has been discussed in
detail also in Parts 1.4 and 3.1.2, and within the simple
criteria used, it was not unreasonable to use velocity
changes to infer blood flow changes. Fluctuations in the MCA
blood velocities and variation in the side-to-side symmetry
occur within short time intervals in normal individuals,
1 TO 1^7J
so probably also occur in pathological conditions.
To try to keep blood velocity fluctuations to a minimum, the
serial TCD studies were performed at the same time of day,
with the patient in the same position (usually supine), with
measurement of the End Tidal C02 to ensure that there were
no major changes in respiration. In order to be counted as
an increase, the symptomatic MCA blood velocity had to
increase by at least 25% of the value on the asymptomatic
side, which is outside the side-to-side asymmetry found in
normal individuals . ' ■*"57 As the true direction of the
MCA cannot be assessed with spectral TCD, and to try to
reduce inaccuracies in velocity measurements occurring as a
result of stretching or distortion of the MCA (from infarct
swelling causing mass effect) the MCA velocity measurements
were always made at the same depth, and the direction of the
375
probe and its position on the temporal bone noted so that any-
gradual change in MCA position in the course of the serial
TCD studies could be assessed. In fact, this was not a
problem as the MCA positions did not appear to alter in any
of the patients. The patients with the most extensive in¬
farcts tended to be those with undetectable MCA (+/- ICA)
blood velocities, indicative of ICA and MCA occlusion, but
possibly with detectable reversed flow in the ACA and de¬
tectable flow in the PCA. Thus, as long as only large veloc¬
ity increases were used to indicate change, and as long as
it was accepted that this change might indicate one of
several different mechanisms as outlined above, it was
probably not unreasonable to infer that an increase in the
symptomatic MCA blood velocity meant increased flow in the
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MCA main stem to the MCA territory. J
The TCD findings were corroborated by other means in
more than half of the study patients (MCTT study, angiogra¬
phy or post mortem). Cerebral arterial occlusions are not
static after an acute ischaemic stroke, therefore arterial
blood velocity measurements will change with time after
stroke onset. It is not valid to assume that the symptomatic
arterial blood velocity measured five hours after the
stroke is the same as the value immediately after the
stroke, or the value 24 hours later. The nearer in time to
the stroke onset, the more likely that the blood velocity is
as it was immediately after the stroke, so any increase
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measured from that point is more likely to represent "im¬
proved flow" or recanalisation. A normal blood velocity
measured soon after the stroke may mean that the artery has
already recanalised, or that the block is very peripheral,
or that the flow in the patent branches is so good that it
masks the effect of one large branch being occluded. With
TCD it is simply not possible to distinguish between these
possibilities. Whichever is the correct explanation, a
"normal" blood velocity suggests better blood flow than a
patient with a greatly reduced or "poor" blood velocity.
Therefore it is important to remenber that the TCD findings
are dynamic after acute ischaemic stroke, and the state of
the arterial circulation in the hours or days prior to the
study cannot be assumed from the TCD result at one point in
time.
The cerebral infarcts were visible in almost all the
TACI patients scanned within 12 hours of symptom onset, and
many of the PACI patients. Even patients scanned as early as
two hours had clearly visible (though subtle) infarcts. The
subjective impression was that infarcts involving the basal
ganglia were easier to see than cortical infarcts because of
the loss of visibility of the lentiform nucleus. The disso¬
ciation of infarct extent from infarct swelling was simple
in practice. There were very few disagreements between the
two neuroradiologists reviewing the CT brain scans, and
usually this was over minor degrees of swelling (ie a "2"
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instead of a "3"), not major (ie a "2" instead of a "5").
Part Two Chapter Three gives the results of the formal
interobserver agreement study for site and extent, swelling,
and haemorrhagic transformation of cerebral infarcts as seen
on CT brain scans. Previously studies of infarct swelling in
stroke patients have simply measured infarct volumes serial¬
ly on CT brain scans, 227 /255/265,266,305 and found that the
volume increased during the first week and thereafter de¬
creased. But this measure gave no information about why the
volume was increasing - whether the infarct had become more
extensive or just more swollen. Volume measurements also
give no information about the extent of the infarct and the
amount of swelling due to it.
In order to examine the relationship between the
swelling and extent of infarction, and between infarct
swelling and other factors, a method of separating the
infarct swelling from extent was required. In practice, the
method described in this thesis was simple to apply and
clearly separated infarct swelling from extent. For each
given infarct extent there were several possible amounts of
swelling. For example a medium-sized infarct involving the
anterior half of the peripheral part of the MCA territory
(CT code "4") could have anything from no swelling (swelling
code "0") to enough swelling to cause midline shift (swell¬
ing code "5"). Similarly an extensive infarct involving the
whole MCA territory (code "8") could have no swelling ("0")
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or maximum swelling causing midline shift and effacing the
basal cisterns (swelling code "6"). Even the smallest corti¬
cal infarct (CT code "1") could have no swelling, or if the
swelling was maximal, cause some effacement of the lateral
ventricle (swelling code "2" or "3"). Therefore the variable
amount of swelling for each infarct extent made it feasible
to study the influence of factors on infarct extent and
swelling.
The clinical outcome measure was even simpler than
the CT brain scan and TCD measures - was the patient alive
and at home at three months after the stroke, or not? Such a
simple outcome measure would probably not suffice in more
sophisticated studies for example in drug trials, but was
adequate for this observational study.
The strongest risk factor for severe infarct swelling
was the extent of the infarct - the more extensive the
infarct, the greater the amount of swelling and the worse
the outcome. Infarct size may have confounded all the other
variables examined, particularly the MCA blood velocity
changes, but the small number of patients in the study meant
that it was not really possible to perform useful multiple
regression analyses. However the likely effect of infarct
size and extent should be kept in mind when interpreting the
effect of the blood velocity changes. It was possible to
compensate in part for infarct size by examining the effect
of change in MCA blood velocity on change in infarct swell-
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ing, although this reduced the number of patients even
further because of failure to serially scan all patients.
The changes in symptomatic MCA blood velocity ap¬
peared to have the opposite effect on swelling to what might
have been expected from experimental work.^^ ^
Patients whose symptomatic MCA blood velocity increased
within the first five days after the stroke had less swell¬
ing than those with no change or a decrease in the MCA blood
velocity. In addition, the greater the change in the veloci¬
ty, the less the infarct swelling. The latter association
was quite strong (Spearman rank correlation coefficient
-0.48, 0.05>p>0.01) despite the small number of patients in
the study. These latter two factors provide the best evi¬
dence that in stroke patients, improved blood velocity in
the main artery supplying the infarct (implying reperfusion)
was beneficial in causing less infarct swelling and a better
clinical outcome. The improved clinical outcome was also
good evidence against "delayed reperfusion injury" being
clinically significant.58,344,345
Was it possible that patients with early reperfusion
and massive infarct swelling who died early were missed from
the study? None of the patients who died within the first
five days had any improvement in their symptomatic MCA blood
velocity, the blood velocity remaining almost zero in all
but one patient who had a near-normal blood velocity within
eight hours of the stroke but which declined to zero by day
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three. It seems unlikely that any patients were missed
because they died too quickly to be imaged because a very
complete register of all stroke patients admitted to the
hospital was kept by the physicians with an interest in
stroke during the time of the study.
The age of the patient had no apparent association
with infarct swelling. This may be because there were too
few patients under the age of of 60 years in the study, or
because age has no effect on infarct swelling.
There was no association between plasma glucose
measured within 24 hours of onset of stroke, or plasma
albumin measured within a week of stroke, and infarct swell¬
ing. As discussed in Part 3.1.3 and 3.3.7, the lack of
association with plasma glucose may be because the measured
value was different from the value at the time of the
stroke. Most of the patients had elevated plasma glucose
within the first 24 hours of stroke, possibly part of the
stress response. The lack of association with plasma albumin
may have been because a) there is no association between
plasma albumin and infarct swelling, b) very few patients
had a low albumin, or c) the small number of patients in the
study.
Within these very simple criteria, it would appear
that contrary to experimental evidence, an improvement in
blood flow to the ischaemic/infarcted tissue was beneficial
- it was associated with less swelling in the infarct (or
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certainly no worse swelling) and a better chance of recover¬
ing sufficiently to return home after the stroke. No im¬
provement in flow was associated with more infarct swelling
and greatly reduced chance of going home. This is in keeping
O 4 Q
with the recently published work of Ringelstein et al J
showing that haemorrhagic transformation of the infarct was
reduced, and clinical outcome improved, by reperfusion of
the ischaemic tissue (demonstrated by angiography or TCD) in
patients with acute carotid territory ischaemic stroke.
Patients who did not reperfuse (spontaneously or therapeuti¬
cally induced) had larger infarcts with more haemorrhage and
worse clinical outcome. Similar results have recently been
published by Moulin et al2^^ (demonstrated by angiography,
TCD or SPECT) and Baird et al27^ (demonstrated by SPECT) on
clinical outcome in patients with or without reperfusion
following thrombolysis for acute carotid territory ischaemic
stroke.
The implication of these findings is that treatments
intended to increase blood flow to the infarct in the first
few days should be beneficial assuming that the risk of
other serious adverse effects, such as haemorrhagic trans¬
formation, is small. Therefore thrombolysis is unlikely to
cause severe infarct swelling simply by speeding recanalisa-
tion. Most of the velocity changes examined in this study
occurred after 24 hours. It is likely that if improved blood
flow to the infarct results in better clinical outcome that
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most benefit will occur if reperfusion is as early as possi¬
ble after stroke onset, but these results suggest that there
may still be some benefit from reperfusion even after sever¬
al days. Hopefully thrombolysis would be administered and
cause recanalisation within 24 hours of symptom onset, and
not up to three to five days. Therapeutic recanalisation,
occuring earlier, might be associated with even more im¬
provement in outcome than shown in this study, which relied
in most cases on spontaneous recanalisation occurring later
after stroke onset. This is therefore further supportive
evidence for methodologically sound, large trials of throm¬
bolytic and antithrombotic drugs in acute ischaemic stroke.
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Summary of Chapter Four
1. 47 patients with symptoms of large MCA territory acute
ischaemic stroke are described.
2. The time of maximum infarct swelling was between two and
five days after stroke onset.
3. Various patterns of change in the symptomatic MCA blood
velocity were observed, some improving, some passing through
a "hyperaemic" phase, some a "stenotic" phase, some not
improving or deteriorating. Patients with a TACI stroke had
a lower initial blood velocity in the symptomatic MCA than
those with a large PACI stroke.
4. Acute infarct swelling was most strongly correlated with
the size and extent of the infarct.
5. The better the initial MCA blood velocity, the less the
swelling and the better the outcome.
6. If the symptomatic MCA blood velocity improved within the
first five days after stroke onset the clinical outcome was
better than if the MCA blood velocity did not improve or
deteriorated.
7. Age, plasma glucose and albumin did not obviously influ¬
ence swelling in the infarct.
8. Reperfusion injury may occur, but reperfusion appeared to
be associated with a better outcome than not reperfusing.
9. This result has favourable implications for trials of
treatments for acute ischaemic stroke intended to increase
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blood flow to the ischaemlc/lnfarcted tissue in the first
few days after the stroke such as thrombolytic or antithrom¬
botic drugs.
This study was presented at the Second European Stroke
Conference in Lausanne, Switzerland, in June 1992. The
authors were awarded the prize for the best work presented
orally at the conference, and in consequence the paper
describing the work was automatically accepted for publica¬
tion in Cerebrovascular Diseases. A copy of the final paper
is included in Appendix 9.
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Summary of Part Three
1. Experimental work on the formation of oedema in acute
cerebral infarcts is described, with emphasis on the influ¬
ence of changes in blood flow to the infarct at different
times after stroke onset.
2. The methodology of the study to examine the effect of
changes in blood flow to acute cerebral infarcts in stroke
patients using non-invasive imaging technigues, and largely
taking advantage of the tendancy towards spontaneous reca-
nalisation is described.
3. Patients whose blood flow to the infarct improves during
the first three to five days after onset of the infarct have
significantly less swelling in their infarct, and a signifi¬
cantly better outcome than those whose blood flow remains
poor.
4. Therapies aimed at improving blood flow to cerebral
infarcts in the first 24 hours after symptom onset have a
good chance of being beneficial.
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Part Four





Thrombolysis in Acute Ischaemic Stroke - Does it Work? :
Introduction :
4.1.1 Introduction
4.1.2 Theoretical reasons why thrombolysis might be
beneficial in acute ischaemic stroke
4.1.3 Review and overview analysis of all published data
on the use of thrombolysis in acute ischaemic stroke.
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4.1.1 Introduction
The possibility of using thrombolytic drugs to treat
acute ischaemic stroke was the stimulus which initiated this
project. In Part Four the following will be discussed :
a) the theoretical reasons why thrombolysis might be
beneficial in acute ischaemic stroke;
b) a review and overview analysis of the results of
studies on the use of thrombolytic drugs to treat
patients with acute ischaemic stroke to date;
c) describe the protocol for the pilot randomised
controlled trial of intraarterial thrombolysis in
patients with acute ischaemic stroke;
d) the results of the trial thus far.
4.1.2 Theoretical reasons why thrombolysis might be benefi¬
cial in patients with acute ischaemic stroke.
So far, despite intensive research efforts, no effec¬
tive treatment for acute ischaemic stroke has been found. It
remains the third commonest cause of death in the developed
world, preceded by ischaemic heart disease and all cancers
combined. However unlike ischaemic heart disease and
cancer, stroke leaves many more people disabled and depend¬
ant on family and social or health services. Despite a
decline in stroke mortality in some but not all
countries, 0 there is rather little evidence of a decline
in incidence.63 Therefore, anticipated demographic changes,
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and thus increasing stroke numbers, make it even more impor¬
tant to find an effective treatment.^5
Therapeutic approaches to the treatment of acute
ischaemic stroke should reflect logical application of our
present understanding of the sequence of events in the
ischaemic brain leading to cerebral infarction. Following
interruption of the blood supply, some tissue probably
suffers irreperable damage within minutes, but a variable
amount remains in a "shut down" but viable state possibly
c 1
for several hours or even days. The concept of this
"ischaemic penumbra" is now well established by electrophys-
C O
iological work in animalsJJ and Positron Emission Tomography
R fl 4 *3 4 9
(PET) in stroke patients. ' ' Neutralisation of toxic
metabolites released from infarcted cells or restoration of
the blood supply might save the ischaemic tissue and improve
outcome. Thus two basic approaches have evolved, a) to
protect ischaemic but still viable neurones from further
damage by toxic metabolites, and b) to improve the blood
supply to ischaemic brain.
Using the first approach, nimodipine has not been
shown to be of any benefit in moderately large groups of
7 1
patients. Newer excitatory amino acid antagonists are
being evaluated but may have unacceptable toxicity (eg
psychosis and cardiac arrhythmias), and it remains to be
seen whether the benefit in animals can be translated into
benefit in elderly stroke patients.7®
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Using the second approach, haemodilution is ineffec-
fi O
tive in the generality of ischaemic stroke patients.
Antithrombotic therapy (with heparin, warfarin or aspirin)
has not been properly tested in large randomised clinical
trials. Although variably used in acute stroke,we do not
know if these drugs improve outcome. A large randomised
controlled trial of aspirin and heparin in acute ischaemic
stroke (the International Stroke Trial) has recently begun
in Europe and in the USA.^14
That leaves thrombolysis, a theoretically attractive
treatment with proven ability to dissolve arterial thrombus
Ten
elsewhere in the body with clinical benefit, but with the
potentially unattractive adverse effect of converting a
simple (pale) infarct into a haematoma. Thrombolytic drugs
O C 1
were first used in the late 1950's for acute stroke. J
Since then the result of treating over 2800 acute ischaemic
stroke patients has been reported in the world literature.
Despite this we do not know if thrombolysis works, nor what
the risks of treatment are. Most of the literature consists
of case reports or small series, with only six small rando¬
mised trials.27^'352''354'355'Rather than review
historically the use of thrombolytic drugs to treat cerebral
o c 7
ischaemia, J it is the intention to examine critically and
quantitatively the evidence that thrombolytic drugs might
work in acute ischaemic stroke without unacceptible risks.
Given the heterogeneity of the pathogenesis and
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outcome of acute ischaemic stroke, and that the magnitude of
any treatment effect may be modest, both a proper control
group and adeguate numbers of patients are essential to
■3CO
ensure an unbiased and precise trial result. JO Many of the
reported studies have methodological inadequacies that make
their evaluation of thrombolysis in acute ischaemic stroke
inconclusive. It is hoped that this review will demonstrate
that thrombolysis has a good chance of improving outcome in
acute ischaemic stroke without unacceptable risk, and that
properly conducted large randomised trials (on the scale of
the myocardial infarction thrombolysis trials) would be
reasonable to do and likely to yield a definative answer.
The majority of acute focal cerebral ischaemic events
are due to embolism or in situ thrombosis (see Part One,
1 9 -3
Chapter One). J A small proportion are due to "boundary
zone" ischaemia secondary to a hypotensive episode or inter¬
nal carotid artery (ICA) occlusion. Approximately 20% are
lacunar, commonly attributed to degenerative changes in
O A
small perforating arteries. ^ Most of the discussion in this
introduction will refer to large artery territory thromboem¬
bolic stroke.
Thrombolytic drugs work in acute myocardial infarc¬
tion by lysing the thrombus quickly and restoring vessel
KQ
patency. The Second International Study of Infarct Sur¬
vival (ISIS-2) showed that streptokinase reduced mortality
after myocardial infarction by 25%. Aspirin confers
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similar benefit, and the effect of both is a 50% reduction
in vascular mortality at five weeks.
In the brain, (in Caucasian populations) about 20% of
presumed embolic (cardiac or artery-to-artery) middle cere¬
bral artery (MCA) occlusions recanalise spontaneously within
24 hours and about 80% do so within one week of
1 1 Q IOC
onset,but these figures are no more than "best
estimates". It is difficult to extract the spontaneous lysis
rate of artery-to-artery embolism from the figures for
cardiac embolism (often patients have both potential
sources), and there is little information on recanalisation
of acute internal carotid artery (ICA) occlusions in the
neck. Spontaneous reperfusion following thrombotic cerebral
artery occlusion (thought to be more common in Oriental
people) has been little studied but appears to be less
likely than recanalisation after embolic occlusion. /JD
Therefore, in the population with ischaemic stroke due to
large vessel disease the spontaneous recanalisation rate
will be at best approximately 20% at 24 hours, but may
depend on where the occlusion is (ICA or MCA), what it
consists of (fibrin embolus, platelet embolus or thrombus),
and its age. Although these figures emphasise the lack of
information regarding spontaneous recanailsation of occluded
cerebral arteries, there is clear evidence that spontaneous
lysis of thrombus does occur. So, the question for thrombo¬
lytic therapy is, can this spontaneous process be accelerat-
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ed in time to restore useful brain function, without unac¬
ceptable risk?
4.1.3 A review and overview of all published data on the
use of thrombolysis in acute ischaemic stroke
There have been over 60 reports in the world litera¬
ture to date. Six were randomised trials , 27^ ' 352-356 ancj
O Q _ O ZT /T
four had retrospective or non-random control groups.
Of the remaining, 35 or more were so called "open trials"
and 20 or so were case reports. The trials were identified
by a thorough literature search (using Index Medicus), by
tracing references cited in thrombolysis papers, and by
discussion with other researchers interested in thrombolysis
from all over the world. All published randomised trials are
included, as well as all non-randomised trials, and most
case reports in the English, French, German, and Japanese
literature. Additional unpublished information was supplied
by the investigators of the larger more recent trials. It is
probable that some acute stroke patients have been treated
with thrombolysis but not reported in the literature, and
potential bias because of this must be borne in mind when
OCT
interpreting the following analysis. 0
Randomised trials (Table 4.1.1 and Figure 4.1.1).
Of the six randomised trials, the two by Meyer et al
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352/353 were conducted prior to the invention of CT scanning
so some patients with primary intracerebral haemorrhage or
haemorrhagic infarction may inadvertently have been includ¬
ed, and thrombolytic treatment would probably have made
matters worse. The numbers were small, and the outcome
measure was clinical evaluation at ten days, which may be
too early for valid assessment. In the first study there was
no difference in outcome between the treated and control
groups. In the second, larger study, the treated group fared
worse. However patients were included up to 72 hours after
onset, and although the mean time to treatment was not
stated, trial intervention may have been too late. It is
generally thought that treatment for acute ischaemic stroke
should begin as soon as possible, certainly within 24 hours
of onset.
9 7 fi
The randomised trials by Mori et al, ° Ohtomo et
al,354 Abe et a^355 ancj t^e japanese Thrombolysis Study
Group (JTSG)356 used CT scanning to exclude intracerebral
haemorrhage as a cause of stroke before randomisation, and
for follow up after treatment. Mori et al studied MCA and
ICA recanalisation and found that 9/19 patients given in¬
travenous (IV) tissue Plasminogen Activator (tPA), within
six hours of symptom onset, recanalised compared with 3/12
9 7 fi
given placebo. Ohtomo et al published a Japanese multi-
center randomised trial of low dose IV urokinase (UK) in
acute thrombotic cerebral infarction given within five days
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of symptom onset.^54 Abe et al (also Japanese) published a
randomised trial of IV urokinase for acute ischaemic stroke
given up to 30 days after symptom onset (more than half of
occ
the patients were treated four days after onset or more). JJ
The JTSG studied clinical improvement after embolic stroke
and found that 37/51 patients randomised to 34 mg t-PA iv
improved compared with 26/47 given placebo within six hours
of symptom onset.Additional information on drug, dosage,
route of administration, time to treatment and outcome
measure is given in Table 4.1.1. Note that Table 4.1.1
includes not only the six truly randomised trials (upper
half) but also the four nonrandomised trials (described
below), which are often referred to as "controlled" trials
in the literature, to emphasise the distinction.
Figure 4.1.1 shows the results of an overview analy-
sigjoo 0£ death (a) and death or deterioration (b) following
thrombolytic therapy for acute ischaemic stroke. The analy¬
sis is of published results for the six randomised trials,
and additional information was supplied by E Mori and T
Yamaguchi (for the JTSG). Although deterioration was as¬
sessed differently in each trial, the overview technique
minimises the problem of trying to compare different trials
and end point measurements by not comparing randomised
controlled trials directly with each other. Rather, the
overview compares the magnitude and direction of any treat¬
ment effect contained within the individual trials and
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yields an estimate of the overall treatment effect.
Analysis of all six trials shows that the risk of
death is increased by 20% with thrombolysis but with a wide
confidence interval which includes the possibility of a 31%
reduction to 151% excess. The risk of death or deterioration
(all six trials) is reduced by 37% with thrombolysis, but
the wide confidence interval includes the possibility of a
66% reduction to 14% excess.
Analysis of the four trials conducted with the bene¬
fit of CT scanning (therefore reliably excluding cerebral
haemorrhage as the cause of symptoms) shows a reduction in
the risk of death of 37% (95% CI : 74% reduction to 47%
excess) with thrombolytic treatment, and shows a reduction
in the risk of death or deterioration of 56% (95% CI : 20 to
76% reduction [2p = 0.007]). This provides some evidence
that thrombolysis is beneficial in acute ischaemic stroke,
not enough to recommend routine treatment but certainly
enough to encourage larger randomised trials.
Studies with a retrospective or non-random control group
(Table 4.1.1).
The study by Hacke et al363 on vertebrobasilar occlu¬
sion illustrates the difficulty of including a retrospective
control group. Although the treated and control groups were
similar in many respects, 12/23 (54%) of the controls were
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unconscious at diagnosis and entry into the trial, compared
with 15/45 (35%) of the treated group, perhaps reflecting
increasing awareness of the condition and earlier diagnosis.
Epidemiological studies have shown that vertebrobasilar
stroke can cause mild symptoms and does not always progress
to coma with the uniformly bleak outcome that Hacke et al
have suggested.25 Therefore, the prospective treated and
retrospective control patients may have been different in
prognosis, and it is not valid to use the sicker group
treated conventionally as a control for the later "treated"
group. The other three studies which included a "control"
group, did not state how the patients were chosen or how
treatment was allocated.55^-555
"Open" trials and case reports (Tables 4.1.2 and 4.1.3).
The primary aim of these studies was to assess safety
and find an optimal dose. They are a heterogeneous group of
reports, some using the IV, some the intraarterial (IA)
route of drug administration, different drugs, dose of drug,
inclusion criteria and outcome events (recanalisation or
clinical improvement). It is not possible to make any com¬
ment about benefit because there were no controls. It is
even difficult to draw any conclusions about safety as the
natural history of cerebral infarction is so variable and
there were no controls with which the development of cere¬
bral oedema and haemorrhagic transformation could be com-
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pared.
The studies which examined reperfusion (using serial
angiography) considered together showed some degree of
recanalisation in 61% of patients within 24 hours. This is
better than the reported spontaneous rate of 20% at 24 hours
after onset (see above) and is of the same order of magni¬
tude as was found in the acute myocardial infarction throm¬
bolysis studies which used angiography to assess recanalisa¬
tion .369
These conclusions are encouraging but tentative. The
numbers of patients are small and there may have been publi-
*3 fi 7
cation bias, ° although in the field of thrombolysis in
acute ischaemic stroke, positive as well as negative results
seem to be presented with equal enthusiasm!
Does thrombolysis increase the risk of cerebral haemorrhage?
(Tables 4.1.4 and 4.1.5 and Figure 4.1.2)
Thrombolytic drugs given for extracranial vascular
disease increase the risk of haemorrhage both in the brain
*3 c n
and elsewhere in the body. DU Therefore, thrombolysis for
acute ischaemic stroke might increase the risk of cerebral
haemorrhage, but how big is this risk? Thrombolysis might,
by reducing infarct size or other mechanism, actually reduce
the rate of haemorrhagic transformation of the cerebral
9 c: c
infarct. Studies of the natural history of ischaemic
stroke suggest that approximately 5% of simple (pale) in-
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farcts undergo symptomatic haemorrhagic transformation with
or n
formation of space occupying haematomas, though there is
little good information on the "natural" rate of haemorrhag¬
ic transformation. Most reports are limited by the method of
patient selection, for example, post mortem series, retro¬
spective CT studies, and some prospective CT studies in
which only patients who survived or deteriorated were
scanned. In addition most studies include some patients who
received antithrombotic treatment of some sort, and thus for
several reasons may have overestimated the frequency of
haemorrhagic transformation. Pathological studies show some
degree of petechial haemorrhage in almost all infarcts,
O C c 07c
though CT scanning detects this less frequently
Petechial haemorrhage is thought to be asymptomatic and thus
probably does not matter clinically, although this has not
been studied. Based on the best information available, we
estimate that the spontaneous rate of symptomatic haemor-
9 R 4
rhagic transformation of the infarct is approximately 5%
and that the rate of asymptomatic (petechial) haemorrhagic
transformation is between 15% and 45%27^ but this may be an
overestimate. The rate probably varies with the extent of
9 S R 9 7 R
the infarct and possibly with stroke aetiology. J
Using all the published data available, the rate of
haemorrhagic transformation after thrombolysis for acute
ischaemic stroke was estimated. Table 4.1.4 shows the risk
of asymptomatic petechial haemorrhagic transformation
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(without clinical deterioration), and table 4.1.5 the risk of
symptomatic intracerebral haematoma (with clinical deterio¬
ration) . The true rate of haemorrhagic transformation can
only be found from large randomised controlled trials
(including at least several thousand patients) but summing
all the data available at present may at least give an
estimate of the likely order of magnitude of haemorrhagic
transformation. All the data including case reports has been
included so as to give as unbiased assessment as can be
obtained at present. Note that the time to treatment, route
of administration, type of drug and total dose of thrombo¬
lytic drug (in some studies very low doses of thrombolytic
drug were used), definition of symptomatic and asymptomatic
haemorrhagic transformation, and patient characteristics
were different in each study. Therefore this analysis can
only provide an estimate of the likely haemorrhagic trans¬
formation rate. Note the huge variation in the reported rate
of asymptomatic petechial haemorrhage. This may partly
reflect bias in interpretation of CT scans, or it may be due
to different freguencies and timing of CT scanning after
thrombolysis, different doses of drug, or inclusion of
different types of ischaemic stroke and thus should be
viewed with this in mind. The estimated rate of symptomatic
intracerebral haematoma formation following thrombolysis
(5%) is similar to the estimated expected natural history.
The haematoma rate varies between studies and appears to be
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higher with tPA (Figure 4.1.2), as might be expected from
the recently presented ISIS-337® and GISSI-2371 results in
acute myocardial infarction.
The randomised trials (with CT scanning) all found
massive haemorrhagic infarction slightly more often in
07 C
placebo than thrombolysis-treated patients. Mori et al
found haemorrhagic transformation of mild degree in 26% of
tPA treated and 33% of placebo treated patients. Ohtomo et
ai354 founci 2/169 UK treated patients developed haemorrhagic
transformation of their infarct of mild degree, and 1/181
placebo treated patient developed a severe symptomatic
"3 E C
intracerebral haematoma. Abe et alJ J found no symptomatic
intracerebral haematomas with UK. In the JTSG trial there
were four massive haemorrhagic infarcts in the tPA treated
group and five in the control group with equal numbers of
patients in each group.
None of the large "open" stroke trials found a rela¬
tionship between dose of drug and symptomatic intracerebral
haematoma formation, but they suggested that a time delay of
over six hours from onset, hypertension, and possibly treat¬
ing patients who already had a low density area visible on
CT, may be risk factors.27®'372'373 Matsumoto et al374 have
treated 52 acute ischaemic stroke patients with a wide range
of doses of UK and not demonstrated any definite relation¬
ship between cerebral haemorrhage and dose, time after
onset, or age of patient but they suggested that haemor-
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rhages were more often symptomatic in recanalised patients
(Figure 4.1.3). No definite association with recanalisation
9 7ft
was found in the Acute Stroke Study Group trial, nor by
Miyakawa.275 Therefore, it appears that although one would
expect thrombolytic treatment to increase the frequency of
symptomatic cerebral haematoma formation, no definite asso¬
ciation has been found in over 2800 patients that have been
treated so far.
Does thrombolysis increase the risk of space-occupying
oedema formation in the cerebral infarct? (Table 4.1.6)
The cause of severe infarct oedema is unclear. The
aetiology of cerebral infarct oedema and its relationship to
infarct perfusion has been discussed in Part Three Chapter
One. The frequency of cerebral oedema with brain herniation
is difficult to extract from the thrombolysis studies but
does not appear to be increased. Mori et al27^ found massive
brain swelling occurred in 9% of patients who reperfused
compared with 35% whose symptomatic cerebral artery remained
occluded (26% of tPA and 25% of placebo treated patients).
Which drug should be used?
Most of the available thrombolytics have been tested
in stroke, using the oral, IV, and IA routes of administra¬
tion, and at a wide range of doses. Table 4.1.2 shows that
in the small non-randomised studies so far there is little
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difference in immediate patency rates between the more expen¬
sive tPA and SK or UK, and no obvious optimum dose. But, the
number of patients is small and there may be publication
bias. Several "open" studies have failed to identify an
optimum dose.278'372-374
The lack of a clear benefit for one drug or dose is
not unexpected. ISIS-3378 and GISSI-2371 combined had to
randomise over 60000 patients to show that the reduction in
vascular deaths after MI was the same whether SK, tPA or
anistreplase was used. But there was a highly significant
excess of cerebral haemorrhages with tPA: 7/1000 compared
with 3/1000 with SK.376
Extrapolation from ISIS 3 and GISSI-2 suggests that
the clinical benefit for thrombolysis in acute ischaemic
stroke should be about the same no matter which agent is
used, but the cerebral haemorrhage rate might be higher
following tPA. This seems to be the case if this simple
analysis of the available studies is correct (Tables 4.1.4
and 4.1.5 and Figure 4.1.2). In view of the overwhelming
evidence from the 60000 patients randomised in the acute
myocardial infarction trials, it would probably be prefera¬
ble to study SK rather than tPA in acute ischaemic stroke,
at least to start with.
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What about dose and mode of administration of thrombolysis,
elderly patients, and time limit to treatment after onset?
Any treatment for acute stroke must be easy to admin¬
ister to avoid delay. The standard IV dose for myocardial
■377
infarction is 1.5 MU streptokinase (SK) or lOOmg tPA.
Smaller intracoronary doses were used in early studies to
try to maximise local thrombolytic effect and reduce system¬
ic adverse effects, but any benefit was more than offset by
■icq
the extra one or two hours delay due to angiography. It
is suspected that, if thrombolysis is shown to work in acute
ischaemic stroke, the drug of choice will be SK 1.5 MU IV :
cheap, easy to administer, least risky, and with a proven
track record in acute myocardial infarction.
If thrombolysis is to be a worthwhile treatment for
acute ischaemic stroke, then it should be available for the
elderly, the most commonly affected age group. Cerebral
amyloid angiopathy has been cited as a reason for increased
risk of haemorrhage in the elderly.®7® The few studies where
thrombolytics have been used in elderly stroke patients (70
years plus) and the results for the elderly patients can be
separated from the rest of the patients, do not show a
definitely increased haemorrhage rate compared with younger
patients (Figure 4.1.3). The Acute Stroke Study Group27® did
not find an increased cerebral haemorrhage rate in patients
up to 80 years of age. Several other reports®7^'380'381 0f
thrombolysis in elderly stroke patients have shown benefit
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but this is anecdotal.
ISIS-2360 showed that in elderly myocardial infarct
patients treated with thrombolysis, the proportional reduc¬
tion in mortality was the same as for younger patients and
the absolute reduction was greater. The elderly perhaps have
the most to gain from a treatment which reduces disability
from stroke, and thrombolysis certainly deserves a trial at
all ages.
A time limit of six hours from onset to treatment was
set by most of the recent thrombolysis studies, although the
sparse data available do not show a sharp increase in ad-
*3 7 4
verse effects between six and 24 hours. Several Japanese
studies have included patients for several days after the
stroke with no obvious increase in adverse
effects.'^83' Although it is unlikely that
neurones will survive many hours of ischaemia, we do not
really know enough about the duration of neuronal viability
after acute cerebral artery occlusion to introduce time
limits to treatment. Time limits can only be established by
large randomised, controlled trials. In most parts of the
world stroke patients go to hospital (if at all) in a "slow
ambulance", and few reach hospital and have a CT scan by six
hours. Although it was possible to recruit patients within
90 minutes of symptom onset in the National Institutes of
Health (NIH) t-PA study^^'^^ (and very early recruitment
is continuing in the NIH randomised controlled trial of t-
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PA) elsewhere in the world it is likely to take many years to
change the current slow referral pattern. Therefore future
trials should examine the problem of maximum time limit by
including patients up to 24 hours after onset; otherwise we
will never know the risk/benefit ratio of thrombolytic
treatment between 6 and 24 hours.
If very early treatment is the aim, is there a danger
of exposing patients who are having a TIA to thrombolysis?
OO7
LevyJO found that 50% of TIAs last less than 30 minutes,
and in patients with a deficit persisting at 60 minutes,
less than 2% will resolve spontaneously in each subsequent
one hour period. Therefore, there is very little danger of
treating a TIA with thrombolytics if patients showing dis¬
tinct signs of improvement in the first one to two hours are
excluded.
4.1.4 Concluding Comments
Experience with thrombolysis in acute ischaemic
stroke suggests that the risks are not excessive and there
may be some benefit. However, the standard of methodology
used in most of the "trials" so far means that this conclu¬
sion must be very tentative and no more than hypothesis
generating. It has been enough, however, to encourage
Italian, Australian and American investigators who have
recently started randomised trials of intravenous thromboly-
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sis (SK/aspirin/both or neither, SK/aspirin/placebo, and t-
PA/placebo respectively) in acute ischaemic stroke.
Considerable expertise has now accrued showing the
value of thrombolysis and aspirin in acute myocardial in¬
farction. As well as demonstrating benefit in young other¬
wise healthy myocardial infarction patients, ISIS-3 has
shown that other subgroups of myocardial infarction pa¬
tients, traditionally regarded as "high risk" for thromboly¬
sis, gain considerable benefit from it - this includes the
elderly, and those with hypertension, previous peptic ulcer,
■j 7 n
and recent stroke.
It is this mass of evidence from the use of thrombol¬
ysis in myocardial infarction, as well as the limited expe¬
rience in ischaemic stroke, which makes it imperative and
urgent to test thrombolysis properly in acute ischaemic
stroke. There is no place for more non-randomised trials in
this assessment. Safety cannot be assessed unless the major
adverse effects of the treatment under trial are controlled
for, which in this case mimick the natural history of the
disease - cerebral haemorrhage and severe infarct oedema.
Acute stroke treatment research is rejecting com¬
pounds thought to have therapeutic promise as fast as they
can be invented, but with remarkably little good evidence to
do so. Thrombolysis in acute myocardial infarction was
almost rejected in error after inumerable small trials had
missed its real benefit. It was only after the overview of
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these trials and the subsequent very large
trials360'370,371 that the clear benefit was demonstrated,
Q O O
clear enough to change clinical practice. 00
Thrombolysis for acute ischaemic stroke deserves
large and methodologically sound trials designed to answer a
simple question : does it work ?
Fortunately, since this project began, several large
and more methodologically sound trials (mentioned above in
Italy, Australia and the USA) have started, and hopefully we
will have a definitive answer on the benefit of thrombolysis
in the not-too-distant future.
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Author Drug Route Dose Time Outcome Measure Results
from onset Treated Control
No. % No. %
Randomised
Meyer Fib/ iv 2.5-11.5 <72hr clinical improvement 20 45 20 45
C3St) Plas x 105u at 10 days
Meyer SK iv 2.5-17.5 <72hr clinical improvement 37 43 36 58
(353) x 105u at 10 days
Mori tPA iv 34-50 mg <6hr recanalisation 19 47 12 25
(176)
Ohtomo UK iv 6x104u <5days clinical improvement 169 56 181 42
(35f) per day at 4 weeks
for 7 days
Abe UK iv 6 x 104u <30days clinical improvement 54 63 53 43
(39$ per day at 1 and 4 weeks
for 7 days
JTSG tPA iv 34mg <6hrs clinical improvement 51 72 47 55
(4 at 4 weeks
Non Randomised
Hacke SK/ ia 4 x105u <24 hr clinical improvement 45 44 23 0
UK approx.
Okada tPA iv 26-50mg <6 hr clinical improvement 15 47 11 9
(5W at one month
Abe UK iv 6-12 x up to 6 clinical improvement 62 71 22 36
(3tS) 105u months at one month
Larcan UK iv 16.5-38.5 36hr+ clinical improvement 36 47 41 17
(*W x105u
Table 4.1.1 "Controlled" Trials of thrombolysis for acute
ischaemic stroke.
No. = total number of patients; % = % of patients who im¬
proved clinically or recanalised.(276) Where two assessment
times are given, the % improved refers to the later time.
JTSG = Japanese Thrombolysis Study Group (356); Fib = fibri¬
nolysis Pla = plasmin.
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"Open" Studies of Thrombolysis for Acute Ischaemic
Stroke: Recanalisation
Author Year Drug Route Dose Number %
of patients recanalised
Del Zoppo (3<W) 1988 SK IA 0.06-2.5X 105u 20 75
Theron (3Sl) 1989 SK IA 0.25-1.5x 105u 12 100
Maisa (4<x) 1988 SK IA 2.5x105u 16 100
Zeumer(ifOi) 1985 SK/UK IA various 29 86
Berg-Dammer^) 1991 SK IA 105u 3 100
Baird (St7) 1992 SK IV 1 ,5x105u 5 38
TOTAL FOR SK = 75/ 93 = 80% RECANALISED
Zeumer (39<r) 1984 UK IA 0.5-1.25x105u 2 10
Mori (2T7) 1990 UK IA 1.8-3.2x105u 48 44
Lehman (ms) 1989 UK IA 2-3x105u 10 80
Ikeda (3^0) 1990 UK IA 4.2x105u 13 85
Siepman (37?) 1991 IX IA up to 7.5x105u 11 64
Casto (427) 1992 UK IA 5.6x105u 4 80
Berg-Dammer^sn) 1991 UK IA 2-7.5X 105u 7 100
Mobius(w8) 1991 UK IA 3-9.5x105u 18 77
Seikman(3go) 1991 UK IA 8x105u 2 100
Matsumoto(57t) 1991 UK IA 2.4-12x 105u 52 58
Miyakawa(575) 1984 UK IV/IA 7-9x105u 49 59
Williams (H25) 1992 UK IA 5-10x105u 2 66
TOTAL FOR UK = 134/217 = 62% RECANAUSED
ASSG(273) 1991 tPA IV 12.5-44mg 93 36
Karnik (i&t) 1992 tPA IA 20mg 1 100
Yamaguchi(*i03) 1991 tPA IV 10, 20, 30 mg 58 43
Hennerici(373) 1991 tPA IV 70mg 18 44
von Kummer(4oir) 1991 tPA IV 70/1 OOmg 27 56
Brucker (hiS) 1992 tPA IV 100mg 25 89
von Kummer (4*t>) 1992 tPA IV 100mg 32 53
TOTAL FOR tPA = 154/284 = 54% RECANAUSED
TOTAL ALL PATIENTS = 363/594 = 61% RECANALISED
Studies are listed according to drug used and increasing dose. "Number of patients" refers to total number
of patients in the study. UK=urokinase, SK=streptokinase, tPA= tissue-type Plasminogen Activator. IA =
intraarterial, IV = intravenous route of drug administration. ASSG = Acute Stroke Study Group
Table 4.1.2 : "Open studies of Thrombolysis for Acute Is¬
chaemic Stroke : Recanalisation
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"Open" Studies of Thrombolysis for Acute "Ischaemic"
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Terashi (4Zg) 1990 UK IV 6x104u/day 171 35
for 7 days
Yamaguchi(4<^ 1991 UK IV 6x104u/day 77 45
for 7 days
Abe(5?3 1981 UK IV 6x104u/day 51 70
for 7 days
Fukase(4ac) 1972 UK IV 104-10=u 949 68
Mori (Z77) 1990 UK IA 1.8-3.2x105u 22 55
Lehman(5K) 1989 UK IA 2-3x105u 10 70
Fujishima(/)QG) 1986 UK IV 3x105u 143 79
Ikeda^Q 1990 UK IA 4.2x105u 13 53
Mobius(3f{5) 1989 UK IA 2x105u 14 71
Mihara(42i) 1982 UK IV 3x105u 33 78
Abe (^2) 1981 UK IV 6x105u/day 49 80
for 7 days
Berg-Dammer(3R7) 1991 UK IA 2-7.5x105u 7 57
Seipman(379) 1991 UK IA 7.5x105u 11 64
Zeumer^) 1985 UK/ IA various 29 59
SK
Zeumer(Hoj) 1989 UK IA 2.5-7.5x105u 7 57
Matsumoto(i?/>) 1991 UK IA 2.4-12X105U 52 59
Miyakawa(37j) 1984 UK IV/IA 7-9x105u- 49 45
Williams (423) 1992 UK IA 5-10X105U 3 33
Fletcher(/jaEj 1976 UK IV 1.4-3.3x106u 31 52
Nenci(4Cfj 1983 UK IV 1.7x106u 4 75
Labauge(t<c7) 1978 UK IV 6-34.5x105u 24 42
TOTAL FOR UK = 1133/ 1747 = 65% IMPROVED
Terashi (nffl) 1990 tPA IV 3.6x104AKU/day 171 59
for 7 days
Ohtomo (33i 1988 tPA IV 3.6-6x104AKU/day 131 69
for 7 days
YamaguchiffcQ 1991 tPA IV 1.7-3.4mg/day 145 66
for 7 days
NIH Study($TZ) 1991 tPA IV 50-70mg 94 26
Hennerici(TT3) 1991 tPA IV 70mg 18 28
von Kummer(4o4) 1991 tPA IV 70or100mg 27 35
Overgaard(43C) 1992 tPA IV 100mg 21 85
Brucker (42S") 1992 tPA IV/IA 100mg 28 29
von Kummer (42^ 1992 tPA IV 100mg 32 44
TOTAL FOR tPA = 373/ 667 _ 56% IMPROVED
TOTAL ALL PATIENTS=1545/2464 = 63% IMPROVED
Table 4.1.3 : "Open" Studies of Thrombolysis for Acute
Ischaemic Stroke : Clinical Outcome
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Table 4.1.4 : Asymptomatic Intra-cerebral Petechial Haemor¬
rhage Following Thrombolysis for Acute Ischaemic Stroke.
Author Year Drug Route Dose Number of %
of admin. patients Affe
Del Zoppo(jqt?) 1988 SK IA 0.06-2.5 20 20
x105u
Zeumer(,?i4) 1984 SK IA 1.25x105u 2 50
Theron(3SI) 1989 SK IA 0.25-1.5x105u 12 16
Berg-Dammer(3rir!) 1991 SK IA 105u 3 0
Maisa(^cg 1988 SK IA 2x105u 16 0
Hacked) 1988 SK IA 4x105u 45 5
Frink^cft) 1990 SK IV 1.5x106u 1 0
TOTAL FOR SK 9/97 = 9.2% PETECHIAL HAEMORRHAGE
Yamaguchi (4c3) 1991 UK IV 6x104u/day 77 5
for 7 days
Ohtomo(3£4) 1985 UK IV 6x104u/d 169 1
for 7 days
Harembert(4ic) 1979 UK IA 1.5x105u 1 0
Mori(z77) 1990 UK IA 1.8-3.3x105u 43 12
Jungreis(mt) 1989 UK IA 2.1x105u 1 0
Lehmann(3S$ 1989 UK IA 2-3x105u 10 0
FujishimaHoS) 1986 UK IV 3x105u 143 0
lkeda(3%) 1990 UK IA 4.2x105u 13 0
Casto (447) 1992 UK IA 5.6x105u 5 20
Berg-Dammer(3«}7) 1991 UK IA 6-7x105u 10 20
Seipman(37<j) 1991 UK IA 7.5x105u 11 30
Zeumer(eci) 1989 UK IA 7.5x105u 7 14
Abe (3{£) 1984 UK IV 6-12X105U 62 0
Seikmann(3<j0) 1991 UK IA 8x105u 2 0
Miyakawa(37S) 1984 UK IA/IV 7-9x105u 49 26
Matsumoto(37v) 1991 UK IA 2.4-12x105u 52 20
Nenci(4ofe) 1983 UK IV 1.7x106u 4 0
TOTAL FOR UK = 46/867= 5% PETECHIAL HAEMORRHAGE
Yamaguchi (4<$ 1991 tPA IV 1,7-3.4mg/day 145 0
for 7 days
Yamaguchi(4o2J 1991 tPA IV 17-51 mg 58 21
ASSG (2.-J8) 1991 tPA IV 12.5-44mg 104 20
Bruckmann (4ii) 1989 tPA IV 25.9mg 1 10C
Okada (ntf) 1991 tPA IV 26-56mg 15 33
JTSG(ist) 1992 tPA IV 34mg 51 39
Mori (ZTk) 1991 tPA IA 34 or 50mg 19 66
Buteux(4i3) 1988 tPA IA 50mg 1 10C
NIH Study(3rj2) 1991 tPA IV 50-70mg 94 10
von Kummer(4C4) 1991 tPA IV 70/1 OOmg 27 22
von Kummerp»ab) 1992 tPA IV 100mg 32 28
Turning) 1991 tPA IV 100mg 1 0
Overgaard{f30) 1992 tPA IV 100mg 21 0
Wildemannfttf) 1990 tPA IV 100mg 1 0
Herderschee(4tb) 1991 tPA IV 100mg 2 50
Henze( | ) 1987 tPA IA 10Omg 1 0
Brucker (423) 1992 tPA IV 100mg 28 25
Jafar (431) 1991 tPA IV 150mg 1 0
TOTAL FOR tPA = 101/582 = 17% PETECHIAL HAEMORRHAGE
GRAND TOTAL ALL DRUGS = 156/1546 = 10% PETECHIAL HAEMORRHAGE
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Table 4.1.5 : Intra-cerebral Haematoma with Clinical Dete¬
rioration Complicating Thrombolysis for Acute "Ischaemic"
Stroke.
Author Year Drug Route of Dose Number of %
Admin. patients Affected
Sussman (jsi) 1958 F IV/IA various 3 0
Clark (4(7) 1960 F IV/IA 2-10x105u 10 0
Meyer (352) 1963 T IV 2x105u 20 5
Atkin (413) 1964 F IA 5x105u 1 0
Del Zoppo pcfi) 1988 SK IA 0.6-2.5x105u 20 0
Theron £3?() 1989 SK IA 0.25-1.5x105u 12 8
Berg-Dammer (3^) 1991 SK IA 105u 3 0
Maisa (400) 1988 SK IA 2x105u 16 6
Hacke (p(A) 1988 SK IA 4x105u 45 4
Meyer (*>S"3) 1964 SK IV 2.5-7.5x105u 37 3
Frink (<ttf}) 1990 SK IV 1.5x106u 1 0
TOTAL for SK = 7/135 = 5% CEREBRAL HAEMATOMA
Yamaguchi (403) 1991 UK IV 6x1 O^u/d for 7 days 77 1
Ohtomo(i£4) 1985 UK IV 6x104u/d for 7 days 169 0
Abe (3SZ) 1981 UK IV 6-60x104u/d/7d 101 1
Hass (m^i) 1966 UK IA 105u 1 100
Harembert (410) 1979 UK IV 1.5x105u 1 0
Mori (277) 1990 UK IA 1.8-3.2x1 05u 43 9
Jungreis (An) 1989 UK IA 2.1x105U 1 0
Lehman (5<K) 1989 UK IA 2-3x105u 10 0
Miharafczi) 1982 UK IV 3x105u 33 0
Fujishima (405) 1986 UK IV 3x105u 143 0.6
Ikeda (3%} 1990 UK IA 4.2x105u 13 23
Casto (427) 1992 UK IA 5.6x105u 5 0
Berg-Dammer (3*7) 1991 UK IA 2-7.5x105u 7 0
Abe (3(£) 1984 UK IV 6-12x105u 86 1
Abe (282) 1981 UK IV 6x104u/d for 7 days 106 0.9
Seipmann (374) 1991 UK IA 7.5x105u 11 0
Zeumer (401) 1989 UK IA 7.5x105u 7 0
Seikmann (38d 1991 UK IA 8x105u 2 0
Matsumoto (TW) 1991 UK IA 2.4-12x105u 52 12
Fletcher (40Z.) 1976 UK IV 1.4-3.3x106u 31 12
Nenci (4c4) 1983 UK IV 1.7x106u 4 0
Larcan (3b*) 1977 UK IV 1.2-2.4x106u 36 0
Labauge (tK>7) 1978 UK IV 6-34x105u 37 0
Miyakawa(VE) 1984 UK IV/IA 7-9x105u 49 4
TOTAL for UK = 26/1025=3% CEREBRAL HAEMATOMA
Yamaguchi -^03) 1991 tPA IV 1.7-3.4mg/d for 7 d 145 0
ASSG (27?) 1991 tPA IV 12.2-44mg 104 11
Karnik (4Zt) 1992 tPA IA 20mg 1 0
Bruckmann ^2) 1989 tPA IV 25.9mg 1 0
Yamaguchi (4«3) 1991 tPA IV 17-51mg 58 15
Okada (3b4) 1991 tPA IV 26-50mg 15 46
JTSG (isfc) 1992 tPA IV 34mg 51 8
Mori (£7fc) 1991 tPA IV 34/50mg 19 10
Buteux (4i3) 1988 tPA IA 50mg 1 0
NIH Study(374 1991 tPA IV 50-70mg 94 5
Hennerici (573) 1991 tPA IV 70mg 18 5
vonKummer (404) 1991 tPA IV 70/1 OOmg 27 5
von Kummer (42^ 1992 tPA IV 100mg 32 9
Overgaard (4JC) 1992 tPA IV 100mg 21 5
Turrin ftiq) 1991 tPA IV 100mg 1 0
Wildemann (his) 1991 tPA IV 100mg 1 0
Flerderschee (4ife) 1991 tPA IV 100mg 2 0
Henze(| ) 1987 tPA IA 100mg 1 0
Brucker (42£) 1992 tPA IV 100mg 28 4
Jafar (4i|) 1991 tPA IV 150mg 1 0
TOTAL for tPA = 48/621= 8% CEREBRAL HAEMATOMA
GRAND TOTAL ALL DRUGS = 81/1781 = 5% CEREBRAL HAEMATOMA
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Severe Cerebral Infarct Oedema following
Thrombolysis for Acute Ischaemic Stroke.




Theronpst) 1989 SK IA 0.25-1.5
x 105u
12 8
Fujishima (*cs) 1986 UK IV 3 x105u 143 0.7
Ikeda (y$ 1990 UK IA 4.2 x 105u 13 8
NIH Study (572.) 1991 tPA IV 50-70mg 74 3
Von Kummer (4dt) 1991 tPA IV 70/1 OOmg 21 33
Koudstaal (s3i) 1988 tPA IV 100mg 2 100
Mori (271) 1991 tPA IV 34-50mg 19 26
TOTAL = 18/284 = 6% SEVERE INFARCT OEDEMA
Note that severe infarct oedema was diagnosed by routine CT scan, and only studies which mentioned
it as a complication have been included in the above table. "Number of patients"refers to total number
of study patients. None of the above were randomised trials. SK = streptokinase, UK = urokinase, tPA
= tissue plasminogen activator, IA = intraarterial, IV = intravenous.
Table 4.1.6 : Severe Cerebral Infarct Oedema Following
Thrombolysis for Acute Ischaemic Stroke.
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THROMBOLYSIS FOR ACUTE "ISCHAEMIC" STROKE
THROMBOLYSIS vs CONTROL: MORTALITY
Trials Events/Patients Stratified Odds Ratio & 95% C.L.
analysed Thrombolysis Control (O-E) Var.
MEYER 1963 7/20 7/20 0-0 2-3
MEYER 1964 13/37 4/36 4-4 3-3
ABE 1981* 1/54 1/53 0-0 0-5
OHTOMO 1985* 3/169 6/181 -1-3 2-2
MORI 1991* 2/19 2/12 -0-5 0-9
YAMAGUCHI 1992* 3/51 4/47 -0-6 1-6
ALL TRIALS 29/350 24/349 20 10-8
Treatment effect 2P > 0.1; NS
TRIALS WITH CT* 9/293 13/293 -2-4 5-1
Redn.
± s.d.













Figure 4.1.1 A Overview analysis of death following the use
of thrombolytic drugs to treat acute "ischaemic" stroke.
Note that the two trials by Meyer were done without the
benefit of CT scanning to exclude cerebral haemorrhage as
the cause of symptoms prior to treatment. "Yamaguchi" refers
to the Japanese Thrombolysis Study Group trial. 0-E = ob¬
served minus expected number of events in the treated group;
Var = variance; Redn = reduction. An odds ratio of less than
1 indicates that thrombolytic treatment may be beneficial,
and the 95% confidence interval gives the range of possible
therapy effects. Meyer 1963(352), Meyer 1964(353),
Ohtomo(354), Abe(355), Mori(276), Yamaguchi (356).
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THROMBOLYSIS FOR ACUTE "ISCHAEMIC" STROKE
THROMBOLYSIS vs CONTROL: DEATH OR DETERIORATION
Trials Events/Patients Stratified Odds Ratio & 95% C.L.
analysed Thrombolysis Control (O-E) Var.
MEYER 1963 8/20 8/20 0-0 2-5
MEYER 1964 14/37 8/36 2-8 3-9
ABE 1981* 1/54 3/53 -1-0 1-0 •
OHTOMO 1985* 4/169 14/181 -4-7 4-3
MORI 1991* 5/19 5/12 -1-1 1-7
YAMAGUCHI 1992* 7/51 10/47 -1-9 3-5
ALL TRIALS 39/350 48/349 -5-9 16-8
Treatment effect 2p > 0.1; NS

















Figure 4.1.1 B Overview analysis of death or deterioration
following the use of thrombolytic drugs to treat acute
ischaemic stroke. see Legend Figure 4.1.1.A for interpreta¬
tion and references.
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Intracerebral Haemorrhagic Complications following
















(CT or PM diagnosis)
Symptomatic Intracerebral
Haemorrhage
(CT or PM diagnosis)
tP A Spontaneous
Figure 4.1.2 Comparison of the spontaneous rate of haemor¬
rhagic transformation of the cerebral infarct with that
following the use of thrombolytic drugs in acute ischaemic
stroke. See Tables 4.1.4 and 4.1.5 for exact figures.
SK = streptokinase, UK = urokinase, tPA = tissue Plasminogen
Activator. The spontaneous rate is an estimate based on the
rates of haemorrhagic transformation found in the prospec¬
tive studies which used CT scanning. It is no more than a
"best guess" and the limitations of the studies of haemor-
ragic transformation have been discussed in Part One Chapter
Six. Note that all reports of thrombolysis have been includ¬
ed in this figure, not just the randomised studies.
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Figure 4.1.3 Data from Matsumoto.(374)
UK = urokinase






The Edinburgh Pilot Randomised Controlled Trial of Thrombol¬
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4.2.1 Introduction
When this trial was first thought of, the idea of
treating acute ischaemic stroke with thrombolytic drugs was
considered to be a little unusual. A history of cerebrovas¬
cular disease is a standard contraindication to the use of
thrombolytic drugs in acute myocardial infarction because of
the theoretical risk of cerebral haemorrhage. And yet when
looked at objectively, there are two good reasons why this
attitude about thrombolysis as a treatment for acute is¬
chaemic stroke may be wrong.
Firstly the evidence to date suggests that under¬
standing of the natural history of acute ischaemic stroke is
poor with respect to the frequency of haemorrhagic transfor¬
mation of the infarct and severe infarct oedema, and why
some patients (and how many) recanalise and not others. It
is assumed that a drug which causes cerebral haemorrhage
when used to treat other conditions may have devastatingly
bad effects when used in acute stroke. Ignorance about the
natural history of acute ischaemic stroke is mainly due to
(until recently) the lack of practical techniques with which
to investigate it, and the lack of any proven treatment to
stimulate interest among the medical profession
OOQ
generally. These investigative tools are now available
(CT brain scanning, non-invasive vascular imaging), and they
should start to be used more systematically to answer these
questions.
4 21
Secondly, acute ischaemic stroke is an occlusive
vascular disease, so why should a drug which has been shown
to work for occlusive vascular disease elsewhere in the
body359,360,370,371,376 (myocardial infarction) not also be
effective in treating acute cerebrovascular occlusive dis¬
ease?
The need to find a treatment for acute ischaemic
stroke is increasing as our population ages.A
treatment which reduced disability by even a modest amount
such as 10% to 20% would be worthwhile as acute ischaemic
stroke is so common. It was with these thoughts in mind that
the Edinburgh Pilot Thrombolysis Trial was started. A rando¬
mised controlled trial was obviously essential because the
natural history and complications of acute ischaemic stroke
(spontaneous recanalisation, haemorrhagic transformation of
the infarct and severe infarct oedema) mimick the likely
beneficial and adverse effects of thrombolytic treatment.
Information about acute ischaemic stroke and atti¬
tudes to treatments change very rapidly. At the time of
setting up the trial in 1989 and early 1990, the concept of
thrombolysis in stroke was so new that decisions about the
trial protocol had to be made using the scant information
available and a large amount of common sense (which could be
less generously described as guess work). To try to give a
flavour of the debate which took place between involved
parties at the time, the major issues of the trial design -
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type of patient to be included, end point analysis, investi¬
gations, mode of administration of thrombolysis, time window
to treatment, etc, will be discussed in detail below.
4.2.2 Ethical approval
In some ways this was the easiest part of the organi¬
sation of the whole project. Approval for the study was
granted, without any objection, by the Lothian Area Ethics
of Medical Research Subcommittee, for a randomised con¬
trolled trial of intraarterial streptokinase 250000 units or
placebo (saline), with cerebral angiography, in patients
with extensive acute ischaemic stroke, in January 1990.
4.2.3 Study population and inclusion criteria
Because so little was known about the risk of throm¬
bolytic treatment in the acute stages of a stroke, it was
decided that only patients whose prognosis was already poor
with current management ie TACI and possibly large PACI
strokes should be included. J The work of AR Naylor on vali
dating the MCTT technique in the Western General
•3HQ
Hospital, suggested that the number of patients with
severe strokes admitted to the Western General Hospital
would be small (no other reliable information on number of
stroke patients admitted to the hospital was available at
the time), so it was unlikely that a local trial would
demonstrate conclusively any clinical effect (ie improved
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outcome) of thrombolytic treatment. Little was known about
the behaviour of acute cerebral embolic and thrombotic
occlusions. There is a natural lysis rate of presumed embol¬
ic cerebral arterial occlusions of approximately 20% at 24
hours after stroke onset,^®'^^'^^ but this may depend on
the type of occlusion, where it is, what its origin was (eg
atheroma from the cervical carotid artery or cardiogenic
embolus), so it was considered important to find out more
about the response of cerebrovascular occlusions to thrombo¬
lytic therapy.
Occlusive lesions in the cerebral circulation may
behave differently to those in the coronary circulation. The
latter are predominantly due to fresh thrombus forming on an
•ICQ
acutely ruptured atheromatous plaque. J;7 If thrombolytic
drugs cannot lyse cerebral artery occlusions then they are
unlikely to have much impact on clinical outcome. There were
no randomised controlled trials examining lysis rates, only
dose range finding studies where all patients received
thrombolytic treatment. It was therefore decided to start by
examining the surrogate endpoint of recanalisation primari¬
ly, and clinical outcome secondarily, thus gaining experi¬
ence of the use of thrombolysis in stroke.
A power calculation indicated that 30 patients would
be needed to demonstrate improved lysis of the cerebral
artery occlusion from the expected 20% spontaneous rate to
60% with thrombolysis, and fewer patients if thrombolytic
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treatment was more effective. The 60% estimate of possible
thrombolytic effect was based on a) the result of the liter¬
ature review of thrombolysis in stroke in which the small
non-randomised angiographic studies suggested that thrombol¬
ysis might result in a 60% arterial recanalisation rate
(Table 4.1.2), and b) the intraarterial thrombolysis in
myocardial infarction trials which also found a recanalisa¬
tion rate of around 60% following thrombolysis (Part Four
Chapter One). More patients would be required if the true
recanalisation rate was actually lower.
As stroke is a disease mainly affecting the elderly,
it was considered inappropriate to have an upper age limit,
but a lower age limit of 18 years was set because of the
need to obtain informed consent for patients randomised in
the trial.
The other inclusion criteria were that patient had to
be independant prior to their stroke, and be able to give
consent to enter the trial (or have a relative who could act
for them). Patients with a history of previous stroke were
still eligible for the trial as long as there was no residu¬
al disability. The patients were to be carefully examined by
a stroke neurologist and classified according to the OCSP
9 R
clinical classification. J They must have either a TACI or
large PACI acute ischaemic stroke. A CT brain scan was
essential to exclude cerebral haemorrhage or tumour as the
cause of stroke symptoms (see below).
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4.2.4 Mode of administration of thrombolysis
There was considerable debate among interested par¬
ties about the merits and demerits of intra-arterial and
intravenous treatment. Although intravenous administration
was more practical and quicker, a larger dose of thrombolyt¬
ic drug (probably 1.5 MU) would be required compared with
the intraarterial dose (250000 U) based on information from
KQ O C Q
the myocardial infarction trialsThere was great
concern that the larger dose would result in greater risk of
haemorrhagic transformation of the infarct, as well as of
systemic adverse effects, with adverse effects on outcome.
Clearly if recanalisation was to be the trial endpoint, a
reliable method of demonstrating this would be required,
convincing to doctors in other centres, not just those
participating in the trial. As this was a preliminary study,
and at the time the only truly reliable method of demon¬
strating cerebral arterial pathology was angiography, the
surrogate endpoint of recanalisation required angiography to
ascertain treatment effect. With a catheter in the sympto¬
matic cerebral artery, it was reasonable to administer the
thrombolytic drug intraarterially, enabling the lower dose
to be used and perhaps also reducing the risk of adverse
effects.
In the future, practical treatments for acute is-
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chaemic stroke should be administered in the simplest possi¬
ble way to reduce time delays. Thrombolysis, if it works and
becomes available for treatment of acute ischaemic stroke,
would be administered more practically and quickly by the
intravenous route. It was not the intention in this trial to
advocate intraarterial treatment of acute ischaemic stroke,
but simply to assess its efficacy in recanalising occluded
cerebral arteries.
4.2.5 Time limit to treatment
Most recent "trials" (non-randomised) of thrombolysis
have had a six hour onset-to-treatment time limit, stating
that previous "trials" of thrombolytic treatment had found
an increased rate of cerebral haemorrhage if treatment was
given after six hours. No evidence of this was found in the
extensive search of the literature, but several largely
anecdotal examples of thrombolytic treatment after six hours
not causing increased haemorrhagic transformation of the
infarct were found.
Most suspected acute ischaemic stroke patients in the
UK go to hospital in a "slow ambulance", so few reach hospi¬
tal under six hours. It is unrealistic to expect referral
patterns to change in the near future, and there will always
be stroke patients who reach hospital late because they live
alone and have to wait until someone finds them, and there
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are those who awake with their stroke symptoms. In both
groups the time of onset may be uncertain. For these reasons
it was considered important to study the ability of throm¬
bolysis to lyse cerebral arterial occlusion and get some
idea of the risks and benefits of thrombolytic treatment up
to 24 hours after stroke onset. It was decided that patients
should be included up to 24 hours after onset of symptoms,
to allow for those who awake with a stroke, and stratified
the randomisation into three groups : "under six hours",
"six to twelve hours", and "twelve to 24 hours" after symp¬
tom onset.
4.2.6 Which Drug ?
There was considerable information about the risks
and benefits of the main thrombolytic drugs from their use
in the myocardial infarction trials,although the
trials comparing the commonly available thrombolytic drugs
directly had not been completed.^7®'^71'^7® Streptokinase
(SK) was the least expensive (£85.00 per treatment for MI),
then urokinase (UK), then tPA (£816.00 per treatment for
acute MI). SK was slightly less effective than tPA at reca-
nalising acute coronary occlusions (though reocclusion was
more frequent with tPA),"^®'^77 but it was felt at the time
of starting the pilot stroke trial there was insufficient
evidence of increased clinical benefit to justify the ten
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times increased cost of tPA instead of SK. Urokinase is more
widely used in Europe, and has the advantage of being non-
allergenic, but there was little experience of its use in
the UK, and it was more expensive than streptokinase. For
these reasons it was decided that SK should be used in the
pilot stroke trial. Table 4.2.1 compares the properties of
•jcn
the commonly available thrombolytic drugs.
The choice of drug has since been supported by the
ISIS-3 and GISSI-2 results.^In these large trials
in acute MI (60000 patients combined), both tPA and strep¬
tokinase produced the same clinical benefit in terms of
reduction in vascular death. However there was a highly
significant excess of intracerebral haemorrhage with tPA: 7
per 1000 patients treated instead of 3 per 1000 patients
treated with streptokinase.
4.2.7 Dose of Drug
The behaviour of thrombolytic drugs, particularly SK,
in an individual is unpredictable, mainly due to the
presence of cross reacting antibodies from
streptococci.^50/377 These may reduce the efficacy of the SK
and consequently in acute myocardial infarction, a large
dose (1.5 million IU) given intravenously is standard. There
have been few dose-range-finding studies for acute myocar¬
dial infarction. The earlier studies used intracoronary
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administration, and 250000 IU was found to be
effective.500000 to 1.5 million IU have been used
for intravenous administration. On the same principal, and
to keep potential systemic adverse effects to a minimum, it
was decided that 250000 IU of SK should be used intraarteri-
ally. This may be inadequate, although haematological stud¬
ies have shown that this amount is sufficient to induce
•377
systemic fibrinolysis in 90% of individuals. The thrombo¬
lytic effect of SK lasts for up to 24 hours, so it was felt
that this was a reasonable dose to start the pilot stroke
trial with.
4.2.8 Exclusion criteria
The exclusion criteria were as follows:
-SK treatment more than five days or less than one year
previously (because of the risk of allergic reactions)
-pregnancy or recent childbirth
-active peptic ulceration
-recent trauma or surgery
-bleeding diathesis
-anticoagulant treatment (warfarin)
-other serious medical condition which on its own would have
made survival beyond three months unlikely
-hypertensive (diastolic < 110 mmHg)
-symptoms obviously improving since onset, ie likely to be a
TIA.
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4.2.9 Imaging Tests Pre-Randomisation
All patients must have had a CT brain scan to exclude
a cerebral haemorrhage or other non stroke pathology as the
cause of symptoms. At the beginning of the study, it was
also thought that there should be no visible recent infarct
on the CT scan because of a suggestion from previous
"trials" of thrombolysis in acute ischaemic stroke of an
increased risk of haemorrhagic transformation if patients
who already had a cerebral infarct visible were given throm¬
bolysis. Again, as with the time limit to treatment, the
objective evidence for this was lacking. Although frequently
stated in previous "trials" of thrombolysis that it was
dangerous to use thrombolysis if an infarct was already
visible, no data could be found to support this. However it
seemed prudent at least at the start of the trial, to ex¬
clude patients with obvious areas of recent infarction
visible likely to be the symptomatic lesion. The protocol
was later changed to exclude patients only if there was
haemorrhage visible (or another cause of symptoms such as a
tumour) as it quickly became apparent that even the patients
we scanned very early after symptom onset had a new infarct
visible, so it was unrealistic to exclude them.
Transcranial Doppler was performed to confirm vessel
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occlusion, and an MCTT if time and isotope availability-
permitted. If the symptomatic MCA had a normal blood veloci¬
ty and was likely to be patent then the patient was excluded
from the trial, as I did not wish to expose patients likely
to have a patent MCA to the risk and discomfort of angiogra¬
phy. If there was any doubt about the accuracy of the TCD
result, for example if the patient was restless or there was
a poor temporal bone window, then the patient was included.
Ideally these patients should have had an MCTT study, but at
the time of starting the pilot trial, the gamma camera and
computer processing set up mean that although the transit
time data can be acquired in the Neuroradiology Department,
it had to be processed in the Nuclear Medicine Department
computer in a different part of the hospital. This would
have involved an extra half hour time delay to randomisa¬
tion. If the data processing could have been done in the
Neuroradiology Department, the entire MCTT study would take
ten to fifteen minutes, comparable to the time taken to
perform TCD.
4.2.10 Consent and randomisation procedures
If the trial inclusion criteria were satisfied, the
patient's or a close relative's consent was sought. A copy
of the consent document is included in Appendix Seven. This
must have been signed by the patient, or relative, and the
doctor explaining the trial procedure. The consent procedure
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was kept as simple as possible similar to the consent proce¬
dure for ISIS-2.3^0 A patient, or the relative of a patient,
who has just suffered a stroke is likely to be confused,
frightened, and unable to take in a complicated explanation
of trial procedure. The patients were likely to be dysphasic
if the infarct was in the left hemisphere, and possibly
unaware of their deficit if the infarct was in the right
hemisphere. The consent procedure adopted for the pilot
trial concentrated on the lack of any treatment for stroke
at the moment, the fact that clot-dissolving treatments work
in heart attacks and showed promise in stroke, but that it
was uncertain if the benefits outweighed the risks. The
patient, or relative, was given plenty of opportunity to ask
guestions about the trial before consenting to take part and
also excouraged to ask about anything of concern at any time
thereafter.
The patient was prepared for angiography. Ready
prepared, serially numbered, randomisation packs containing
everything reguired to make up a dose of SK or placebo were
kept in a fridge next to the angiography suite. One of these
was selected depending on which randomisation group the
patient fell into (0-6, 6-12, 12-24 hours) and given to a
house officer or non-trial member of medical staff to make
up and bring to the angiogram suite. These packs were made
of opaque black plastic and contained an instruction sheet,
a fifty ml bag of normal saline, needles, a five ml syringe,
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a mediswab, and either a box containing a vial of 250000IU
SK or a box containing an empty glass vial of similar weight.
From the outside the packs appeared identical and were
simply marked with the sequential randomisation numbers. The
treatment infusion was prepared by a doctor not directly
involved in the trial such as the Neurology house officer,
into the fifty ml bag of saline, and passed to the nurse
assisting with the angiogram without telling the radiologist
or trial neurologist whether the bag contained SK or the
saline placebo. This was to ensure blinding of the doctors
directly involved in the trial to reduce bias as much as
possible. Care had to be taken by the doctor making up the
infusion, as SK being a protein froths in solution, to
ensure that not too many air bubbles developed. The nurse
assisting with the angiogram procedure drew up the prepared
infusion into a 50 ml syringe taking care to exclude all air
bubbles, and handed it to the radiologist, who infused it
intraarterially. The materials from the infusion randomisa¬
tion pack were replaced in the pack by the doctor making up
the infusion, the pack was sealed and returned to Pharmacy
who checked that the infusion had been correctly prepared.
The intention was to administer the infusion as
blindly as possible. It was difficult to tell the difference
between the placebo and treatment infusions unless the
syringe was closely inspected, so this was as blind a method
as could be devised without an actual placebo powder, which
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would have been difficult to produce and very expensive.
4.2.11 Angiography and treatment infusion
If the clinical, CT and TCD criteria were met, and
consent was given, the patient was prepared for angiography.
An arterial introducer sheath was inserted under local
anaesthetic, into the femoral artery (usually the right) and
a diagnostic angiogram of the symptomatic carotid artery was
performed. If an arterial occlusion was confirmed, the drug
or placebo was infused into the occluded artery through the
diagnostic catheter with the tip placed as close to the
point of occlusion as possible. If the occlusion was in the
MCA, a cerebral microcatheter would be placed through the
diagnostic catheter and the tip advanced as close to the
lesion as possible so that the treatment infusion could be
given close to the occluding thrombus.
The angiogram of the symptomatic artery was repeated
immediately after the treatment infusion had finished. The
cerebral catheter was removed leaving the intra-arterial
sheath in the femoral artery (to protect the puncture site
from bleeding and to allow access for follow up
angiography), and the patient transferred to the Neurology
Ward for careful nursing care. Eighteen to twenty-four hours
after the stroke onset, if the patient was well enough, the
angiogram of the symptomatic artery was repeated. The cathe-
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ter and sheath were removed, and the patient returned to the
Neurology Ward for at least 24 hours for intensive post-
angiography nursing care. If stable, the following day the
patient was returned to the care of the General Medical
staff in the General Medical Wards, where they would have
gone directly after admission had they not entered the
thrombolysis trial.
4.2.12 Medical staff responsibility for the patient
For the first 48 hours after randomisation, the
patient was under the care of either Professor CP Warlow or
Dr PAG Sandercock in the Neurology Ward. This arrangement
was similar to the concept of a coronary care unit, where
the patient spends the first few days of admission under the
care of one Physician, and is then transferred to a General
Medical Ward under the care of the Physician on whose acute
receiving day he was originally admitted. We adopted this
strategy after careful discussion with the General Physi¬
cians in our hospital, who were keen to remain nominally in
charge of the acute stroke patient during the first few days
after admission, but recognised the need for specialist
medical and nursing care such as could be provided best in
the Neurology Ward.
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4.2.13 Clinical follow up
The patients were carefully monitored during and
after angiography, with two-hourly neurological nursing
observation (Glasgow Coma Scale) and standard post-angiogra-
phy checks (BP, pulse, puncture site check).
For the trial assessment, the following were
recorded (all described in detail in Appendix 8):
-Conscious level : Reaction Level Scale was used as this
avoided the "pseudoscoring" with the Glasgow Coma Scale
which occurs with dysphasic patients (Appendix Eight).
-Motor Function : This was measured using the Motricity
Index pre and post angiography, at three and fourteen days,
and at three and six months.
-Disability : This was measured using the Oxford Handicap
Scale (derived from the Rankin Scale) and the Barthel Index,
both at 14 days, three and six months.
Unless there was a clear contraindication it was
decided that the patients should start on aspirin 300 mg
daily at 24 hours after the stroke, to be continued indefi¬
nitely.
4.2.14 Imaging follow-up
This was as follows:
-CT brain scanning : This was performed at 24 hours, three
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and fourteen days, and whenever there was a new clinical
indication such as falling conscious level. Standard non-
contrast scan, ten mm slice interval only,
-TCD : Four hourly in the first 24 hours, daily for the
first week, twice in the second week, and thereafter if
indicated.
-MCTT : if performed pre-randomisation, at three and four¬
teen days.
Summary of Chapter Two
1. The philosophy behind the thrombolysis trial is described
with emphasis on the points of major debate at the time of
setting up the trial.
2. Patient inclusion and exclusion criteria are described.
3. Imaging criteria are described.
4. The consent and randomisation procedures are described.
5. The mode of administration of the treatment, and post
treatment imaging and clinical follow up are described.
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SK APSAC UK SCU-PA RT-I'A
2-chain l-chain
Half-life (min) 23 90 16 7 8 5
Fibrin enhancement 1 + 1 + 2 + 4 + 4 + 3 +
Plasma proteolytic state 4 + 4 + 3 + 2 + 2 + 1 +
Duration of infusion 60 min 2-5 min 5-15 min Several Several Several
hours hours hours
Thrombus specificity 0 0 0 0 0 0
(vs. hemostatic plug)
Incidence of reperfusion 60-70 60-70 60-70 60-70 60-70 60-70
(% within 3 hr)
Speed of reperfusion (min) 45 45 45 45 45 45
Frequency of reocclusion 15 10 10 NA 20 20
(estimated %)
Simultaneous administration No No No Yes Yes Yes
of heparin
Bleeding complications 4+ 4+ ■ 4 + 4 + 4 + 4+
Allergic side effects Yes Yes No No No No
Antigenicity Yes Yes No NK NK NK
Expense 1 + 2 + 3 + 4 + 4+ 4 +
*SK denotes streptokinase, APSAC acylated plasminogen-streptokinase activator complex, UK urokinase, SCU-PA
recombinant single-chain urokinase plasminogen activator, RT-PA recombination tissue-type plasminogen activator, NA
data not available, NK not known, 0 none, and 4+ highest. The clinical data were derived mostly from reported experience
with current intravenous dosages in the treatment of acute myocardial infarction.
Table 4.2.1 Comparative properties of commonly available
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The Interim Results of the Edinburgh Pilot Thrombolysis
Trial : February 1991 to January 1992.
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4.3.1 General Results
The pilot intraarterial thrombolysis trial was ready
to start in late February 1991. The first patient was rando¬
mised on June 3rd 1991. All acute stroke patients admitted
to the Western General Hospital were theoretically consid¬
ered for the thrombolysis trial, but most of them had very
obvious reasons for exclusion such as too mild a stroke, or
other disabling illness. The patients who were very actively
considered for randomisation but rejected, are listed in
Table 4.3.1. The reasons for rejection will be discussed in
detail below, as they are indicative of the type of problem
encountered in trials of treatment for acute ischaemic
stroke, particularly thrombolysis, and should be considered
in future trial design.
The first patient randomised was the tenth patient
actively considered for the trial. Prior to that, in the
first three months of the trial, five patients had been
excluded because an infarct was already clearly visible on
the CT brain scan in the symptomatic area (although the
patients were all scanned within or at six hours from symp¬
tom onset). It had been suggested in previous reports of
non-randomised trials, that these patients were at high risk
of haemorrhagic transformation following thrombolysis.
357,364 Aiso the literature at the time suggested that
infarcts were rarely seen under twelve hours from symptom
onset.^^'^^'^^'^^7 This was clearly not true. There was
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so much concern about how much importance should be attached
to early visibility of the infarct as a warning of increased
cerebral haemorrhage risk after thrombolysis, that I took
the CT scans of the five patients (considered for the trial
but rejected because of infarct visibility) to the First
International Meeting on Acute Stroke in Geneva in May 1991.
There I was able to show the scans to Dr Okada, Dr Ringel-
stein, Dr Matsumoto, Professor Mori, Professor Hacke and Dr
Deisenhammer, all of whom had published the results of small
non-randomised trials of thrombolysis in stroke. There was
total disagreement about a) whether or not an infarct was
visible, and b) whether they would have included each pa¬
tient in a thrombolysis trial on the strength of the appear¬
ance of the CT scan. Thereafter the trial protocol changed
to use the CT scan just to exclude cerebral haemorrhage or
tumour and to ignore the presence of visible infarction.
One patient was excluded because she had received
streptokinase for a myocardial infarction eight days earli¬
er. If thrombolysis were shown to work, then in this circum¬
stance one could use a different thrombolytic drug such as
urokinase, but in the context of a randomised trial, this
was not possible.
The CT scanner broke down half way through the brain
scan of another patient (number two), without obtaining
views of the symptomatic area. The patient was not rando¬
mised in the thrombolysis trial, but she was randomised to
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anticoagulant therapy in the International Stroke Trial.-*14
The following day, when the CT scanner had been repaired,
she was rescanned and had a primary intracerebral haemor¬
rhage as the cause of symptoms, but despite (or because of)
the anticoagulant treatment, her neurological state had
improved quite dramatically in the intervening 24 hours!
In patient number five it proved impossible to obtain
even a few diagnostic CT images because the patient had
marked nausea, was restless and had continuous hemiballismic
arm movements. He had a right hemisphere stroke and part of
his non-cooperation was because of lack of awareness of his
illness. The following day he was more settled and the CT
scan revealed a large right MCA territory infarct, and an
infarct of the left caudate nucleus. Several patients since
then with large right hemisphere infarcts have also proved
very difficult to manage because of incomprehension of their
condition, lack of cooperation and restlessness. It may be
that in order to investigate and treat these patients, heavy
sedation and possibly a general anaesthetic is required,
difficult to justify at the moment for an unproven treatment
in the context of a trial. Perhaps once proven treatments
for acute ischaemic stroke are available, anaesthetists will
be more willing to administer sedative drugs in the acute
phase of the stroke.
Only one patient (number eleven) had no relative
available to discuss consent. It had been expected that
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obtaining consent might be one of the most difficult and
frequent problems in an acute stroke treatment trial. Many
elderly people live alone, and dysphasia would be common,
but most of the patients arrived at hospital accompanied by
relatives, who were only too keen to have someone taking an
interest, and understood the reasons for the trials. In
another large hospital in our city, the majority of acute
stroke patients do not even have a CT brain scan (Dr B
Chapman, personal communication).
One patient (number fourteen) was inadvertently
randomised into the International Stroke Trial after a
telephone discussion of her clinical condition. On later
review by medical staff with an interest in stroke, it
became clear that her infarct was much more extensive than
originally described, and she would have been suitable for
the thrombolysis trial.
Another patient (number fifteen) was discussed within
one hour of stroke onset, directly with the neurology regis¬
trar on call, and described by the GP as having a dense
hemiparesis with dysphasia. When the patient arrived four
hours after onset (she had been sent in a slow ambulance),
she was found to have a mild partial hemiparesis and dysar¬
thria making the stroke a LACI rather than a large PACI, and
therefore unsuitable for the thrombolysis trial. In addition
her symptoms had clearly improved between onset and arrival
at hospital, and she would not have consented to angiogra-
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phy. This illustrates one of the difficulties in distin¬
guishing between lacunar and cortical infarcts which was
encountered on several occasions, usually with junior medi¬
cal staff or those who do not see stroke patients frequent¬
ly, but difficulties can occur even with experienced stroke
doctors (Part Two, Chapters Three and Four). Wider awareness
of a simple classification such as the OCSP clinical classi¬
fication might help reduce this problem.
Patient number sixteen with a medium sized PACI was
randomised in the thrombolysis trial, but at angiography was
found to have an incidental, unsuspected aneurysm arising
from the intracavernous portion of the internal carotid
artery, in addition to the peripheral MCA branch occlusion
which was the cause of the stroke. Although there are anec¬
dotal reports of patients with aneurysms being given throm-
lOf]
bolytic drugs with no ill effect, ou the risks are not well
quantified and it was not within the confines of the trial
to give the patient an infusion which might increase the
chances of aneurysm haemorrhage. The angiogram was terminat¬
ed without giving the infusion, and the patient was rando¬
mised, uneventfully, in the 1ST.
On only one occasion was the "stroke team busy" and
unable to assess the patient. The on call radiology cover
for acute stroke trials was provided by myself (or Dr R
Sellar for one week in December), and Dr Richard Lindley (or
colleague on the few occasions when he was on holiday) for
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clinical assessment. One occasion out of the entire year was
not bad considering the domestic and other work committments
which we all have. If the treatment was of proven benefit,
then normal out of hours medical cover would be provided as
in coronary care units.
The final reason for failure to randomise more pa¬
tients was time delay in between the patient reaching hospi¬
tal and the stroke team being contacted. Two patients
(numbers thirteen and nineteen) were simply not referred for
over twelve hours, although one reached hospital one hour
after onset, and the other at eight hours. They were simply
overlooked, and this is in spite of considerable publicity
for the stroke trials in the hospital. Several other pa¬
tients waited in the Casualty Department for several hours
before being referred. Patients were only considered for the
stroke trials, or even imaging, with the consent of the
Physician in charge of the case, so referral was discretion¬
ary.
4.3.2 Publicity
In order to raise awareness of the trials multiple
publicity measures were initiated. Prior to the start of the
trials, the background theory and protocols were presented
at a Western General Hospital "Grand Round" at which most of
the hospital medical staff were present. All new junior
medical staff received a letter giving information about the
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trials, and what to do in the event of discovering a stroke
patient. Notices advertising the thrombolysis and Interna¬
tional Stroke Trials were placed in the Casualty Department,
the Medical Wards, Neurology Wards, and notice boards around
the hospital. These notices gave clear instructions in the
form of a flow diagram, of which patients are suitable and
how to contact the stroke team. Other notices were put up
giving instructions about a simple way to arrange CT scans
and Carotid Duplex examinations on any patients (not just
stroke patients). This was intended to make life easier for
the busy junior medical staff, by replacing a trip to the
Neuroradiology Department and a hunt for a Neuroradiologist
to request a CT scan on a stroke patient, with a simple
telephone call. Both Dr Lindley and I carried radiopagers
and could be contacted at any time. Dr Lindley's was a
"message pager" so a message could be sent with all relevant
details obviating the need for the sender to wait for Dr
Lindley to return their call. In addition Dr Lindley met the
previous day's receiving medical registrar every weekday
morning to find out about any stroke admissions during the
previous 24 hours that he did not already know about. De¬
spite all these measures there were still long delays in
referral of patients to the stroke team, in some cases the
patient reaching hospital more quickly than being referred
once in hospital (Table 4.3.1).
In order to make life even easier for the receiving
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medical staff, the Bed Bureau (a Health Board service which
keeps track of hospital bed availability in the city and
allocates patients to vacant beds) was asked to page Dr
Lindley when a patient with a probable stroke had been
referred to the Western General Hospital. He would check the
Casualty Department periodically so that he often reached
the patient before the receiving medical registrar. This
improved referral times for patients coming through Bed
Bureau, but not those who came direct to Casualty by ambu¬
lance after a 999 call.
In August 1991 the Western General Hospital Casualty
Department closed so thereafter the Western General Hospital
could only admit acutely ill patients referred by their GP
through Bed Bureau, or transfers from other hospitals. The
young acute stroke patients who tended to come direct to
hospital after an ambulance 999 call, thereafter went to
another large hospital in the city where the Casualty serv¬
ices became concentrated. This was a tragedy because there
was little interest in acute stroke in that hospital, and
many of the patients did not even have a CT brain scan to
diagnose the cause of their stroke or assist with planning
secondary prevention.
In the summer of 1991, publicity about the interest
in acute stroke in the Western General, and the benefits
that this can provide in terms of patient management, was
increased by talking and writing to GPs in the Western
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General Hospital catchment area. These measures all take
time to work. In 1992/93 an acute stroke unit will be estab¬
lished in the Western General Hospital which, a bit like
coronary care units, will raise awareness of the possibility
of treating acute ischaemic stroke, and remove some of the
complacent "there's no treatment so why do anything at all"
attitude which prevails at present (Figures 4.3.1 A and B).
Hopefully a happy medium, somewhere in between the scenarios
depicted in these two Figures, will eventually be achieved.
4.3.3 Randomised Patients in the Streptokinase Trial
Five patients were randomised in 1991 of whom four
received a treatment infusion. These will be described
individually in chronological order. The patient who was
randomised but did not receive the treatment infusion was
the one described above who had an asymptomatic ICA aneurysm
found on angiography.
Patient One : This 64 year old man was the tenth patient to
be considered for the trial, and he very nearly was not
included because a "public figure" was admitted with a
subarachnoid haemorrhage the same morning and was due for
angiography at the same time. Fortunately the patient with
the subarachnoid haemorrhage was stable and it was possible
to postpone their angiogram by several hours.
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Clinical features: Patient One collapsed at 10.00 am and was
found immediately by his wife. She made a "999" call, and he
reached the WGH at 10.20am. He had previously been active and
in good health apart from mild peripheral vascular disease,
mild angina (on no regular treatment) and asthma. He took
medication for asthma only. Risk factors for stroke included
former smoking habit and his mother had died of a stroke
aged 56. On examination he had expressive and mild receptive
dysphasia, a dense hemiparesis affecting the right face, arm
and leg, a right homonymous hemianopia, so was a definite
TACI. He was referred to the stroke team at 11.00.
Imaging Studies: The CT brain scan at 1300 hours showed an
area of decreased density in the left basal ganglia and
white matter lateral to the left lateral ventricle (Figure
4.3.2a). TCD showed no detectable flow in the left ICA, or
MCA, and only a very low velocity turbulent bidirectional
signal in the region of the A1 segment of the ACA (Figure
4.3.3a). The PCA was patent. The velocity in the right MCA
was normal but in the right ACA was increased consistent
with supply to both the right and left A2s (Figure 4.3.3b).
The findings were consistent with a left ICA occlusion in
the neck. Cervical Carotid Duplex examination and MCTT
studies were not done prerandomisation in the interest of
time. Consent was obtained from his wife, a retired auxilli-
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ary nurse from the Department of Neurosurgery.
Angiography : Angiogram of the left common carotid showed an
occlusion just below the bifurcation in the bulb. The irreg¬
ular appearance suggested acute thrombotic occlusion rather
than dissection (Figure 4.3.4a). Angiogram of the right
common carotid showed patent ICA, MCA, ACA, and filling of
the stump of the left A1 and the whole of the left ACA more
distally, confirming the TCD findings (Figure 4.3.4b). The
treatment infusion was administered at 14.40 hours into the
left common carotid artery just below the point of occlu¬
sion. The patient suffered no ill effects during the proce¬
dure. Repeat films of the left common carotid artery at the
end of the infusion period showed no change in the appear¬
ance of the occlusion.
Imaging Follow-up: Repeat TCD 12 hours after symptom onset
showed slight increase in the turbulent low velocity signal
in the region of the left Al, and a very low velocity signal
in the region of the proximal left MCA (Figures 4.3.3 c +
d). The findings on the right side were unchanged. Angiogra¬
phy at 24 hours after onset showed proximal extension of the
left CCA occlusion, a slight improvement in the filling of
the left Al segment of the ACA from the right ICA, and a
hint of filling of the left MCA (Figure 4.3.4 c and d). CT
brain scan at 24 hours and three days after the stroke
showed a well demarcated infarct in the basal ganglia and
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white matter lateral to the left lateral ventricle (code 30)
with some swelling (code 3) but without heamorrhage. TCD on
day three showed a further improvement in the left MCA and
A1 segment of the ACA's velocity (Figure 4.3.3 e and f). No
further change in the blood velocity pattern occurred up to
the last TCD study at three months after the stroke. CT
scans at 2 weeks and three months after onset showed little
change apart from gradual atrophy of the affected tissue.
There was no haemorrhage, even minor, at any time.
Clinical follow up: The patient was discharged to rehabili¬
tation at one month. His neurological state changed little,
with no return of power to the right side by three months,
but slight improvement in dysphasia. His comprehension at
three months was full and he was able to answer yes and no
with occasional half sentances. His Oxford Handicap score
was five at two weeks and four at three months. His Barthel
Index was 14 at two weeks and 39 at three months. At six
month follow up he was living at home, cared for by his
wife. His Oxford Handicap Score was four and Barthel Index
was 32. This patient was randomised to saline.
Patient two: This 29 year old, previously healthy woman on
no medication, collapsed at 1400 hours in a street near the
WGH, and was brought to the WGH by ambulance. She reached
hospital 50 minutes after symptom onset (14.50), and was
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assessed by the stroke team at 15.30 hours. She had no known
risk factors for stroke.
Clinical features: She had a dense hemiparesis affecting the
right side of the face, arm and leg, a right homonomous
hemianopia and a complete expressive dysphasia with good
comprehension. She had had a headache on the left side of
her head for three days prior to admission.
Imaging studies: CT brain scan at 1700 hours showed an ill
defined low density consistent with ischaemia in the left
basal ganglia, deep hemispheric white matter and adjacent
cortex (code 50), with some mass effect (code 2), but no
haemorrhage (Figure 4.3.5a). TCD showed reduced velocity in
the left MCA (though still clearly detectable), with greatly
increased velocity in the left ACA (Figure 4.3.6 a and b),
and normal velocities in the right MCA (peak velocity
lOOcm/s) and ACA. Carotid Duplex showed reduced velocity in
the Left CCA and ICA with a low amplitude, bidirectional,
high pulsatility waveform which has been described in dis¬
section. An MCTT study was not performed as the daily allo¬
cation of isotope had already been used. Consent for angiog¬
raphy was obtained from the patient and her parents.
Angiography: The left MCA was occluded just beyond its
origin, with no evidence of dissection in any of the vessels
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(Figure 4.3.7 a). The treatment infusion was given at 1940
hours into the distal left ICA, after an attempt to place a
microcatheter in the left MCA had failed. Angiogram immedi¬
ately after the infusion showed partial recanalisation of
the left MCA (Figure 4.3.7 b). The patient suffered no ill
effects during the infusion.
Imaging Follow-up: TCD at eight hours after onset showed a
higher velocity in the left MCA than on admission (though
still slightly reduced). At 18 hours the velocity was the
same as in the right MCA, although the diastolic flow was
higher on the left in keeping with hyperaemia. Repeat angi¬
ography at 18 hours showed complete recanalisation of the
left MCA (Figure 4.3.7 c). CT brain scan at one and three
days after onset showed swelling in the left MCA territory
infarct (code 3) with some diffuse increase in density
suggestive of petechial haemorrhage (Figure 4.3.5 b and c).
The velocity in the left MCA increased to greater than that
in the right MCA from day two until day 14 when the veloci¬
ties became equal (Figure 4.3.6 c + d) and thereafter the
left MCA velocity remained normal. This indicated a period
of marked hyperaemia in the symptomatic MCA. CT brain scan
at two weeks showed some decrease in the swelling and the
petechial haemorrhage.
Clinical Follow-up: The patient improved neurologically.
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There were no systemic bleeding complications, or problems
with the angiogram puncture site. At two weeks she was able
to say a few words and her hemianopia had resolved. Her
motricity index improved from zero at day three to 23 at two
weeks and 151 at three months. Her Oxford Handicap Score was
five at two weeks and three at three months. Her Barthel
Index was 36 at two weeks and 50 at three months. She re¬
turned home (a third floor flat with no lift) at three and a
half months. At six month follow up her Oxford Handicap
Score was two and her Barthel Index was 50. She continued to
live in her third floor flat but had not returned to work.
Her speech was slow but otherwise normal. She was randomised
to streptokinase.
A transoesophageal echocardiogram has revealed a floppy
atrial septum with a small ASD. This was the probable cause
of her stroke.
Patient Three : This 68 year old man collapsed at home at
1300 hours, and was found immediately by his wife who called
his GP. He arrived at the WGH at 1405 hours. He was assessed
by the receiving medical registrar and thought to have only
a dense left hemiparesis (ie a LACI), so there was some
delay in his assessment by the stroke team.
Clinical features : When seen by Dr Lindley, the patient was
noted to have total neglect of his left side, and probably a
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left homonymous hemianopia, to be drowsy, agitated, and
confused, in addition to a total hemiparesis of the left
face, arm and leg (power grade 0/5 all groups on the MRC
scale), making the diagnosis a TACI not a LACI. He was an ex
smoker, and was hypertensive on admission (BP 180/100) but
was not known to be hypertensive previously. He had no other
risk factors for cerebrovascular disease. His past history
included bleeding gastric erosions in 1981 (he had been told
to avoid aspirin), and he consumed around 70 to 80 units of
alcohol per week.
Imaging Studies : CT brain scan at 1600 hours was of poor
quality because of patient movement, but showed an ill
defined area of low density in most of the right hemisphere
MCA territory (code 80) consistent with early infarction
(Figure 4.3.8). There was no haemorrhage. No velocity signal
was detected in the right MCA or ACA by TCD, though a normal
velocity signal was detected in the right PCA. The left MCA
velocity was normal, and the left ACA was slightly in¬
creased. Cervical carotid Duplex ultrasound showed occlusion
of the right ICA just above its origin. An MCTT study showed
delay in arrival of isotope in, and in transit through the
right cerebral hemisphere, confirming the TCD result. Con¬
sent for angiography and randomisation in the trial was
obtained from the patient's wife.
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Angiography : Due to the patient's confusion, and problems
with emergency radiology cover, he was not ready for angiog¬
raphy until 20.45 hours (eight hours after onset). The
procedure was very difficult due to the patient's agitation.
Despite 60 mg of Diazemuls IV and two persons restraining
him, he moved continually, and the angiogram films were
poor. Only views of the right carotid artery were obtained,
confirming an occlusion of the ICA just above its origin
(Figure 4.3.9a). The ECA was patent. The treatment infusion
was given into the bulb of the right CCA, continual patient
movement making it impossible to maintain catheter position
in the ICA itself. Angiogram film following the end of the
infusion showed that perhaps slightly more of the ICA origin
was patent (Figure 4.3.9b). The patient suffered no ill
effects from the infusion, and returned to the neurology
ward with the right femoral artery sheath in position.
Imaging Follow-up : TCD on the following two days did not
show any change in cerebral blood velocities from the admis¬
sion findings. The CT scanner broke down the day after the
angiogram and was out of action for two days, so the first
follow-up CT brain scan was obtained 48 hours after the
infusion. It showed an infarct of the whole right MCA terri¬
tory with mass effect causing midline shift but no haemor¬
rhage (Figure 4.3.8b). The angiogram and MCTT studies were
not repeated as the patient was still very confused and it
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was felt that sedation of the patient would be unethical. The
femoral sheath was removed uneventfully 18 hours after the
angiogram. There were no bleeding complications.
Clinical Follow-up : The patient remained confused, with
fluctuating conscious level. He was noted to be quite hyper¬
tensive in the 12 hours following angiography (BP 230/130).
This was treated with repeated doses of droperidol and
nifedipine which brought his blood pressure down to 160/90.
There was no alteration in his hemiparesis, or neglect. Two
days after admission he developed atrial fibrillation with a
rapid ventricular rate, and had periodic respiration. His
cerebral blood velocities varied markedly with the phases of
the periodic respiration. Mannitol was given IV for presumed
cerebral infarct oedema pending the CT brain scan. Following
the CT brain scan he continued to deteriorate, becoming
comatose, and died 3.75 days after the stroke.
Post Mortem : This confirmed occlusion (presumed thrombotic)
of the right ICA, extending to occlude the right MCA and
ACA. The right PCA was patent, as were the left hemisphere
arteries. There was a large right MCA territory infarct with
swelling causing brain stem compression. There was no hae¬
morrhage in the infarct, but there was a small brainstem
haemorrhage thought to be a terminal event secondary to
brain stem compression. There was some atheroma in both
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carotid bulbs, but no large plaque of atheroma to explain
the right ICA occlusion. Examination of the rest of the body
showed left ventricular hypertrophy and multiple renal
infarcts thought to be the consequence of accelerated phase
hypertension. There was no evidence of bleeding anywhere
apart from in the brainstem. He was randomised to streptoki¬
nase .
Patient four : This previously well 38 year old man de¬
veloped sudden onset left hemiparesis with dysarthria and
neglect at 06.30 hours as he was getting ready to go to
work. He was referred to the WGH by his GP and arrived at
the Western General Hospital at 08.25. The receiving Medical
Registrar referred him to the Neurology Registrar as both Dr
Lindley and myself were on holiday.
Clinical findings: On examination he was drowsy but orien¬
tated, with neglect of the left side, probable left homony¬
mous hemianopia (difficult to be certain because of the
neglect), dense hemiparesis of the left face and arm and
mild hemiparesis of the left leg. He had smoked 20 to 40
cigarettes per day for 20 years, but had no other known risk
factors for cerebrovascular disease.
Imaging studies : CT brain scan at 10.15 hours showed a low
density in the anterior part of the right MCA territory with
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sparing of the basal ganglia and minimal mass effect (Figure
4.3.10). TCD showed a reduced velocity in the proximal right
MCA, with no signal detected beyond one cm from its origin
(Figure 4.3.11a). An MCTT study was not done. The carotid
Duplex ultrasound did not show any plague or stenosis.
Verbal consent for angiography and randomisation in the
thrombolysis trial was obtained from the patient and his
father (by telephone).
Angiography : The angiogram showed an occlusion at the
origin of the first main branch of the right MCA (M2 seg¬
ment) with a small patent branch (Figure 4.3.12a). There was
initial difficulty in advancing a microcatheter into the
right MCA, so half of the treatment infusion was adminis¬
tered in the distal right ICA. A second attempt to place the
microcatheter tip in the occluding thrombus was successful,
and the rest of the infusion was given into the thrombus.
The arteries distal to the thrombus were patent (Figure
4.3.12b). Repeat angiogram film after the infusion was
completed showed that the M2 segment had reoccluded (Figure
4.3.12c). The patient suffered no ill effects during the
angiogram and returned to the neurology ward.
Imaging Follow-up : Angiography was repeated the next day
(at 30 hours after stroke onset). This showed a tight steno¬
sis at the trifurcation of the right MCA, consistent with
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partial recanalisation, with improved filling of the distal
branches (Figure 4.3.12d). CT brain scan at 24 hours showed
a more clearly defined infarct in the right MCA territory
anteriorly and peripherally with some mass effect but no
haemorrhage (Figure 4.3.10b). The appearance was similar on
day three apart from some minor petechial haemorrhage at the
margins of the infarct. CT brain scan at two weeks showed a
reduction in mass effect and no haemorrhage.
TCD 24 hours after the infusion showed that the right
MCA blood velocity had improved, but was still reduced
compared with the left MCA (Figure 4.3.11b). A focal high
velocity jet was detected at about 50 mm depth consistent
with a focal stenosis of the right MCA. This appearance
persisted for the first two weeks after the stroke (Figure
4.3.11 c, d).
Clinical Follow-up : 18 hours after the infusion the patient
had a haematemesis, so aspirin was not started. There were
no other bleeding complications. On day seven he was alert
with persistent neglect of the left, and no change in power
of the left face or arm, but the left leg was slightly
weaker. By day 14 the power in the left leg had improved to
the admission level and there was still no change in the
other neurological signs. His Barthel Index was 20 with an
Oxford Handicap Score of 5. He was transferred to rehabili¬
tation on day 14. This patient was randomised to streptoki-
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nase.
The patient was readmitted to the WGH with a further stroke
two months after the first stroke which had lead to randomi¬
sation in the streptokinase trial. His conscious level was
diminished, he was aphasic and had right arm and leg weak¬
ness. Further investigations at that time revealed subacute
bacterial endocarditis. At the time of the admission with
the first stroke he had microscopic haematuria, but this had
been attributed to minor haemorrhage following the strep¬
tokinase infusion and not investigated further. There were
no other signs of endocarditis at the time, but presumably a
cardiac embolus was, in retrospect, the cause of his stroke.
At the three month follow up assessment for the streptoki¬
nase trial he was severely handicapped - totally dependent,
requiring constant attention day and night. It is likely
that his recovery from the first stroke was severely im¬
paired by the second stroke so it is difficult to say what
benefit, if any, he may have had from the trial treatment.
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4.3.4 Discussion
The trial was very labour intensive. The most time
consuming and difficult to organise part was the angiogra¬
phy, because that required a nurse, a radiographer (prefera¬
bly two), a radiologist, and a vacant angiogram room. The
angiogram room had to be prepared for each patient and there
were several occasions when there were other patients wait¬
ing for angiography who had to be deferred. The patients had
to give consent not just for the trial treatment, but for
angiography also - two risks instead of one - angiography is
not pleasant. A minimum amount of cooperation was required
from the patient for the angiogram to be successful and
worthwhile.
Although only four patients were randomised out of
six who had angiography as a prelude to randomisation, with
each patient difficulties were encountered which have impor¬
tant implications for the design of acute stroke trials and
the management of acute stroke generally. At angiography of
the first patient there was debate about where the treatment
infusion should be given - whether into the occluded left
CCA or into the distal right ICA in the hope that it might
reach the left hemisphere and open the left MCA via the left
ACA. Intravenous administration would avoid this problem.
The patient's hospital management was straightforward with
no complications of the stroke or angiogram. His progress in
the rehabilitation hospital was slow but uncomplicated.
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Sadly the nurse who visited him and his wife to perform the
six month follow - up assessment was the first person to
visit them since his discharge from rehabilitation two
months previously. The patient was in a wheel chair, house¬
bound because of steps at front and back doors, and totally
dependent on his wife. Consequently she was able to leave
him only occasionally and with great difficulty for short
shopping trips. It is probable that because she was a former
nurse and capable person, the community services thought
that they would cope well and little home support or assess¬
ment had been offered. The trial nurse was able to arrange
social work assessment for aids in the home, alert the GP
and district nurse to the problem, and put the patient and
his wife in contact with a local patient self-help group.
This patient, relatively speaking, had made what was regard¬
ed as a satisfactory recovery from a severe stroke, but
"satisfactory" is a pretty poor substitute for someone who
was only 64, and previously active.
The second randomised patient, the 29 year old fe¬
male, also made uncomplicated progress in hospital after the
trial treatment. However the angiography delayed the time to
trial treatment by at least an hour, possibly longer, and
one wonders if her outcome might have been better had the
infusion been administered earlier. Her stroke was eventual¬
ly attributed to an embolus of cardiac origin from a congen¬
ital atrial septal anomaly, which was only detected using
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the more sensitive (compared with transthoracic) transoeso-
phageal echocardiography. Occult cardiac defects are being
increasingly recognised as a cause of stroke in the young,
but the best management is unclear. Should aspirin, or long
term anticoagulation be offered? A small regular dose of
aspirin is probably not unreasonable, plus simple measures
such as not sitting still for long periods of time, good
fluid intake, not smoking, careful anticoagulant prophylaxis
for surgery and not taking the oral contraceptive pill may
be as helpful until more is known about the natural history
of these occult cardiac defects.
The third patient was much more difficult to manage
because of his confusion and restlessness. He required large
doses of benzodiazepines during the angiogram. It was diffi¬
cult to know how well oxygenated he was as he kept removing
the percutaneous pC>2 monitor and oxygen mask. On returning
to the ward after the trial infusion, his blood pressure was
very high and was lowered pharmacologically, but it is not
known if reducing the blood pressure in the acute stages of
an ischaemic stroke is advisable or not. If reduced too much
there might be further impairment of the cerebral circula¬
tion, but in this patient there was concern that the hyper¬
tension might predispose to cerebral haemorrhage. Considera¬
bly more experience will be required with patients with
strokes of all severities to find out what is best in such
situations. It is also unclear what should be done about
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intravenous fluids and control of respiration. More experi¬
ence is required.
The fourth patient randomised may have suffered more
by being in a trial than had he not been. It was regretable
that he was randomised in the one week of the entire year
when both the radiologist and clinician most familiar with
the streptokinase trial were on holiday. On the first admis¬
sion the cause of the stroke was never established, and
although there were some warning signs of the probable
underlying cause, these were not followed up. The microscop¬
ic haematuria was attributed to the trial treatment and
ignored, and the fact that he was only 38 and, despite being
a very heavy smoker, previously well, did not provoke an
exhaustive search for a source of embolus. The high profile
of the acute stroke trial may have overshadowed the common
sense approach to routine clinical practice. Inclusion of
patients in a trial concerned with one aspect of their
management should not detract from the other routine as¬
pects .
It was decided at the beginning of the trial, that it
would be reasonable for me, but not any other medical staff
involved in the trial, to find out whether the treatment
infusion was streptokinase or saline, two weeks after admin¬
istration. It is obviously far too early to draw any broad
conclusions from the results, but a few comments are worth¬
while .
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Firstly there were no significant cerebral haeraor-
rhagic complications, although all the patients who were
given streptokinase had deranged blood coagulation, as
measured on a peripheral arterial sample taken four hours
after the trial infusion, but not after saline. One patient
(No. 4) had a systemic bleeding complication.
Three patients received streptokinase and one saline
placebo. One patient died (SK), two made poor recoveries
(one SK, one placebo), and one made a good recovery and
returned to independent living (SK). One patient recanalised
the occluded MCA quickly (SK), one showed partial recanali-
sation of the occluded MCA by 24 hours (SK), one showed
minimal evidence of recanalisation of the MCA above an
occluded CCA by 24 hours (placebo), and the other had no
evidence of recanalisation from an ICA occlusion at all
(SK) .
After my departure from the WGH, the pilot thromboly¬
sis trial stopped because of lack of a dedicated member of
staff. Hopefully the WGH will be able to continue similar
work by joining one of the intravenous multicentre rando¬
mised controlled thrombolysis trials now underway, such as
the Multicentre Acute Stroke Trial - Italy.
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Summary of Chapter Three
1. Patients considered for the Thrombolysis Trial and rea¬
sons for exclusion are described to illustrate some of the
problems encountered.
2. Publicity measures to promote the trial are described.
3. Each of the four patients randomised in the Thrombolysis
Trial are described in detail.
4. The pilot trial terminated after one year because I left
the WGH, but it is hoped that the WGH will continue similar
work by joining one of the multicentre randomised controlled
trials of thrombolysis now being set up.
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Table 4.3.1 Patients who were actively considered for the
Pilot Intraarterial Thrombolysis Trial, and reason for
exclusion where appropriate - February 1991 to December
1991. All times are from stroke onset.
i
















\ -1 1- ..I +.
1 j 59 5.5 7.8 | 2.3 1 8-2 i 0.4 infarct visible in hosp.
2 | 80 1.5 2.5 ! 1.0 ! 3-° ! 0.5 haemorrhage LTC
3 I 82 3.0 3.0 I 0.0 1 3.75 0.75 infarct visible rehab
4 ! 64 4.9 6.5 i L4 7.25 | 0.75 infarct visible rehab
5 1 66 0.9 3.0 ! 2.1 4.5 1.5 unscannable died
6 ! 70 inWGH 0.5 I 0.5 4.0 | 3.5 SK given for MI died
7 | 66 4.5 7.5 | 3.0 8.5 1.0 infarct visible LTC
8 ! 84 6.5 7.5 I 1.0 7.75 0.25 infarct visible LTC
9 i 67 in WGH 1.0 | 1.0 i 1.75 0.75 rapid recovery LTC
10 | 64 1.0 1.5 | 0.5 3.0 | 1.5 R rehab
11 I 84 4.0 6.0 I 2.0 I NR I NR I consent unobtainable 1 in hosp.
12 | 29 0.75 1.5 ! 0.75 2.0 0.5 R home
13 | 79 8.5 24.0 | 15.5 ! NR NR not referred dead
14 i 84 in WGH 0.75 I 0.75 I 2.0 i 1.25 1ST in hosp.
15 ! 55 4.0 4.0 l 0.0 I 4.0 | 0.0 lacunar infarct home
16 ! 61 2.5 3.0 | 0.5 1 4-° ! 1.0 aneurysm home
17 I 68 1.0 3.0 1 2.0 1 4.0 1.0 R died
18 i 78 5.0 6.0 ] 1.0 ! NTR ! NR "stroke team busy" in hosp.
19 l 72 1.0 10.0 I 9.0 1 14.0 1 NR time delay I died























time delay in hours betv^'een arrival in hospital and referral to "Stroke Team"
time delay in hours between referral to "Stroke Team" and CT brain scan
patient randomised into a concurrent trial, the International Stroke Trial
randomised in the thrombolysis trial




Figure 4.3.1 A The "expectant" policy of stroke management.
? "Top Gun" approach?
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Figure 4.3.1 B "Minimalist" management.
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Figure 4.3.2a Patient One : CT brain scan at 2.5 hours after
onset of acute ischaemic stroke prior to randomisation.
There was ill defined low density in the left parietal white
matter and basal ganglia.
Figure 4.3.2b Patient One : CT brain scan at three days
after stroke onset showing a large subcortical infarct
involving the left basal ganglia and deep hemispheric white
matter. No haemorrhage.
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Figure 4.3.3 Patient One : a,b. Transcranial Doppler find¬
ings at 2.5 hours after onset of acute ischaemic stroke.
a) Left ACA (symptomatic side) - only a low velocity turbu¬
lent bidirectional flow signal was detected on the sympto¬
matic side. No MCA signal detected. The signal shown was in
the region of the ACA.
b) Right MCA and ACA (asymptomatic side). The signal above
the baseline was the ACA, and was increased above the ex¬
pected normal level in keeping with supply to both A2 seg¬
ments .
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Figure 4.3.3 Patient One continued : c,d. Transcranial
Doppler at twelve hours after symptom onset.
c) Left - there was a very low velocity turbulent signal
detectable in the MCA main stem, compatible with minimal
blood flow into it.
d) Left - the signal in the region of the ACA had increased,
in keeping with marginally better flow to the left hemi¬
sphere .
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Figure 4.3.3 Patient One continued : e,f. Transcranial
Doppler three days after acute stroke onset.
e) Left MCA - a much more distinct signal was detectable in
the left MCA. It was still considerably reduced from normal,
but was definitely present.
f) Left ACA - the signal in the ACA had increased further
and was reversed, in keeping with persistent occlusion of
the left ICA and collateral supply from the right ICA.
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Figure 4.3.4 Patient One : a,b. Angiogram at three hours
after stroke onset.
a) Left carotid injection - the CCA was occluded in the
bulb.
b) Right carotid injection - the ICA was patent and filled
the right intracranial arteries normally. The left A1 was
just visible but there was no flow back into the left MCA.
a) b)
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Figure 4.3.4* Patient One : c,d. Angiography 18 hours after
symptom onset.
c) Left CCA - the occlusion had moved more proximally.
d.) Right CCA injection - there was marginally better filling






Figure 4.3.5 Patient Two : a. CT brain scan at three hours
after symptom onset. There was a low density area with
slight mass effect in the left basal ganglia extending out
to the left parietal cortex.
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Figure 4.3.5 continued Patient Two : b. CT brain scan at
three days after symptom onset. The low density area in the
left basal ganglia and parietal cortex had become more
distinct. Swelling in the infarct had increased but there
was no midline shift. The margins of the infarct were a
little hyperdense suggesting that there may have been some
mild petechial haemorrhage.
Figure 4.3.5 continued. Patient Two : c. CT brain scan at
two weeks after symptom onset. The swelling had resolved but
there was still low density in the left basal ganglia.
However the infarct extent was much more difficult to see -
an example of the "fogging" effect.
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Figure 4.3.6 Patient Two : a,b. Transcranial Doppler within
three hours of symptom onset.
a) Left MCA (symptomatic side) - reduced but still detect¬
able signal in keeping with an MCA main stem or first branch
occlusion. The right MCA mean blood velocity at the same









b) Left ACA - greatly increased velocity in keeping with













Figure 4.3.6 continued. Patient Two : c,d. Transcranial
Doppler three days after symptom onset.
c) Left MCA - the mean velocity was increased (upper limit
of normal for this age group is 86) and the pulsatility
index (PI) was low in keeping with hyperaemia.
cL) Right MCA for comparison - the velocity was normal.
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Figure 4.3.7 Patient Two : a,b,c. Cerebral angiography pre
and post treatment infusion.
a) Left carotid injection within four hours of symptom
onset- the left MCA was occluded in the main stem. There was
no evidence of dissection of the internal carotid artery.
b) Left carotid injection - immediately after the treatment
infusion - the left MCA had partially recanalised.
c) Left carotid injection 18 hours after symptom onset- the
left MCA had completely recanalised.
481
Figure 4.3.8 Patient Three : a. CT brain scan at three hours
after symptom onset. The image quality was degraded by
movement but an area of low density was visible in the right
MCA territory with some mass effect.
Figure 4.3.8 Patient Three : b. CT brain scan at two days
after stroke onset. There was infarction of the whole MCA
and part of the PCA and ACA territories with massive swell¬
ing, midline shift and effacement of the basal cisterns. No
haemorrhage.
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Figure 4.3.9 Patient Three : Angiography at eight hours
after symptom onset.
a) Right carotid injection - the right ICA is occluded just
above its origin. The outline of the bulb appears smooth
without atheromatous plaque.
b) Right carotid injection - immediately after the treatment
infusion - no change in the appearance of the occlusion.
a) b)
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Figure 4.3.10 Patient Four : a. CT brain scan two hours
after onset of symptoms. Ill defined low density is visible
in the anterior part of the right MCA territory consistent
with infarction.
Figure 4.3.10 Patient Four : b. CT brain scan three days
after symptom onset. The right MCA infarct was more clearly
visible and shows some mass effect and increase in density
of the tissue at the margins of the infarct suggestive of
minor petechial haemorrhage.
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Figure 4.3.11 Patient Four : Transcranial Doppler.
a) Right MCA three hours after symptom onset - the velocity
was markedly reduced. The mean blood velocity in the left
MCA was 60 cm/sec.
b) Right MCA 24 hours after treatment infusion - the veloci¬




Figure 4.3.11 Patient Four continued : Transcranial Doppler
c) Eight days after symptom onset : the right MCA - the mean
velocity was increased at a depth of 50 mm only, consistent
with a persistent focal stenosis at the MCA trifurcation.
d) Left MCA at 50 mm depth - asymptomatic side for compari¬
son .
486
Figure 4.3.12 Patient Four : Cerebral Angiography.
a) Right side, three hours after symptom onset through a
microcatheter placed in the MCA - there was an occlusion
the trifurcation of the MCA with only a small temporal
branch remaining patent.
b) Right MCA with the tip of the microcatheter embedded
the thrombus after the first part of treatment infusion
the MCA distal to the thrombus is patent.
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Figure 4.3.12 Patient Four continued : Cerebral Angiography
c) Right MCA through the microcatheter in the distal ICA at
the end of the treatment infusion - the MCA had reoccluded
at the same point.
d) Right MCA 30 hours after stroke onset - early and late
phases of the angiogram series showed partial recanalisation
of the MCA with a persistent stenosis at the MCA trifurca-




Thrombolysis in Acute Ischaemic Stroke - Does it work?
The Intraarterial Thrombolysis Pilot Trial and Acute Stroke
Treatment Trials in General.
Discussion.
4.4.1 Lessons from the pilot trial
4.4.2 Future trials of thrombolysis in acute ischaemic
stroke
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4.4.1 Lessons from the pilot trial
This small pilot study, though unsuccessful in reach¬
ing its target or any meaningful conclusion, was neverther-
less useful in that it highlighted many aspects of acute
stroke management which are poorly dealt with at present. It
also gave useful insights to aid the design of future stroke
trials. Some of the important messages have already been
discussed in Chapter Three, but other points will be covered
hear.
Obtaining consent from patients or their relatives
for this complex trial was not difficult in spite of the
angiography and potential risk of cerebral haemorrhage. Most
patients seemed to be aware that there was little treatment
that could be offered for the acute stroke, and knew that
"clot dissolving" drugs work in myocardial infarction. They
were prepared to accept the unquantified risk of cerebral
haemorrhage for the possibility of benefit from streptoki¬
nase. It had been anticipated that obtaining consent would
be one of the most difficult hurdles to overcome, but it was
not. Future acute stroke trials with less daunting protocols
should have little problem with consent. Consent must be
humane and the explanation of the nature of the trial sim¬
ple. The patient and their relatives are frightened and
confused and not able to take in complicated explanations.
There must be ready access at all times to informed staff
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who can answer questions.
Randomisation in a trial should not detract from or
distract the medical staff from the routine medical care of
the patient. Patients should be managed appropriately wheth¬
er they are in a trial or not. Acute stroke trials are
likely to increase so care must be taken not to forget
routine medical practice.
Patients can get to hospital quickly after an acute
ischaemic stroke, but once they reach hospital there are
numerous time delays which interfere with their rapid inves¬
tigation and implementation of therapeutic manoevres. Pa¬
tients seem to get to hospital more quickly if they go
direct to the Casualty Department without involving their
General Practitioner. Many of the delays in hospital seem to
result from the perception that there is little that can be
offered therapeutically to stroke patients. However that
does not mean the same thing as total neglect of even basic
nursing care and medical practice. Patients may wait several
hours in the Casualty Department waiting to be seen by the
receiving doctor and for a bed to be made available in a
ward, meanwhile they develop bed sores, aspirate, become
hypoxic, have arrythmias or blood pressure variations which
further impede their cerebral circulation, etc. There is
probably quite a lot of benefit for stroke patients just in
improving attention to simple measures of medical care,
before any pharmacological treatment becomes available. Some
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of this is speculative, but so little is known about "second¬
ary insults" after acute ischaemic stroke. Proper medical
and nursing care must go hand in hand with any pharmacologi¬
cal measures, as in the treatment of any other common medi¬
cal condition.
Patients with large acute ischaemic strokes are
difficult to manage, and if therapeutic intervention is to
succeed in the future, then more attention will need to be
given to managing intercurrent events such as marked hyper¬
tension or hypotension, oxygenation, fluid balance, and
probably factors such as blood coagulability, maintaining
regular respiration, and posture to name a few. Monitoring
will be required to detect such abnormalities, possibly more
than could be easily provided on a General Medical ward with
current staffing levels. Therefore Acute Stroke Units are
probably essential to allow proper administration of drugs,
monitoring and treatment of events in the acute phase of the
"3 O C
stroke which might adversely affect outcome. In an indi¬
vidual patient each of these factors may have a minor effect
on outcome, but when added together and when applied to the
total population of stroke patients, even avoidance of minor
insults may produce significant and worthwhile benefits in
outcome.
Sedation of acute stroke patients will probably also
be necessary to allow proper management. Neuroanaesthetic
techniques used to manage acute head injuries, subarachnoid
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haemorrhage, and primary intracerebral haemorrhage may be
appropriate for acute ischaemic stroke also.
4.4.2 Future trials of thrombolysis in acute ischaemic
stroke
Future trials must be as simple as possible to en¬
courage the cooperation of already busy medical staff who
will see a treatment for stroke as extra work. There are
several stages in the admission and investigation of stroke
patients at each of which further delays can occur so that
the final time when a therapeutic measure can be offered
gets further and further postponed. In acute ischaemic
stroke, it is likely that if any of the promising acute
treatments are to work, that they must be administered with
minimum time delay. Therefore the admission and investiga¬
tion procedure for stroke patients should be kept as simple
and brief as possible. Trials of promising treatment for
stroke should reflect this. Hospital practice is complicated
enough already without introducing complex trial protocols.
The intraarterial thrombolysis pilot trial was neces¬
sarily complicated because of the question it was address¬
ing. It was not intended that cerebral angiography or rou¬
tine non-invasive imaging tests, apart from a CT scan,
should be used in the majority of stroke patients. For acute
stroke trials to succeed in general hospitals where most
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stroke patients are admitted, the protocols must be simple -
the patients must be easy to identify, the entry criteria
broad without too many exclusions, the investigations mini¬
mal, and the follow up done by staff outside the hospital.
Most acute stroke patients are first seen by junior medical
staff on admission to hospital. They are inexperienced, and
may be overwhelmed by complex neurology. Even making the
diagnosis of a stroke may be difficult.
The moral dilemma concerning the treatment of elderly
patients is very important in acute stroke. All our trial
patients were under 70 years of age, and there is a general
reluctance to treat elderly patients with a severely disa¬
bling disease, although attitudes to care of the elderly
change constantly. The large thrombolysis in myocardial
infarction trials have shown that the elderly have the most
to gain from thrombolytic treatment, and the same may be
true of treatments for acute ischaemic stroke.360,370,371 A
better understanding of the benefits (or otherwise) of
treating elderly stroke patients is far in the distant
future. This cannot really be assessed until a successful
treatment is found. Only then will we be able to say if a
treatment which improves mortality is worthwhile, or if it
just increases the number of heavily dependant elderly
patients by keeping alive those who might otherwise have
died.
Acute stroke is a difficult disease to treat. Deci-
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sions must be made quickly, so trials must be as simple as
possible. The thrombolysis trial was complicated, but the
treatment procedure was not intended to be adopted into day
to day practice. If thrombolysis does work, then it will
need to be given by the simplest quickest route possible
after the minimum number of investigations. CT brain scan
and intravenous administration would be the most adaptable
to general use.
Acute ischaemic stroke is a distressing illness : to
the patient, the patient's family and friends, and to the
medical and nursing staff caring for the patient. Decisions
about how much rescussitative and supportive care to offer a
patient who has suffered a severe stroke are very difficult
"3Q 1
to make, and each case must be judged individually. These
decisions may become even more difficult when a proven
treatment becomes available, and it will take very large
trials to find the true risk/benefit ratio for all types and
severities of stroke. For example, a treatment which reduces
death or disability by 25% might reduce the number of pa¬
tients who die following a TACI stroke, and increase the
number of independant survivors, but paradoxically might
also increase the number of dependant survivors. The same
treatment might decrease the mortality and increase the
number of independant survivors following a POCI, PACI or
LACI stroke, but only decrease slightly if at all the number
of dependant survivors. The moral dilemmas posed by these
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possibilities are a long way in the future. We have to find
a treatment for acute ischaemic stroke first.
Since I began thinking about thrombolysis in 1988,
there has been a general groundswell of interest in throm¬
bolysis in acute ischaemic stroke, and a trendend away from
dose range finding studies to randomised controlled trials,
with improved methodology. There are now five multicentre
randomised controlled trials of thrombolysis in acute is¬
chaemic stroke underway or just about to start :
- the Multicentre Acute Stroke Trial -Italy
(SK/SK+aspirin/aspirin/control - 6 hours),
- the Australian Streptokinase Trial (SK/Placebo- 4 hours),
- the NIH tPA Trial (tPA/Placebo 180 minutes),
- the Multicentre Acute Stroke Trial - France (SK/Placebo -
6 hours),
- the European Cooperative Acute Stroke Study (tPA/placebo)
In addition there are three cooperative projects underway to
collect and review the results of future randomised con¬
trolled trials to try to derive results and disseminate
important information more quickly. These are :
- the Thrombolysis in Acute Stroke Pooling Project based in
Lyon in France,
- the Acute Stroke Trials Registry based in Ottawa, Canada,
- the Cochrane Collaboration Stroke Review Group.
All of this will provide some information, but I suspect
that even larger trials will be needed, akin to the myocar-
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dial infarction trials, before the true risk/benefit ratios
of thrombolysis - different drugs, ages, time after onset,
doses, combination with other drugs - are established con¬
clusively.
The Edinburgh Thrombolysis Trial was a small drop in
the ocean of work needed to establish whether thrombolysis
might work. If it has served to raise consciousness, coun¬
teract complacency and encourage a rethink of some of the
established ideas about cerebrovascular disease, then it has
been worthwhile.
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Summary of Part Four
1. A review of published data on the use of thrombolysis in
acute ischaemic stroke shows that most of the trials of
thrombolysis used methodology which does not allow any
assessment of its value in acute ischaemic stroke.
2. Six randomised controlled trials have been published, and
overview analysis of these does show some evidence of bene¬
fit, sufficient to encourage large randomised trials with
sound methodology.
3. The background to the Intraarterial Pilot Thrombolysis
Trial has been described.
4. Each patient randomised to date in the Pilot Thrombolysis
Trial is described in detail.
5. General points regarding the management of acute stroke
patients, and their relevance to acute stroke treatment
trials, highlighted by the experience with the patients
randomised in the thrombolysis pilot trial are discussed.
6. There are now five multicentre randomised controlled
trials of thrombolysis in acute ischaemic stroke underway
around the world, and a Fibrinolysis Therapy Trialists'
Collaboration to analyse and disseminate quickly the results
of trial overviews set up.
7. Thrombolysis in acute ischaemic stroke is now on a meth¬
odologically much sounder footing.
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Appendix 1 : Definitions,
a.Stroke
Rapidly developing clinical symptoms and/or signs of focal
and at times global (applied to patients in deep coma and to
those with subarachnoid haemorrhage), loss of cerebral
function, with symptoms lasting more than 24 hours or lead¬
ing to death, with no apparent cause other than that of
Q Q *3
vascular origin, (after HatanoJJJ from the WHO, and also
9 R
used in the Oxfordshire Community Stroke Project ).
b.Cerebral Ischaemia
Rapidly developing clinical symptoms and/or signs of focal
and at times global (patients in coma) loss of cerebral
function due to sudden interruption of the blood supply to
the area of brain subtending those functions. The duration
of interruption of the blood supply will determine whether
the brain tissue actually dies (infarction) or recovers.
Appendix 2: The Oxfordshire Community Stroke Project (OCSP)
Clinical Classification of Acute Ischaemic Stroke.
The OCSP classifies all acute stroke patients into one of
2 S
four clinical syndromes (Bamford et al 1991) :
Total Anterior Circulation Syndrome (TACS)
Partial Anterior Circulation Syndrome (PACS)
Posterior Circulation Syndrome (POCS)
Lacunar Syndrome (LACS)
This is a simple classification to apply and most patients
fit fairly easily into one of the categories. It is intended
for the classification of cerebral ischaema but can be
applied to cerebral haemorrhage also. When the lesion is
known to be an infarct then "I" for "infarction" can be
substituted for the "S" for "syndrome". The clinical fea¬
tures of each of the syndromes are as follows:
1) Total Anterior Circulation Syndrome (TACS) : Patients
must have all three of :
a) new higher cerebral dysfunction (eg dysphasia, dysgra-
phia, visuospatial disorder);
b) homonymous visual field defect; and
c) ipsilateral motor and/or sensory deficit of at least two
areas of the face, arm and leg.
If the conscious level is impaired and formal testing of
higher cerebral function or the visual fields was not possi¬
ble, a deficit is assumed to be present.
2) Partial Anterior Circulation Syndrome (PACS) : Patients
presenting with :
only two of the three components of the TACS;
or with higher cerebral dysfunction alone;
or with a motor/sensory deficit more restricted than those
classified as a LACS (eg confined to one limb, or to face
and hand but not to the whole arm).
3) Posterior Circulation Syndrome (POCS) : Patients present¬
ing with any of the following;
ipsilateral cranial nerve palsy with contralateral motor
and/or sensory deficit;
bilateral motor and/or sensory deficit;
disorder of conjugate eye movements;
cerebellar dysfunction without ipsilateral long tract defi¬
cit (ie ataxic hemiparesis);
or isolated homonymous visual field defect.
4) Lacunar Syndrome (LACS) : Patients presenting with :
pure motor stroke, or
pure sensory stroke, or
sensori-motor stroke, or
ataxic hemiparesis.
Although patients with faciobrachial and brachiocrural
involvement are included, those with more restricted defi¬
cits are not.
Appendix 3 : Coding for cerebral infarcts as seen on CT
brain scans.
Site and extent of lesion: Refers only to recent lesions
likely to be symptomatic.
Infarcts in the MCA territory :
00 normal (includes age-appropriate atrophy, +
generalised periventricular lucency)
10 small cortical infarct in the MCA territory
20 infarct involving most of the basal ganglia (larger
than 1.5 cm diameter - striatocapsular)
30 infarct in the white matter lateral to the lateral
ventrical (larger than 1.5 cm in diameter - also
striatocapsular but nearer to the vertex)
40 infarct of the front half of the peripheral MCA
territory excluding the basal ganglia
50 infarct of the posterior half of the peripheral
MCA territory excluding the basal ganglia
60 infarct of the whole of the peripheral MCA terri
tory not including the basal ganglia
70 infarct of the whole of the peripheral MCA terri
tory plus part of the basal ganglia
80 infarct of the entire MCA territory
Infarcts outside the MCA territory:
01 infarct of part or all of the PCA territory
02 infarct of the ACA territory
03 borderzone infarct (MCA/PCA, or MCA/ACA)
04 brainstem or posterior fossa infarct
05 lacunar infarct (small subcortical infarct less
than 1.5 cm diameter)
Other :
90 primary intracerebral haemorrhage - site indicated
by code as for infarcts
Infarcts at more than one site were indicated by combining
the codes, for exapmle "11" = small cortical MCA infarct
plus PCA infarct.
Definition of the amount of swelling of the infarct
0 no swelling
1 effacement of the sulci overlying the infarct
2 1 + slight compression of the ipsilateral lateral
ventricle
3 complete effacement of the ipsilateral lateral
ventricle
4 effacement of the ipsilateral lateral and third
ventricles
5 4 + shift of the midline structures away from the
infarcted side
6 5 + effacement of the basal cisterns
Definition of the amount of haemorrhage associated with the
infarct
0 none
1 petechial haemorrhage (minor punctate areas of
blood density (approx 60 to 80 Hounsfield Units) at
the margins of or within the infarct)
2 small confluent haematoma < 2 cm in diameter within
the infarct
3 haematoma > 2 cm in diameter within the
infarct
Appendix 4 : Codes for describing the likely pattern of
cerebral arterial occlusion suggested by Transcranial Dop-
pler Ultrasound in patients with acute ischaemic stroke.
primary codes describing the symptomatic MCA blood velocity:
700 symptomatic MCA velocity 25% > asymptomatic (ie
hyperaemia)
600 symptomatic MCA blood velocity = asymptomatic
500 symptomatic MCA velocity = 50-75% (ie more than 25%
reduction) of the asymptomatic MCA blood velocity
400 focal high velocity in the symptomatic MCA with
decreased velocity superficially (ie focal stenosis)
300 symptomatic MCA blood velocity = 25 to 50% of the
asymptomatic MCA blood velocity
200 symptomatic MCA velocity less than 25% of the
asymptomatic MCA blood velocity
100 absent symptomatic MCA blood velocity
000 absent symptomatic MCA and ACA blood velocity signal
secondary codes (to be used in conjunction with primary) :
010 increased velocity ACA on symptomatic side
(by 25% more than asymptomatic side)
020 increased velocity PCA on symptomatic side
(by 25% more than the asymptomatic side)
030 increased velocity both ACA and PCA on symptomatic
side
tertiary codes describing collateral pathways suggesting ICA
disease proximal to the skull base (to be used in conjunc¬
tion with the primary)
001 reversed direction of flow in the ACA on
symptomatic side
002 reversed opthalmic artery flow on the symptomatic
side
003 reversed ACA and opthalmic artery flow on the
symptomatic side
Appendix 5 :
Codes for describing the likely pattern of cerebral arterial
occlusion suggested by the isotope Mean Cerebral Transit
Time in patients with acute ischaemic stroke.
primary codes describing the abnormalities in the symptomat¬
ic hemisphere:
700 transit time on the symptomatic side faster than
on the asymptomatic
600 transit time on the symptomatic side = asymptomatic
500 transit time prolonged in the posterior half of the
symptomatic side
400 transit time prolonged in the middle half of the
symptomatic side
300 transit time prolonged in the anterior half of the
symptomatic side
200 transit time prolonged in the entire symptomatic
hemisphere
secondary codes (to be used in conjunction with the
primary):
020 1-2 second difference in transit time between sides
010 2 or more seconds difference " " " "
030 bilaterally prolonged transit
tertiary code suggesting ICA disease proximal to the skull
base :
001 loss of the normal antero-posterior gradient
The normal range of hemispheric transit time was 2.5 to 7.7
seconds, with no more than one second difference between
equivalent parts of the hemispheres. Transit time was nor¬
mally faster in the anterior 2/3 to 3/4 of the brain than in
the posterior 1/3 to 1/4, therefore loss of the normal
anteroposterior gradient indicated that the transit time
posteriorly equalled that anteriorly.
Appendix 6 : Map of the Western General Hospital.
The route from the general medical ward to the CT scanner is
marked by arrows, with lifts marked "L". The journey takes
five minutes walking, but ten minutes pushing a trolley or
bed.
Appendix 7 : Consent form for the Thrombolysis Trial.
Streptokinase in Cerebral Infarction Study
Department of Neurology and Neuroradiology
Western General Hospital, Edinburgh.
We would like to explain to you some of the research which
we are doing and then ask if you want to help with it.
Background : Every day, all over the country, lots of people
come into hospital who have just had a stroke, caused by a
blood clot blocking a blood vessel which supplies part of
the brain. So far no successful treatment has been found
for this. Drugs which could dissolve the blood clot might
help. We know that these drugs are very helpful in heart
attacks, and we think that they might help patients who have
had a stroke. If you agree to take part, then in addition
to all the normal treatments which you would have received
anyway, you will have special x-rays taken of the blocked
blood vessel (angiogram). If the test confirms the blockage
clot-dissolving treatment will be given.
What treatment is given? : If the blood vessel is blocked by
a clot, you will be given aspirin which will help dissolve
the clot (and help prevent new clots forming). In addition
some patients will be given an additional treatment with
streptokinase which can speed up the clot dissolving proc¬
ess. Other patients will be given treatment with a simple
salt solution, this will help us to find out whether aspirin
alone is enough to unblock arteries, or whether streptoki¬
nase is needed as well.
How the treatment is given? : The special x-rays of the
blocked blood vessel (angiogram) are taken by injecting x-
ray dye along a small plastic tube placed into the blood
vessel system at the top of the leg, and the additional
treatment is also given through the same tube. Afterwards,
the plastic tubing will be removed. The whole process will
take about three guarters of an hour.
Risks : There is a small chance that doing the x-rays of the
blood vessels could worsen the stroke, but we are doing only
the minimum x-rays reguired, and believe that the benefits
outweigh the risks. The clot dissolving treatment can cause
allergic reactions, bleeding, and falls in blood pressure.
We are using a very small amount of the drug and believe
that these side effects are unlikely.
If you agree that you/your relative should take part in the
study, then we would like you to sign this document. This
will confirm that we have discussed what is involved, and















Extension to pain 2
Flexion to pain(abn)3
Flexion to pain(n) 4
Localises to pain 5
Normal 6





Conscious level- Reaction Level Scale:
1) Alert
No delay in response
Orientated
2) Drowsy or confused
Responsive to light stimulation, talk, touch, single
shout.
3) Very drowsy or confused
Responsive to strong stimulation, repeated shouting,
shaking, pain stimulation










Beginnings of prehension 11
Grips (but not against gravity) 19
Against gravity 22
Against pull but weak 26
Normal 33









Movement not against gravity/limited range
Movement against gravity/full range
Weaker than other side
Normal
(use this last scoring for the other movements)
Shoulder abduction (from chest)-
Arm score
Leg
Ankle dosiflexion (from plantar flexed)-




Oxford Handicap Scale (Modified Rankin)
0= No symptoms
1= Minor symptoms which do not interfere with lifestyle
2= Minor handicap-symptoms which lead to some restriction
in lifestyle, but do not interfere with the patients' capac¬
ity to look after themselves
3= Moderate handicap-symptoms which significantly restrict
lifestyle and/or prevent totally independent existence
4= Moderately severe handicap-symptoms which clearly
prevent independent existence though not needing constant
attention
5= Severe handicap-totally dependent, requiring attention
day and night
Barthel Index (with modified scoring)
Code Criteria
5 Fully independent
4 Minimal help required
3 Moderate help required













The modified scoring is used and derived from the codes 1 to
5 of each item above.
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Comments, Opinions, and Reviews
Thrombolysis in Acute Ischemic Stroke:
Does It Work?
J.M. Wardlaw, MRCP, FRCR, and C.P. Warlow, FRCP
Background: This article is presented to provoke further discussion regarding the use of thrombolytic
drugs to treat acute ischemic stroke.
Summary of Review: Overview analysis of the six randomized trials of thrombolysis in acute ischemic
stroke available in the world literature shows a 20% increase in the odds of death and a 30% reduction in
the odds of death or deterioration (both with wide confidence intervals, neither result significant) after
thrombolytic treatment for acute ischemic stroke. Exclusion of the two trials conducted without the
benefit of computed tomographic scanning shows a 37% reduction in the odds of death (95% confidence
interval, 74% reduction to 40% excess) and a significant reduction of 56% in the odds of death or
deterioration after thrombolytic treatment (95% confidence interval, 20-76% reduction; 2p = 0.007).
Analysis of all published studies (randomized and nonrandomized) shows that there does not appear to
be an excess risk of hemorrhagic transformation of the cerebral infarct or of severe edema formation.
Conclusions: We believe the present evidence is sufficiently encouraging to warrant proper testing of
thrombolysis in sufficiently large and well-designed randomized clinical trials to influence clinical
practice. (Stroke 1992;23:1826-1839)
Key Words • cerebral ischemia • clinical trials • thrombolytic therapy
Stroke has defied the considerable efforts of med¬ical science to find an effective treatment andremain the third most common cause of death
in the developed world, preceded only by ischemic heart
disease and all cancers combined.1 However, unlike
ischemic heart disease and cancer, stroke leaves many
more people disabled and dependent on family and
social or health services. Despite a decline in stroke
mortality in some but not all countries,1 there is rather
little evidence of a decline in incidence.2 Therefore,
anticipated demographic changes, and thus increasing
stroke numbers, make it even more important to find an
effective treatment.3
Therapeutic approaches should reflect logical appli¬
cation of our present understanding of the sequence of
events in the ischemic brain leading to cerebral infarc¬
tion. After interruption of the blood supply, some tissue
probably suffers irreperable damage within minutes, but
a variable amount remains in a "shut-down" but viable
state for several hours.4 The concept of this "ischemic
penumbra" is now reasonably well established by elec¬
trophysiological work in animals4 and positron emission
tomography.5 Neutralization of toxic metabolites re¬
leased from infarcted cells or restoration of the blood
supply might save the ischemic tissue and improve
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outcome. Thus two basic approaches have evolved; 1) to
protect ischemic but still viable neurons from further
damage by toxic metabolites and 2) to improve the
blood supply to ischemic brain.
Using the first approach, nimodipine has not been
shown to be of any benefit in moderately large groups of
patients.'1 Newer excitatory amino acid antagonists are
being evaluated but may have unacceptable toxicity
(e.g., psychosis and cardiac arrhythmias), and it remains
to be seen whether the benefit in animals can be
translated into benefit in elderly stroke patients.7
Using the second approach, hemodilution is ineffec¬
tive in the generality of ischemic stroke patients."
Antithrombotic therapy (with heparin, warfarin, or as¬
pirin) has not been properly tested in large randomized
clinical trials. Although variably used in acute stroke,9
we do not know if these drugs improve outcome. A
randomized trial of aspirin and heparin in acute isch¬
emic stroke has begun in Europe.
That leaves thrombolysis, a theoretically attractive
treatment with proven ability to dissolve arterial throm¬
bus elsewhere in the body10 but with the potentially
unattractive adverse effect of converting a simple (pale)
infarct into a hematoma. Thrombolytic drugs were first
used in the late 1950s for acute stroke.11 Since then over
2,800 patients have been reported in the world litera¬
ture. Despite this we do not know if thrombolysis works,
nor what the risks of treatment are. Most of the
literature consists of case reports or small series, with
only six small randomized trials.12"17 Rather than review
historically the use of thrombolytic drugs to treat cere¬
bral ischemia,18 it is our intention to examine critically
and quantitatively the evidence that thrombolytic drugs
might work in acute ischemic stroke without unaccept¬
able risks.
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Given the heterogeneity of the pathogenesis and
outcome of acute ischemic stroke and that the magni¬
tude of any treatment effect may be modest, both a
proper control group and adequate numbers of patients
are essential to ensure an unbiased and precise trial
result." Many of the reported studies have methodolog¬
ical inadequacies that make their evaluation of throm¬
bolysis in acute stroke inconclusive. We hope to dem¬
onstrate in this article that thrombolysis has a good
chance of improving outcome in acute ischemic stroke
without unacceptable risk, and that properly conducted
large randomized trials (on the scale of the myocardial
infarction thrombolysis trials) would be reasonable to
do and likely to yield a definitive answer; indeed, several
less ambitious trials have already started (see below).
Why Might Thrombolysis Work?
The majority of acute focal cerebral ischemic events
are due to embolism or in situ thrombosis.2" A small
proportion are due to "boundary zone" ischemia sec¬
ondary to a hypotensive episode or internal carotid
artery (ICA) occlusion. Approximately 20% are small
subcortical infarcts commonly attributed to degenera¬
tive changes in small perforating arteries,21 although
some authors dispute this. Most of the discussion in this
article will refer to large artery territory thromboem¬
bolic stroke.
Thrombolytic drugs work in acute myocardial infarc¬
tion, which is usually due to acute thrombotic occlusion
of a coronary artery, by lysing the thrombus quickly and
restoring vessel patency.22 The Second Internationa!
Study of Infarct Survival (ISIS-2) showed that streptoki¬
nase (SK) reduced mortality after myocardial infarction
by 25%.23 Aspirin confers similar benefit, and the effect
of both is a 50% reduction in mortality at 5 weeks. The
cause of many acute ischemic strokes, as outlined above,
is acute embolic or thrombotic cerebral artery occlu¬
sion. Therefore, there are good theoretical reasons why
thrombolysis might alsowork in the cerebral circulation.
In the brain, the information on spontaneous recan-
alization of thrombotic or embolic cerebral artery oc¬
clusion is scanty. Based on the limited evidence avail¬
able from Caucasian populations, about 20% of
presumed embolic (cardiac or artery-to-artery) middle
cerebral artery (MCA) occlusions (main stem or
branch) may recanalize spontaneously within 24 hours,
and possibly as many as 80% do so within 1 week of
onset,24-25 but these figures are no more than "best
estimates." It is difficult to extract the spontaneous lysis
rate of artery-to-artery embolism from the figures for
cardiac embolism (often patients have both potential
sources), and there is little information on recanaliza-
tion of acute ICA occlusions in the neck. Spontaneous
reperfusion after thrombotic cerebral artery occlusion
(thought to be more common in Oriental peoples) has
been little studied but appears to be less likely than
recanalization after embolic occlusion.26-27 Therefore, in
the population with ischemic stroke due to large vessel
disease, the spontaneous recanalization rate will be at
best approximately 20% at 24 hours but may depend on
the location of the occlusion (ICA or MCA), its com¬
position (fibrin embolus, platelet embolus, or throm¬
bus), and its age. Although these figures emphasize the
lack of information regarding spontaneous recanaliza¬
tion of occluded cerebral arteries, there is clear evi¬
dence that spontaneous lysis of thrombus does occur. So
the question for thrombolytic therapy is whether this
spontaneous process can be accelerated in time to
restore useful brain function without unacceptable risk.
What Do We Know So Far From Using
Thrombolytio Jppigs in Ischemic Stroke?
There have been over 60 reports in the world litera¬
ture to date. Six were randomized trials,12-17 and four
had retrospective or nonrandom control groups.28"31 Of
the remaining, 35 or more were so-called open trials and
approximately 20 were case reports. The trials were
identified by literature search (using Index Medicus), by
tracing references cited in thrombolysis articles, and by
discussion with other researchers interested in throm¬
bolysis. All published randomized trials are included in
this analysis as well as all nonrandomized trials and
most case reports in the English, French, German, and
Japanese literature. It is probable that some acute
stroke patients have been treated with thrombolysis but
not reported in the literature, and potential bias be¬
cause of this must be borne in mind when interpreting
the following analysis.32
Randomized Trials
Of the six randomized trials shown in Table 1 and
Figure 1, the two by Meyer et a!12-13 were conducted
before the invention of computed tomographic (CT)
scanning, and therefore some patients with primary
intracerebral hemorrhage or hemorrhagic infarction
may inadvertently have been included. The numbers
were small, and the outcome measure was clinical
evaluation at 10 days, which may be too early for valid
assessment. In the first study there was no difference in
outcome between the treated and control groups. In the
second, larger study, the treated group fared worse.
However, patients were included up to 72 hours after
onset, and although the mean time to treatment was not
stated, trial intervention may have been too late. It is
generally thought that treatment for acute ischemic
stroke should begin as soon as possible, certainly within
24 hours of onset.
The randomized trials by Mori et al,14 Ohtomo et al,15
Abe et al,16 and the Japanese Thrombolysis Study
Group (JTSG)17 used CT scanning to exclude intrace¬
rebral hemorrhage as a cause of stroke before random¬
ization and for follow-up after treatment. Mori et al
studied MCA and ICA recanalization and found that
nine of 19 patients given intravenous tissue plasminogen
activator (t-PA) within 6 hours of symptom onset recan-
alized compared with three of 12 given placebo.
Ohtomo et al published a Japanese multicenter ran¬
domized trial of low-dose intravenous urokinase (UK)
in acute thrombotic cerebral infarction given within 5
days of symptom onset. Abe et al (also Japanese)
published a randomized trial of intravenous urokinase
for acute ischemic stroke given up to 30 days after
symptom onset (more than half of the patients were
treated 4 days or more after onset). The JTSG17 studied
clinical improvement after embolic stroke and found
that 37 of 51 patients randomized to 34 mg t-PA i.v.
improved compared with 26 of 47 given placebo within
6 hours of symptom onset. Additional information on
drug, dosage, route of administration, time to treat¬
ment, and outcome measure is given in Table 1. Note
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Table 1. "Controlled" Trials of Thrombolysis for Acute "Ischemic" Stroke
Results
Time Treated Control
Author Drug Route Dose from onset Outcome measure No. % No. %
Randomized
Meyer13 Fib/ IV 2.5-11.5 <72 hours Clinical improvement 20 45 20 45
Pia xlO5 units at 10 days
Meyer13 SK IV 2.5-17.5 <72 hours Clinical improvement 37 43 36 58
x 103 units at 10 days
Mori14 t-PA IV 34-50 mg <6 hours Recanalization 19 47 12 25
Ohtomo15 UK IV 6x 104 units <5 days Clinical improvement 169 56 181 42
per day at 4 weeks
for 7 days
Abe16 UK IV 6x 10J units <30 days Clinical improvement 54 63 53 43
per day at 1 and 4 weeks
for 7 days
JTSG17 t-PA IV 34 mg <6 hours Clinical improvement 51 72 47 55
at 4 weeks
Nonrandomized
Hacke28 SK/ IA 4x 10s units <24 hours Clinical improvement 45 44 23 0
UK approx.
Okada29 t-PA IV 26-50 mg <6 hours Clinical improvement 15 4g 11 9
at 1 month
Abe30 UK IV 6-12 Up to 6 Clinical improvement 62 71 22 36
x 10s units months at 1 month
Larcan31 UK IV 16.5-38.5 36 hours+ Clinical improvement 36 47 41 17
x 10s units
No., total number of patients in each group; %, % of patients who improved clinically, or recanalized.14 Where two assessment times are
given, the % improved refers to the later time. JTSG, Japanese Thrombolysis Study Group; Fib, fibrinolysin; Pla, plasmin; SK, streptokinase;
t-PA, tissue-type plasminogen activator; UK, urokinase; IV, intravenous; IA, intra-arterial.
that Table 1 includes not only the six truly randomized
trials (upper half) but also the four nonrandomized
trials (described below), which are often referred to as
"controlled" trials in the literature to emphasize the
distinction.
Figure 1 shows the results of an overview analysis33 of
death (Figure 1A) and death or deterioration (Figure
IB) after thrombolytic therapy for acute ischemic
stroke. The analysis is of published results for the six
randomized trials, and additional information was sup¬
plied by E. Mori and T. Yamaguchi for the JTSG.
Although deterioration was assessed differently in each
trial, the overview technique minimizes the problem of
trying to compare different trials and end point mea¬
sures by not comparing randomized, controlled trials
-directly with each other. Rather, the overview compares
he magnitude and direction of any treatment effect
sontained within the individual trials and yields an
estimate of the overall treatment effect.
Analysis of all six trials shows that the risk of death is
■ncreased by 20% with thrombolysis but with a wide
onfidence interval (CI) that includes the possibility of
31% reduction to 151% excess. The risk of death or
eterioration (all six trials) is reduced by 37% with
trombolysis, but the wide CI includes the possibility of
66% reduction to 14% excess.
Analysis of the four trials conducted with the benefit
f CT scanning (therefore reliably excluding cerebral
hemorrhage as the cause of symptoms) shows a reduc¬
tion in the risk of death of 37% (95% CI, 74% reduction
to 47% excess) with thrombolytic treatment and shows a
reduction in the risk of death or deterioration of 56%
(95% CI, 20-76% reduction [2p = 0.007]). This provides
some evidence that thrombolysis is beneficial in acute
ischemic stroke; this benefit is not enough to recom¬
mend routine treatment but certainly enough to encour¬
age larger randomized trials.
Studies With a Retrospective or
Nonrandom Control Group
The study by Hacke et al:s on vertebrobasilar occlu¬
sion illustrates the difficulty of including a retrospective
control group (Table 1). Although the treated and
control groups were similar in many respects, 12 of 22
(54%) of the control subjects were unconscious at
diagnosis and entry into the trial compared with 15 of 43
(35%) of the treated group, perhaps reflecting increas¬
ing awareness of the condition and earlier diagnosis.
Epidemiological studies have shown that vertebrobasi¬
lar stroke can cause mild symptoms and does not always
progress to coma with the uniformly bleak outcome that
Hacke et al have suggested.34 Therefore, the prospective
treated and retrospective control patients may have
been different in prognosis, and it is not valid to use the
sicker group treated conventionally as a control for the
later treated group. The other three studies that in-
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THROMBOLYSIS FOR ACUTE "ISCHAEMIC" STROKE
THROMBOLYSIS vs CONTROL; MORTALITY
Trials Events/Patient* Stratified Odda Ratio & 95% G.L Redn.
analysed Thrombolysis Control (O-E) Var. (Thrombolysis: Control) i s.d.
MEYER 1963 (12) 7/20 7/20 0-0 2-3
MEYER 1964 (13) 13/37 4/36 4-4 3-3
ABE 1981" (16) 1/54 1/53 0-0 0-5 -
OHTOMO 1985* (15) 3/169 6/181 -1-3 2-2 ■
MORI 1991* (i^^ 2/19 2/12 -0-5 0-9 -
YAMAGUCHI 1992* (17) 3/51 4/47 -0-6 1-6 ■
ALL TRIALS 29/350 24/349 20 10-8
Treatment effect 2P > 0.1; NS
TRIALS WITH CT* 9/293 13/293 -2-4 5-1
Treatment effect 2P > 0.1; NS
00 0-5 1 0 1-5 20
Thrombolysis Thrombolysis
THROMBOLYSIS FOR ACUTE "ISCHAEMIC" STROKE
THROMBOLYSIS vs CONTROL: DEATH OR DETERIORATION
Events/Patients Odds Ratio i 95% C.L.
anatysad Thrombolysis Control (O-E) Var.
MEYER 1963 (12) 8/20 8/20 0-0 2-5
MEYER 1964 (13) 14/37 8/36 2-8 3-9
ABE 1981* (16) 1/54 3/53 -10 10 •
OHTOMO 1985*05) 4/169 14/181 -4-7 4-3
MOR11991* (1A) 5/19 5/12 -1-1 1-7
YAMAGUCHI 1992*(17) 7/51 10/47 -1-9 3-5
ALL TRIALS 39/350 48/349 -5-9 16-8
Treatment effect 2p > 0.1; NS




Figure 1. Overview analysis of the random¬
ized trials of thrombolysis for acute ischemic
stroke. Panel A: Odds ofdeath; panel B: odds of
death or deterioration for thrombolytic therapy
vs. placebo. Note that the two trials by Meyer
were done without computed tomographic (CT)
scanning. "Yamaguchi" refers to the Japanese
Thrombolysis Study Group trial. O—E, ob¬
served minus expected number of events in the
treated group; Var, variance; Redn, reduction.
An odds ratio <1 indicates that thrombolytic
treatment may be beneficial, and the confidence
limit (C.L.) gives the 95% confidence intervalfor
the odds ratio indicating the range of possible
therapy effects.
0-0 0-5 1-0 1-5 20
Thrombolysis Thrombolysis
better I worse
eluded a control group (Table 1) did not state how
the patients were chosen or how treatment was
allocated.29-31
Open Trials and Case Reports
The primary aim of the studies shown in Tables 2 and
3 was to assess safety and find an optimal dose. They are
a heterogeneous group of reports, some using the
intravenous and some the intra-arterial route of drug
administration, with different drugs, doses of drug,
inclusion criteria, and outcome events (recanalization
or clinical improvement). It is not possible to make any
comment about benefit because there were no control
groups. It is even difficult to draw any conclusions about
safety because the natural history of cerebral infarction
is so variable and there were no control subjects with
which the development of cerebral edema or hemor¬
rhagic transformation could be compared.
The studies that examined reperfusion (using serial
angiography) considered together showed some degree
of recanalization (partial or complete) in 61% of pa¬
tients within 24 hours of symptom onset. This appears to
be better than the estimated spontaneous rate of recan¬
alization of 20% at 24 hours after onset (see above). It
is encouraging that 61% recanalization is of the same
order of magnitude as was found in the acute myocar¬
dial infarction thrombolysis studies, which used angiog¬
raphy to assess recanalization.70 Although these figures
are very tentative, all available data are included and
suggest the presence of a useful treatment effect.
These conclusions are encouraging but tentative, the
numbers of patients are small, and there may have been
publication bias,32 although in the field of thrombolysis
in acute ischemic stroke positive as well as negative
results seem to be presented with equal enthusiasm.
Does Thrombolysis Increase the Risk
of Cerebral Hemorrhage?
Thrombolytic drugs given for extracranial vascular
disease increase the risk of hemorrhage both in the
brain and elsewhere in the body.23 Therefore, throm¬
bolysis for acute ischemic stroke might increase the risk
of cerebral hemorrhage, but how big is this risk? Throm¬
bolysis might, by reducing infarct size or other mecha-
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Table 2. Open Studies of Thrombolysis for Acute Ischemic Stroke: Recanalization
No. of Percent
Author Year Drug Route Dose patients recanalized
Del Zoppo35 1988 SK IA 0.06-2.5 x 105 units 20 75
Theron36 1989 SK IA 0.25-1.5x 10s units - 12 100
Maisa37 1988 SK IA 2.5 x 105 units 16 100
Zeumer38 1985 SK/UK IA Various 29 86
Berg-Dammer39 1991 SK IA 10* units 3 100
Baird40 1992 SK IV 1.5x 105 units 5 38
Total for SK 75/93=80% recanalized
Zeumer11 1984 UK IA 5-7.5x 10s units 2 10
Mori42 1990 UK IA 1.8-3.2x 10s units 48 44
Lehmann43 1989 UK IA 2-3x 105 units 10 80
Ikeda44 1990 UK IA 4.2x 105 units 13 85
Siepmann45 1991 UK IA Up to 7.5x 105 units 11 64
Casto46 1992 UK IA 5.6x 105 units 4 80
Berg-Dammer39 1991 UK IA 2-7.5x 105 units 7 100
Mobius47 1991 UK IA 3-9.5 x 105 units 18 77
Seikmann48 1991 UK IA 8x 105 units 2 100
Matsumoto49 1991 UK IA 2.4-12X 105 units 52 58
Miyakawa50 1984 UK IV/IA 7-9x 105 units 49 59
Williams51 1992 UK IA 5-10x 10s units 2 i 66
Total for UK 139/222 = 62% recanalized
ASSG52 1992 t-PA IV 12.5-44 mg 93 36
Karnik53 1992 t-PA IA 20 mg 1 100
Yamaguchi54 1991 t-PA IV 10, 20, 30 mg 58 43
Hennerici55 1991 t-PA IV 70 mg 18 44
von Kummer56 1991 t-PA IV 70 or 100 mg ->7 56
Brucker57 1992 t-PA IV 100 mg 25 89
von Kummer58 1992 t-PA IV 100 mg 32 53
Total for t-PA 154/284;=54% recanalized
Total all patients 368/599=61% recanalized
Studies are listed according to drug used and increasing dose. No. of patients, total number of patients in study; ASSG,
Acute Stroke Study Group; SK, streptokinase; UK, urokinase; t-PA, tissue-type plasminogen activator; IA, intra-arterial; IV,
intravenous.
nism, actually reduce the rate of hemorrhagic transfor¬
mation of the cerebral infarct.71 There is relatively little
good information on the "natural" rate of hemorrhagic
transformation of acute ischemic strokes. Most reported
studies are limited by the method of patient selection,
for example, postmortem series, retrospective CT stud¬
ies, and some prospective CT studies in which only
patients who deteriorated were scanned. In addition,
most studies include some patients who received an¬
tithrombotic treatment of some sort, and thus for sev¬
eral reasons these studies may have overestimated the
frequency of hemorrhagic transformation. There is only
one prospective study that used serial CT scanning at
predetermined intervals after acute ischemic stroke
(regardless of symptoms), and it suggested that approx¬
imately 5% of simple (pale) infarcts undergo symptom¬
atic hemorrhagic transformation with formation of
space-occupying hematomas72 (some patients in that
study also received antithrombotic treatment). Patho¬
logical studies show some degree of petechial hemor¬
rhage in almost all infarcts, although CT scanning
detects this less frequently.71-7-1 Petechial hemorrhage is
thought to be asymptomatic and thus probably is not
clinically important, although this has not been studied.
Based on the best information available, we estimate
that the spontaneous rate of symptomatic hemorrhagic
transformation of the infarct is approximately 5%72 and
that the rate of asymptomatic (petechial) hemorrhagic
transformation is between 15% and 45%,73 but this may
be an overestimate. The rate probably varies with the
extent of the infarct71 and possibly with stroke
etiology.73
Using all the published data available, we have esti¬
mated the rate of hemorrhagic transformation after
thrombolysis for acute ischemic stroke (Tables 4 and 5).
The true rate of hemorrhagic transformation can only
be found from large randomized, controlled trials (in¬
cluding at least several thousand patients), but summing
all the data available at present may at least give an
estimate of the likely order of magnitude of hemor-
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Table 3. Open Studies of Thrombolysis for Acute "Ischemic" Stroke: Clinical Outcome
No. of Percent improved
Author Year Drug Route Dose patients clinically
Del Zoppo35 1988 SK IA 0.6-2.5xlO3 units 20 75
Theron36 1989 SK IA 0.25-1.5x 10s units 12 83
Berg-Dammer39 1991 SK IA 103 units 3 100
Maisa37 1988 SK IA 1-2.5 xlO3 units 15 73
Total for SK 39/50= 78% improved
Terashi59 1990 UK IV 6x I04 units/day for 7 days 171 35
Yamaguchi54 1991 UK IV 6x 104 units/day for 7 days 77 45
Abe60 1981 UK IV 6x I04 units/day for 7 days 51 70
Fukase61 1972 UK IV lO'-lO3 units 949 68
Mori42 1990 UK IA 1.8-3.2x 103 units 22 55
Lehmann43 1989 UK IA 2-3X105 units 10 70
Fujishima62 1986 UK IV 3x 10s units 143 79
Ikeda44 1990 UK IA 4.2x 105 units 13 53
Mobius47 1989 UK IA 2x 103 units 14 71
Mihara63 1982 UK IV 3x 103 units 33 78
Abe60 1981 UK IV 6x 103 units/day for 7 days 49 80
Berg-Dammer39 1991 UK IA 2-7.5xlO3 units 7 57
Siepmann45 1991 UK IA 7.5 x 103 units 11 64
Zeumer38 1985 UK/SK IA Various 29 59
Zeumer41 1989 UK IA 2.5-7.5 x 103 units 7 57
Matsumoto49 1991 UK IA 2.4-12x 103 units 52 59
Miyakawa50 1984 UK IV/1A 7-9x 10s units 49 45
Williams3' 1992 UK IA 5-10x 105 units 3 33
Fletcher64 1976 UK IV 1.4-3.3X 106 units 31 52
Nenci65 1983 UK IV 1.7x 106 units 4 75
Labauge66 1978 UK IV 6-34.5x 103 units 24 42
Total for UK 1133/1747=65% improved
Terashi59 1990 t-PA IV 6 mg/day for 7 days 171 59
Ohtomo67 19.88 t-PA IV 6-10 mg/day for 7 days 131 69
Yamaguchi34 1991 t-PA IV 1.7-3.4 mg/day for 7 days 145 66
NIH Study68"-681' 1992 t-PA IV 50-70 mg 94 26
Hennerici55 1991 t-PA IV 70 mg 18 28
von Kummer36 1991 t-PA IV 70 or 100 mg 27 35
Overgaard69 1992 t-PA IV 100 mg 21 85
Brucker57 1992 t-PA IV/IA 100 mg 28 29
von Kummer58 1992 t-PA IV 100 mg 32 44
Total for t-PA 373/667=56% improved
Total all patients 1,545/2.464 = 63% improved
Studies are listed according to drug used and increasing dose. Various different measures were used to determine clinical
improvement, and patients with various types of acute ischemic stroke syndrome were included. NIH, National Institutes of Health; No.
of patients, total number of patients in study; SK, streptokinase; UK, urokinase; t-PA, tissue-type plasminogen activator; IA,
intra-arterial; IV, intravenous.
rhagic transformation. All the data, including case re¬
ports, have been included to give as unbiased an assess¬
ment as can be obtained at present. Note that the time
to treatment, duration of treatment, route of adminis¬
tration, type of drug, and total dose of thrombolytic
drug (in some studies very low doses of thrombolytic
drug were used), definition of symptomatic and asymp¬
tomatic hemorrhagic transformation, and patient char¬
acteristics were different in each study. Therefore, this
analysis can only provide an estimate of the likely
hemorrhagic transformation rate. Table 4 shows the
rate of asymptomatic petechial hemorrhagic transfor¬
mation (without clinical deterioration), and Table 5
shows the rate of symptomatic intracerebral hematoma
formation (with clinical deterioration) after thromboly¬
sis. Note the huge variation in the reported rate of
asymptomatic petechial hemorrhage. This may partly
reflect bias in interpretation of CT scans, or it may be
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Table 4. Asymptomatic Intracerebral Petechial Hemorrhage After Thrombolysis for Acute Ischemic Stroke
No. of Percent
Author Year Drug Route Dose patients affectec
Del Zoppo35 1988 SK IA 0.06-2.5 x 105 units 20 20
Zeumer38 1985 SK/UK IA Various 29 17
Theron36 1989 SK IA 0.25-1.5x I05 units 12 16
Berg-Dammer39 1991 SK IA 105 units 3 0
Maisa37 1988 SK IA 2x 105 units 16 0
Hacke28 1988 SK IA 4xl05 units 45 5
Frink74 1990 SK IV 1.5x 10' units 1 0
Total for SK 11/124 ==9% petechial hemorrhage
Yamaguchi54 1991 UK IV 6x 104 units/day for 7 days 77 5
Ohtomo15 1985 UK IV 6x 104 units/day for 7 days 169 1
Harenberg75 1979 UK IA 1.5 x 105 units 1 0
Mori42 1990 UK IA 1.8-3.3x 10s units 43 12
Jungreis76 1989 UK IA 2.1 x 105 units 1 0
Lehmann43 1989 UK IA 2-3x 105 units 10 0
Fujishima62 1986 UK IV 3x 105 units 143 0
Ikeda44 1990 UK IA 4.2x I05 units 13 0
Casto46 1992 UK IA 5.6x 105 units 5 20
Berg-Dammer39 1991 UK IA 6-7x 105 units 10 20
Siepmann45 1991 UK IA 7.5 xlO5 units 11 14 30
Zeumer" 1989 UK IA 5-7.5 x 105 units 7 14
Abe38 1984 UK IV 6-12x 105 units 62 0
Seikmann48 1991 UK IA 8x 105 units 2 0
Miyakawa50 1984 UK IA/IV 7-9x I05 units 49 26
Matsumoto49 1991 UK IA 2.4-12X 10s units 52 20
Nenci65 1983 UK IV 1.7x 106 units 4 0
Total for UK 46/867 =5% petechial hemorrhage
Yamaguchi54 1991 t-PA IV 1.7-3.4 mg/day for 7 days 145 0
Yamaguchi54 1991 t-PA IV 17-51 mg 58 21
ASSG52 1992 t-PA IV 12.5-44 mg 104 20
Bruckmann77 1989 t-PA IV 25.9 mg 1 100
Okada29 1991 t-PA IV 26-56 mg 15 33
JTSG17 1992 t-PA IV 34 mg 51 39
Mori14 1991 t-PA IA 34 or 50 mg 19 66
Buteux78 1988 t-PA IA 50 mg 1 100
NIH Study68a o8b 1992 t-PA IV 50-70 mg 94 10
von Kummer56 1991 t-PA IV 70 or 100 mg 27 22
von Kummer58 1992 t-PA IV 100 mg 32 28
Turrin79 1991 t-PA IV 100 mg 1 0
Overgaard69 1992 t-PA IV 100 mg 21 0
Wildemann80 1990 t-PA IV 100 mg 1 0
Herderschee81 1991 t-PA IV 100 mg 2 50
Henze82 1987 t-PA IA 100 mg 1 0
Brucker57 1992 t-PA IV 100 mg 28 25
Jafar83 1991 t-PA IV 150 mg 1 0
Total for t-PA 101/582=17% petechial hemorrhage
Grand total all drugs 158/1,573=10% petechial hemorrhage
Only studies that included routine computed tomographic (CT) brain scans after treatment are included (thus excluding all studies before
the invention of CT scanning). Studies are listed according to drug used and increasing dose. No. of patients, total numbers of patients in
study; ASSG, Acute Stroke Study Group; JTSG, Japanese Thrombolysis Study Group; NIH, National Institutes of Health; SK.
streptokinase; UK, urokinase; t-PA, tissue-type plasminogen activator; IA, intra-arterial; IV, intravenous.
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Table s. Intracerebral Hematoma With Clinical Deterioration Complicating Thrombolysis for Acute "Ischemic" Stroke
Author Year Drug Route Dose No. of patients Percent affected
Sussman" 1958 F IV/IA Various 3 0
Clarke84 1960 F IV/IA 2-10x 105 units 10 0
Meyer12 1963 T IV 2x 103 units 20 5
Atkin85 1964 F IA 5x 105 units 1 0
Del Zoppo33 1988 SK 1A 0.6-2.5 x 103 units 20 0
Theron36 1989 SK IA 0.25-1.5 x10s units 12 8
Berg-Dammer39 1991 SK IA 103 units 3 0
Maisa37 1988 SK 1A 2x 103 units 16 6
Hacke28 1988 SK IA 4x 103 units 45 4
Meyer13 1964 SK IV 2.5-7.5 x 103 units 37 3
Frink74 1990 SK IV 1.5x 10" units 1 0
Total for SK 7/135=5% cerebral hematoma
Yamaguchi34 1991 UK IV 6x 104 units/day for 7 days 77 1
Ohtomo15 1985 UK IV 6x 104 units/day for 7 days 169 0
Abe40 19S1 UK • IV 6-60xl04 units/day for 7 days 101 1
Hass84 1966 UK IA 10s units 1 100
Harenberg75 1979 UK IV 1.5 x 10s units 1 0
Mori42 1990 UK IA 1.8-3.2x 103 units 43 9
Jungreis76 1989 UK IA 2.1 x 103 units 1 0
Lehmann43 1989 UK IA 2-3x 105 units 10 0
Mihara63 1982 UK IV 3x 1(P units 33 0
Fujishima62 1986 UK IV 3x 10s units 143 0.6
Ikeda44 1990 UK IA 4.2x 10s units 13 23
Casto44 1992 UK IA 5.6x 10s units 5 0
Berg-Dammer39 1991 UK IA 2-7.5 x 105 units 7 0
Abe30 1984 UK IV 6-12x 103 units 86 1
Abe16 1981 UK IV 6x 104 units/day for 7 days 106 0.9
Siepmann45 1991 UK IA 7.5 x 103 units 11 0
Zeumer41 1989 UK IA 7.5 x 10s units 7 0
Seikmann48 1991 UK IA 8x 103 units 2 0
Matsumoto49 1991 UK IA 2.4-12X 103 units 52 12
Fletcher44 1976 UK IV 1.4-3.3x10" units 31 12
Nenci65 1983 UK IV 1.7x 10" units 4 0
Larcan31 1977 UK IV 1.2-2.4x10" units 36 0
Labauge64 1978 UK IV 6-34x 10s units 37 0
Miyakawa50 1984 UK IV/IA 7-9x 105 units 49 4
Total for UK 26/1,025 =3% cerebral hematoma
Yamaguchi34 1991 t-PA IV 1.7-3.4 mg/day for 7 days 145 0




1992 t-PA IA 20 mg 1 0
1989 t-PA IV 25.9 mg 1 0
Yamaguchi34 1991 t-PA IV 17-51 mg 58 15
Okada29 1991 t-PA IV 26-50 mg 15 46
JTSG17 1992 t-PA IV 34 mg 51 8
Mori14 1991 t-PA IV 34/50 mg 19 10
Buteux78 1988 t-PA IA 50 mg 1 0
NIH Study48a-68b 1992 t-PA IV 50-70 mg 94 5
Hennerici33 1991 t-PA IV 70 mg 18 5
von Kummer36 1991 t-PA IV 70 or 100 mg 27 5
von Kummer38 1992 t-PA IV 100 mg 32 9
Overgaard59 1992 t-PA IV 100 mg 21 5
Turrin79 1991 t-PA IV 100 mg 1 0
Wildemann80 1990 t-PA IV 100 mg 1 0
Herderschee81 1991 t-PA IV 100 mg 2 0
Henze82 1987 t-PA IA 100 mg 1 0
Brucker37 1992 t-PA IV 100 mg 28 4
Jafar83 1991 t-PA IV 150 mg 1 0
Total for t-PA 48/621=8% cerebral hematoma
Grand total all drugs 81/1,781=5% cerebral hematoma
Cerebral hematomas were diagnosed by routine computed tomographic brain scan or post mortem. Studies are listed according to drug
used and increasing dose. No. of patients, total number of patients in study; ASSG. Acute Stroke Study Group; JTSG, Japanese
Thrombolysis Study Group; NIH, National Institutes of Health; F. fibrinolysin; T, thrombolysin; SK, streptokinase; UK, urokinase; t-PA,
tissue-type plasminogen activator; IV, intravenous; IA, intra-artcrial.
due to different frequencies and timing of CT scanning
after thrombolysis, different doses of drug, or inclusion
of different types of ischemic stroke and thus should be
viewed with this in mind. The estimated rate of symp¬
tomatic intracerebral hematoma formation after throm¬
bolysis (5%) is similar to the estimated expected natural
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Petecnial Haamorrnage
(CT or PM Diagnosis)
Symptomatic Intracerebral
Haemorrnage
{CT or PM Diagnosis)
FIGURE 2. Bar graph showing comparison of the spontane¬
ous rate of hemorrhagic conversion in cerebral infarcts with
that after the use of thrombolytic drugs in acute ischemic
stroke (see Tables 4 and 5 for exact figures). SK, streptoki¬
nase; UK, urokinase; tPA, tissue plasminogen activator; CT,
computed tomographic; PM, postmortem.
tPA Spontaneous
history. The cerebral hematoma rate varies between
studies and appears to be higher with t-PA (Figure 2).
Although this may be due to a number of factors
including differences in frequency and timing of CT
scanning, postmortem rates, or different doses of drug,
the trend is similar to the cerebral hemorrhage rate
found when SK and t-PA were compared in ISIS-3S7 and
GISSI-288 in acute myocardial infarction. Ascertain¬
ment of the true cerebral hemorrhage rate with each
thrombolytic drug will only be possible by direct com¬
parison in large randomized trials similar to the myo¬
cardial infarction studies.87-88 Two small randomized
trials that compared low-dose UK with t-PA54-59 found
no significant difference in outcome or hemorrhagic
transformation rates.
The randomized trials (with CT scanning) all found
massive hemorrhagic infarction slightly more often in
placebo-treated than in thrombolysis-treated patients.
Mori et al14 found hemorrhagic transformation of mild
degree in 26% of t-PA-treated and 33% of placebo-
treated patients. Ohtomo et al15 found that two of 169
UK-treated patients developed hemorrhagic transfor¬
mation of the infarct of mild degree, whereas one of 181
placebo-treated patients developed a severe symptom¬
atic intracerebral hematoma. Abe et al16 found no
symptomatic intracerebral hematomas with UK. In the
JTSG trial there were massive hemorrhagic infarcts in
four of 51 patients in the t-PA-treated group and in five
of 47 patients in the control group.17
None of the large open stroke trials found a relation
between dose of drug and symptomatic intracerebral
hematoma formation, but they suggested that a time
delay of over 6 hours from onset,52 hypertension, and
possibly treating patients who already had a low-density
area visible on CT may be risk factors.55-('8i'-68b Matsu-
moto and Satoh49 have treated 52 acute ischemic stroke
patients with a wide range of doses of UK and have not
demonstrated any definite relation between cerebral
hemorrhage and dose, time after onset, or age of
patient. They suggested that hemorrhages were more
often symptomatic in recanalized patients, but this
conclusion was based on very small numbers (Figure 3).
No definite association with recanalization was found in
the Acute Stroke Study Group trial52 or by Miyakawa
and Sakuragawa.50 Therefore, it appears that although
one might expect thrombolytic treatment to increase
symptomatic hemorrhagic transformation of cerebral
infarcts, using the limited data available at present, the
risk is of an order of magnitude similar to the estimated
natural rate. The true risk of hemorrhagic transforma¬
tion of the cerebral infarct after thrombolysis can be
found only by large randomized, controlled trials using
serial CT scanning (or magnetic resonance imaging or
postmortem series when appropriate) in all patients.
Does Thrombolysis Increase the Risk of
Space-Occupying Edema Formation
in the Cerebral Infarct?
The cause of severe infarct edema is unclear. It may
be due to "reperfusion injury," and therefore thrombol¬
ysis might worsen this condition.89 As far as can be
ascertained, severe infarct edema is not simply due to
recanalization90-91 and occurs naturally in approximately
5% of large infarcts.71 However, the data on symptom¬
atic cerebral infarct edema formation are even more
limited than those for hemorrhagic transformation (Ta¬
ble 6). The frequency of cerebral edema with brain
herniation is difficult to extract from the thrombolysis
studies but does not appear to be increased. Many
studies did not mention severe infarct swelling, although
it may have occurred. Mori et al14 found that massive
brain swelling occurred in 9% of patients who reper-
fused compared with 35% who did not (26% of t-PA-
treated and 25% of placebo-treated patients).
We have prospectively examined reperfusion in 47
patients with partial or total MCA territory infarcts92:
infarct swelling was greatest in the largest infarcts and
in patients whose symptomatic MCA remained oc¬
cluded on angiography or transcranial Doppler ultra¬
sound. Patients who reperfused within the first 3 days of
onset had smaller infarcts with less edema and a better
clinical outcome.
What About Dose and Mode of Administration of
Thrombolysis, Elderly Patients, and Time Limit
to TTreatment After Onset?
To avoid delay, any treatment for acute stroke must
be easy to administer. The standard intravenous dose
for myocardial infarction is 1.5 megaunits SK or 100 mg
t-PA. Smaller intracoronary doses were used in early
studies to try to maximize local thrombolytic effect and
reduce systemic adverse effects, but any benefit was
more than offset by the extra 1 or 2 hours of delay
caused by angiography.93 Intravenous administration of
thrombolysis would also be quicker than intra-arterial
administration in acute ischemic stroke.
If thrombolysis is to be a worthwhile treatment for
acute ischemic stroke, it should be available for the
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FIGURE 3. Bar graphs showing effect of
time after stroke onset (top panel), age of
patient (second panel), total dose of uroki¬
nase (third panel), and recanalization (bot¬
tom panel) on cerebral hemorrhagic compli¬
cations. From Matsumoto and Satoh.49
elderly, the most commonly affected age group. Cere¬
bral amyloid angiopathy has been cited as a reason for
increased risk of hemorrhage in the elderly.94 The few
studies in which thrombolytics have been used in elderly
stroke patients (aged older than 70 years) do not show
a definitely increased hemorrhage rate compared with
younger patients. Figure 3 shows the results of Matsu¬
moto and Satoh49 in patients aged up to 86 years. The
Table 6. Severe Cerebral Infarct Edema After Thrombolysis for Acute Ischemic Stroke





Theron-14 1989 SK IA 0.25-1.5X 10s units 12 8
Fujishima42 1986 UK IV 3x10s units 143 0.7
Ikeda" 1990 UK IA 4.2x10s units 13 8
NIH Study483-4"" 1992 t-PA IV 50-70 mg 74 3
von Kummer'4 1991 t-PA IV 70 or 100 mg 21 33
Koudstaal89 1988 t-PA IV 100 mg 2 100
Mori14 1991 t-PA IV 34-50 mg 19 26
Total 18/284=6% severe infarct edema
Severe infarct edema was diagnosed by routine computed tomographic scan, and only studies that
mentioned it as a complication have been included. No. of patients, total number of patients in study;
NIH, National Institutes of Health; SK, streptokinase; UK, urokinase; t-PA, tissue plasminogen
activator; IA, intra-arterial; IV, intravenous.
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Acute Stroke Study Group52 included patients aged up
to 80 years and did not find an increased cerebral
hemorrhage rate in the older patients. Several other
reports36-45-48 of thrombolysis in elderly stroke patients
have shown benefit, but this is anecdotal.
ISIS-223 showed that in elderly myocardial infarct
patients treated with thrombolysis, the proportional
reduction in mortality was the same as for younger
patients and the absolute reduction was greater. The
elderly perhaps have the most to gain from a treatment
that reduces disability from stroke, and thrombolysis
certainly deserves a trial at all ages.
A time limit of 6 hours from onset to treatment was
set by most of the recent thrombolysis studies, although
the sparse data available do not show a sharp increase in
adverse effects between 6 and 24 hours.41' Several Jap¬
anese studies have included patients for several days
after stroke with no obvious increase in adverse ef-
fects.15-16-59-50-67 Although it is unlikely that neurons
survive many hours of ischemia, we do not really know
enough about the duration of neuronal viability after
acute cerebral artery occlusion to introduce time limits
to treatment. Time limits can only be established by
large randomized, controlled trials. In most parts of the
world stroke patients go to the hospital (if at all) in a
"slow ambulance," and few reach the hospital and have
a CT scan by 6 hours. Although it was possible to recruit
patients within 90 minutes of symptom onset in the
National Institutes of Health (NIH) t-PA study68"-681'
(and very early recruitment is continuing in the NIH
randomized, controlled trial of t-PA), elsewhere in the
world it is likely to take many years to change the
current slow referral pattern. Therefore, future trials
should examine the problem of maximum time limit by
including patients up to 24 hours after onset; otherwise,
we will never know the risk/benefit ratio of thrombolytic
treatment between 6 and 24 hours.
If very early treatment is the aim, is there a danger in
exposing patients who are having a transient ischemic
attack (TIA) to thrombolysis? Levy95 found that 50% of
TIAs last less than 30 minutes, and in patients with a
deficit persisting at 60 minutes, less than 2% will resolve
spontaneously in each subsequent 1-hour period.
Therefore, there is very little danger in treating a TIA
with thrombolysis if patients showing distinct signs of
improvement in the first 1-2 hours are excluded.
Which Drug Should Be Used?
Most of the available thrombolytics have been tested
in stroke, using oral, intravenous, and intra-arterial
routes of administration and a wide range of doses.
Table 2 shows that in the small nonrandomized studies
thus far there is little difference in immediate patency
rates between t-PA, SK, or UK and no obvious optimum
dose. The number of patients is small, however, and
there may be publication bias. Several open studies have
failed to identify an optimum dose.49-52-56-68"-6811
The lack of a clear benefit for one drug or dose is not
unexpected. ISIS-3 and GISSI-2 combined had to ran¬
domize over 60,000 patients to show that the reduction
in vascular deaths after myocardial infarction was the
same whether SK, t-PA, or anistreplase was used. But
there was a highly significant excess of cerebral hemor¬
rhages with t-PA: seven of 1,000 compared with three of
1,000 with SK.87
Although studies of thrombolysis in myocardial in¬
farction may not be directly relevant to the use of
thrombolysis in acute ischemic stroke, investigators
should be aware of the now vast amount of information
available from studies of thrombolysis in cardiovascular
disease. Extrapolation from ISIS-3 and GISSI-2 sug¬
gests that the clinical benefit for thrombolysis in acute
ischemic stroke should be about the same no matter
which agent is used, but the cerebral hemorrhage rate
might be higher after t-PA. Our simple analysis of the
available data (Tables 4 and 5 and Figure 2) tends to
support this, and certainly SK (or any of the other
available thrombolytic drugs) should not be rejected in
favor of t-PA without being adequately tested.
Conclusions
Experience with thrombolysis in acute ischemic
stroke suggests that the risks are not excessive and there
may be some benefit. However, the standard of meth¬
odology used in most of the trials thus far means that
this conclusion must be very tentative and no more than
hypothesis generating. It has been enough, however, to
encourage Italian, Australian, and American investiga¬
tors, who have recently started randomized trials of
intravenous thrombolysis (SK/aspirin/both or neither,
SK/aspirin/placebo, and t-PA/placebo, respectively) in
acute ischemic stroke.
Considerable expertise has now accrued showing the
value of thrombolysis and aspirin in acute myocardial
infarction. As well as demonstrating benefit in young,
otherwise healthy, myocardial infarction patients,
ISIS-3 has shown that other subgroups of myocardial
infarction patients, traditionally regarded as high risk
for thrombolysis, gain considerable benefit from it,
including the elderly and those with hypertension, pre¬
vious peptic ulcer, and recent stroke.87
It is this mass of evidence from the use of thrombol¬
ysis in myocardial infarction, as well as the limited
experience in ischemic stroke, that makes it imperative
and urgent to test thrombolysis properly in acute isch¬
emic stroke. There is no place for more nonrandomized
trials in this assessment. Safety cannot be assessed
unless the major adverse effects of the treatment under
trial are controlled for, which in this case mimic the
natural history of the disease; cerebral hemorrhage and
severe infarct edema.
i Acute stroke treatment research is rejecting com¬
pounds thought to have therapeutic promise as fast as
they can be invented, but with remarkably little good
evidence to do so, and this must stop. Thrombolysis in
acute myocardial infarction was almost rejected in error
after innumerable small trials had missed its real ben¬
efit. It was only after the overview of these trials22 and
the subsequent very large trials23-87-88 that the clear
benefit was demonstrated, which was clear enough to
change clinical practice.96
Thrombolysis for acute ischemic stroke deserves large
and methodologically sound trials designed to answer a
simple question: Does it work?
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A Meta-Analysis of All Published Data on the Use
of Thrombolytic Therapy
to Treat Acute Ischemic Stroke
J.M. Wardlaw1 and C.P. Warlow2
Acute ischemic stroke is the third most common cause of death in the devel¬
oped world and leaves many more patients disabled [2], Despite this, however,
there is as yet no treatment of proven benefit. Thrombolysis has been exten¬
sively tested in acute myocardial infarction (a vascular disease with some
similarities to acute ischemic stroke) for which it is now an established treat¬
ment [4], having been shown to reduce the incidence of vascular death by
about 25%. Thrombolysis might also improve outcome after acute ischemic
stroke by speeding recanalization of occluded cerebral arteries, and reducing
the amount of permanent neuronal damage.
Thrombolysis has not been extensively tested in acute ischemic stroke, al¬
though the first attempts to use it were in the late 1950's [10]. Early studies
were hampered by the inability to distinguish between intracerebral hemor¬
rhage and infarction as the cause of acute stroke symptoms, until the develop¬
ment of CT scanning in the early 1970's. The natural history of acute ischemic
stroke is complex and the assessment of any treatment must be by randomized
controlled trial, especially with thrombolysis where the likely adverse effects
(cerebral hemorrhage and possible severe infarct edema) mimic the natural his¬
tory of the disease. There have been more than 60 reports of the use of throm¬
bolysis in acute ischemic stroke in the world literature so far, but we have con¬
centrated on the published randomized controlled trials to see whether analysis
using the overview technique [3] would show evidence of a beneficial or detri¬
mental treatment effect on stroke outcome.
Subjects and Methods
We have tried to identify all published work on the use of thrombolytic drugs
to treat acute ischemic stroke by a thorough literature search using Index
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Medicus, by tracing references cited in thrombolysis papers, and by discussion
with other researchers interested in thrombolysis. We were able to identify 5
published trials which were truly randomized and had a control group. We
have not included trials with retrospective control and prospective treated
groups, nor trials where it was unclear how the control patients were selected.
The overview technique was used to analyze the effect of thrombolysis on
death, and on death or deterioration after acute ischemic stroke without and
with the benefit of CT scanning.
Results
Five truly randomized controlled trials of thrombolysis in acute "ischemic"
stroke were identified. These comprise two trials by Meyer and colleagues in
1963 [6] and 1964 [7], Abe and coworkers in 1981 [1], Ohtomo and colleagues
in 1985 [9] and Mori and investigators in 1992 [8]. The two by Meyer were done
prior to the development of CT scanning and may inadvertently have included
patients with cerebral hemorrhage or hemorrhagic infarction as the cause of
stroke rather than true ischemic strokes. Those by Abe, Ohtomo, and Mori and
their respective coworkers were all done with the benefit of CT scanning.
The trials added together included a total of 601 patients. Although differ¬
ent drugs, dose of drug, time to treatment, type of ischemic stroke, and end-
point were used in the 5 trials, the overview (or meta-analysis) allows compari¬
son of different trials to look for an overall treatment effect. In the case of the
trials by Meyer, Abe, and Ohtomo, the published information was used, but
additional information on deterioration was supplied by Professor Mori.
Analysis of all 5 trials shows that the risk of death is increased by 32% with
thrombolysis (95% CI: 30% reduction to 150% excess), and the risk of death
or deterioration is reduced by 26% (95% CI: 57% reduction to 27% excess).
Analysis of the trials by Abe, Ohtomo, and Mori conducted with the benefit
of CT scanning (and therefore truly ischemic stroke) shows a reduction in the
risk of death of 40% (95% CI: 79% reduction to 70% excess) with throm¬
bolytic treatment, and in the risk of death or deterioration a reduction of 63%
(95% CI: 22% -82% reduction). The reduction in the risk of death or deterio¬
ration with thrombolysis in the CT-guided trials is significant (2p = 0.012) and
provides some evidence that thrombolysis is likely to be beneficial in acute
ischemic stroke, and certainly needs to be properly evaluated.
Discussion
Although there is now increasing information on the use of thrombolysis in
acute ischemic stroke from uncontrolled "dose escalation" studies, the data
from these studies cannot be used to assess treatment, as the major adverse ef-
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fects of thrombolysis - cerebral hemorrhage and severe infarct edema - were
not controlled for (and in this case they mimic the natural history of ischemic
stroke).
Information from recent larger randomized controlled trials of thrombolysis
in acute ischemic stroke will be available in the near future. Professor Yamaguchi
has presented results of the Japanese multicenter randomized controlled trial at
this Symposium. Several randomized controlled trials of thrombolysis in acute
ischemic stroke are planned or in progress in Europe and the USA.
However, the overview analysis of the scant information from the 5 random¬
ized controlled trials of thrombolysis so far available provides some evidence
that thrombolysis may be beneficial, certainly enough to encourage much larg¬
er randomized trials. Very large trials, on the scale of the thrombolysis in
myocardial infarction studies [5] including many thousands of patients, will be
needed to establish the true beneficial and adverse effects of thrombolytic
treatment. Trials should allow patient entry up to at least 12 h (and possibly
24) after symptom onset because in many parts of the world stroke patients
go to the hospital, if at all, in a "slow ambulance" and it is unrealistic to expect
that to change overnight. Studies should include elderly patients and as wide
a spectrum of ischemic stroke as possible so that the risk/benefit ratio can be
identified for all age groups and types of ischemic stroke. The overview analy¬
sis has shown that thrombolysis is a promising treatment for acute ischemic
stroke and provides sufficient justification for the testing of thrombolysis in
large randomized controlled trials.
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